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ABSTRACT"
Endometriosis! is! a! common! disease,! affecting! 10%! of! women! of! reproductive! age.!
Pharmacological!agents!play!an!important!role!in!control!of!symptoms!as!well!as!disease!
suppression!but!are!limited!by!systemic!side!effects.!!Although!surgical!management!is!
helpful! for! some,! there! is! an! increasing! reliance! on! medical! treatment! and! the!
exploration! of! new! treatments! such! as! selective! progesterone! receptor! modulators!
(SPRMs).!!
The!aim!of!this!interventional!descriptive!cohort!study!was!to!assess!the!changes!in!the!
ectopic!endometrial!deposits!of!twenty!patients!with!pelvic!endometriosis!after!a!threeU
month!treatment!course!of!ulipristal!acetate!(Esmya!).!Post!treatment!histological!and!
immunohistochemistry! changes! were! correlated! to! changes! in! the! macroscopic!
appearance!of!the!disease!and!changes!in!symptom!severity.!
Features! of! progesterone! receptor!modulator! associate! endometrial! changes! (PAEC)!
were! seen!within!eutopic!endometrial! samples,!as!expected,!but!no! single!specimen!
exhibited! the! full! features! of! PAEC.! ! The! ectopic! endometrium!exhibited! a! different!
pattern!of!features!with!cystic!dilatation,!ciliated!metaplasia!and!infrequent!mitoses!a!
more! common! finding.! ! The! presence! of! these! features! correlated! with! the! clinical!
impact!of!the!drug!and!may!offer!some!insight!into!the!drugs!mechanism!of!action.!!!
A! good! clinical! response! to! ulipristal! acetate! was! seen! in! 56%! of! the! cohort! with!
statistically!significant!improvements!in!pain!scores!and!overall!quality!of!life!relating!to!
endometriosis,!which!was!maintained!after!stopping!treatment.!!Ulipristal!acetate!was!
considered!acceptable!by!the!cohort!with!the!median!change!described!as!‘better,!and!
a!definite!improvement!that!has!made!a!real!and!worthwhile!difference’.!
Ulipristal! acetate! appears! to! offer! an! effective! treatment! for! endometriosis! with!
histological!changes!in!keeping!with!the!known!experience!of!PAEC.!!The!safety!of!this!
compound!remains!to!be!elucidated!but!the!results!from!this!pilot!study!are!encouraging!
and!should!prompt!further!exploration.!!
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PREFACE"
Endometriosis!is!a!common!disease,!affecting!10%!of!women!of!reproductive!age.!!The!
clinical! symptoms! are! painful! menstruation,! persistent! pelvic! pain,! pain! during!
intercourse!and!infertility.!Pharmacological!agents!play!an!important!role!in!control!of!
symptoms!as!well!as!disease!suppression,!especially!in!young!women!who!wish!to!retain!
their!fertility.!!This!currently!involves!nonUsteroidal!antiUinflammatory!drugs!(NSAIDs)!or!
hormonal!agents,!such!as!progestogens!or!gonadotrophin!releasing!hormone!(GnRH)!
analogues.!Systemic!side!effects!limit!the!effective!use!of!many!such!hormonal!agents.!
Ulipristal!acetate!(UPA)!(Esmya!)!is!a!selective!progesterone!receptor!modulator!that!
acts!mainly!on!the!progesterone!receptors!of!the!reproductive!tract.!It!has!recently!been!
introduced!to!clinical!practice!as!a!preUoperative!treatment!of! fibroids.! !Studies!have!
demonstrated! histological! changes! in! the! endometrial! lining! of! the! uterus! after!
treatment!with!ulipristal!acetate.!However,!whether!similar!changes!occur!in!the!ectopic!
endometrium! in! pelvic! endometriosis! remains! to! be! elucidated.! Dependent! on! the!
nature!of!any!such!changes,!ulipristal!acetate!may!form!the!basis!of!a!new!treatment!
modality.!!
The!study!aim!was!to!assess!the!changes!in!the!ectopic!endometrial!deposits!of!patients!
with!pelvic!endometriosis!after!a!threeUmonth!treatment!course!of!ulipristal!acetate.!
Post!treatment!histological!changes!were!described!and!then!correlated!with!changes!
in!the!macroscopic!appearance!of!the!disease!and!symptom!severity.!
Patients! with! laparoscopically! diagnosed! endometriosis,! requiring! further! surgical!
treatment!were!given!a!threeUmonth!course!of!5mg!ulipristal!acetate!daily,!prior!to!any!
planned!surgery.!!No!other!modification!to!the!planned!clinical!management!was!made.!!
At!the!treatment!laparoscopy,!the!disease!was!reUclassified,!and!samples!obtained!for!
histological! analysis! of! both! the! ectopic! deposits! and! the! eutopic! endometrium.! ! In!
addition,!symptoms!and!quality!of!life!were!assessed!at!various!time!points!throughout!
the! study! to! assess! effectiveness! and! tolerability.! ! The! study!was! carried! out! over! a!
period!of!two!years!to!achieve!a!recruitment!target!of!20!subjects.
!
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Chapter"1:!ENDOMETRIOSIS"
1.1! THE"DISEASE"
Endometriosis!was!originally!described!by!Sampson!in!1927!but!has!more!recently!been!
defined!by!Giudice,!in!2004,!as!the!presence!of!tissue!resembling!the!endometrium!in!
locations!outside!the!uterus.(1)(2)!!A!consensus!definition!by!the!European!Society!of!
Human! Reproduction! and! Embryology! (ESHRE)! is! ‘the! presence! of! endometrialUlike!
tissue!outside!the!uterus,!which! induces!a!chronic,! inflammatory!reaction’.(3)! ! It! is!a!
poorly!understood!condition!with!considerable!variability!in!clinical!presentation;!some!
patients! experience! severe! and! debilitating! symptoms! whilst! others! have! only! mild!
symptoms! that! have! little! impact! on! their! quality! of! life.! ! A! lack! of! nonUinvasive!
diagnostic! tools!means! it! can! only! be! diagnosed! at! laparoscopy! or! through! invasive!
biopsy!often!resulting!in!a!diagnostic!delay.! !As!such! it! is!difficult! to!define!the!exact!
prevalence! but! is! it! considered! to! be! common! U! affecting! 5U10%! of! women! of!
reproductive!age.(4)!!
However,!the!prevalence!is!much!higher!in!certain!groups!–!for!instance,!it!is!diagnosed!
in!up!to!25%!of!women!presenting!with!gynaecological!symptoms!in!the!UK!and!USA,!
with!a!peak!incidence!between!30!and!45!years!of!age.(5)!!Despite!this!high!prevalence,!
there! is! limited! understanding! about! the! condition! with! regard! to! aetiology,!
pathogenesis!and!management.!!The!current!range!of!conservative,!medical!and!surgical!
management! options! each! have! their! own! unique! limitations;! meaning! there! is!
significant!interest!in!novel!therapeutic!agents!for!the!treatment!of!endometriosis.!
1.2! PATHOGENESIS"
In!endometriosis,!ectopic!endometrial!tissue!deposits,!which!are!morphologically!and!
biologically! similar! to! eutopic! endometrium,! are! found! in! aberrant! locations.! ! These!
deposits! contain! functional! endometrial! glands! and! stroma! and! can! respond! to!
endogenous!hormonal!stimulation,!in!a!similar!way!to!the!eutopic!endometrium,!leading!
to!a!cycle!of!proliferation!and!menstrual!type!bleeding!at!the!site!of!these!implants.(5)!!
Local! inflammatory! processes! occur! in! response! to! these! deposits! leading! to! the!
deposition!of!fibrin!and!the!generation!of!adhesions.!As!this!process!progresses,!deep!
infiltrating!lesions!develop!and!endometriomas!can!form!within!the!ovaries.!
!
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The!precise!aetiology!of!endometriosis!is!not!known.!!There!are!a!number!of!theories!
with! regard! to! the!origin!of! the!ectopic!endometrial! tissue:! retrograde!menstruation!
causing! peritoneal! endometriosis,! coelomic! metaplasia! leading! to! ovarian!
endometriosis!and!abnormalities!of!persistent!Mullerian!duct!remnants!explaining!the!
development!of!rectovaginal!endometriosis.(5,6)!!However,!these!deposits!of!abnormal!
cells! should! be! identified! and! destroyed! by! the! cellUmediated! arm! of! the! immune!
system.! ! The! lack! of! cell! clearance! by! macrophages,! irrespective! of! their! origin,!
contributes! to! the! persistence! of! these! abnormally! located! cells! in! patients! with!
endometriosis.!!The!reason!behind!this!persistence!in!some!individuals!and!not!in!others!
is!poorly!understood!but!there!is!a!proven!familial!component!to!the!condition!–!either!
with!respect!to!the!origin!of!the!ectopic!endometrial!cells!or!the!subsequent!persistence!
of!those!cells!in!that!ectopic!location.!!The!inheritance!is!polygenic!and!leads!to!a!seven!
times!higher!incidence!in!patients!with!a!family!history!of!endometriosis.(4)!
Although! the!aetiology!of! the!disease! is!unknown!some!aspects!of!pathogenesis!are!
becoming!clearer,!which!has!resulted!in!some!models!of!pathogenesis!becoming!widely!
accepted! in! the! literature.! ! As! such! there! are! three! key! aspects! to! consider! when!
exploring!the!pathological!processes!behind!the!establishment!of!ectopic!endometrial!
lesions!in!endometriosis:!!
1)! how!the!lesions!become!established!at!the!ectopic!location,!
2)! how!the!cells!behave,!once!they!are!established!to!promote!their!persistence,!
3)! why!the!immune!system!fails!to!clear!them!from!their!ectopic!location.!
Unfortunately,!there!is!no!clear!single!mechanism!that!explains!all!the!known!features!
and!experimental!data,!which!means! that!each! of! the!models!described!have!either!
exceptions!or!flaws.!!
1.2.1! Establishment(of(ectopic(endometrial(lesions(
Retrograde)menstruation)
The!concept!of!endometrial!cells!and!fragments!reaching!the!pelvic!peritoneum!by!a!
process! of! reflux! though! the! Fallopian! tubes! during! menstruation! was! originally!
suggested!by!Sampson!in!1929!(1)!and!is!now!the!most!accepted!theory.(7,8)!!This!theory!
is! supported! by! the! fact! that! conditions! such! as! cervical! stenosis! that! promote!
retrograde! menstruation! are! associated! with! an! increased! incidence! of!
!
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endometriosis.(9)!!However,!cases!of!endometriosis!are!seen!in!prepubescent!girls!and!
the!fact!that!retrograde!menstruation!is!far!more!common!(76U90%)!in!healthy!subjects!
than!the!accepted!prevalence!of!endometriosis!(10%),!both!suggest!other!factors!are!
involved.(10)!
Another!criticism!is!that!this!model!fails!to!explain!the!fact!that!disease!is!found!outside!
the!peritoneal!cavity!in!locations!such!as!the!lung!and!brain.!!This!was!also!considered!
by!Sampson!at!the!time!of!his!initial!observation!when!he!also!described!vascular!and!
lymphatic!spread!of!endometrial!cells(11),!suggesting!that!endometrial!cells!can!reach!
ectopic! locations! via! metastatic! spread! through! vessels! not! just! via! retrograde!
menstruation.!
Metastatic)or)embolic)theory)
Work!by!Javert!in!1949!and!Aoki!in!1967,!highlighted!the!importance!of!haematogenous!
metastasis! and! suggested! that! endometriotic! inclusions!within! glands! resulted! from!
transportation! of! endometrial! cells! from! the! uterine! body! through! lymphatic!
channels.(12,13)! ! In! patients! with! deeply! invasive! rectovaginal! disease! and! bowel!
endometriosis,!lymph!node!inclusions!are!more!common!and!their!presence!is!linked!to!
disease!burden.!!In!contrast,!those!with!peritoneal!or!isolated!ovarian!disease!are!much!
less! likely! to! have! lymph!node! involvement.! ! A! comprehensive! review!by! Jerman! in!
2015(14),! concluded! that! lymphatic! spread! is! involved! in! the! spread! of! eutopic!
endometrium!from!the!uterus!but!may!also!be!involved!in!the!spread!of!endometriotic!
cells! to! draining! lymph! nodes! and! so! may! contribute! to! the! dissemination! and!
persistence!of!the!disease.!!!
A!case!report!describing!a!rapidly!growing!ovarian!endometrioma!that!was!managed!
surgically! revealing! a! large! endometriotic! cyst! growing! within! a! pelvic! lymph! node,!
highlights! some! of! the! features! of! this! model! of! pathogenesis.(15)! ! The! systematic!
review! of! the! published! cases! of! lymph! node! involvement! discussed! in! the! report!
demonstrates!that!whilst!endometrial!tissue!can!be!found!in!both!pelvic!and!paraUaortic!
lymph!nodes,! it! is!quite!rare!and!when! it!does!occur! it! is!usually!glandular! inclusions!
consistent!with! endometriosis! rather! than! formed! endometriotic! cysts.! ! The! current!
focus!of!research!in!this!area!is!centered!around!the!importance!of!sentinel!lymph!nodes!
and!their! role! in!disease!recurrence.! ! It!has!been!suggested!that!residual!cells! in!the!
lymphatics!could!be!a!target!for!hormonal!suppression!post!excision!and!so!they!may!
!
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play!a!prognostic!and!predictive!role!in!the!impact!and!longevity!of!surgical!management!
of!endometriosis.(16,17)!!
Endometrial)stem)cell)implantation)
More!recently!the!retrograde!menstruation!model!has!been!refined!to!suggest!that!it!is!
endometrial!progenitor!cells!and!bone!marrowUderived!mesenchymal!stem!cells! that!
differentiate!into!endometrial!cells!at!ectopic!locations!U!having!reached!that!location!
either!as!a! result!of! retrograde!menstruation!or!by! transportation! in! the!vascular!or!
lymphatic!circulation.!!The!ability!of!such!stem!cells!to!differentiate!and!proliferate!mean!
they! are! ideally! placed! to! establish! themselves! in! ectopic! locations.! ! The! work! by!
Leyendecker!et#al.(18)!found!that!receptor!expression!is!paralleled!in!the!basalis!layer!
of! the!eutopic!endometrium!and! the!ectopic!endometrial! lesions,! suggesting!ectopic!
cells! may! originate! in! the! basalis! layer.! They! also! demonstrated! that! endometrial!
shedding! of! the! basalis! layer! in! women! with! endometriosis! occurs! at! a! higher! rate!
compared! to! healthy! women,! highlighting! this! as! a! possible! source! of! ectopic!
endometrial!cells.!
Coelomic)origins)
An!alternative!theory!is!that!endometriotic!cells!have!a!coelomic!origin.!!Embryological!
studies! have! demonstrated! that! the! peritoneum,! Mullerian! ducts! and! germinal!
epithelium!of!the!ovary!are!all!derived!from!the!coelomic!epithelium.!!One!theory!is!that!
coelomic!metaplasia!occurs,!such!that!mesothelial!cells!differentiate!into!endometriumU
like! cells,! which! then! respond! to! increasing! levels! of! sex! steroids! after! puberty.(19)!!
Under!conditions!of!hormonal,!environmental!or!infective!stress!these!epithelial!cells!
may! differentiate! into! endometrial! epithelium! in! an! ectopic! location! such! as! the!
peritoneum(7)!or!they!may!be!cells!left!over!from!Mullerian!duct!migration.(20)!!This!
theory! elegantly! explains! why! deposits! of! endometriosis! can! occur! outside! the!
abdominal!cavity!in!the!peritoneum!of!the!lung!but!the!fact!that!metaplasia!occurs!more!
frequently!with!age!is!inconsistent!with!the!pattern!of!incidence!of!endometriosis.!
1.2.2! Ectopic(endometrial(persistence(
Once! the!endometrial! cells!have! reached! the!ectopic! location! they!must!attach! to!a!
surface! to! persist! at! that! ectopic! location.! ! Eutopic! epithelial! cells! in! subjects! with!
endometriosis!are!known!to!have!an! increased!proliferative!capacity(21)!but! for!that!
capacity!to!be!realised!in!the!ectopic!location!the!cells!must!adhere!to!the!extracellular!
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matrix!and!potentially!modify!the!local!environment!to!promote!persistence.!!It!appears!
that!the!stromal!cells!are!the!key!to!adherence!and!the!epithelial!cells!allow!invasion!
and!growth!of!the!deposits.(7)!
The!persistence!of!ectopic!deposits!is!multifactorial,!but!alteration!of!cell!cycle!control!
seems! to! play! a! role.! ! The! upregulation! of! the! antiUapoptotic! gene! BCLU2! has! been!
demonstrated! in! eutopic! and! ectopic! endometrium(22)! and! mutation! of! the! tumor!
suppressor! gene! PTEN!has! been! demonstrated! in! 21%!of! endometriotic! cysts! of! the!
ovary.(23)!!In!women!with!endometriosis!these!alterations!in!cell!cycle!control!occur!in!
conjunction!with!changes!in!the!local!extracellular!environment!to!promote!continued!
cell!survival.!
Extracellular)matrix))
The! proteolytic! capacity! of! the! epithelial! cells! of! women! with! endometriosis! also!
appears! to! be! increased.! ! This! is! achieved! by! altered! expression! of! plasminogen!
activators!and!matrix!metalloproteinases!(MMPs).(8)!!In!endometriosis,!urokinase!type!
plasminogen! activator! (uPA)! and! MMPU3! expression! is! increased! in! the! eutopic!
endometrium!when!compared!to!controls!and!the!increased!expression!is!even!more!
marked!in!the!endometriotic!tissue!and!peritoneal!fluid.(24,25)!!The!increase!of!these!
activators! promotes! plasmin! deposition,! which! in! turn! promotes! degradation! of!
extracellular!matrix!and! synthesis!of!growth! factors.! !As! such! this!altered!expression!
within!those!subjects!with!endometriosis!helps!the!lesions!to!establish.!
Adhesion! of! endometrial! cells! at! ectopic! sites! appears! to! be! triggered! by! an! injury!
process! at! the! peritoneal! surface.! ! Whether! this! change! is! heritable! or! acquired! is!
unclear!but!upUregulation!of!matrix!metalloproteinase!(MMP)!U3,!intercellular!adhesion!
molecule!1!(ICAMU1),!transforming!growth!factorUbeta!(TGFU#),!and!interleukinU6!(ILU6)!
are!involved!in!the!influencing!the!interaction!with!the!extracellular!matrix!and!ability!
of!the!immune!system!to!clear!ectopically!sited!cells.(20)!
Local)oestrogen)production)
Oestrogen!plays!an!important!role!in!the!repair!of!the!endometrium!after!menstruation.!!
The! proliferation! of! the! basalis! layer! and! reUestablishment! of! the! vascular! supply! is!
dependent! on! the! oestrogen,!which! is! synthesised! by! the! ovary,! adrenal!glands! and!
adipocytes.!!Initially,!androstenedione!is!converted!to!estrone!by!the!aromatase!P450!
!
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enzyme!before!being!converted!to!oestradiol.! !The!activity!of!the!aromatase!enzyme!!!!!!
P450!is!controlled!by!a!cAMP!cell!signalling!cascade!by!the!prostaglandin!E2,!which!is!
itself!synthesised!by!cyclooxygenaseU2!(COXU)!from!arachidonic!acid.(7)!
Usually,! aromatase! activity! in! the! endometrium! is! undetectable! but! in!women!with!
endometriosis!the!activity!is!increased!in!both!the!eutopic!and!ectopic!endometrium.!!
This! means! oestradiol! can! be! produced! locally! and! so! promotes! the! growth! and!
persistence! of! ectopic! deposits,! irrespective! of! the! endogenous! ovarian! cycle! of!
oestradiol! production.! ! This! may! explain! why! pharmaceutical! treatments! aimed! at!
lowering!oestrogen!levels!may!not!be!effective!in!all!patients!with!endometriosis.(26,27)!
Progesterone)resistance)
An! abnormal! response! to! progesterone! or! “progesterone! resistance”! has! been!
described!and!is!based!on!the!observation!that!some!patients!with!endometriosis!do!
not! respond! to! progesterone! therapy.(28)! ! In! normal! eutopic! endometrium,!
progesterone! promotes! paracrine! signalling! that! induces! the! enzyme! 17#U
hydroxysteriod! dehydrogenase! type! 2! (17#UHSDU2)! in! stromal! cells! to! metabolise!
oestradiol! to! the! less! biologically! active! estrone.! ! This! does! not! appear! to! occur! in!
endometriosis,!which!may!be!as!a!result!of!altered!progesterone!receptor!expression.!!
Work! by! Attia! et# al.! has! demonstrated! that! progesterone! receptor! B! (PRUB)! is! not!
expressed!in!endometriosis!and!progesterone!receptor!A!(PRUA)!is!only!expressed!at!low!
levels.(29)!!This!results!in!a!significantly!reduced!capacity!to!metabolise!oestradiol!and!
this! couple!with! increased! local! production,! as! outlined! above,! results! in! high! local!
concentrations.! ! The! impact!of!this!change! is! impaired!differentiation!and!decreased!
apoptosis,!promoting!cell!survival.!
Progesterone! resistance! has! also! been! demonstrated! in! the! luteal! phase! of! the!
menstrual! cycle! of! those! with! endometriosis.(30)! ! In! a! gene! expression! analysis! an!
incomplete!transition!from!the!proliferative!to!early!secretory!phase!was!demonstrated,!
resulting!in!a!phenotype!more!suited!to!cellular!survival.!!A!blunting!of!the!progesterone!
induced!reduction!of!mitosis!was!also!seen.!!The!impact!of!these!changes!is!impaired!
differentiation!and!decreased!apoptosis;!promoting!cell!survival!and!implantation!of!any!
refluxed!endometrial!cells.!!!!
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Angiogenesis)
The!pelvic!peritoneum!is!one!of!the!most!common!sites!for!endometriotic!lesions!but!is!
relatively!avascular.!!For!an!endometrial!deposit!to!thrive!and!proliferate!at!an!ectopic!
site,!such!as!the!peritoneum,!new!blood!vessel!growth!must!be!promoted.!!It!is!this!new!
growth! that! creates! the! typical! red! lesions!within! the! peritoneum.! ! This! process! of!
angiogenesis!is!often!accompanied!by!neuroUangiogenesis!at!those!peritoneal!lesions!
resulting!in!increased!nerve!supply,!which!contributes!to!the!pain!symptoms!associated!
with!the!disease.(20)!
The! inflammatory! cytokines! ILU8! and! tumor! necrosis! factorU$! (TNFU$)! promote!
adhesion,!proliferation!and!angiogenesis.!!In!addition!vascular!endothelial!growth!factor!
(VEGF)!is!consistently!detected!at!high!concentrations!in!the!peritoneal!fluid!of!women!
with!endometriosis.(31)!!The!level!of!expression!appears!to!correlate!with!the!stage!of!
disease! and! is! abundant! in! the! glandular! tissue! of! peritoneal! implants! and!
endometriomas.!!VEGF!expression!appears!to!be!under!the!control!of!oestradiol(32)!so!
the!aberrant!local!oestradiol!levels!described!above!are!likely!to!promote!angiogenesis!
through!VEGF!upregulation.!
1.2.3! Immune(dysfunction(
Immune!dysfunction!appears!to!play!a!role!in!endometriosis!and!may!help!to!explain!
why!the!disease!becomes!established!in!some!women!and!not!in!others!and!may!also!
be! the! key! to! why! the! disease! is! cleared! by! some! individuals! but! in! others! rapid!
progression!is!seen.!!The!exact!involvement!of!the!immune!system!remains!incompletely!
understood!but!aspects!of!both!the!innate!and!adaptive!systems!are!involved.!
Inflammation)
Endometriosis! is! an! inflammatory! condition! and! neutrophils! and! macrophages! are!
recruited! in!response!to!this! inflammation.(33)! ! The! inflammatory!response! is!key!to!
many!of!the!clinical!features!of!the!disease!and!the!subversion!of!the!normal!response!
to! inflammation! appears! to! play! a! role! in! the! pathogenesis! of! endometriosis.! ! The!
recruitment! of! macrophages! promotes! the! production! of! proUinflammatory! and!
chemotactic!cytokines,!as!well!as!the!angiogenic!factors!ILU8,!TNFU$!and!VEGF,!described!
above.(7)!
!
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In! addition! to! macrophages,! neutrophils! appear! to! be! important.! ! The! life! span! of!
neutrophils! in! endometriosis! seem! to! be! extended! and! antiUapoptotic! factors! in! the!
peritoneal!fluid!of!endometriosis!patients!appear!to!contribute!to!that!longevity.!!This!
contributes!to!the!proUinflammatory!environment!and!promotes!the!establishment!and!
persistence!of!ectopic!foci!of!endometrium.(34)!!
Cytokine! dysregulation! is! also! a! component! part! of! immune! dysfunction! in!
endometriosis.! ! The!proUinflammatory! cytokines!U! interleukinU1! (ILU1),! tumor!necrosis!
factor! alpha! (TNFU$),! interferon! gamma! (IFNU%),! granulocyteU! macrophage! colonyU
stimulating!factor!(GMUCSF),!and!the!antiUinflammatory!cytokines:!ILU4,!ILU6,!and!ILU10,!
are!all!upregulated!in!individuals!with!endometriosis.!!The!innate!immune!system!is!in!a!
very! fine! balance! and! disturbing! the! inflammatory! signalling! mechanisms! tends! to!
promote!a!proUinflammatory!state!and!enables!ectopic!endometrial!cells!to!persist.(7)!
NK)cell)dysfunction)
Refluxed!endometrial!tissue!that!reaches!the!pelvis!should!be!cleared!by!the!immune!
system,!but!this!clearance!appears!to!be!impaired!in!endometriosis.!!Studies!looking!at!
the!eutopic!endometrium!in!endometriosis!have!shown!that!the!endometrial!cells!are!
more! resistant! to! NKUcell! lysis.(35)! ! The! release! of! secretory! factors! from! the!
endometrial! stromal! cells! appears! to! be! behind! this! dysfunction! and! is! likely! to! be!
contributed! to! by! macrophage! dysfunction.(36)! ! One! factor! that! appears! to! be!
implicated!in!this!process!is!intercellular!adhesion!molecule!1!(ICAMU1)!that!is!secreted!
by! endometrial! cells! to! create! an! immune! privileged! environment! at! ectopic!
endometrial!sites.(37)!
Adaptive)immune)dysfunction)
Cell! mediated! immunity! also! appears! to! be! altered! in! endometriosis.! ! Ordinarily,!
cytotoxic! TUcells! are! responsible! for! clearance! of! abnormal! cells! and! cells! containing!
intraUcellular!parasites.!!Their!action!is!promoted!by!Th1!TUhelper!cells,!whereas!Th2!TU
helper! cells!promote!BUcell! activation!and!antibody!production! in! response! to!extraU
cellular!pathogens.!!However,!in!endometriosis!the!balance!of!TUhelper!cells!favours!Th2!
TUhelper!cells,!in!response!to!high!levels!of!ILU4.!!This!causes!high!levels!of!antibodies!to!
endometrial!cells!–!a!response!that!is!ineffectual!against!ectopic!endometrial!cells.!!This!
antibody!response!may!explain!why!women!with!endometriosis!have!higher!rates!of!
miscarriage!and!implantation!failure.(7)!
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1.3! CLINICAL"FEATURES"
The! clinical! features! of! endometriosis! are! painful! menstruation! (dysmenorrhoea),!
persistent! pelvic! pain! (nonUmenstrual! pelvic! pain),! pain! during! intercourse!
(dyspareunia),! ovulation! pain,! pain! and! difficulty! passing! stool! (dyschezia),! pain! on!
passing!urine!(dysuria),!chronic!fatigue,!and!subfertility.(6)!!The!cyclical!response!of!the!
ectopic!endometrium!to!endogenous!sex!steroids!and!paracrine!signalling!causes!the!
chronic!inflammatory!response,!described!above.!!The!inflammatory!milieu!of!cytokines!
and!prostaglandins!are!responsible!for!stimulating!nerves!within!the!pelvis!and!explain!
the!localised!pain!and!dysmenorrhea,!as!well!as!promoting!a!neuropathic!component!to!
the! pain! symptoms.! ! As! this! inflammatory! process! progresses! the! development! of!
adhesions!and!peritoneal!scarring!cause!further!pain!by!limiting!the!free!movement!of!
the! intraUabdominal! viscera.! ! It! is! not! completely! clear!whether! the! development! of!
deeply! infiltrating! lesions! and! endometriomas! are! a! progression! of! this! chronic!
inflammatory!process!or!are!a!separate!biological!entity.!!
Unfortunately,!the!combination!of!chronic!inflammation,!adhesion!formation,!uterine!
and!Fallopian!tube!dysfunction!and!iatrogenic!damage!during!surgical!management!of!
endometriosis! can! lead! to! either! primary! or! secondary! infertility.! ! This! problem! is!
exacerbated! by! the! fact! that! endometriosis! is! often! found! with! concomitant!
adenomyosis!making!assisted!reproductive!techniques!less!effective.(38,39)!!
Endometriosis!is!considered!to!exist!in!three!clinically!distinct!forms:!peritoneal!disease,!
endometriomas!and!deeply!invasive!disease.(4)!!Peritoneal!endometriosis!presents!as!
deposits!or!implants!over!the!peritoneal!surfaces!of!the!pelvis!and!abdomen!as!well!as!
the!surface!of!the!ovaries.!!Whereas!endometriomas!are!cysts!within!the!ovarian!tissue,!
lined!with!endometrioid!mucosa!that!develop!a!pseudoUcapsule!of!compressed!ovarian!
tissue! around! them.! The! final! subtype! of! endometriosis! presents! as! a! solid!mass! of!
fibromuscular! tissue,! often! found! between! the! vagina! and! rectum! (rectoUvaginal!
nodules),!and!tends!to!be!identified!on!magnetic!resonance!imaging!(MRI)!of!the!pelvis.!!
Whether!these!three!types!of!disease!are!separate!entities!or!represent!a!continuum!of!
the!same!pathological!process!remains!to!be!fully!elucidated.!!However,!current!thinking!
is!that!deeply!invasive!endometriosis!(DIE)!and!rectoUvaginal!disease!may!represent!a!
separate!subtype!that!can!be!completely!eradicated!with!extensive!excisional!surgery!U!
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although!such!surgery!carries!with! it!greater!risks,! it!often!produces!better!symptom!
resolution.!!
1.4! DIAGNOSTIC"PATHWAY"
1.4.1! History(and(clinical(examination(
The! presence! of! the! three! classic! symptoms! of! dysmenorrhoea! [OR! 8.1! (7.2–9.3)],!
cyclical! abdominopelvic!pain! [OR!5.2! (4.7–5.7)]!and! dyspareunia/postUcoital!bleeding!
[OR!6.8!(5.7–!8.2)]!are!common!in!endometriosis,!although!the!lack!of!these!symptoms!
does!not!exclude!the!diagnosis.!!Other!frequently!found!symptoms!are!heavy!menstrual!
bleeding![OR!4.0!(3.5–4.5)],!infertility![OR!8.2!(6.9–9.9)],!and!urinary!tract!symptoms![OR!
1.2!(1.0–1.3)].!!The!ESHRE!(European!Society!of!Human!Reproduction!and!Embryology)!
guidance!on!the!management!of!endometriosis!recommend!that!the!diagnosis!should!
be!considered!in!those!presenting!with!nonUgynaecological!symptoms!such!as!dyschezia,!
dysuria,!haematuria,!rectal!bleeding,!shoulder!pain,!and!also!that!a!previous!diagnosis!
of!irritable!bowel!syndrome![OR!3.5!(3.1–3.9)]!or!pelvic!inflammatory!disease![OR!5.9!
(5.1–6.9)]!is!suggestive!of!disease.(3,40)!
Clinical!examination!can!be!useful!to!aid!the!diagnosis!but!the!history!taken!from!the!
patient! is! far! more! valuable.! ! In! some! circumstances,! pelvic! examination! is! not!
appropriate!but!where!possible!it!should!be!performed!for!two!reasons.!!It!is!useful!for!
localising! disease,! particularly! nodules! over! the! uterosacral! ligaments! and! in! the!
rectovaginal!septum,!and!it!can!help!guide!the!most!appropriate!imaging!investigation.!!
The!diagnostic!and!management!pathway!recommended!by!NICE!is!illustrated!in!Figure!
1.1.(41,42)
!
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!!
Figure'1.1" Endometriosis"management"pathway"
The#initial#management#pathway#based#on#the#2017#NICE#Guidance#on#the#diagnosis#and#
management#of#endometriosis#(reproduced#with#permission).(41)!
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1.4.2! Imaging(&(preQsurgical(investigation(
The! use! of! investigations! in! the!management! of! endometriosis!must! be! considered!
carefully,!as!the!tools!available!each!have!limitations!and!should!be!arranged!based!on!
the!clinical!suspicion.!!The!most!commonly!used!investigation!is!ultrasound!but!in!some!
cases!MRI,!sigmoidoscopy!and!cystoscopy!are!needed.!!These!are!vitally!important!as!
part! of! the! preUoperative! planning,! particularly! when! considering! excisional!
management!of!disease.!
USS)
Any! patient! with! a! suspected! adnexal! mass! on! clinical! examination! should! have! a!
transvaginal!ultrasound!(TvUSS)!and!its!use!is!recommended!by!ESHRE!as!the!tool!for!
excluding! endometriomas! if! there! is! uncertainty.(3)! !Unfortunately! TvUSS! cannot! be!
used! reliably!to! identify!peritoneal!or!deeply! invasive!endometriosis! (DIE)!within! the!
Pouch! of! Douglas! (POD)! or! rectoUvaginal! septum.! ! Depending! on! the! skills! of! the!
operator,!some!information!can!be!obtained!about!adhesions!and!fluid!filled!pockets!
within!the!peritoneum,!but!these!features!are!not!unique!to!endometriosis!and!so!are!
not!diagnostic.!!
MRI)
Magnetic! resonance! imaging! (MRI)! is! increasingly! used! in! the! evaluation! of! deeply!
invasive! endometriosis! (DIE).! ! Current! guidance! states! that!MRI! is! not! of! value! for!
assessing! peritoneal! disease! location! and! severity! (diagnostic! sensitivity! of! 38%! and!
specificity! of! 74%)(43)! but! it! is! useful! in! assessing! the! extent! and! depth! of! DIE,!
particularly! in! the! rectoUvaginal! septum! and! paraUrectal! space,! or! when! ureteric!
involvement!is!suspected.!!MRI!is!also!of!value!in!assessing!ovarian!endometriomas!or!
haematosalpinx! if! TvUSS! imaging! is!unclear!or! suspicious! features!are! identified! that!
require!further!evaluation!prior!to!surgery.!!!
Sigmoidoscopy)&)Cystoscopy)
Evaluation!of!the!bladder!and!bowel!is!necessary!if!a!patient!presents!with!dysuria!or!
dyschezia!symptoms.!!The!depth!of!invasion!can!be!assessed!using!MRI!but!visualisation!
of! the! lesions! by! the! operating! surgeon! prior! to! excision! allows! appropriate! preU
operative!planning!and!ensures!the!appropriate!multidisciplinary!team!and!equipment!
are!available!at!the!time!of!surgery.!!This!maximises!the!extent!of!surgery!that!can!be!
offered!whilst!minimising!the!risks!to!the!patient!as!much!as!possible.!
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1.4.3! Diagnostic(laparoscopy(
The!gold! standard! investigation! is!a!diagnostic! laparoscopy!with!biopsies! to!obtain!a!
histological! diagnosis.! ! At! the! procedure,! the! peritoneum! should! be! thoroughly!
inspected,! the! gynaecological! organs! assessed! and! the! appendix! visualised.!!
Unfortunately,!this!is!an!invasive!investigation!and!carries!with!it!risks!of!serious!harm.!!
As!such!it!is!common!practice!to!treat!the!disease!empirically!with!medical!suppression!
rather! than! performing! surgery.(3)(6)! ! There! is! limited! evidence! to! ascertain! the!
importance!of!histological!confirmation!of!disease.!!The!ESHRE!guidance!suggests!that!
as! a! good! practice! point! visual! inspection! should! be! accompanied! by! histological!
confirmation.! ! However,! they! concluded! that! whilst! positive! histology! confirms! the!
disease,!negative!histology!does!not!exclude!it.!
Laparoscopic)appearance)
Peritoneal! disease! is! described! as! either! clear,! red,! white! or! blue/black.! ! Initially,!
microscopic!deposits!of!cells!cause!a!tissue!reaction!that!leads!to!the!accumulation!of!
inflammatory!exudate!and!peritoneal!fluid!within!a!clear!bleb!on!the!peritoneal!surface!
(clear!endometriosis).!!In!response!to!progesterone!withdrawal!during!the!ovarian!cycle,!
endometrial!cells!within!a!deposit!can!prompt!an!inflammatory!response!and!bleeding!
at!the!ectopic!site,!and!the!deposit!becomes!red! in!colour! (red!endometriosis).! !This!
appearance!is!usually!considered!to!be!active!endometriosis,!which!is!more!likely!to!be!
causing!symptoms.!!Some!of!these!deposits!appear!to!burn#out!and!resolve!to!become!
an!area!of!white!scar!tissue!(white!endometriosis),!which!is!often!inactive!and!is!thought!
to!be!less!likely!to!be!a!cause!for!pain.!!However,!this!scarring!reaction!is!often!seen!in!
association!with!adhesion!formation,!peritoneal!pocketing!and!tethering!of!the!pelvic!
anatomy,!which!can!often!hide!more!active!disease!and!may!be!associated!with!pain!
symptoms!in!patients!with!endometriosis.!
Unfortunately,! some!deposits! seem!to!become!more!persistent!and!deeply! invasive.!!
Whether! this! is! proliferation! of! refluxed! endometrial! cells! and! a! progression! of!
peritoneal!disease!or!cells!of!a!different!embryological!origin!is!unknown,!as!discussed!
previously.! ! These! deposits! tend! to! take! on! a! blue! or! black! colour! (blue/black!
endometriosis)! and! can! often! contain! small! collections! of! haemosiderin! and! altered!
blood.! ! There! tends! to!be!a!greater! tissue! reaction!around! these!deposits!and!more!
!
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distortion! of! the! peritoneum.! ! As! such,! excision! of! such! deposits! rather! than! tissue!
destruction!with!laser!or!electrocautery!is!considered!more!appropriate.!
Endometriotic!cysts!within!the!ovary!(endometriomas)!have!a!typical!bluish!appearance!
and!contain!dark!altered!blood!that!has!a!deep!brown!colour,!as!such!they!are!often!
referred! to! as! chocolate# cysts.! ! These! can! occur! bilaterally! and! prompt! a! significant!
inflammatory!response!that!promotes!adhesion!formation!to!the!pelvic!sidewall,!uterus!
and! to! the! contralateral! ovary,! resulting! in! complete! obliteration! of! the! Pouch! of!
Douglas.!!These!findings!are!referred!to!as!kissing#ovaries!and,!as!a!severe!form!of!the!
disease,!are!likely!to!require!surgical!management!to!achieve!good!symptom!relief.!
Surgical)risks)
A!diagnostic! laparoscopy!may!be!considered!by!some!as!an! intermediate!procedure,!
particularly!if!no!surgical!excision!is!being!planned.!!However,!it!does!require!entry!into!
abdominal!cavity,!establishment!of!a!pneumoperitoneum!and!general!anaesthesia!with!
muscle!relaxation.!!As!such,!it!can!be!considered!a!major!operation!and!carries!with!it!
risks.!!These!are!discussed!in!detail!in!Section!5.5.2.!
Minimising)reliance)on)diagnostic)laparoscopy)))
The! current! consensus! opinion! from! international! groups! such! as! the! World!
Endometriosis! Society! (WES)! and! Society! for! Endometriosis! and! Uterine! Disorders!
(SEUD)! is! that! surgical! management! should! be! used! sparingly! and! that! diagnostic!
laparoscopies!should!become!less!necessary!by!relying!more!on!clinical!evaluation!and!
appropriate!imaging.(6)!
1.4.4! Clinical(staging(and(classification(
The! American! Society! for! Reproductive! Medicine! (ASRM)! revised! classification! of!
endometriosis! is! widely! used! in! both! a! research! and! clinical! setting.! ! It! provides! a!
standardised!method!for!recording!endometriotic!disease!and!assigns!scalar!values!to!
disease!status.! !The!scoring!and!staging!of!disease!was!intended!for!use!as!a! fertility!
prediction! tool! and! to! assess! the! probability! of! pregnancy! following! treatment! of!
disease.(44)!!Unfortunately,!it!is!not!designed!to!assess!pain!and!correlates!poorly!to!the!
symptoms!experienced!by!patients.!
An! international! meeting! of! scientists! and! clinicians! was! arranged! by! the! National!
Institutes!of!Health!(NIH),!in!collaboration!with!the!American!Society!for!Reproductive!
!
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Medicine!(ASRM)!to!discuss!classification,!entry!criteria!and!outcome!measure!in!clinical!
trials!in!endometriosisU!the!“Art!and!Science!of!Endometriosis”!meeting.!!They!focused!
on!pain!assessment!and!the!tools!used!to!objectively!record!changes!in!endometriosis!
symptoms.(45)!!The!consensus!statement!–!‘Pain!scoring!in!endometriosis:!entry!criteria!
and!outcome!measures!for!clinical!trials’,!produced!by!this!group!was!approved!by!the!
Special!Interest!Group!on!Endometriosis!of!the!ASRM!and!European!Society!for!Human!
Reproduction! and! Embryology! (ESHRE).! ! Such! consideration! in! the! design! of! future!
clinical!trials!is!becoming!accepted!amongst!endometriosis!researchers.(46)!
Biberoglu)and)Behrman)(B&B))scale)
The! Biberoglu! and! Behrman! (B&B)! scale(47)! is! used! in! an! inconsistent! manner! in!
research!studies,!has!never!been!validated!or!been!shown!to!be!reproducible.!!It!is!also!
of! limited!use!clinically!and!the!component!parts!of!the!scale!are!often! included! in!a!
standard!clinical!assessment.!!However,!it!is!a!wellUestablished!assessment!tool!and!is!
commonly!used!in!a!research!setting.!
ASRM)classification)
The!ASRM! classification!was! presented! by!Paolo!Vercellini! at! the!Art! and! Science! of!
Endometriosis! meeting,! including! his! published! metaUanalysis! of! 1054! consecutive!
patients!undergoing!surgery!for!endometriosis!between!1996!and!2002.!!He!concluded!
that! the! classification! stage! is! not! predictive! of! postUoperative! results! or! symptom!
recurrence.! ! However,! the! conclusion! of! the! group!was! that! the!ASRM! classification!
should!still!be!used!at!baseline!for!the!classification!of!disease.!
1.5! CLINICAL"MANAGEMENT"
1.5.1! Conservative(management(
NonUsteroidal!antiUinflammatory!drug!(NSAID)!therapy!with!the!addition!of!paracetamol!
and!weak!opiates!such!as!codeine,!can!be!very!effective!and!are!used!to!good!effect!in!
primary!care.(48)!!This!approach!is!effective!for!symptom!control!but!is!unlikely!to!have!
a!significant!effect!on!disease!progression.! !The!disadvantages!of!NSAID!use!are!side!
effects!such!as!peptic!ulceration!and!ovulation!inhibition!as!well!as!the!fact!that!their!
use! is! contraindicated! in! patients!with! poorly! controlled! asthma.! ! The! use! of! opiate!
analgesia,!even!weak!opiate!drugs!such!as!codeine,!carries!with!it!a!risk!of!dependence!
and!side!effects!such!as!constipation.!
!
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Although!not!a!popular!choice!and!one!that!may!increase!the!risk!of!disease!progression,!
some!patients!choose!to!manage!their!symptoms!conservatively!using!analgesia!either!
regularly!or!on!an!as#needed!basis.!!This!approach!tends!to!be!favoured!by!those!who!
do!not!tolerate!hormonal!treatments!and!those!wishing!to!start!a!family.!!It!is!often!the!
patients!in!whom!fertility!is!the!primary!concern!that!struggle!with!the!difficult!decision!
between!managing!pain!symptoms!versus!the!desire!for!children.!
1.5.2! Medical(management(
As!endometriosis!is!an!oestrogenUdependent!and!oestrogen!driven!disease,!hormonal!
manipulation!and!suppression!of!oestrogen!production!form!the!basis!of!much!of!the!
medical! treatments.! ! Initially,! hormonal! manipulation! is! trialed! with! a! simple!
contraceptive!agent!such!as!the!combined!oral!contraceptive!pill!(COCP)!(as!licensed!or!
triUcycled!to!minimise!menstrual!bleeding!time)!or!a!progesterone!only!pill!(POP),!which!
inhibits!ovulation.!!Although!concerns!have!been!expressed!that!oestrogen!within!the!
COCP!could!aggravate!the!disease!by!suppressing!progesterone!production!or!opposing!
its! action,! this! has! not! been! supported! by! studies! or! indeed! in! clinical! practice.! In!
addition!to!improving!dysmenorrhoea,!nonUmenstrual!pelvic!pain!and!dyspareunia(3);!
the! COCP! is! also! particularly! valuable! for! minimising! endometrioma! recurrence!
rates.(49)!
This!first!line!management!can!be!initiated!empirically!without!a!confirmed!diagnosis,!
which!minimises!any!delay!between!treatment!and!diagnosis!and!helps!to!avoid!the!cost!
and!potential!morbidity!of!invasive!surgical!investigation.!If!a!patient!fails!to!respond!or!
their! symptoms! progress! after! a! period! of! effective! symptom! control,! laparoscopic!
confirmation!is!required!before!pursuing!second!line!medical!therapy.!!This!approach!is!
promoted!by!the!European!Society!of!Human!Reproduction!and!Embryology!(ESHRE)(3),!
reflecting!the!findings!of!the!2009!Cochrane!review!showing!there!was!no!difference!in!
pain! management! outcome! between! the! oral! contraceptive! pill! and! GnRH!
analogues.(50)!!
Second! line! medical! therapy! usually! consists! of! continuous! progesterone! provision!
either!as!the!levonorgestrel!intraUuterine!system!(LNGUIUS!(Mirena®)),!continuous!oral!
norethisterone! (NET),! an! etonogestrel! implant! or! depot! injections! of!
medroxyprogesterone!acetate!(MPA).(51)!!These!tend!to!be!used!following!confirmation!
of! the! diagnosis! at! laparoscopy! but! in! certain! circumstances! they! can! be! used!
!
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empirically.! ! The!Mirena®! has! quite! variable! effectiveness! but! is! very! successful! for!
certain! groups! of! patients,! such! as! those! with! dysmenorrhoea! predominant!
endometriosis!or!concurrent!adenomyosis.!
Although!not!all! these!forms!of!continuous!progesterone!have!been!considered,!two!
Cochrane! reviews! have! demonstrated! that! medroxyprogesterone! acetate! is! more!
effective!for!symptom!control!than!placebo;!with!the!most!recent!review!reporting!a!
Peto!OR!of!3.00!(99%!CI!1.70!to!5.31,!two!studies,!n=!204,!I2!=!22%)!for!the!number!or!
women! achieving! a! greater! than! 50%! reduction! in! visual! analogue! scale! pain! score!
immediately!after!MPA!treatment.(52,53)!!
If! these! second! line!treatments!are! ineffective,! treatment!may!progress! to! complete!
suppression!of! the!hypothalamicUpituitaryUovary!(HPO)!axis!with!a!GnRH!agonist.(54)!!!
This!approach!has!been!compared!headUto!head!with!progestogen!and!been!shown!to!
be!associated!with!a!greater!improvement!in!pelvic!pain!score!(MD!3,!95%!CI!2.08!to!
3.92,! one! study,! n=47).(53)! ! The! removal! of! oestrogenic! stimulation! using! GnRH!
analogues! is! often! effective! but! carries! a! high! treatment! burden.! ! The! associated!
menopausal! symptoms!and!osteoporosis! risk!mean! that! long! term!use! is! limited.! !A!
Cochrane!review!on!the!use!of!GnRH!analogues!in!2009!suggested!the!use!of!add!back!
hormone!replacement!therapy!(HRT)!as!a!routine!to!counter!these!side!effects.(55)!!
The!ESHRE!guidelines!recommend!the!use!of!hormonal!contraceptives,!progestogens,!
antiUprogestogens,!or!GnRH!agonists!as!they!reduce!endometriosis!pain.(3)!!There!is!no!
specific!guidance!as!to!the!sequence!in!which!they!should!be!trialed!or!the!duration!of!
treatment,!and!no!clear!evidence!exists!to!demonstrate!which!is!more!effective.!!!This!
stepwise,! threeUtiered! approach! to! medical! therapy! is! useful! but! it! is! important! to!
remain!flexible!when!planning!treatment!and!consider!patient!preference,!side!effect!
profiles!and!costs.!
Hormonal! therapies! are! not! suitable! for! every! patient! and! often! a! combination! of!
ineffective! symptom! control,! progressive! symptoms,! intolerance! of! side! effects! or!
contraindications! limit! their! use.! It! is! quite! common! for! patients! to! find! they! have!
exhausted!the!medical!options!and!so!are!left!considering!a!surgical!solution.!
!
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1.5.3! Surgical(management(
Surgical! management! is! considered! when! first! line! medical! therapy! is! ineffective,!
disease! appears! to! have! progressed! despite! medical! therapy! or! clinical! assessment!
indicates!severe!disease!such!as!deeply!invasive!endometriosis!(DIE)!of!the!rectovaginal!
septum!and!uterosacral!complex!or!large!endometriomas!that!are!unlikely!to!respond!
to!medical! treatment.! ! In! situations!where! surgery! is! required! to!make! a! diagnosis!
laparoscopic! removal!of!endometriosis! should!be!considered!at! that! surgery.(56)! ! !A!!
Cochrane!review! in!2014!highlighted!that! laparoscopic!surgery! resulted! in!decreased!
pain!when!compared!to!diagnostic! laparoscopy;!both!at!six!months!(OR!6.58,!95%!CI!
3.31!to!13.10,!3!RCTs,!171!participants,!I2!=!0%)!and!at!twelve!months!(OR!10.00,!95%!CI!
3.21!to!31.17,!1!RCT,!69!participants).(57)!
There!is!worldwide!consensus!that!excision!is!preferable!to!ablation!but!RCTs!have!not!
demonstrated! a! benefit! from! excision.(58)! ! Overall,! laparoscopic! excision! of!
endometriosis!is!more!effective!than!placebo!at!reducing!pain!and!improving!quality!of!
life!but!surgery!is!ineffective!in!20%!of!patients!and!there!is!a!30%!placebo!response!rate!
from!surgery!so!it!has!its!limitations.(59)!!It!should!also!be!noted!that!any!surgery!carries!
with!it!operative!risks!and!patients!must!be!fully!informed!of!those!risks!prior!to!making!
a!decision!about!surgical!management.!
The! ESHRE! guidelines! suggest! that! complete! excision! of! disease! is! important! when!
managing!deeply!invasive!disease!and!endometriomas!as!it!results!in!better!pain!relief.!
Performing! an! ovarian! cystectomy! also! helps! reduce! the! risk! of! recurrence! when!
compared!to!drainage!and!fulguration.!!In!the!case!of!DIE,!surgery!should!be!completed!
by!a!surgeon!with!the!appropriate!laparoscopic!skills!as!complete!excision!offers!better!
pain! control! than! less! extensive! surgery! coupled! with! postUoperative! hormonal!
suppression!using!GnRHa!therapy.(3,60)!!The!surgical!expertise!of!the!operator!is!key!to!
successful! surgical! management! as! there! is! a! growing! acceptance! amongst!
endometriosis!specialists!that!a!single!extensive!operation!to!remove!all!DIE!is!curative.!!!!!!
Unfortunately,! it! should! also! be! noted! that! there! is! a! significant! postUoperative!
recurrence! rate! U! 10! to! 55%! within! 12! months.(61)! ! The! risk! of! recurrence! can! be!
ameliorated!using!simple!medical!treatment!such!as!the!progesterone!only!pill! in!the!
immediate!postUoperative!period,!which!can!be!continued!longerUterm,!dependent!on!
the!patient’s!fertility!wishes.!!!In!situations!of!recurrence!any!repeat!surgery!is!likely!to!
!
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be!less!effective!at!managing!pain!and!comes!with!greater!risk!of!morbidity!and!so!with!
diminishing!returns!from!repeated!surgery!a!greater!reliance!on!medical!treatment!is!
needed.(59)! ! Consequently,! there! is! a! clear! need! for! more! research! into! medical!
treatments,!in!particular!ones!in!which!the!side!effect!profile!is!more!tolerable!so!that!
longer!term!medical!treatment!can!be!considered.!
When!all!the!available!data!was!considered!in!an!overview!of!Cochrane!reviews!relating!
to!endometriosis!there!was!low!and!moderate!quality!evidence!for!GnRH!analogues!and!
the! levonorgestrelUreleasing! intrauterine! system! (LNGUIUS),! respectively,! when!
compared!to!placebo.!!However,!they!concluded!there!was!no!consistent!evidence!with!
respect!to!comparing,!oral!contraceptives!and!goserelin,!estrogen!plus!progestogen!and!
placebo,!or!progestogens!and!placebo.(62)!!This!lack!of!evidence!needs!addressing!with!
head!to!head!trials!of!medical!and!surgical!treatments!but!it!also!suggests!that!there!
may!be!a!place!for!new!treatments,!as!considered!below.!!!!!!
1.6! NEW"MEDICAL"TREATMENTS/EVALUATIONS"
PreHempt)
The!ESHRE!guidelines!do!not!support!the!use!of!postUoperative!medical!treatment!as!an!
adjunct!to!surgery!to!improve!pain!as!it!is!ineffective,!but!they!do!suggest!longUterm!use!
(>6!months)!can!be!helpful!for!secondary!prevention!of!disease.!!The!guidelines!do!not!
distinguish!between!the!COCP!and!LNGUIUS.!
The!PREUEMPT!Trial!(Preventing!Recurrence!of!Endometriosis!by!Means!of!long!acting!
Progestogen!Therapy!is!a!large!randomised!controlled!clinical!trial!of!women!undergoing!
surgery! for! endometriosis! in! which! subjects! will! be! given! long! acting! progestogens!
(either!as!threeUmonthly!injections!(depo!Provera)!or!as!a!progesterone!releasing!intraU
uterine!device,!or!longUterm!treatment!with!the!oral!contraceptive!pill!postUoperatively.!!
The!aim!of!the!study!is!to!provide!information!on!which!treatment!is!the!most!effective!
in!terms!of!symptom!relief,!sideUeffects,!acceptability!and!costs.!!This!study!is!eagerly!
awaited! as! it! will! provide! a! clearer! strategy! for! the! management! of! postUoperative!
patients.!
GnRH)antagonists)
The!use!of!GnRH!analogues!to!establish!a!hypoUoestrogenic!state!is!common!place!in!the!
management!of!endometriosis.! !The!issue!of!menopausal!type!side!effects!is!partially!
!
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resolved!using!addUback!HRT!but!some!patients!still!find!this!treatment!intolerable.!!The!
onEoff! nature! of! these! drugs! makes! fine! adjustment,! dependent! on! side! effects,!
impossible.! ! Therefore,! research! has! been! undertaken! to! explore!GnRH! antagonists,!
which! suppress! the! hypothalamicUpituitaryUovary! (HPO)! axis! sufficiently! to! relieve!
symptoms!without!giving!hypoUoestrogenic!side!effects.!!The!basis!behind!this!strategy!
is! the! oestrogen! threshold! hypothesis,! which! suggests! promotion! of! endometriosis!
requires!a!high!oestrogen!concentration!whereas!only!a!low!concentration!is!required!
to! ensure! normal! bone! metabolism! and! ameliorate! menopausal! side! effect!
symptoms.(63,64)!!It!is!hoped!that!by!dose!adjustment!of!GnRH!antagonists,!clinically!
useful! suppression! of! the! HPO! axis! will! be! achieved! without! dropping! below! the!
oestrogen!threshold.!
Two,!Phase!3!clinical!trials!have!been!completed!to!evaluate!the!efficacy!and!safety!of!
Elagolix!in!premenopausal!women!with!endometriosis.!!!The!results!were!presented!at!
the!72nd!American!Society!for!Reproductive!Medicine!Scientific!Congress!&!Expo!(ASRM)!
in!Salt!Lake!City!in!October!2016!and!are!encouraging.!!At!both!three!and!six!months,!
there!is!a!dose!dependent,!statistically!significant!reduction!in!dysmenorrhea!and!nonU
menstrual!pelvic!pain!when!compared!to!placebo.!!!!!
!
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Chapter"2:!HISTOPATHOLOGY"OF"THE"ENDOMETRIUM"
The!endometrium!is!an!important!part!of!the!functionality!of!the!uterus!and!is!a!key!
component!of!the!female!reproductive!system.!!The!response!of!the!endometrium!to!
the!hormonal!milieu!produced!by!the!hypothalamicUpituitaryUovarian!axis!determines!
the!menstrual!cycle,!provides!a!receptive!environment!for!an!early!developing!embryo!
and!forms!a!central!part!of!the!pathophysiology!of!endometriosis.!!An!understanding!of!
the!anatomy,!physiology!and!histopathology!of!the!endometrium!is!vital!when!exploring!
the! pathological! processes! involved! with! endometriosis! and! the! action! of! any!
pharmacological!interventions.!!
2.1! EMBRYOLOGY"
The!embryonic!development!of!the!uterus!from!intermediate!mesodermal!tissue!begins!
at!about!nine!weeks!of!life.!!As!the!ovary!descends!from!the!genital!ridge!to!just!below!
the!rim!of!the!true!pelvis,!the!cranial!portions!of!the!paramesonephric!ducts!develop!
into!the!uterine!tubes!and!the!caudal!parts!fuse!to!form!the!uterine!canal.!!The!fused!
paramesonephric!ducts!give!rise!to!the!corpus!and!cervix!of!the!uterus!and!then!also!
fuse!with!the!sinovaginal!bulbs!to!create!the!upper!vagina.!!The!corpus!of!the!uterus!is!
surrounded! by! mesenchymal! tissue! that! goes! on! to! form! the! myometrium! and!
peritoneal!covering.(65)!
2.2! ANATOMY"
The!uterus! is! a!hollow,!pearUshaped!organ,!measuring!approximately!9cm! long,!6cm!
wide!and!4cm!thick.!!It!is!made!up!of!three!layers:!the!outer!serous!layer!(peritoneum),!
the! middle! layer! of! smooth! muscle! (myometrium)! and! the! inner! glandular! layer!
(endometrium).!!The!myometrium!makes!up!the!bulk!of!the!uterine!tissue!and!consist!
of! interlacing! smooth! muscle! fibres,! connective! tissue,! blood! vessels,! nerves! and!
lymphatics.!The!endometrium!forms!the!inner!layer!but!is!not!sharply!separated!from!
the!myometrium!because!the!tubular!glands!and!associated!stromal!tissue!dip!down!
into!the!muscle!layer.(66)(67)!
!
!
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The!endometrium!is!made!up!of!abundant!endometrial!glands!which!are!surrounded!by!
stromal!tissue.!!The!density!of!this!stromal!tissue!is!determined!by!the!depth!from!the!
endometrial! surface.! ! The! deepest! tissue,! closest! to! the! myometrium,! is! called! the!
stratum# basalis! and! contains! dense! stromal! tissue.! ! This! layer! is! not! shed! during!
menstruation!and!allows!regeneration!of!the!endometrium!with!each!cycle.!!The!outer!
two!thirds!of!the!endometrium!contain!less!dense!stromal!tissue!(stratum#functionalis).!!
It!is!this!layer!that!demonstrates!morphological!differences!throughout!the!menstrual!
cycle!in!response!to!cyclical!production!of!sex!steroids!and!is!then!lost!at!menstruation.!!
There! is!no!anatomical!border! between! these! layers!but! they!are!differentiated!and!
defined!by!their!function!(Fig.!2.1).!!The!surface!of!the!endometrium!and!the!crypts!of!
the!individual!glands!are!covered!by!a!single!layer!of!continuous!columnar!epithelium.!
!
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!
Figure'2.1" Histology"of"the"uterine"wall"""
A# low# power# view#of# the# endometrium# demonstrating# abundant# endometrial# glands#
surrounded#by#stromal#tissue#in#two#morphologically#distinct#zonesE#stratum#basalis#and#
stratum#functionalis#(H&E)#(reproduced#with#permission).(68)#
!
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2.3! ENDOMETRIAL"PHYSIOLOGY"
The!cycle!of!proliferation,! secretion!and! shedding! seen! in! the!stratum# functionalis! is!
driven!by!the!hormonal!changes!of!the!hypothalamicUpituitaryUovarian!(HPO)!axis.!!It!is!
this! cycle! that! controls!menstruation! throughout! a!woman’s! reproductive! life! and! is!
often!the!focus!of!managing!benign!gynaecological!conditions!such!as!endometriosis.!
2.3.1! Endocrine(control(
Control!of!the!HPO!axis!is!initiated!by!pulsatile!production!of!gonadotrophin!releasing!
hormone!(GnRH).!!GnRH!is!a!decapeptide!that!is!released!by!2000U3000!neurons!found!
in!the!preUoptic!nuclei,!arcuate!nucleus!and!periventricular!nucleus!of!the!hypothalamus!
in! response! to! neural! input! from!higher! centres! in! the! brain.! ! The! frequency! of! this!
release!is!key!to!its!downstream!effect!and!it!is!through!alterations!in!pulsatility!that!
negative!feedback!is!achieved.!!The!natural!frequency!of!GnRH!release!is!once!every!60!
minutes! but! this! is! influenced! by! gonadotrophins,! oestrogen! and! progesterone.! ! At!
different!points!in!the!cycle!the!frequency!varies!between!>1!pulse/hour!and!<1!pulse!
every!2U3!hours,!with!these!frequencies! favouring!LH!(luteinising!hormone)!secretion!
and!FSH!(follicle!stimulating!hormone)!secretion,!respectively.(69)(70)!
The!GnRH!neurones!release!their!hormone!into!the!portal!vessels!supplying!the!anterior!
pituitary! (adenohypophysis).! ! In! the! anterior! pituitary! gland! GnRH! binds! to! a! GTP!
(guanosine! triphosphate)! linked! transmembrane! receptor! resulting! in! increased!
intracellular! Ca2+! and! activation! of! protein! kinase! C! and! cAMP! (cyclic! adenosine!
monophosphate).! ! These! intracellular! changes!promote!protein!phosphorylation!and!
result!in!the!following!cellular!responses:!
!! synthesis!of!gonadotrophins!ready!for!storage!
!! mobilisation!of!stored!FSH!and!LH!ready!for!release!
!! immediate!release!of!FSH!and!LH.!
InUvitro!studies!of!pituitary!cells!suggest!that!GnRH!is!not!required!for!the!release!of!
stored!LH!and!FSH!but!it!is!needed!to!maintain!the!synthesis!of!gonadotrophins.!!As!such,!
repeated!exposure!in!a!pulsatile!manner,!is!needed!to!ensure!adequate!pituitary!stores.!
Evidence!suggests!that!there!are!two!pools!of!gonadotrophins!within!adenohypophyseal!
cells;!a!pool!for!immediate!release!which!respond!to!pulsatile!GnRH!and!a!reserve!pool!
which!require!a!more!continued!stimulus!to!be!released.!!The!relative!size!of!these!two!
!
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pools! represent! the! pituitary! sensitivity! and! reserve,! respectively,! and! they! vary!
throughout!the!cycle.!!It!is!the!balance!of!these!two!pools!that!allow!GnRH!to!have!a!
selfUpriming!action,!as!it!promotes!transfer!of!gonadotrophins!from!the!reserve!pool!to!
the! immediately! releasable! pool.! This! ‘selfUpriming’! is! most! active! around! the! midU
cycle.(69)!!
In! the!early! follicular!phase! the!pulsatile!nature! of!GnRH! release! leads! to!a! similarly!
pulsatile!release!of!FSH!and!LH!from!the!anterior!pituitary.!!Follicle!stimulating!hormone!
acts!on!the!ovary!to!promote!follicle!recruitment!and!development.!!As!follicles!continue!
to! develop! oestrogen! levels! rise! and! this! has! negative! feedback! action! on! the!
hypothalamus!and!so!suppresses!the!release!of!further!FSH!and!LH!from!the!anterior!
pituitary.!!As!a!consequence!the!levels!of!gonadotrophins!within!the!pituitary!increase!
but!this!appears!to!have!the!greatest!effect!on!the!reserve!pool.(69)!
During!the!late!follicular!phase,!there!is!a!further!increase!in!oestradiol!secreted!by!the!
ovary!as! the!dominant! follicle!begins!to!grow!preferentially! in! response! to!paracrine!
signalling.! ! This! results! in! maximum! sensitivity! of! the! adenohypophysis! to! the! selfU
priming!action!of!GnRH,!which!is!contributed!to!by!a!slight!rise!in!progesterone!as!the!
granulosa!cells!of!the!dominant!follicle!begin!progesterone!secretion.!!This!heightened!
sensitivity!results!in!a!gonadotrophin!surge,!which!results!in!ovulation!35U44!hours!after!
the!onset!of!that!LH!release.(69)!!!!!
The!luteal!phase!of!the!cycle!is!characterised!by!an!increasing!level!of!progesterone.!!In!
the! late! luteal!phase,! there! is!progressive! reduction! in! sensitivity!and! reserve!of! the!
adenohypophysis,!which!persists!into!the!early!follicular!phase!of!the!next!cycle.!!This!is!
likely! to! be! related! to! decreasing! levels! of! oestrogen! and! progesterone! but! inhibin,!
released! by! the! ovary,! may! also! play! a! role.! ! This! pattern! of! hormonal! release! is!
illustrated!in!Figure!2.2.!
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Figure'2.2! Endocrine!changes!through!menstrual!cycle!!!
Changes(in(concentration(of(anterior(pituitary(and(ovarian(hormones(through(menstrual(cycle((reproduced(with(permission).(68)((
!
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2.3.2! Action(of(the(hormones(on(the(endometrium(
Hormonal! control! of! the! endometrial,! epithelial,! stromal,! and! presumably! the!
endothelial! cells! is!mediated! by! estrogen! receptors! and! progesterone! receptors.(71)!!
The! levels! of! oestrogen! and! progesterone! and! the! relative! balance! of! these! two!
hormones! determine! the! endometrial! response! throughout! the! ovarian! cycle.!!
Oestrogen!is!the!dominant!hormone!in!the!follicular!phase!of!the!ovarian!cycle!and!it!
has! a! proliferative! effect! on! the! endometrium.! ! In! the! luteal! phase,! progesterone!
production!increases!significantly!and!oestrogen!production!is!lower,!relatively,!so!the!
balance!of!hormones!is!towards!progesterone.!!This!causes!a!secretory!change!within!
the!endometrium!in!preparation!for!implantation.!
2.4! ENDOMETRIAL.HISTOLOGY.
The! histopathological! appearance! of! the! endometrium! is! influenced! by! the! above!
cyclical!changes!in!ovarian!hormones.!!The!balance!of!sex!steroids!influences!both!the!
glandular!epithelium!and!stroma!of!the!stratum'functionalis.! !As!such!the!histological!
appearance!can!be! used!as!a!guide! for!dating!human!endometrium!but! there! is! low!
inter0observer!agreement!and!so!this!cannot!be!completely!relied!upon.(72)(73)!!Seven!
morphologic!criteria!are!described!in!the!book!‘Pathologic!Basis!of!Disease’(67)!to!allow!
this!dating!process!to!occur:!
!! Gland' mitoses! 0! indicate! proliferation! and! are! increasingly! common! in! the!
proliferative!phase!of!the!cycle;!
!! Tortuosity' of' glands! 0! the! thickness! of! the! endometrium! reflects! gland!
development;! in! the! proliferative! phase! tortuosity! is! increased! gradually! in!
response!to!oestrogen!but! it!becomes!most!pronounced!during!the!secretory!
phase;!
!! Basal'vacuolation!0!is!taken!as!morphological!evidence!of!ovulation!and!occurs!
36!to!48!hours!after!ovulation;!
!! Secretion! 0!visible!secretion! is!seen!within!the!lumen!of!the!glands! in!the!mid!
portion! of! the! secretory! phase! and! towards! the! later! stages! becomes!
inspissated;!
!! Stromal'oedema!0!this!varies!between!individuals!in!the!proliferative!phase!and!
may! be! absent,! whereas! the! oedema! seen! in! the! secretory! phase! is! more!
consistent!and!uniform;!
!
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!! Predecidual'reaction!0!this!is!first!evident!around!arterioles!in!the!late!secretory!
phase!and!progresses!until!just!before!menstruation;!!!
!! Leucocyte' infiltration! 0! there! are! a! few! lymphocytes!within! the! endometrium!
throughout!the!cycle,!but!neutrophil! infiltration!begins!about!two!days!before!
the!onset!of!menstruation.!
2.4.1! Phases(of(development(and(histological(features(
Menstrual*
The!cycle!begins!with!the!menstrual!phase!when!the!stratum'functionalis! is!breaking!
down!and!being!shed.!!Disintegration!of!the!stratum'functionalis!and!escape!of!blood!
into!the!stroma!marks!the!beginning!of!this!process!at!the!end!of!the!secretory!phase!of!
the! previous! cycle.! ! The! histological! features! of! this! phase! are! glandular! exhaustion!
leading!to!gland!collapse!with!prominent!necrosis,!haemorrhage!and!intravascular!fibrin!
thrombi.(73)!
Proliferative*
This! phase! of! the! cycle! is! variable,! and! its! duration! is! the!main! determinant! of! the!
menstrual!cycle!length.!!Under!the!influence!of!FSH!and!oestrogen!there!is!rapid!growth!
of!glands!and!stroma!from!the!stratum'basalis!to!regenerate!the!stratum'functionalis.!!
This! rapid! cell! division! and! migration! from! the! stratum' basalis! layer! explains! the!
extremely!rapid!and!efficient!regenerative!properties!of!the!human!endometrium!seen!
after!the!necrosis!and!tissue!breakdown!of!menstruation.(71)!!This!proliferation!is!spilt!
into! early,! mid! and! late! phases! with! morphological! differences! seen! as! the! phases!
progress.!!!
In! the!early!proliferative!phase,! there!are!multiple! small,! regular!glands! (Figure!2.3).!!
These!are!short!and!straight! in!appearance!and!are!evenly!distributed!through!quite!
compact!stroma.!!!The!glandular!epithelium!is!thin!at!the!surface!with!occasional!areas!
of!pseudo0stratification!within!the!glands.!!The!nuclei!are!round!to!ovoid!in!shape!and!
there! are! occasional!mitotic! figures.! ! This! proliferation! seems! to! be! independent! of!
oestradiol,! and! immunohistochemical! staining! indicates! minimal! oestrogen! receptor!
(ER)!and!progesterone!receptor!(PR)!expression.(71)!!However,!the!deeper!tissues!of!the!
stratum'functionalis!are!more!likely!to!be!positive!suggesting!receptor!expression!and!
the!dependence!on!oestrogen!changes!as!proliferation!progresses.!!!
!
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Figure'2.3. Early.proliferative.phase.endometrium.(H&E)...
Early'proliferative'phase'endometrium'showing'slight'pseudo>stratification'of'nuclei'and'
occasional' mitotic' figures' (H&E)' (courtesy' of' PathologyOutlines.com' &' The' Global'
Library'of'Women’s'Medicine).(73)'
Progress! into! the!mid!proliferative!phase! is!associated!with!gland!growth! to!a!more!
elongated! form! and! greater! variation! in! the! associated! stroma.! ! Now,! there! are!
numerous!mitotic!figures!in!both!the!epithelium!and!stroma!reflecting!the!significant!
proliferation!of!the!tissues.!!This!is!demonstrated!using!immunohistochemical!staining!
for! Ki67,! a! proliferation! marker,! which! shows! widespread! staining! throughout! the!
epithelium! and! stroma! (Figure! 2.4).! ! In! addition,! ER! (oestrogen! receptor)! and! PR!
(progesterone!receptor)!expression! is! increased!and!more!uniform!in!the!mid!to! late!
proliferative! phase,! with! ER! expression! reaching! a! peak! in! the! mid0proliferative!
phase.(71)!!At!this!stage!no!vacuolation!or!secretion!is!seen.!
!
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Figure'2.4. Mid.proliferative.phase.endometrium.(IHC:.Ki67)...
Mid' proliferative' endometrium' stained' for' Ki>67' (proliferation' marker)' showing' the'
intensity'of'proliferative'activity,'particularly'within'the'glandular'epithelium''(courtesy'
of'PathologyOutlines.com'&'The'Global'Library'of'Women’s'Medicine).(73)'
In!the!late!proliferative!phase!subnuclear!vacuoles!begin!to!form!but!are!still!seen!in!less!
than!50%!of!the!glands.!!The!glands!become!more!tortuous!and!the!pseudo0stratification!
of!the!epithelium!is!more!apparent.!!Mild!oedema!can!be!seen!within!the!stroma!and!
the!surface!epithelium!becomes!more!undulant!in!nature.!
Ovulation*
Ovulation!occurs!at!the!mid0point!of!a!280day!cycle!and!does!so!in!response!to!a!surge!
of!LH.!!Proliferation!of!the!endometrium!ceases!and!the!secretory!phase!begins.!!The!
presence!of!subnuclear!vacuoles! in!more!than!50%!of!the!glandular!epithelial!cells! is!
taken!as!morphological!evidence!of!ovulation.!
!
!
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Secretory*phase*
The!secretory!phase!is!much!more!uniform!in!length!at!14!days!but!does!show!some!
variation.! ! During! this! phase! progesterone! inhibits! further! proliferation! and! induces!
secretory! activity! within! the! endometrial! glands.! ! Similar! to! the! proliferative! phase,!
secretion! is!spilt!into!early,!mid!and! late!phases!with!morphological!differences!seen!
with!each!phase.!
The!early!phase!is!associated!with!the!progression!of!the!subnuclear!vacuoles!towards!
the!luminal!surface!of!the!epithelial!cells.!!The!subnuclear!positon!of!the!vacuoles!give!
the!epithelium!a!‘piano!key’!appearance!around!day!16!(Figure!2.5)!and!the!glands!show!
minimal!proliferative!activity!as!evidenced!by!reduced!Ki67!staining!(Figure!2.6).!!By!day!
17!the!vacuoles!are!level!with!the!nuclei!and!then!by!day!18!have!reached!the!luminal!
aspect!of!the!cell,!such!that!the!nuclei!are!pushed!towards!the!base.!
!
Figure'2.5. Secretory.endometrium.(H&E)..
Subnuclear'vacuoles'(day'16)'giving'a'typical'‘piano'key’'appearance'to'the'glandular'
epithelium' (courtesy' of' PathologyOutlines.com' &' The' Global' Library' of' Women’s'
Medicine).(73)'
!
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Figure'2.6. Secretory.endometrium.(IHC:.Ki67)...
Day'17'endometrium' in'which' the'vacuoles' reach' the' level'of' the'nuclei' (courtesy'of'
PathologyOutlines.com'&'The'Global'Library'of'Women’s'Medicine).(73)'
In!the!mid!secretory!phase!secretions!are!discharged!into!the!gland!and!this!is!typically!
maximal!at!day!20021.!!The!glands!become!increasingly!tortuous!and!dilated!with!mucus.!!
Stromal!oedema!increases!throughout!this!phase!in!preparation!for!implantation,!with!
the!endometrium!at!its!most!receptive!on!day!22.!!Towards!the!end!of!this!phase!the!
arterioles!in!the!stroma!become!more!prominent.!!
Immunostaining! during! the! mid0secretory! phase! shows! stromal! staining! for! the!
proliferation! marker! Ki67! showing! that! cell! cycling! has! been! downregulated! in! the!
glandular!epithelium.!!The!epithelial!and!stromal!cells!are!both!positive!for!ER!staining,!
but!the!intensity!is!reduced!compared!to!the!proliferative!endometrium.!!The!PR!pattern!
is!similar!to!Ki67,!with!staining!confined!to!only!predecidual!stromal!cells.!
On!reaching!the!end!of!the!secretory!phase!the!glands!become!exhausted,!the!mucus!
become!inspissated!and!the!glands!begin!to!shrink.!!This!creates!a!serrated!pattern!to!
the! glands.! ! At! day! 23024! pre0decidual! changes! begin,! typically! in! the! perivascular!
!
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stroma;!increased!stromal!oedema,!stromal!cell!hypertrophy!(with!Ki67!immunostaining!
confined!to!stromal!cells!only)!and!accumulation!of!cytoplasmic!eosinophilia!mark!this!
change.!!Associated!with!this!there!is!a!non0inflammatory!infiltration!of!granulocytes,!of!
which!most!are!lymphocytes.!!!
At!day!27!the!infiltration!of!granulocytes!is!more!prominent,!and!areas!of!focal!necrosis!
develop.!!This!progresses!to!glandular!and!stromal!breakdown!with!prominent!necrosis!
and!haemorrhage!on!day!28.!
These!changes!are!summarised!in!Table!2.1.!!!
!
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DAY. PHASE. ENDOMETRIAL.FEATURES.
1. Menstrual! !! Disintegration!of!the!stratum'functionalis!and!escape!
of!blood!into!the!stroma!marks!the!beginning!of!
menstruation!
2.
3.
4. Proliferative'
'
(FSH'&'
oestrogen'
dependent)!
Early! !! Thin!surface!epithelium!!
!! Small,!straight,!short!and!regular!glands!
!! Glands!separated!widely!by!compact!stroma!
!! Slight!pseudo0stratification!
!! Occasional!mitotic!figures!
!! Round0to0ovoid!nuclei!
5.
6.
7.
8. Mid! !! Tall!columnar!epithelial!cells!
!! Longer!curving!glands!with!more!variable!stroma!!
!! Numerous!mitotic!figures! !
9.
10.
11. Late! !! Undulant!surface!epithelium!
!! Tortuous!glands!with!prominent!mitotic!activity!and!
pseudo0stratification!
!! Dense!stroma!with!mild!oedema!and!mitotic!figures!
!! Subnuclear!vacuoles!in!<50%!of!glands!
12.
13.
14.
15!
.
Secretory'
'
(oestrogen'&'
progesterone'
dependent)!
Ovulation!marks!the!beginning!of!the!secretory!phase!
0! subnuclear! vacuoles! in! ≥! 50%! of! glands! is! morphological!
evidence!of!ovulation!
16. Early! !! Prominent!subnuclear!vacuolation!
17. !! Vacuoles!reach!level!of!nuclei!
18. !! Vacuoles!reach!the!luminal!surface!and!so!the!nuclei!
approach!base!of!cell!
19. Mid! !! Intraluminal!secretion!begins!and!becomes!maximal!
at!day!20021!20.
21.
22. !! Stromal!oedema!is!maximal!in!preparation!for!
implantation!
23. !! Spiral!arterioles!become!prominent!
24. Late! !! Perivascular!pre0decidualisation!occurs!
0! stromal!cell!hypertrophy!with!accumulation!of!!!!!
cytoplasmic!eosinophilia!
!! Tortuous!glands!become!serrated!in!appearance!as!
they!begin!to!collapse!and!regress!
25.
26. !! Stromal!granulocytes!(mostly!lymphocytes)!begin!to!
appear!
27. !! Prominent!stromal!granulocytes!with!focal!necrosis!
28. !! Glandular!and!stromal!breakdown!with!prominent!
necrosis!and!haemorrhage!
Table'2.1' Histological'features'of'endometrium'through'menstrual'cycle'''
Number'of'days'in'each'phase'of'the'cycle'based'on'a'standard'cycle'length'of'28'days.!
!
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2.5! HISTOLOGY.OF.ENDOMETRIAL.PATHOLOGY.
There!are!several!conditions!where!the!usual!cyclical!changes!and!classic!proliferative!
and!secretory!patterns!of!the!endometrium!are!disturbed.!!These!are!described!below,!
along!with!their!histological!features.!!
2.5.1! Disordered(proliferation(
Disordered! proliferation! is! associated!with! anovulatory! cycles! and! is! common! in! the!
perimenopause.! ! It! results! from! unopposed! oestrogen! stimulation0! either! from! an!
exogenous!source!or!is!the!result!of!a!cycle!in!which!progesterone!stimulation!is!lacking!
in!the!second!half!of!the!cycle.!
The!histological!features!are!a!lack!of!uniformity!within!the!proliferative!endometrium!
with! some! glands! being! cystically! dilated! and! others! having! shallow! budding! but! a!
normal!gland!to!stroma!ratio.!!The!epithelial!cells!show!metaplastic!changes!and!become!
ciliated.!!There!is!associated!endometrial!breakdown!and!haemorrhage!despite!being!in!
the! proliferative! phase.! ! These! features! are! the! earliest! histological! changes! on! a!
continuum!with!endometrial!hyperplasia.(74)!
2.5.2! Endometrial(hyperplasia(
Endometrial!hyperplasia!is!the!presence!of!irregular!endometrial!glands!and!an!increase!
in!the!gland!to!stroma!ratio.!!It!is!the!result!of!prolonged!oestrogenic!stimulation!and!
can!be!classified!into!3!main!types;!simple,!complex!and!atypical.(75)(76)!!Although!most!
women!with!this!condition!do!not!develop!carcinoma,!atypical!hyperplasia!is!considered!
a! precursor! to! endometrial! carcinoma,! particularly! in! younger! women! and! those!
developing!well!differentiated!endometrioid!adenocarcinoma.(77)!
The! peak! incidence! is! seen! in! women! in! their! early! 50s! for! simple! hyperplasia!
(142/100,00!woman0years)!and!complex!hyperplasia!(213/100,!000!woman0years);!and!
then!in!their!early!60s!for!atypical!hyperplasia!(56/100,00!woman0years).(75)!!The!risk!
factors! for! development! of! hyperplasia! are! related! to! oestrogen! exposure! without!
appropriate! or! sufficient! progestin! to! counterbalance! that! oestrogen.! ! Endogenous!
oestrogen! exposure! results! from! conditions! such! as! chronic! anovulation,! obesity,!
diabetes!mellitus,!polycystic!ovarian!syndrome!(PCOS)!and!oestrogen!secreting!ovarian!
tumours.(78)! !Alternatively,!hormone! replacement! therapy! (HRT)!and! Tamoxifen!use!
provide!exogenous!oestrogen!in!some!women.!
!
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The!classification!of!endometrial!hyperplasia!has!been!the!focus!of!considerable!debate!
within!the!published!literature.!!There!are!four!different!systems!in!existence!but!the!
WHO!classification!and!the!endometrial!intraepithelial!hyperplasia!system!are!the!most!
commonly! considered.(76)(79)(78)! ! The! World! Health! Organisation! (WHO)! system!
classifies!endometrial!hyperplasia!according!to!four!combinations!of!glandular!crowding!
and!nuclear!atypia:!simple!hyperplasia!(SH),!complex!hyperplasia!(CH),!simple!atypical!
hyperplasia! (SAH),!or! complex!atypical!hyperplasia! (CAH),!although! the! two! forms!of!
atypical!hyperplasia!(AH)!are!often!considered!as!one!category!as!cellular!atypia!is!more!
sinister!than!changes!in!glandular!architecture.(76)!!The!problem!with!this!system!is!high!
intra0! and! inter! observer! variability! and! no! consensus! on! the! cytological! features! of!
atypia,!making! reproducibility! difficult.(80)! ! Another! concern! is! that! there! does! not!
appear!to!be!a!definite!stepwise!progression!from!simple!to!atypical!hyperplasia.!!As!
such! it!does!not! fully!meet! the!criteria! for!a! classification! scheme.! ! The!endometrial!
intraepithelial! hyperplasia! system! is! an! alternative! –! using!morphometric! data! from!
computer! image! analysis! to! classify! lesions! as! either! endometrial! hyperplasia! (EH),!
endometrial! intraepithelial!neoplasia! (EIN)!or! cancer.(78)! ! This! system!shows!greater!
reproducibility! amongst! pathologists! and! a! closer! correlation! to! clinical! outcome.!!
However,!either!of!these!two!classification!systems!can!be!used!and!considered!safe!
when!an!experienced!pathologist!is!available.(79)!
Simple*hyperplasia*
Simple!hyperplasia!is!characterised!by!minimal!endometrial!glandular!crowding!and!no!
cytological! atypia.! ! The! glands! are! usually! round! but! can! be! irregular! and! cystically!
dilated.!!The!epithelium!is!pseudostratified!or!mildly!stratified!with!occasional!mitotic!
figures! and! often! shows! ciliated! cell!metaplasia.! ! The! stroma! shows! variable!mitotic!
activity! and! uniformly! distributed! blood! vessels.! ! As! such,! it! can! have! a! similar!
appearance!to!disordered!proliferative!endometrium!leading!to!a!low!rate!of!diagnostic!
agreement!between!pathologists.(77)(80)!
The!risk!of!progression!to!endometrial!carcinoma!is!consider!to!be!low!(0.701.5%)(78).!!
These!changes!will!often!regress,!particularly!if!the!oestrogenic!stimulus!that!promoted!
them!remits.!
!
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Complex*hyperplasia*
Complex! hyperplasia! is! characterised! by! greater! endometrial! glandular! crowding,!
architectural! irregularity!and!bud0like!projections! seen! in! the!glands! (Figure!2.7).! !By!
definition,!normal!stromal!cells!are!present!between!the!glands.!!The!nuclei!are!uniform!
in! size! and! shape! and! the! cells! have! normal! polarity0! i.e.! there! is! no! cytological!
atypia.(77)!
This! condition! is! associated!with! an! intermediate! risk! of! progression! to! endometrial!
carcinoma!(309%).!It!is!managed!with!progesterone!therapy!in!pre0menopausal!patients!
with!hysterectomy!and!bilateral!salpingo0oophorectomy!considered!in!those!who!are!
post0menopausal.(78)!
!
Figure'2.7. Complex.hyperplasia.(H&E)...
Closely'packed'glands'with'architectural'irregularity'and'numerous'bud>like'projections'
(courtesy'of'PathologyOutlines.com'&'The'Global'Library'of'Women’s'Medicine).(77)'
Atypical*hyperplasia*
Atypical!hyperplasia!is!the!presence!of!cellular!atypia,!usually!focal,!in!tissue!showing!a!
pattern! of! complex! glandular! crowding.! ! Whilst! cellular! atypia! can! occur! in! simple!
hyperplasia,!it! is! rare!(Figure!2.8).! !The!atypical!cellular!changes!are:!enlarged,!round!
!
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nuclei!with!hyperchromasia!and!the!formation!of!nucleoli,!cellular!dyspolarity,!irregular!
nuclear!stratification,!and!cytoplasmic!eosinophilia!with!necrotic!debris.!
There!is!20030%!risk!of!progression!to!endometrial!carcinoma!and!also!a!significant!risk!
of! concurrent! endometrial! carcinoma! if! the! diagnosis! is!made! using! an! endometrial!
biopsy!alone.(77)(78)! !As!such,!the!management! is!often!hysterectomy!with!bilateral!
salpingo0oophorectomy;!although!treatment!with!progestogen!or!hysterectomy!alone!
can!be!considered!in!the!pre0menopausal!patient.!
!
Figure'2.8. Atypical.simple.hyperplasia.(H&E)...
Glands' lined'by'cells'with'eosinophilic'cytoplasm'and'dyspolaric,'stratified'nuclei'with'
moderate'anisonucleosis'and'hyperchromasia.''Prominent'nucleoli'are'seen'in'many'of'
the' nuclei.' ' Necrotic' debris' is' present' in' some' gland' lumina' (courtesy' of'
PathologyOutlines.com'&'The'Global'Library'of'Women’s'Medicine).(77)!!
2.5.3! Endometrial(polyps(
An!endometrial!polyp!is!defined!as!a!‘grossly!pedunculated!mass!composed!of!cystically!
dilated!glands!with!fibrous!stroma!and!thick!walled!blood!vessels’(81).!!These!can!be!
associated!with!normal!microscopic!findings!but!in!up!to!one!third!they!are!associated!
!
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with!endometrial!hyperplasia.! !The!glands!within!a!polyp!tend!to!be!unresponsive!to!
progesterone!and!so!are!associated!with!abnormal!uterine!bleeding!(AUB).!
The!histological!features!of!polyps!are:!attenuated!endometrium!on!three!sides,!cystic!
change!within!the!endometrial!glands,!large!thick0walled!blood!vessels,!fibrous!stroma!
containing! fibroblast! like! cells! and! abundant! extracellular! connective! tissue.! ! The!
endometrial!glands!tend!to!be!proliferative!or!inactive!reflecting!their!unresponsiveness!
to!progesterone!and!the!associated!stromal!cells!very!rarely!show!atypia.!
2.5.4! Endometrial(carcinoma(
Endometrial! carcinoma! is! the! most! common! gynaecological! malignancy,! with! an!
estimated!incidence!of!15020!per!100,000!women!per!year.(82)!!In!the!UK,!the!incidence!
is!increasing!and!went!up!by!29.3%!between!1993!and!2005.(69)!!This!increase!has!been!
attributed!to!increased!obesity,!the!use!of!tamoxifen!for!breast!cancer!and!increased!
life!expectancy.!
The!classification!of!endometrial!cancer!separates!it!into!two!broad!categories!based!on!
oestrogen! dependence,! tumorigenesis! and! clinical! outcome.! ! ! Type! I! (endometrioid!
adenocarcinoma)!endometrial!cancers!are!oestrogen!dependent!and!often!arise!on!a!
background!of!endometrial!hyperplasia.(83)!!As!such!there!is!significant!overlap!in!the!
risk! factors! of! these! two! conditions.! ! Factors! such! as! obesity,! diabetes,! poor! diet!&!
lifestyle,! early! menarche,! late! menopause,! nulliparity,! PCOS,! functional! ovarian!
tumours,!tamoxifen!use!and!unopposed!oestrogen!therapy,!are!known!to!increase!the!
risk.! !These!cancers!tend!to!occur! in!younger!patients,!have!a! less!aggressive!clinical!
course!and!better!50year!survival.!!!Type!II!(serous!adenocarcinoma)!endometrial!cancers!
are!not!oestrogen!dependent!but!tend!to!occur!in!the!atrophic!endometrium!of!older!
patients.!!They!tend!to!be!of!a!higher!grade!and!have!a!poorer!prognosis.(69)!
In!cancers,!the!stepwise!accumulation!of!alterations!and!errors!in!cell!cycle!regulation!
lead!to!dysfunctional!cell!growth.! !However,! the!genetic!mechanisms!by!which!these!
two! types! of! endometrial! cancer! develop! is! very! different.! ! In! Type! I! cancers! PTEN!
(phosphatase! and! tensin! homolog! deleted! on! chromosome! ten)! gene! silencing! in!
conjunction!with!defects!in!DNA!mismatch!repair!genes!lead!to!microsatellite!instability.!
(82)!!PTEN!is!a!tumour!suppressor!gene!and!its!dysfunction!leads!to!activation!of!multiple!
signalling!pathways,!including!the!PI3K/Akt!pathway;!affecting!cell!proliferation,!rates!of!
!
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apoptosis!and!cell!migration.(82)!!As!such!it!is!a!promoter!of!carcinogenesis!but!is!also!
seen!in!endometrial!hyperplasia.!!The!frequency!of!loss!of!PTEN!expression!has!been!
shown! to! be! related! to! the! type! of! hyperplasia!with! the! highest! frequency! seen! in!
complex! atypical! hyperplasia,! suggesting! a! link! to! progression! of! hyperplasia! to!
endometrial!intraepithelial!neoplasia!(EIN)!and!then!on!to!endometrial!carcinoma.(84)!!!
An!additional!factor!in!Type!I!cancers!are!mutations!in!the!K0ras!oncogene,!which!has!
been!detected!in!10030%!of!endometrioid!endometrial!cancers.!!The!frequency!of!this!
mutation!is!proportional!to!the!complexity!of!any!hyperplasia.!!As!such!the!presence!of!
K0ras!mutation! in! pre0malignant! biopsy! samples!may! be! a!marker! of! progression! to!
malignancy.(82)!
The!steroid!receptors,!and!in!particular!the!ratio!of!the!two!isoforms!of!the!progesterone!
receptor! (PR):! PR0A/PR0B! may! play! a! role! in! pathogenesis! of! endometrioid!
adenocarcinoma.!!Progesterone!acts!through!the!PR!to!negatively!regulate!the!effect!
oestrogen!has!on!the!endometrium.!This!action! is!controlled!by!the!ratio!of!the!two!
isoforms! as! PR0B! acts! as! an! endometrial! oestrogen! agonist! and! PR0A! acts! as! a!
transcription! repressor! of! PR0B.! ! As! such! an! alteration! of! the! ratio! to! a! more! PR0B!
predominant!one!can!increase!the!chance!of!endometrial!hyperplasia!and!play!a!role!in!
the!impact!of!unopposed!oestrogen!on!endometrial!cancer!risk.!!Progesterone!therapy!
is!effective!for!reducing!risk!in!such!patients!as!it!leads!to!a!downregulation!of!PR!and!so!
reduces!the!agonistic!effect!of!any!endogenous!or!exogenous!oestrogen.!!
However,!Type! II! endometrial! carcinomas!arise!on!a!background!of!atrophy!and!are!
associated!with!mutations!in!the!TP53!tumour!suppressor!gene!in!71085%!of!cases!and!
over0expression! of! the! HER02/neu! oncoprotein! in! 9030%! of! all! endometrial!
adenocarcinomas.(82)!!!As!such!they!arise!independently!of!hormonal!changes!and!tend!
to!be!seen!later!in!life!when!more!genetic!mutations!have!been!accumulated.!!!
Endometrioid*adenocarcinoma*
Macroscopically,!endometrial!carcinoma!appears!as!a!raised,!rough,!papillary!area!with!
a!disrupted!and!ulcerated!surface;!usually!occupying!at! least!half!of! the!endometrial!
cavity.(85)!!The!tumours!often!arise!at!the!fundus!or!the!posterior!wall!and!the!degree!
of!the!tumour!growth!within!the!cavity!does!not!correlate!with!the!risk!of!myometrial!
invasion.!
!
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The! glandular! pattern! and! cellular! features! resemble! that! of! the! proliferative! phase!
endometrium!but! have! a!more! complex! architecture! that!may! include! solid! growth,!
maze0like! interconnected! lumens,! a! villoglandular! appearance,! or! cribriform! growth!
(Figure!2.9).! ! The!epithelial! cells! tend! to!be! larger! than!expected! in! the!proliferative!
phase,!but!the!cytological!changes!are!very!variable!between!different!individuals!and!
also!within!areas!of!the!same!tumour.!!The!presence!of!mitotic!figures!can!also!be!quite!
variable.!!Stromal!changes!tend!to!be!less!useful!when!characterising!adenocarcinoma!
but!the!presence!of!foam!cells!(lipid!laden!stromal!histiocytes)!are!a!common!finding!in!
adenocarcinoma!and!represents!a!reactive!response!to!necrotic!tumour!cells.(85)!!!!
!
Figure'2.9. Well.differentiated.endometrioid.endometrial.adenocarcinoma.(H&E).
Unlike' the' EIN' lesion' above,' the' glands' are' no' longer' visible' individually,' but' are'
arranged' as' folded' villoglandular' sheets'(courtesy' of' PathologyOutlines.com' &' The'
Global'Library'of'Women’s'Medicine).'(86)'
2.5.5! Endometriosis((
Endometriosis!is!characterised!by!the!presence!of!uterine!endometrial!tissue!outside!of!
the!normal!location!and!so!histologically!both!endometrial!glands!and!stromal!tissue!can!
be! seen! in! ectopic! endometrial! deposits! (Figure! 2.10).(2)! ! In! addition,! fibrosis! and!
!
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hemorrhage!are!often!associated!with!endometriotic!deposits,!but!these!features!are!
very!much!less!specific.!!Observation!of!them!adds!weight!to!the!diagnosis!if!they!occur!
in!the!presence!of!either!glands!or!stroma.(87)!!These!tissues!can!respond!to!ovarian!sex!
steroids,!leading!to!cyclical!changes!within!the!tissues,!but!overall!they!tend!to!have!a!
more!proliferative!pattern!than!the!normal!endometrium.(88)!
!
Figure'2.10. Endometriosis.(H&E)..
A'small'cluster'of'endometrial'glands'and'stroma'with'hemorrhage'are'seen'to'the'left'
of'the'panel,'near'the'surface'of'the'fallopian'tube'(courtesy'of'PathologyOutlines.com'
&'http://library.med.utah.edu).(88)'
The!glandular!epithelial!layer!is!one!cell!thick!and!is!made!up!of!tall!columnar!cells!with!
eosinophilic! cytoplasm! and! ovoid! nuclei! showing! regular! vertical! orientation.! ! In!
addition,!cilia!are!sometimes!observed!on!the!luminal!surface!of!these!cells.!!There!tends!
to! be! few! mitoses! and! the! overall! appearance! is! that! of! an! inactive! or! irregular!
proliferative!pattern.!!However,!a!more!active!proliferative!pattern!and!some!secretory!
changes!can!also!be!observed.!!As!such,!there!is!not!a!classic!glandular!appearance!of!
endometriosis.(89)!
The!stromal!cells!are!small!spindle0shaped!cells!with!minimal!cytoplasm.!!They!appear!
very!similar!to!the!stromal!cells!of! the!eutopic!endometrium.! !Associated!with!these!
!
!
CHUTE!Thesis!(1.4)! 0!57!0!
CHANGES(IN(HISTOLOGY(FOLLOWING(ULIPRISTAL(THERAPY(IN(ENDOMETRIOSIS(
(CHUTE)(
stromal! cells! is! a! delicate! reticulin! network! in! which! hyperemic! small! vessels! are!
observed! in! some! cases.(90)! ! In! the! presence! of! cyclically! functioning! endometriosis!
varying! degrees! of! decidualisation! can! be! seen! within! the! stroma;! glycogen!
accumulation! within! the! cytoplasm,! increased! vascularity! and! stromal! oedema! are!
examples!of!such!changes.!!The!exogenous!provision!of!progestins!can!also!prompt!a!
similar! pseudo0decidualisation! response.! ! Additional! stromal! features! that! are!
sometimes! observed! include! the! presence! of! haemosiderin! laden! macrophages,!
inflammatory!infiltrates!and!collections!of!smooth!muscle!fibers.(89)!
It! is! important! to! recognise! that! not! all! these! features! are! seen! in! all! cases! and!
sometimes! the! epithelial! or! stromal! component! is!missing,!making! a! firm! diagnosis!
difficult.!!This!is!particularly!true!with!disease!found!in!the!ovary!as!the!stromal!features!
of!endometriosis,! such!as!haemosiderin! laden!macrophages,! can!be!confused!with!a!
haemorrhagic! cyst! in! the! ovary! or! a! mature! corpus! luteum.! ! In! non0ovarian!
endometriosis! this! confusion! is! less! likely!and! so!a!diagnosis! can!be!made!based! on!
suggestive! histopathological! features! and! the! clinical! descriptors! observed! at!
laparoscopy.(89)!
Although! endometriosis! is! hormonally! responsive! and! sometimes! the! histological!
features!seen!in!the!endometriotic!foci!are!congruent!with!histological!changes!seen!in!
the!eutopic!endometrium!this!is!often!not!the!case.(89)!!Commonly!there!are!no!cyclical!
changes!in!the!ectopic!endometrium!but!there!are!some!morphological!features!that!
are!associated!with!a!higher!chance!of!congruency:!minimal!associated!fibrosis,!greater!
numbers!of!stromal!cells!and!greater!associated!vascularity.!!The!association!between!
fibrosis! and! a! reduced! degree! of! responsiveness!may! explain!why!more! established!
lesions,! such! as! deeply! invasive! endometriosis! (DIE)! and! endometriomas,! are! less!
amenable!to!hormonal!therapy!and!often!require!surgery!to!achieve!symptom!control.!
The!chance!of!seeing!cyclical!changes!will!also!be!influenced!by!the!expression!of!various!
steroid! receptors! within! each! lesion! 0! with! reduced! expression! of! ER! and! PR! being!
associated! with! less! synchronicity! to! the! eutopic! endometrium.! As! such!
immunohistochemistry! to! explore! that! expression! may! provide! useful! information!
about! the! character! and! hormone! responsiveness! of! any! lesion.! ! As! that! hormone!
responsiveness! appears! to! influence! the! likelihood! of! a! medical! treatment! being!
effective! it! is! sensible! to! explore! this! when! considering! a! novel! pharmacological!
!
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intervention.! ! ! A! study! published! in! 2007! looking! at! ureteral! endometriosis! causing!
ureteric!obstruction!illustrated!that!ER!and!PR!expression!is!seen!in!both!the!epithelial!
and! stromal! cells,! but! CD10! expression! was! limited! to! only! the! stromal! cells.(91)!!
However,! a! complete! understanding! of! receptor! expression! in! endometriosis! is! still!
lacking.!
2.6! ENDOMETRIAL.RECEPTOR.EXPRESSION.&.ENDOMETRIOSIS.
The!use!of!immunohistochemistry!to!explore!receptor!expression!within!tissues!is!a!key!
part!of!histopathological!assessment.!!The!expression!of!either!cell!surface!receptors,!
cell!surface!proteins!or!nuclear!apparatus!can!be!used!to!identify!the!functionality!of!the!
cells! being! viewed.! ! The! anatomical! location,! histological! appearance! together! with!
information! about! cell! functionality! allows! a! histopathologist! to! fully! assess! the!
specimen!and!therefore!make!a!diagnosis.!
Assessing! cell! functionality! in! both! eutopic! and! ectopic! endometrial! samples! can! be!
achieved! by! various! immunohistochemical! stains.! ! Perhaps,! unsurprisingly! the! three!
main!steroid!receptors!0!oestrogen,!progesterone!and!androgen,!can!be!looked!at!but!
there!are!other!markers!that!may!also!be!of!value!when!exploring!endometrial!function.!!
An!understanding!of!these!immunohistochemical!stains!is!needed!to!assess!endometrial!
response!to!any!pharmacological!agent.!
2.6.1! ER,(PR(&(AR(
Steroid!hormones!interact!with!their!target!cells!via!specific!nuclear!receptors.!!Receptor!
binding!initiates!gene!transcription!and!a!cascade!of!downstream!molecular!and!cellular!
events.(92)!!Oestrogen!receptor!(ER)!and!progesterone!receptor!(PR)!expression!within!
the! endometrium! is! controlled! by! oestrogen! and! progesterone,! and! along! with! the!
androgen!receptor!(AR)!is!varied!through!the!menstrual!cycle.!!These!three!receptors!
are!key!to!endometrial!function!and!may!be!influenced!by!pharmacological!agents!that!
exert!a!clinical!effect!on!the!endometrium.!!
Progesterone*Receptor*
There!are!two!isoforms!of!the!human!PR,!which!are!encoded!for!by!a!single!gene.!!The!
PR0A!form!is!164!amino!acids!shorter!than!PR0B!and!acts!as!a!co0repressor!of!PR0B!and!
other! steroid! receptors.(93)! ! PR0B,! however,! acts! as! a! strong! transcription! activator.!!
There!is!a!significant!decline!in!PR!expression!in!the!glandular!epithelium!of!the!stratum'
!
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functionalis,!as!the!endometrium!transitions!from!a!proliferative!to!a!secretory!state!but!
the!expression!in!the!stromal!cells!is!maintained.!!Localisation!studies!have!shown!that!
although!stromal!expression!is!maintained,!the!balance!of!PR0A:PR0B!changes!to!favour!
PR0A.! ! In! the! stratum' basalis,! the! expression! is! more! uniform! in! both! cell! types,!
throughout!the!cycle.(92)!
The!PR!is!expressed!on!peri0vascular!stromal!cells!and!not!on!vascular!endothelial!cells!
of!the!human!uterus.!!Therefore,!changes!in!progesterone!levels!are!likely!to!impact!on!
the! balance! of! vasoconstriction! and! endometrial! bleeding! by! an! indirect! action!
mediated!by!those!perivascular!stromal!cells.(92)!
Wöfler!et'al.!conducted!a!study!to!observe!the!pattern!of!PR0A!and!PR0B!expression!in!
patients!with!endometriosis.! !Whilst! they!confirmed! the! findings!described!above! in!
their!control!group!they!noted!no!cycle!dependent!pattern!and!a!huge!variety!of!inter0!
and! intra0individual! variation! in!PR!expression! in!endometriosis!patient!group.! ! They!
suggest!this!dysregulation!might!contribute!to!the!pathophysiology!of!endometriosis.!
(94)!!However,!this!finding!suggests!using!specific!PR0A!and!PR0B!immunohistochemical!
antibodies!is!unlikely!to!yield!useful!results!with!regards!to!ectopic!endometrium.!!!
Oestrogen*Receptor*
There!are!two! isoforms!of!human!ER0!ER!!and!ER".! ! In!the!stratum'functionalis!ER!!
expression! in!both!glandular!and! stromal!cells! increases! throughout! the!proliferative!
phase! and! then! declines,! secondary! to! progesterone! suppression,! in! the! secretory!
phase.!!Similar,!to!PR,!ER!!expression!in!the!stratum'basalis!is!more!uniform!in!both!cell!
types,! throughout!the!cycle.(92)! !However,! if!an!average!of!all!phases!are!taken! into!
account!the!expression!of!ER!!in!glandular!epithelial!cells!shows!a!steady!gradient!from!
strong!expression!at!the!basal!layer!through!to!weak!expression!at!the!surface!epithelial!
cells.(95)!
ER"!appears!to!regulate!the!action!of!oestrogen!on!endometrial!vessels.!!ER"!is!the!only!
sex!steroid!receptor!expressed!on!endothelial!cells.(92)!!
Androgen*Receptor*
Androgens!can!suppress!oestrogen!and!progesterone!receptors!and!have!an!inhibitory!
effect! on! the! endometrium! leading! to! endometrial! atrophy.! ! AR! expression! is!
predominantly!in!the!stromal!cells!and!immunostaining!for!AR!tends!to!be!less!intense!
!
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than!for!ER!and!PR.(95)!!Expression!is!maximal!in!the!early!proliferative!phase!and!then!
decreases!through!the!remaining!cycle!with!the!changes!most!notable!in!the!stratum'
basalis.(95)! ! These!changes!are!explained!by! the!observation! that!expression!can!be!
upregulated! by! oestradiol! (E2)! and! down! regulated! by! progesterone! (P)!
administration.(96)!!The!use!of!progesterone!antagonists!has!been!shown!to!increase!
AR!expression!in!the!stroma!and!induce!AR!expression!in!the!glandular!epithelium.(97)!!
As!such,!it!is!thought!that!the!changes!in!AR!expression!may!be!the!mechanism!by!which!
anti0progestins!exert!their!anti0proliferative!effect!on!the!endometrium.(92)!!!!!!
2.6.2! CD10(
Enkephalinase!or!CD10!is!a!human!membrane0associated!neutral!peptidase!that!is!used!
widely!in!lymphoma!phenotyping.(98)!!It!has!been!shown!to!be!a!marker!for!endometrial!
stromal!cells!in!eutopic!and!ectopic!endometrium!as!well!as!neoplastic!lesions.(99)!!The!
study! by! Croisman! and! Meir! in! 2003,! demonstrated! the! use! of! CD10!
immunohistochemistry!as!a!diagnostic!tool!in!samples!of!ectopic!endometrium!where!
stromal!cells!are!obscured!by!haemorrhage,!inflammation,!cystic!dilatation,!and!fibrosis,!
to!distinguish!endometriosis!from!mimickers!such!as!endosalpingiosis!and!mesothelial!
hyperplasia.(98)!!
2.6.3! Ki67(
Ki067! is! a! nuclear! antigen! present! only! in! cells! undergoing! the! cycle! of! changes!
associated!with!mitosis!and!has!been!used!to!evaluate!tumours!to!provide!prognostic!
information! and! guidance! on! risk! of! recurrence.(100)(101)(102)! ! The! use! of! Ki067!
immunohistochemistry! in! the! endometrium! has! been! explored! with! respect! to! the!
cyclical! endometrial! changes.! ! Expression! of! Ki67! increases! through! the! proliferative!
phase!in!response!to!rising!oestrogen!levels!and!then!tends!to!decrease!in!the!secretory!
phase!when!mitosis!is!less.(103)!!In!proliferative!samples!the!pattern!of!staining!reflects!
the!activity!of!the!tissues0! !Ki67!staining! is! largely!confined!to!the!stratum'basalis!as!
proliferation!is!driven!from!this!layer.(71)!
As!endometriosis!can!behave!in!an!invasive!manner,!the!use!of!such!markers!has!been!
explored! to! see! if! it! would! provide! information! that! would! allow! the! prediction! of!
severity!for!patients!with!endometriosis.!!The!case!control!study!by!Kahyaoglu!et'al.!did!
show! a! moderate! correlation! between! the! Ki067! proliferation! marker! and! stage! of!
disease,!such!that!Ki067!staining!can!be!viewed!as!a!marker!for!disease!severity.(100)!!Ki0
!
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67!staining!has!been!used! in!the!assessment!of!suppression!of!the!AKT!pathway! in!a!
mouse!model,!where!a!reduction!in!pathway!activation!was!associated!in!less!ectopic!
disease!establishment!and!reduced!Ki067!expression.(104)!
2.6.4! PTEN(
The!PTEN! (phosphatase! and! tensin! homolog! deleted! on! chromosome! ten)! gene! is! a!
tumor!suppressor!gene!localised!on!chromosome!10!(10q23024),!which!encodes!a!4030
amino!acid!protein.!!The!protein!it!encodes0!PTEN,!is!a!lipid!phosphatase!that!modulates!
cell! signal! transduction! pathways! by! acting! on! phospholipid! phosphatidylinositol0
(3,4,5)0triphosphate! (PIP3)! signalling.(82)! ! As! such! it! negatively! regulates! the!
serine/threonine! kinase! Akt! pathway! by! phosphorylating! downstream! signalling!
proteins;! inhibiting! cell! survival,! cell! proliferation,! angiogenesis! and! cellular!
metabolism.(105)!
Abnormalities! of! the! PTEN! gene! have! been! found! in! a! number! of! tumours! and,! in!
particular!in!up!to!80%!of!cases!of!endometrioid!carcinoma.(82)!!A!study!by!Mutter!et'
al.! in! 2000! used! immunohistochemistry! staining! to! compare! PTEN! expression! in!
endometrioid!adenocarcinoma!and!endometria!altered!by!unopposed!oestrogen.(84)!!
This!demonstrated!a!progressive!and!increasingly!contiguous!accumulation!of!PTEN0null!
glands!suggesting!a!role! for!PTEN! in!tumourigenesis.! ! In!2006,!Kapucuoglu!et'al.!also!
highlighted! the! association! with! PTEN! loss! and! the! development! of! endometrioid!
endometrial!carcinomas;!including!a!link!between!that!association!and!the!expression!
of!the!anti0apoptotic!bcl02!protein.(106)! !However,! loss!of!PTEN!expression!has!poor!
sensitivity! (44%)! and! specificity! (51%)! as! a! marker! of! progression! from! atypical!
endometrial!hyperplasia!to!endometrial!carcinoma.(107)!
There!is!mounting!evidence!for!a!relationship!between!cancer!and!endometriosis!with!
respect! to! the! cellular! pathways! involved! and! the! regulation! of! the! cell! cycle.! ! The!
persistence!and!proliferation!of!endometrial!cells!in!ectopic!locations!maybe!promoted!
through!similar!pathways!to!those!seen!in!endometrial!carcinoma.!!As!such,!studies!of!
tumour! suppressors! and! oncogenes! in! endometrial! samples! of! patients! with!
endometriosis!have!been!undertaken!to!explore!the!Akt!pathway!and!the!role!PTEN!loss!
may!play!in!the!promotion!of!endometriosis.(108)!!
!
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Zhang!et'al.!used!immunochemistry!to!demonstrate!that!PTEN!expression!is!reduced!in!
eutopic!endometrium!of!patients!with!endometriosis!when!compared!to!controls.!!Their!
work! on! ectopic! endometrial! cells! in! culture! also! showed! significant! loss! of! PTEN!
expression;!with!Western!blot!analysis!showing!this!reduction!in!expression!was!much!
greater!than!that!seen!for!eutopic!cells!from!patients!with!endometriosis.(109)!!Their!
analysis!showed!this!process!was!oestrogen!dependent,!which! is!in!keeping!with!our!
understanding!of!the!pathogenesis!of!endometriosis.! !Similar!work!has!been!done!by!
Govatati! et' al.,! who! undertook! a! case0controlled! study! that! showed! reduced! PTEN!
expression!in!eutopic!endometria!of!patients!with!Stage!IV!endometriosis!and!that!the!
greatest! effect! was! in! the! glandular! epithelium.(110)! ! The! use! of! PTEN!
immunohistochemical!assessment!on!ectopic!foci!of!endometrium!(endometriosis)!has!
not!previously!been!published.!!!!!!
2.6.5! p63(
There! is! a! 630kDa!membrane! protein! (p63)! that! plays! a! role! in! regulating! epithelial!
proliferation!and!differentiation.!!A!study!by!Neto!et'al.!in!2007,!investigated!expression!
of!this!protein!in!peritoneal!deposits,!endometriomas!and!endometriotic!nodules.!!They!
found! that! expression! varied! between! the! types! of! endometriosis! with! peritoneal!
deposits! expressing! the! highest! positivity! (93%).! ! However,! the! significance! of! this!
finding!and!the!fact!that!the!immunohistochemistry!target!is!only!found!on!the!epithelial!
cells!make!this!marker!of!limited!value.!
2.6.6! VEGF(
Angiogenesis! in! the! endometrium! is! regulated! and! controlled! by! a! multitude! of!
promoters!and!inhibitors,!all!of!which!are!believed!to!be!under!the!influence!of!estradiol!
and! progesterone! during! the! menstrual! cycle.! ! Vascular! endothelial! growth! factor!
(VEGF)!is!a!key!local!mediator!of!the!cyclical!neovascularisation!seen!in!the!functional!
layer! of! the! endometrium.! ! It! appears! to! be! key! to! the! revascularisation! of! the!
endometrium!as!it!repairs!and!begins!to!proliferate,!as!demonstrated!by!increased!levels!
of!VEGF!mRNA!in!the!mid!proliferative!phase.(92)!!
VEGF! concentrations! have! also! been! shown! to! be! higher! in! the! peritoneal! fluid! of!
patients! with! endometriosis! and! VEGF! expression! is! higher! in! patients! with! deeply!
invasive! endometriosis.(31)(111)! ! This! suggests! that! VEGF! may! play! a! role! in! the!
establishment! of! the! endometriotic! deposits! or! the! progression! of! such! deposits! to!
!
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deeply!invasive!plaques!of!disease.!!There!is!limited!published!data!on!the!use!of!VEGF!
immunohistochemistry!in!assessment!of!endometriosis!but!the!highly!vascular!nature!
of! endometriotic! deposits! may! render! VEGF! immunohistochemistry! staining! very!
homogeneous! and! so! unhelpful! in! the! assessment! of! endometriosis.! ! However,! a!
uniform!change!of!expression!might!be!associated!with!pharmacological!treatment!of!
the!disease!and!so!VEGF!IHC!may!yield!meaningful!results.!
2.7! BEHAVIOUR.OF.ECTOPIC.ENDOMETRIUM.
When! considering! endometriosis,! the! histopathological! features! of! that! disease! and!
whether!pharmacological!intervention!might!influence!those!features,!a!key!question!to!
ask!is:!does!the!eutopic!and!ectopic!endometrium!behave!in!the!same!way.!!This!is!a!
complex!consideration!and!can!be!broken!down!into!two!more!specific!questions:!
1)! Does!eutopic!endometrium!within!the!uterus!behave!in!the!same!way!in!both!
patients!with!endometriosis!and!in!those!without!endometriosis?!Or!does!the!
endometrium!behave!differently!in!patients!with!endometriosis!irrespective!of!
the!location!of!that!endometrium?!
2)! Does!a!pharmacological!treatment!for!endometriosis!have!the!same!action!on!
the!eutopic!and!ectopic!endometrium!of!individuals!with!endometriosis?!
Unfortunately,! neither! of! these! questions! is! easy! to! answer! and! our! limited!
understanding!of!the!pathogenesis!of!endometriosis!means!that!we!do!not!have!all!the!
tools!we!might!want!to!explore!this!area!of!women’s!health.(112)
!
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Chapter.3:!SELECTIVE. PROGESTERONE. RECEPTOR.
MODULATORS.(SPRMS).
The!progesterone!receptor!(PR)!is!an!intracellular!protein!that!regulates!transcription!
and!is!activated!by!the!steroid!hormone!progesterone.!!Binding!of!progesterone!causes!
receptor!dimerisation,!nuclear!entry,!DNA!binding!and!subsequently!DNA!transcription!
regulation.! ! Each! progesterone! receptor! ligand! influences! protein! expression! and!
cellular!responses!via!several!mechanisms!that!result!in!a!unique!response!within!each!
type!of!cell!that!expresses!the!progesterone!receptor.!!The!factors!that!influence!protein!
expression! include:! the!variability!of!PR!expression!within! target! tissues,! the! relative!
concentrations!of!co0activators!and!corepressors,!the!response!of!any!other!sex!steroids!
acting! on! those! tissues,! and! the! type! of! activating! ligand;! making! the! physiological!
response!to!PR!binding!complex!and!variable.!
In!addition!to!this!genomic!mechanism,!progesterone!also!exerts!rapid!effects!on!diverse!
signalling!pathways!that!are!independent!of!transcription!and!translation.!!This!action!
appears!to!be!mediated!through!the!cytoplasmic!fraction!of!the!nuclear!PR!(nPR)!and!
adds!a!further!layer!of!complexity!to!the!physiological!response!seen!to!progesterone.!
To! explore! selective! progesterone! receptor! modulators! (SPRMs)! use! for! the!
management!of!endometriosis!we!need!to!consider!the!progesterone!receptor! itself,!
the! physiological! action! of! progesterone! and! its! interaction! with! the! progesterone!
receptor,! and! finally! the! SPRMs! themselves,! which! exhibit! quite! variable! ligand! and!
tissue!responses.!!Although!other!SPRMs!do!exist,!the!discussion!will!be!restricted!to!
Mifepristone,! Asoprisnil,! Onapristone,! Telapristone! and! Ulipristal! acetate! as! these!
compounds!have!either!previously!been!studied!with!respect!to!endometriosis!or!they!
exhibit!a!more!antagonistic!profile,!making!them!more!suited!to!treating!endometriosis.!
!
! .
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3.1! IDENTIFICATION.AND.ASSESSMENT.OF.EVIDENCE.
A!PubMed!and!Cochrane!database!search!for!relevant!publications!was!performed!using!
the! following! search! terms:! ‘progesterone! receptor! modulator’,! ‘SPRM! OR! SPRMs’,!
‘ulipristal!acetate!OR!Esmya!OR!CDB02914’,!‘asoprisnil!OR!J0867’,!‘mifepristone!OR!RU0
486’,! ‘onapristone! OR! ZK98299’,! ‘telapristone! OR! CDB04124’,! ‘endometriosis’,!
‘adenomyosis’,! ‘fibroids! OR! leiomyoma’,! ‘progesterone’,! ‘endometrium’,! ‘steroid!
receptor!expression’,! ‘endometrial!histology’,! ‘immunohistochemistry’.! !The!abstracts!
for!relevant!basic!science!research!&!reviews,!randomised!trials,!cohort!studies,!case!
series!and! systematic! reviews!were!manually!screened! to! identify! those!publications!
containing! relevant! information.! Further! relevant! articles! were! also! identified! from!
citations!within!these!original!publications.!
All! reviews!on!SPRMs!were! included!and!all!studies!of!the!named!SPRM!compounds!
conducted!in!human!subjects!were!included.!Animal!data!were!included!if!considered!
relevant!to!the!management!of!endometriosis,!in!particular!relating!to!ulipristal!acetate!
and!mifepristone.! ! As! the! amount! of! published! literature! on! progesterone! receptor!
modulators!was!found!to!be!small!(<500!abstracts)!no!exclusions!were!necessary.!!This!
allowed!a!broad!assessment!of!the!current!knowledge!on!the!subject!area!as!well!as!an!
understanding!on!the!most!appropriate!way!to!study!ulipristal!acetate.!
!
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3.2! PROGESTERONE.
Progesterone!plays!a!central!role!in!female!reproductive!function!as!well!as!influencing!
other! body! systems! like! the! cardiovascular! and! central! nervous! systems.(113)! ! The!
action!of!progesterone!on!its!receptor!has!three!main!physiological!functions!within!the!
reproductive!system(114):!
1)! uterine! and! ovarian! function;! facilitating! oocyte! maturation,! uterine!
preparation! for! implantation! and! maintenance! of! pregnancy! by! promoting!
uterine!growth,!suppressing!uterine!contractility!and!ensuring!cervical!closure!
(parturition!is!initiated!at!the!end!of!pregnancy!by!withdrawal!of!progesterone!
and!these!suppressive!functions),!
2)! mammary! function;! breast! development! in! pregnancy! and! suppression! of!
lactation!prior!to!birth,!
3)! sexual!response.!
In! the! proliferative! phase! of! the! menstrual! cycle! oestrogen! predominates! and! this!
promotes!proliferation!of!the!epithelial!and!stromal!cells.!!In!addition,!it!promotes!PR!
expression!to!maximise!the!receptiveness!of!the!endometrium!to!progesterone!after!
ovulation!occurs.!!The!production!of!progesterone!by!the!corpus!luteum!ensures!that!
progesterone! is! the!predominant!hormone! in!the!secretory!phase!of!the!cycle!and! it!
promotes!the!following!endometrial!effects:!growth!and!coiling!of!the!spiral!arterioles,!
secretory!transformation!of!the!glands,!infiltration!of!uterine!NK!cells,!transformation!
of! stromal! fibroblasts! to! promote! decidualisation,! and! increased! vascular!
permeability.(115)!
This!central! role!means!the!action!of!progesterone!and!abnormalities! in!response!to!
progesterone!are! implicated!in!many!reproductive!disorders.! ! In!particular,!abnormal!
uterine! bleeding! and! fibroids! but! also! endometriosis,! adenomyosis,! breast! and!
endometrial!cancer,!as!well!as!miscarriage!and!pre0term!labour.(116)!
. .
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3.4! PROGESTERONE.RECEPTOR.
Progesterone!exerts!its!action!on!a!cell!though!the!Progesterone!Receptor!(PR).!!Two!
different!mechanisms!have!been!identified!to!be!responsible!for!mediating!that!cellular!
response0!the!genomic!response!and!the!non0genomic!response.!!Nuclear!progesterone!
receptors!(nPR)!exert!a!direct!genomic!effect!by!acting!as!ligand0activated!transcription!
factors! to! influence! transcription! (117)! but! also! through! cell! surface! receptors!
(membrane! progesterone! receptors! (mPR))! that! are! structurally! similar! to!G0protein!
coupled!receptors!in!a!more!indirect!manner.(118)!
3.4.1! Nuclear(superfamily(receptors(
The! nuclear! hormone! receptor! gene! superfamily! encodes! structurally! related!
intracellular! receptors! for! glucocorticoids,!mineralocorticoids,! and! the! sex! hormones!
oestrogen,!progestin!and!androgen.(119)!!As!a!group!they!are!known!as!ligand0activated!
transcription!factors!and!are!structurally!similar.(120)!!
Each!of!the!receptors!contain!three!major!domains!–!a!ligand0binding!domain!(LBD)!at!
the!carboxyl0terminal!end,!a!variable!domain!at!the!amino0terminal!end!and!the!DNA0
binding! domain! (DBD)! in! the! central! portion! of! the! protein! (Figure! 3.1).! ! The! LBD! is!
moderately!conserved!between!receptors!and!facilitates!the!binding!of!receptor!specific!
ligands.! ! This! ligand! binding! results! in! the! dissociation! of! the! receptor! from! plasma!
proteins!such!as!heat0shock!protein,!which!allows!the!receptors!to!form!homodimers!or!
heterodimers.! ! These! then! bind! to! palindromic! hormone! response! elements! (HREs)!
within!the!DNA!separated!by!three!base!pairs,!e.g.!HRE!NNN!HRE.! !The!DNA0binding!
domain! is!highly!conserved!between!receptors!and!contains!a!sequence!of!70!amino!
acids!that!fold!into!two!zinc0fingers!motifs!that!bind!to!the!major!groove!of!the!DNA!
strand!to!facilitate!the!recruitment!of!the!transcription!machinery!(Figure!3.2).! !Once!
bound,!both!the!LBD!and!the!highly!variable!amino0terminus!determine!the!resultant!
transcription!and!so!are!key!to!the!ligand0receptor!response!seen!within!each!cell.(119)!
!
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Figure'3.1. Structural.organisation.of.the.nuclear.receptor.
The'N>terminal'regulatory'domain'(A>B)' is'highly'variable'and'contains'the'activation'
function'1' (AF>1)' region'which'acts'as'a'weak' transcription'activator' independent'of'
ligand' binding' and' acts' synergistically'with'AF>2' in' the' E>domain.' ' The'DNA'binding'
domain'or'DBD'(C)'contains'two'zinc'finger'portions'that'allow'it'to'bind'to'the'hormone'
response'elements'(HRE)'in'the'DNA'(see'Figure'3.2).''The'hinge'region'(D)'links'the'DBD'
with'the'ligand'binding'domain'(LBD)'(E)'and'aids'intracellular'trafficking.''Although'the'
amino'acid'sequence'of'the'LBD'is'only'moderately'conserved'the'structure'of'8'alpha>
helices'is'highly'conserved.''This'structure'allows'ligand'binding'and'along'with'the'DBD'
creates'the'dimerisation'interface'between'receptors.''The'LBD'is'the'site'of'co>activator'
and'corepressor'binding'and'contains'the'ligand'dependent'activation'function'(AF>2)'
region,'making' it' central' to' transcription' activation.' ' The' C>terminal' domain' (F)' is' a'
highly'variable'portion'of'the'receptor'(reproduced'with'permission).(121,122)'
!
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Figure'3.2. Structure.of.the.human.progesterone.receptor.DNA.binding.domain.
The'DNA'binding'domain'(DBD)'is'represented'by'the'green'and'cyan'ribbon'diagram'
with'the'zinc'atoms'represented'by'grey'spheres.''The'alpha'helices,'associated'with'zinc'
atoms,'produce'‘finger’'like'structure'that'allows'binding'into'the'major'groove'of'the'
DNA'(in'magenta)'(reproduced'with'permission).(121,122)!
!
!
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3.4.2! Progesterone(receptor(isoforms(
The!progesterone!receptor!is!coded!for!by!the!PGR!gene,!which!is!found!on!the!long!arm!
of!chromosome!11!(11q220q23).(123)!!This!gene!codes!for!both!of!the!main!isoforms;!
PR0A!and!PR0B.!!Consequently,!they!are!very!similar!in!structure!with!a!common!ligand0
binding! domain! and! DNA0binding! domain.! ! PR0B! is! longer! with! a! 1640amino! acid!
sequence!at!the!N0terminus!that!is!not!present!in!PR0A,!resulting!in!PR0B!having!three!
transcription!domains!(AF01,!AF02!and!AF03)!compared!to!the!two!domains!present!in!
PRA!(AF01!and!AF02)!(See!Figure!3.3).(124)(125)!!
A!third!translational!start!site!has!been!identified!at!amino!acid!position!595!and!results!
in!a!truncated!PR!isoform,!PR0C.!!As!this!isoform!lacks!the!N0terminus!and!one!zinc!finger!
present!in!PR0A!and!PR0B!it!is!transcriptionally!inactive.!!In'vitro!studies!suggest!it!may!
influence!the!activities!of!PR0A!and!PR0B!but!expression!is!not!seen!in'vivo!and!so!it!plays!
no!real!physiological!role,!and!will!not!be!considered!further.(116,118,126)!
The! two! main! isoforms! have! distinct! transcriptional! activity! due! to! the! additional!
activation! domain! (AF03)! found! at! the! amino0terminal! end! of! the! PR0B! protein.! ! In!
general,!PR0B!is!a!stronger!activator!of!transcription!than!PR0A.!However,!under!certain!
circumstances! PR0A! can! act! as! a! strong! activator! and! in! alternative! circumstances! is!
completely!inactive.!!When!inactive,!PR0A!acts!more!as!a!transdominant!repressor!of!
other!steroid!receptors!such!as!PR0B!and!the!oestrogen!receptor!(ER).!!This!feature!of!
the!PR0A!protein!has!been!mapped!to!the!first!140!amino!acids!of!the!amino0terminus!
and!is!called!the!inhibitory!domain!(ID)!(See!Figure!3.3).!!Although!this!domain!exists!in!
the!PR0B!protein! it! is!suppressed!by!the! longer!N0terminal!segment!and!so!PR0B!acts!
solely!as!an!activator!of!transcription.(120)!
The!action!of!progesterone!on!a!cell!is!determined!by!the!balance!of!expression!of!the!
two!isoforms!and!the!co0receptors!involved!once!DNA!binding!has!occurred.!!These!are!
both! influenced! by! the! type! of! cell! and! the! physiological! environment! of! that! cell,!
making! the! mechanism! of! action! of! progesterone! complex.! ! If! the! possibility! of!
alternative!receptor!ligands!is!considered0!i.e.!progesterone!antagonists!or!SPRMs,!the!
layers!of!complexity!multiply.!!Therefore,!predicting!the!action!of!such!compounds!in!
human!tissue!is!difficult!and!tissue/compound!specific!animal!and!human!studies!are!
required.!
!
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Figure'3.3. Modular.structure.of.PR]A.&.PR]B.
Functional'domains'of'PR>B'and'PR>A,'including'the'DBD'(DNA>binding'domain)'and'LBD'
(ligand' binding' domain),' are' indicated.' AF>3,' >1' and' >2' are' transcription' activation'
domains,'ID'is'an'inhibitory'domain'operative'in'PR>A'only'and'phosphorylation'sites'are'
marked'with'*.'The'proline>rich'region'of'PR>B'that'interacts'with'the'SH3'domain'of'Src'
tyrosine'kinase'is'underlined'(reproduced'with'permission).(116,120,127)''
!
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3.4.3! Transcription(control(
Ligand!binding!to!either!PR0A!or!PR0B!influences!transcription!control!and!thus!protein!
expression!by!two!different!mechanisms.!!Each!of!these!facilitate!binding!of!the!basal!
transcriptional!apparatus!and!co0regulators!that!allow!the!synthesis!of!mRNA!ready!for!
translation.! ! The! isoform!of! PR,! the! ligand! that! has! bound! the! receptor! and! the! co0
regulators!that!the!ligand!bound!receptor!attracts!all!influence!transcription.!
Direct*
Progesterone!binding!to!PR!leads!to!a!conformational!change!in!the!protein!structure!
which!result!in!the!PR!dissociating!from!chaperone!proteins,!such!as!hsp90,!and!forming!
homodimers! or! heterodimers.! ! Once! dimerisation! has! occurred! binding! to! the!
progesterone!response!element!(PRE)!takes!place!and!this!influences!the!recruitment!of!
RNA!polymerase!to!the!initiation!site!to!facilitate!transcription.(124)!
However,!the!resultant!transcription!is!controlled!predominantly!by!the!co0regulators!
that!also!bind!to!the!PR!dimer!DNA!complex.!!Over!300!co0regulators!interact!with!the!
progesterone!receptor!to!influence!transcription!leading!to!activation!or!repression!of!
specific! target! genes.(126)! ! It! is! these! co0regulators! that! influence! the! tissue! and!
physiological!context0specific!actions!of!progesterone!and!are!the!mechanism!through!
which!different!progesterone!receptor!modulators!exert!their!differing!actions!(Figure!
3.4).(113)!!!
One!example!of!a!co0activator! is! the!SRC01!(steroid!receptor!activator!which!recruits!
histone!acetyl!transferases!and!methyltransferases!that!alter!the!chromatin!structure!to!
facilitate! transcription.(118)(128)! ! This! has! been! demonstrated! to! be! the! primary!
cofactor!of!PR!regulation!in!the!uterus!through!knockout!mouse!studies.(129)!!
Co0repressors,!on!the!other!hand,!tend!to!interact!with!the!PR!when!a!more!antagonist!
ligand!is!bound.!!Studies!on!the!action!of!the!SPRM,!Asoprisnil,!have!demonstrated!that!
co0repressors! such! as! NCoR! (nuclear! receptor! corepressor)! and! SMRT! (silencing!
mediator!of!retinoic!acid!and!thyroid!hormone!receptor)!bind!to!both!PR0A!and!PR0B!
and!exert!an!inhibitory!effect.(130)!!!
!
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Figure'3.4. Progesterone.and.SPRM.action.on.transcription.
(A)' Progesterone' binding' leads' to' receptor' dimerisation' and' binding' of' the' receptor'
complex'to'the'progesterone'response'elements'in'the'promoters'of'target'genes.''The'
different'PR'isoforms,'PR>A'&'PR>B,'exert'different'biological'activities'by'interacting'with'
different'co>activators.' 'The'associated'co>activators' influence'the'basal' transcription'
apparatus'and'this'determines'the'resultant'gene'expression.'(B)'SPRM'binding'to'PR>
A/B'and'resultant'dimerisation'allows'greater'recruitment'of'co>repressors'such'as'NCoR'
(Nuclear'Receptor'Corepressor)'and'SMRT'(Silencing'Mediator'of'Retinoid'and'Thyroid'
hormone'receptor).''However,'the'conformational'change'generated'by'SPRM'binding'
also' allows' a' greater' interaction' with' coactivators' such' as' SRC>1' (Steroid' Receptor'
Coactivator>1)'and'AIB1'(Amplified'in'Breast'Cancer>1).''It'is'this'balance'that'determines'
the'action'of'each'SPRM>'as'the'conformational'change'caused'by'each'SPRM'is'slightly'
different.''This'is'further'influenced'by'the'fact'that'the'action'of'a'SPRM'within'a'specific'
tissue' will' also' be' influenced' by' the' balance' of' co>activators' and' co>repressors'
(reproduced'with'permission).(113)!
!
!
CHUTE!Thesis!(1.4)! 0!74!0!
CHANGES(IN(HISTOLOGY(FOLLOWING(ULIPRISTAL(THERAPY(IN(ENDOMETRIOSIS(
(CHUTE)(
Indirect*
The! extra0nuclear! and! indirect! transcription! mechanism! involves! ligand! binding! and!
dissociation!from!chaperone!proteins!but!dimerisation! is!not!required.!Ligand!bound!
progesterone!receptors!interact!with!Src!tyrosine!kinases!in!the!cytoplasm!and!activate!
mitogen0activated!protein!kinase!(MAPK)!cascade!allowing!transcription!activation!and!
resultant! gene! expression.[74,! 76,! 82]! ! It! is! through! this! pathway! that! progesterone!
influences!endometrial!stromal!cells!to!promote!proliferation!in!the!follicular!phase!and!
during!the!peri0implantation!period!by!activation!of!the!ERK/AKT!pathway.(131)!!
3.4.4! NonWgenomic(action(of(progesterone(
Some!of!the!actions!of!progesterone!in!certain!tissues!are!too!rapid!to!be!compatible!
with! transcriptional! activation,! are! not! abolished! by! transcription! inhibitors! and! are!
observed! in! anuclear! cells! like! erythrocytes;! indicating! a! non0genomic! pathway! of!
progesterone!action.!!The!fact!that!membrane!impermeable!progesterone!derivatives!
can!elicit!rapid!cellular!responses!has!been!taken!as!evidence!of!an!alternative!pathway!
but! should! be! viewed! with! caution! as! the! synthesised! membrane! impermeable!
progesterone! used! often! contains! small! quantities! of! free! progesterone! and! so! firm!
conclusions! from! such! studies! are! difficult.! ! Many! different! receptors,! intracellular!
pathways!and!animal!models!have!been!explored.!!!
The!membrane!bound!PR!(mPR)!is!a!classic!7!transmembrane!domain!G0protein!coupled!
receptor,! which! responds! to! progesterone! binding! by! initiating! a! phosphorylation!
cascade.!!This!mechanism!appears!to!play!a!role!in!activation!of!murine!macrophages!in!
response!to!progesterone.(132)!!A!further!example!is!intracellular!kinase!activation!and!
Ca2+! signalling! that! has! been! shown! in! the! VMN! of! the! rat! brain! in! response! to!
progesterone.(133,134)!
The!physiological!impact!of!the!non0genomic!pathway!is!unclear!and!a!review!on!the!
subject!by!Gellersen!et'al.!on!the!subject!in!2009!concluded!that!although!nPRs!are!the!
main!regulators!in!female!reproduction,!the!diverse!tissue!and!cell!specific!responses!to!
progesterone! cannot! simply! be! explained! by! a! single! mechanism! of! transcription!
regulation!at!the!promoter!regions!of!specific!genes.(116)!!Whether!these!pathways!are!
relevant! clinically! and! whether! SPRMs! influence! these! mechanisms! remains! to! be!
elucidated.!
!
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3.5! PROGESTERONE.ACTION.IN.EUTOPIC.ENDOMETRIUM.
The!PR0A!and!PR0B! isoforms!are!both!found! in!the!epithelial!and!stromal!cells!of! the!
endometrium! and! progesterone! exerts! specific! actions! on! each! of! the! cell! types! at!
different! time!points! in! the!cycle.! ! In! the!stratum' functionalis! proliferation!occurs! in!
response! to! oestrogen! during! the! proliferative! phase! of! the! cycle! and! is! further!
promoted! in! the! stromal! cells! by! the! action! of! progesterone.! ! In! the! luteal! phase,!
however,! progesterone! concentration! is! greater,! and! it! has! an! inhibitory! effect! on!
oestrogen!driven!proliferation,!promotes!secretory!changes!in!the!epithelial!cells!and!
decidualisation!of!the!stromal!cells.!!!
Decidualisation!involves!some!stromal!proliferation,!rounding!of!nuclear!structures!and!
accumulation!of!cytoplasmic!glycogen;!and! is!also!associated!with!the!recruitment!of!
various! immune! cells! and! angiogenesis.(135,136)! The! decidualised! stromal! cells!
undergo!apoptosis!on!progesterone!withdrawal!but!they!can!also!resist!oxidative!stress,!
regulate! local! immune! responses! and! behave! in! an! invasive!manner! –! all! properties!
associated!with!ectopic!endometrial!cells!in!endometriosis.(137)!
3.5.1! PRWA:PRWB(ratio(
The!ratio!of!the!PR!isoforms!varies!between!tissues!and!the!balance!of!these!isoforms!
may!contribute!to!the!variable!tissue!response!resulting!from!progesterone!exposure.!
When! PR0A:PR0B! is! greater! than! one,! PR0A! acts! more! as! an! inhibitor! rather! than!
promoter;! so! in! any! tissues,! pathophysiological! environment! or! pharmacological!
modification! where! PR0A! predominates! the! PR0A! driven! cellular! responses! will! be!
strongly! expressed.(118)! ! As! a! transcription! suppressor! it! inhibits! endometrial!
proliferation! and! mediates! the! anti0oestrogen! activity! of! progestins.! ! Mimicking! or!
altering!this!balance!of!PR!expression!may!be!the!key!to!influencing!proliferation!and!
explain! the! endometrial! effects! seen! following! exposure! to! progesterone! receptor!
modulators.!
The! balance! between! these! isoforms!may! also! be! key! to! certain! pathophysiological!
conditions.!!However,!interpretation!of!studies!looking!at!receptor!localisation!must!be!
undertaken!with! caution! as! the! receptors! share! a! significant! proportion! of! common!
sequence.!!Antibodies!can!be!synthesised!for!PR0A!and!PR0B!only!but!shared!amino!acid!
sequence!and!structural!differences!that!potentially!mask!epitopes!make!this!complex.!!
!
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Ensuring!the!antibody!used! is! isotope!specific!and!does!not!also!bind!the!alternative!
receptor!is!vital!for!interpretation!and!can!make!IHC!less!valuable!when!exploring!the!
different!isoforms!and!the!balance!of!expression.(115)(138)(139)!
3.5.2! Isoform(specific(actions(
PR0A! and! PR0B! increase! concordantly! with! oestrogen! concentration! during! the!
proliferative!phase.!!As!no!change!in!the!ratio!between!the!PR!isoforms!occurs!the!action!
on!the!epithelial!and!stromal!cells!is!similar!and!is!centred!around!proliferation.!!PR0A!
levels!in!epithelial!cells!decline!in!the!late!secretory!phase,!whilst!PR0B!remains!constant,!
suggesting!PR0A!may!be!involved!in!the!control!of!glandular!secretion.!!PR0A!appears!to!
be!the!predominant!isoform!seen!in!stromal!cells!but!with!less!late0secretory!decline!in!
expression.(118)!!
Knockout!mouse!models!have!been!used!to!explore!the!function!of!the!progesterone!
receptor.! ! PR0null! homozygous! mice! develop! normally! to! adulthood! but! defects! in!
uterine! growth,! ovulation! defects! and! impaired! implantation! make! reproduction!
impossible.!!These!changes!were!reversed!by!replacing!only!PR0A!(i.e.!PR0B!K.O.!mice),!
in! which! ovarian! function,! implantation! and! fertility! all! returned! to! normal.(140)!!
However,! PR0B! acting! alone! (PR0A! K.O!mice)! promotes! endometrial! hyperplasia! and!
does!not!allow!stromal!decidualisation.(141)!!This!demonstrates!that!PR0A!exerts!most!
of! the! physiological! functions! of! progesterone! and! helps! inhibit! the! PR0B! driven!
endometrial!hyperplasia.!!However,!the!balance!between!the!two!isoforms!seems!to!be!
important!as!overexpression!of!PR0A!relative!to!PR0B!seems!to!also!cause!hyperplasia,!
atypical!changes!in!the!endometrium!and!inflammatory!changes.!!These!findings!may!
give! some! indication! as! to! the! mechanism! behind! the! PAEC! (PRM0associated!
endometrial!changes)!that!SPRMs!can!promote,!which!are!discussed!in!Chapter!4.!!
! .
!
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3.6! PROGESTERONE.ACTION.IN.ECTOPIC.ENDOMETRIUM.(ENDOMETRIOSIS).
Ectopic!endometrial!implants!undergo!growth!and!morphological!change!in!response!to!
oestrogen!and!progesterone.!!Oestrogen!is!known!to!promote!a!proliferative!response!
in!eutopic!epithelial!cells!and!in!keeping!with!that!oestrogen!exposure!appears!to!act!as!
an! endocrine! risk! factor! for! promotion! and! progression! of! disease.! ! Progesterone!
exposure,!however,!has!an!inhibitory!effect,!promotes!disease!regression!and!forms!the!
basis!of!one!of!the!key!approaches!to!medical!management,!discussed!in!Chapter!1.!
3.6.1! PR(balance(of(expression(
The! involvement! of! PR! signalling! and! alterations! in! the! PR0A:PR0B! balance! in!
endometriosis! is! unclear.! ! Decreased! progesterone! responsiveness! (progesterone!
resistance)!in!endometrial!stromal!cells!appears!to!play!a!role!in!endometriosis!but!the!
role! of! PR0expression! is! less! clear.(28)! ! Most! studies! evaluating! PR! expression! in!
endometriosis!have!shown!reduced!levels!in!ectopic!endometrium!compared!to!eutopic!
endometrium,!with!five!showing!a!reduction!and!one!study!showing!no!difference.(118)!!
When!the!difference!between!PR0A!and!PR0B!has!been!explored!no!consistent!finding!
has!been!demonstrated.!!In!peritoneal!lesions!PR0B!is!not!expressed!and!PR0A!expression!
is!reduced,!but!in!ovarian!disease!PR0B!shows!dominant!expression.(142,143)!!
The! most! popular! pathogenic! mechanism! to! explain! endometriosis! is! retrograde!
menstruation! proposed! by! Sampson.(1)! ! The! often! cited! flaw! in! this! theory! is! that!
endometriosis!occurs!in!only!5010%!of!women!but!retrograde!menstruation!is!almost!
universal.!Based!on!the!assumption!that!ectopic!endometrial!deposits!originate!as!cells!
from!the!eutopic!endometrium!that!persist!at!the!ectopic!location,!studies!have!been!
undertaken!to!investigate!differences!in!the!functionality!of!eutopic!endometrial!cells!in!
patients!with!endometriosis!to!help!explain!this!disparity.!
Wölfer!et'al.!undertook!IHC!staining!of!eutopic!endometrial!samples!obtained!during!
diagnostic! laparoscopy! for! patients! with! pelvic! pain! &! infertility! symptoms.! ! They!
demonstrated! that! in! patients! without! endometriosis! expression! of! PR0A! &! PR0B!
increased! during! the! proliferative! and! early! secretory! phase! of! the! cycle! and! then!
decreased!in!the!mid!to!late!secretory!phase!in!epithelial!cells,!as!would!be!expected.!!A!
similar! pattern! was! seen! in! stromal! cells! but! the! decline! in! PR0A! and! PR0B! was!
imbalanced!such!that!by!the!late!secretory!phase!only!PR0A!persisted.(94)!
!
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In!patients!with!endometriosis! this! cycle!dependent!pattern!was!not! seen!and!huge!
levels!of! inter0individual!and! intra0individual!differences! in!PR0A!and!PR0B!expression!
were! seen.! ! PR0A! expression! was! more! consistent! with! the! receptor! identified! in!
epithelial!and!stromal!cells!during!proliferative!and!secretory!phases!of!the!cycle.!!PR0B,!
however,!was!not!detectable!in!some!of!the!proliferative!and!mid0secretory!samples!of!
both!cell!types!and!then!strongly!expressed!in!the!late!secretory!phase!in!the!epithelium!
and!stroma.!!Overall!the!expression!of!PR!was!quite!heterogeneous!and!disrupted.!(94)!!!!!
3.6.2! Progesterone(resistance(
In!patients!with!endometriosis,!the!dysregulation!of!PR!expression!seen!in!the!study!by!
Wölfer!et'al.,!the!work!by!Jones!et'al.(144)!showing!delay!in!endometrial!maturation,!
and!the!transcriptome!analysis!by!Burney!et'al.(30)!showing!molecular!dysregulation!of!
the! proliferative0to0secretory! transition,! are! all! in! keeping! with! the! “progesterone!
resistance”!theory.!!Whether!these!changes!are!just!at!the!isoform!level!or!whether!the!
co0regulators!are!involved!as!well!is!unknown.(137)!!It!is!also!not!clear!whether!any!of!
the!observed!changes!are!seen! in!ectopic!deposits!of!endometrium!in!endometriotic!
deposits! as! very! little! work! has! been! published! on! histological! analysis! and! PR0
expression!assessment!in!such!tissues.!
! !
!
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3.7! PROGESTERONE.RECEPTOR.MODULATORS.
The! selective! progesterone! receptor! modulators! are! steroids! derived! from!
norethindrone.(125)! ! These! compounds! have! shown! various! clinical! effects! and! the!
therapeutic!applications!that!have!been!studied!are!shown! in!Table!1.! !Mifepristone,!
Asoprisnil,! Telapristone! acetate! and! Onapristone! have! been! considered! for! use! in!
Endometriosis! but! are! yet! to! provide! a! licensed! product.! ! The! specific! chemical!
structures!of!these!SPRMs!and!that!of!ulipristal!acetate!are!shown!in!Figure!3.5.!
!
Figure'3.5. Chemical.structures.of.SPRMs..
Compound'numbers'shown'in'brackets'(reproduced'from'company'literature'with'
permission'from'Gedeon'Richter).'
!
!!!!
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COMPOUND. THERAPEUTIC.APPLICATION.
Mifepristone.(RU]486). Termination!of!pregnancy§!
Emergency!contraception§!!
Psychosis!
Cushing!disease§!
Long0term!contraception!
Uterine!fibroids!
Endometriosis!
Alzheimer!disease!
Endometrial!cancer!
Ulipristal.acetate.(CDB]2914;.VA2914). Emergency!contraception§!!
Uterine!fibroids§!
Long0term!contraception!!
Asoprisnil.(J]867). Uterine!fibroids!
Endometriosis!
Long0term!contraception!!
Telapristone.acetate.(CDB]4124). Uterine!fibroids!!
Anemia!
Endometriosis!!
Lonaprisan.(ZK230211). Cancer!
CP8816.and.CP8863. Gynecologic!disorders!!
WAY]255348. Contraception!
Onapristone.(ZK98299). Endometriosis!
Cancer!
ORG]31710.and.ORG]31806*. Contraception!!
Cancer!
PF]2413873*. Endometriosis!!
ZK137316*. Contraception!
Table'3.1' Selective.progesterone.receptor.modulators.(SPRMs)'''
Selective'progesterone'receptor'modulators'(SPRMs)'with'current'or'past'development'
noted' in' the' literature' (those' licensed' are' indicated,' §).' Studies' of' the' compounds'
marked'(*)'have'either'been'discontinued'or'suspended'since'the'1990s'(reproduced'with'
permission).(113)!
!
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3.7.2! Origins(
The!first!progesterone!receptor!modulator!or!anti0progestin!was!discovered!in!the!1982.!!
Some! of! the! five! types! of! steroid! hormones! were! known! to! have! antagonists;!
clomiphene! inhibits! oestrogen! action,! spironolactone! inhibits!mineralocorticoids! and!
cyproterone!acetate! inhibits! the!action!of!androgens.! !However,!no! such!compound!
existed! for! action! against! glucocorticoids! and! in! the! search! for! one! RU486! or!
Mifepristone!was!discovered!as!a!potent!anti0progestin.(145,146)!!Healey!et'al.!explored!
the!functions!of!progesterone!using!this!compound!and!were!able!to!demonstrate!that!
its! administration! to! an! appropriately! primed! endometrium! in! primates! induces!
menstruation.(147,148)!
Mifepristone!was!evaluated!through!the!1980s!as!an!abortion0inducing!agent!but!the!
development!was!slow!due!to!political!pressure!and!the!emotive!nature!of!its!intended!
use.!!Mouse!studies!demonstrated!the!potent!anti0progesterone!properties!of!RU486!
and!this!was!backed!up!by!work!on!female!monkeys!(Macaca'fasicularis)!in!1982.(149)!!
A!license!for!use!in!France!was!granted!in!1988!and!this!prompted!the!first!human!trial,!
in! which! Mifepristone! induced! a! pregnancy! termination! in! 9! out! of! 11!
volunteers.(125,150)!
The!use!of!Mifepristone!in!pregnancy!termination!has!since!developed!and!now!offers!
a!safe,!non0surgical!method!to!those!who!wish!to!use!it.!!This!is!particularly!important!
in!areas!of!the!world!where!healthcare!services!are! limited!and!access!to!alternative!
methods!or!preventative!methods!may!be!limited.!!A!Cochrane!review!demonstrated!
that!the!combination!of!Mifepristone!and!PGE1!analogues!was!highly!effective!and!safe.!
(151)!!This!is!supported!by!the!Royal!College!of!Obstetricians!and!Gynaecologists.(152)!!!
3.7.3! Mechanism(of(action(
The! exact! mechanism! of! action! of! progesterone! receptor! modulators! remains!
incompletely!understood!but!appears!to!be!a!complex!interplay!of!factors!rather!than!a!
single!inhibitory!feature.!!The!anti0proliferative!effects!these!compounds!have!on!the!
endometrium! is! of! huge! potential! in! endometriosis! but! the! way! in! which! each!
compound! regulates! oestrogen0driven! mitosis! in! the! uterine! glands! and! stroma! is!
uncertain.(153)!!The!areas!that!have!been!considered!are!action!at!the!receptor,!control!
of!transcription!through!cofactors!and!upregulation!of!the!expression!of!the!androgen!
receptor.(154)!
!
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Receptor*binding*
Studies! looking! at! the! action! of! Mifepristone! demonstrated! three! features.! Firstly,!
competitive!inhibition!of!PR!occurs!as!a!result!of!RU486!having!higher!binding!affinity!
for!PR!as!compared!to!that!of!progesterone.!!Secondly,!RU486!binding!has!no!impact!on!
receptor! dissociation! from! HSP,! receptor! dimerisation! or! progesterone! response!
element! (PRE)! binding;! highlighting! that! the! antagonistic! result! of! RU486! binding! is!
achieved!by!disturbing!DNA!transcription.!!The!final!feature!noted!is!that!RU486!binding!
leads! to!an!alternative! conformational! change!when!compared! to!progesterone! that!
leads!to!inactivation!of!AF02!and!prevents!coactivator!binding!and!hence!renders!the!
receptor!transcriptionally!inactive.(120)!
Transcription*cofactors*
The!balance!of!agonist!and!antagonist!properties!of!each!SPRM!appear!to!be!because!of!
the!balance!of!co0activators!and!co0repressors!that!interact!with!the!ligand!bound!PR0
dimer,! as! previously! discussed! (Figure! 3.4).! ! This!may! be! as! a! result! of! the! specific!
conformational!changes!induced!by!the!ligand!in!question!allowing!the!co0receptors!to!
be!bound!or!by!influencing!the!rate!of!co0receptor!shuttling!and!degradation!within!the!
endoplasmic!reticulum.(155–157)!
Liu!et'al.! demonstrated! that!progesterone!bound!PR! interacts!only!with! coactivators!
such!as!steroid!receptor!coactivator01!(SRC01)!whereas!Mifepristone!bound!PR!interacts!
weakly!with!SRC01!but!strongly!with!the!corepressor,!silencing!mediator!for!retinoid!and!
thyroid! hormone! receptor! (SMRT)! in' vitro.(158)! ! This! feature! has! also! been!
demonstrated!with!Asoprisnil.!!However,!in!this!study!both!Mifepristone!and!Asoprisnil!
were!shown!to!recruit!the!corepressor,!nuclear!receptor!corepressor!(NCoR),!but!with!
lower!affinity!in!response!to!Asoprisnil!suggesting!a!less!antagonistic!profile.(130)!!
Androgen*receptor*upregulation*
Studies!on!the!rhesus!macaque!endometrium!have!shown!upregulation!of!ER,!PR!and!
AR!in!response!to!chronic!administration!of!Mifepristone,!as!well!as!a!suppression!of!
glandular! secretory! function.(96,97,159)! ! As! androgens! result! in! an! anti0oestrogen!
action!on!the!endometrium,!upregulation!of!the!AR!may!explain!why!SPRMs!have!an!
anti0proliferative!action!on!the!endometrium.!!This!upregulation!of!AR!has!also!recently!
been!demonstrated!in!response!to!ulipristal!acetate.(160)!!!
!
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3.7.4! Endometrial(effects(
The!use!of!progesterone!antagonists!and!SPRMs!is!associated!with!reduced!menstrual!
bleeding!and!amenorrhoea.! !There!are!several!proposed!mechanisms!to!explain!this:!
suppression! of! oestrogen0dependent! endometrial! proliferation! and! mitosis,! direct!
effects!on!endometrial!vasculature,!altered!glucocorticoid!receptor!expression!(reduced!
VEGF!expression)!and!ovulation!inhibition.(161–163)!!In!truth,!it!may!be!a!combination!
of!all!these!mechanisms!but!the!suppression!of!proliferation!seen!in!response!to!PRMs!
is!encouraging!with!respect!to!managing!endometriosis.!!The!known!actions!of!PRMs!on!
the! endometrium! and! the! histological! entity! of! PAEC! have! been! thoroughly!
reviewed(164),!and!are!discussed!in!more!detail!in!Chapter!4.!
!
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3.8! SPRMS.AND.ENDOMETRIOSIS.
Clinical! trials! of! the! use! of! SPRMs! in! the! treatment! of! endometriosis! have! been!
undertaken! for! Mifepristone,! Asoprisnil! and! Telapristone,! with! some! encouraging!
results.! ! These! trials! show! clinical! improvement! of! symptoms! and! the! macroscopic!
appearance!of!the!disease!in!response!to!drug!exposure.!!The!most!promising!of!these!
agents!was!expected!to!be!Asoprisnil!but!work!with!this!compound!was!abandoned!due!
to! concerns! relating! to! PAEC! though! these! findings! have! yet! to! be! formally!
published.(165)! However,! ulipristal! acetate! has! not! been! studied! in! the! context! of!
endometriosis!to!date.!
3.8.1! Mifepristone(((
Kettel! et' al.! have! undertaken! three! small! pilot! studies! of! Mifepristone! use! in!
endometriosis.! !Initially!a!dose!of!100mg/day!was!given!to!six!patients! for!3!months,!
resulting!in!improved!pain!symptoms!but!no!significant!effect!on!the!extent!of!disease!
at! follow! up! laparotomy.! ! Subsequently,! a! dose! of! 50mg/day! of! Mifepristone! was!
administered!to!nine!women!with!endometriosis!for!6!months.!!In!this!pilot!study,!a!55%!
regression!of!disease!was!seen!and!improvement!in!symptoms!in!all!patients.!Finally,!a!
dose! of! 5mg/day! was! used! for! 6! months.! ! Although! this! lower! dose! did! result! in!
symptomatic! improvement! it! failed! to! stablise! the! endometrium! and! induce! the!
anovulatory! amenorrhoea! without! hypo0oestrogenism! seen! with! the! higher!
doses.(166–168)!
Mifepristone!has!also!been!shown!to!induce!apoptosis!in!an!endometrial!cell!line,!which!
may!explain!the!regression!seen!by!Kettel!et'al.!!Han!&!Sidell,!demonstrated!increased!
cellular!binding!of!nuclear!transcription!factor!nuclear! factor0#B!(NF0!#B)! in! cell! lines!
treated! with!Mifepristone.! ! In! addition,! they! also! demonstrated! increased! bax! and!
reduced!bcl>2!expression;!both!apoptosis!regulators!whose!transcription!is!regulated!by!
NF0#B.(169)!!!
However,! this! apoptosis! and! reduction! in! ectopic! endometrial! size! has! not! been!
demonstrated! in! a! mouse! model,! in! which! endometriosis! was! induced! in! mice! by!
injecting!a!suspension!of!endometriotic!cells!into!the!peritoneal!cavity.!!These!animals!
were!administered!mifepristone!and!reduced!expression!of!COX02!and!PGE2!was!seen,!
although!no! significant! change! in!disease!volume!was!demonstrated.! !As!COX02!and!
!
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prostaglandin!E2!are!both!important!in!the!mediation!of!pain!it!suggests!Mifepristone!
may!also!act!through!an!anti0inflammatory!mechanism.(170)!!
Consequently,!a!Mifepristone0loaded!implant!is!currently!in!development!for!the!long0
term!treatment!of!endometriosis.!!It!has!shown!promise!from!both!a!safety!and!efficacy!
point!of!view!in!a!Wister!rat!model!of!endometriosis,!with!a!dose!dependent!inhibitory!
effect!on!the!growth!of!endometrial!explants.(171)!
3.8.2! Asoprisnil(
Asoprisnil,!like!all!selective!progesterone!receptor!modulators,!has!both!partial!agonist!
and! antagonistic! properties.! ! The! balance! of! these! properties! is! specific! to! each!
compound!and!appears!to!be!related!to!the!balance!of!coactivators!and!corepressors.!!!!
Studies!in!rats,!guinea!pigs,!rabbits!and!cynomolgus!monkeys!have!demonstrated!that!
Asoprisnil!can!abolish!menstrual!cyclicity,!induce!endometrial!atrophy!and!inhibit!COX0
2! production.! ! As! such! it! has! been! considered! for! the! treatment! of! fibroids! and!
endometriosis.(130,172,173)!!
Initially,!it!was!studied!for!the!treatment!of!fibroids!and!for!cycle!control.!!In!the!Phase!I!
study,!60!regularly!cycling!premenopausal!women!took!Asoprisnil!for!280days!leading!to!
suppressed!menstruation!but!with!oestrogen!levels!maintained.(174)!!The!Phase!II!study!
that!followed!this!involved!administering!5,!10,!or!25mg,!or!placebo!to!129!women!for!
12! weeks.! ! The! outcomes! were! controlled! uterine! bleeding! and! a! reduction! in!
leiomyoma!volume!and!consequently,!pressure!symptoms.(175)!!!
This!was! followed!up!with!a!small! study!of!patients!who!were!given!Asoprisnil! for!3!
months!prior!to!hysterectomy.! !This!study! identified!the! ‘non0physiological!secretory!
effect’! or! PRM0! associated! endometrial! changes! (PAEC),! as! described! below.(163)!!
Immunohistochemical! analysis! of! the! data! from! this! study! showed! no! loss! of! PTEN!
(phosphatase!and!tensin!homologue)!expression,!!but!a!reduction!in!the!expression!of!
Ki67!in!endometrial!changes.(176)!!!!!!
3.8.3! Onapristone(
Onapristone!is!largely!an!antagonist!like!Mifepristone!and!has!been!tested!against!a!rat!
model!of!endometriosis.!Remission!of!the!surgically!induced!ectopic!deposits!of!disease!
was!seen!in!40%!of!cases!with!a!reduction!in!epithelial!cells!within!ectopic!endometrium!
!
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but!not!eutopic!endometrium.!!This!work!suggests!that!the!two!cell!populations!behave!
differently!in!response!to!SPRMs.(177)!!
3.8.4! Telapristone((Proellex$)(
Use! of! Telapristone! in! the! management! of! women! with! endometriosis! has! been!
evaluated.!!This!study!also!highlighted!the!features!of!PAEC!in!the!subjects!who!took!the!
Telapristone!for!either! fibroids!or!endometriosis.! !Unfortunately,!evidence!of!hepatic!
dysfunction!as!a!result!of!the!study!drug!was!demonstrated!and!so!it!is!not!licensed!for!
use!in!human!subjects.(178)!!!
3.8.5! Ulipristal(acetate(
The!details!of!ulipristal!acetate!with!respect!to!the!management!of!endometriosis!will!
be!discussed!in!more!detail!in!Chapter!4.!!!
However,! it! should! be! noted! that! for! all! SPRMs! there! is! a! lack! of! any! good! quality!
research! into! the! histological! changes! in! ectopic! endometrial! deposits! seen! in!
endometriosis!following!exposure!and!their!use!remains!largely!theoretical.!!It!should!
be!noted!that!in!the!few!studies!looking!at!ectopic!endometrium!in!animal!models!the!
endometriosis!is!induced!by!injecting!endometrial!cells!into!the!peritoneal!cavity!or!by!
surgical!implantation!of!portions!of!eutopic!endometrium!at!ectopic!locations.!!Although!
both! these!methods! are! successful,! they! are! non0physiological! and! the! lesions! they!
create!may!not!behave!in!the!same!manner!as!true!endometriosis.!!As!such!inference!
from!such!models!is!difficult!and!may!lead!to!incorrect!conclusions!about!both!efficacy!
and!safety.!!!
An!understanding!of!the!histological!changes!and!receptor!expression!within!the!ectopic!
endometrium!of!human!subjects,!after!treatment!with!ulipristal!acetate,!may!give!useful!
information! about! the! potential! efficacy! of! this! SPRM! in! the! management! of!
endometriosis.!!Reassurance!about!safety!is!still!required!as!selective!antagonism!of!the!
progesterone! receptor! in! premenopausal! women! who! are! actively! producing!
oestrogens! is! still! of! some! concern! with! respect! to! endometrial! hyperplasia! and!
carcinoma!and!is!completely!unknown!with!respect!to!ectopic!endometrial!deposits!that!
persist!even!after!menstrual!shedding!in!endometriosis.
!
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3.9! SPRMS.AND.ADENOMYOSIS.
The!endometrium!is!abnormally!located!in!adenomyosis,!leading!to!a!diffusely!enlarged!
uterus!with!ectopic! foci!of!endometrial!glands!and!stroma!within!a!hypertrophic!and!
hyperplastic!myometrium.!!!The!abnormal!uterine!bleeding!and!dysmenorrhoea!result!
in!chronic!pelvic!pain!and!significant!symptom!overlap!with!endometriosis,!which!can!
occur!concurrently.!!!This!overlap!of!clinical!presentation!make!distinguishing!the!two!
conditions! difficult! but! the! joint! prevalence! is! estimated! to! be! between! 1.8%! and!
3.3%.(179,180)!
A! mouse! study! in! 2000,! suggested! Mifepristone! could! inhibit! the! genesis! of!
adenomyosis.(181)! ! Then! in!2014!a! study! in!humans! showed! ! caspase!3! !expression!
within!adenomyosis!tissue!was!increased!by!treatment!with!!Mifepristone,!resulting!in!
cell!apoptosis!and!inhibition!of!the!disease.(182)!!Beyond!these!studies!and!the!small!
number!of!studies!exploring!SPRM!use!in!endometriosis!described!above!there!is!little!
published! literature!to!consider.! !However,! the!potential!use!and!safety!of!SPRMs! in!
adenomyosis!remain!an!important!area!of!research.!
!
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Chapter.4:!ULIPRISTAL.ACETATE.
4.1! INTRODUCTION.
Ulipristal!acetate!is!a!selective!progesterone!receptor!modulator!currently!marketed!for!
emergency!contraception!(ellaOne%)!and!the!treatment!of!uterine!fibroids!(Esmya%).!
The!anti0proliferative!action!it!exerts!on!uterine!fibroids!causes!a!reduction!in! fibroid!
size,!a!reduction!in!fibroid!related!symptoms!and!helps!minimise!surgical!complications.!!
As!an!SPRM,!ulipristal!acetate!has!a!unique!action!on!the!endometrium.!!This!action!has!
been! defined! as! a! new! histopathological! phenomenon! and! is! referred! to! as! PRM0!
Associated! Endometrial! Changes! (PAEC).! !Whilst,! these! changes! are! reversible! once!
treatment!stops!and!they!are!not!considered!a!precursor!to!endometrial!hyperplasia,!
caution!about!the!nature!of!these!changes!remains.!
Given! the! anti0proliferative! action! of! ulipristal! acetate! on! eutopic! endometrium! the!
action! on! ectopic! endometrium! and! endometriosis! should! also! be! considered.! ! The!
CHUTE!study!was!designed!to!explore!the!use!of!ulipristal!acetate!for!endometriosis!in!
the! context! of! clinical! safety! and! possible! occurrence! of! PAEC! within! ectopic!
endometrium.!!
4.2! CLINICAL.USE.
4.2.1! Emergency(contraception(
Ulipristal! acetate! was! first! licensed! for! use! as! an! emergency! contraception! in!May!
2009.(183)!!A!dose!of!30mg!can!be!given!up!to!120!hours!after!unprotected!intercourse!
to!either!prevent! or!delay!ovulation! in!order! to! prevent! conception.! ! The!data! from!
Phase! II!&! II!studies!show!a!0.902.1%!pregnancy! rate!but!no! significant!difference! in!
efficacy!up!to!120!hours.(184)! !However,! it! is!maximally!effective!if! taken!as!soon!as!
possible!after!intercourse!and!is!generally!considered!to!be!95%!effective.!!!
4.2.2! Fibroids(
Uterine!leiomyomas!(fibroids)!are!benign!smooth!muscle!tumours!of!the!myometrium,!
whose!growth!in!promoted!by!oestrogen!and!progesterone.!!Their!presence!within!the!
uterus!is!increasingly!common!with!advancing!age,!such!that!20025%!of!women!over!35!
!
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years!and!70%!of!women!over!50!have!fibroids.(185,186)!The!majority!of!women!are!
asymptomatic! but! 20050%! have! symptoms! significant! enough! to! require!
intervention.(187)! The! use! of! medical! therapy! and! interventional! radiological! have!
reduced!the!need!for!surgical!intervention!but!fibroids!still!remain!the!leading!indication!
for!hysterectomy!in!the!UK.(188)!!!
SPRMs*&*fibroids*
Currently!the!only!SPRM!licensed!for!use!in!the!UK!is!ulipristal!acetate!(UPA)!(Esmya®).!!
It!has!an!anti0proliferative,!anti0fibrotic!and!pro0apoptotic!effect!on!leiomyoma!cells!and!
is!consequently!used!for!the!medical!treatment!of!moderate!to!severe!fibroid!related!
symptoms.! ! The!original!marketing!approval! in! the!EU!was!granted!on!23rd! February!
2012!with!the!therapeutic!indication!of!‘pre0operative!treatment!of!moderate!to!severe!
symptoms!of!uterine!fibroids!in!adult!women!of!reproductive!age’.!!!However,!evolving!
safety! and! efficacy! information! resulted! in! a! license! extension! on! 23rd! April! 2015! to!
include!‘intermittent!treatment’.!!As!a!consequence!multiple!three!month!courses!for!
the! medical! management! of! moderate! to! severe! uterine! fibroids! can! now! be!
prescribed.(189)!
Mechanism*of*action*
To!understand!the!action!of!SPRMs!on!fibroids!it!is!important!to!consider!the!response!
of! fibroids! to! the! sex! steroids.! ! Leiomyoma! cells! grow! in! response! to! exposure! to!
oestrogen.!!This!is!explained!by!the!fact!that!the!ratio!of!oestrogen!receptors!(ER)!to!
progesterone! receptors! (PR)! is! higher! in! leiomyomas! when! compared! to! normal!
myometrium.(190)!!Hence!why!medical!treatments!that!suppress!oestrogen!levels!have!
a!positive!impact!on!fibroid!growth.!
The!action!of!progesterone!on!leiomyoma!cells!as!compared!to!myometrial!cells!is!more!
complex!and!was!explored!by!Maruo!et'al.,! in!2003.(191)!!Leiomyoma!cells!in!culture!
were!assessed!after!exposure! to!progesterone!and!quantified! the!expression!of! two!
growth! factors! (epidermal!growth! factor! (EGF),! insulin0like!growth! factor! (IGF0I))! and!
two! apoptosis! factors! (tumour! necrosis! factor0a! (TNF0a),! Bcl02! protein).! ! The! results!
demonstrated!increased!levels!of!EGF!and!Bcl02,!which!promote!cell!growth!and!survival,!
and!decreased!levels!of!IGF0I!and!TNF0a,!which!inhibit!growth!and!promote!apoptosis.!!
This!balance!of!effects!helps!to!explain!why!progesterone!(in!the!LNG0IUS,!for!instance)!
!
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sometimes! improves! symptoms! and! sometimes! promotes! tumour! growth! and!
worsening!symptoms.!
Ulipristal!acetate!exerts!a!tissue0specific!partial!progesterone!antagonist!effect,!which!
has! a! direct! action! on! fibroids! reducing! their! size.(189)! ! The! action! of! the! drug! on!
leiomyoma! cells! results! in! increased! expression! of! cleaved! caspase03! and! decreased!
expression!of!Bcl02;!as!well! as!downregulation!of!angiogenic!growth! factors,! such!as!
vascular! endothelial! growth! factor! (VEGF)! and! it’s! receptor.(192–194)! ! As! a!
consequence,!neovascularisation,!cell!proliferation!and!cell!survival!are!all!inhibited!in!
leiomyoma!cells!but!not!normal!myometrium.!
Collagen!synthesis!and!deposition!are!also!influenced!by!ulipristal!acetate.!!Expression!
of!matrix!metalloproteinases!(MMPs)!is!increased!and!expression!of!tissue!inhibitor!of!
metalloproteinases! (TIMPs)! is! reduced! in! cultured! fibroid! cells! but! not! in! normal!
myometrial!cells.!This!reduction!in!collagen!deposition!within!the!extracellular!spaces!
impairs! tissue! integrity! and! explains! the! consistency! of! fibroid! tissue! seen! at!
myomectomy!following!pre0operative!treatment!with!ulipristal!acetate.(195)!
The!ratio!of!progesterone!receptor!isoforms!(PR0A!&!PR0B)!in!cultured!leiomyoma!cells!
are!modulated!by!ulipristal!acetate.!!This!modulation!results!in!decreased!cell!viability;!
suppressed!expression!of!growth!and!angiogenic!factors!(as!discussed!above);!and!elicits!
endoplasmic!reticulum!stress!and!activation!of!the!mitochondrial!and!tumor!necrosis!
factor0related!apoptosis0inducing!ligand!(TRAIL)!pathways,!resulting!in!apoptosis.(196)!!
In!addition,!ulipristal!acetate!also!acts!centrally!influencing!the!hypothalamic0pituitary0
ovarian!axis!resulting!in!delayed!or!inhibited!ovulation.!!Despite!this!action!it!does!not!
change!the!basic! levels!of! luteinising!hormone!(LH)!or! follicular!stimulating!hormone!
(FSH)!such!that!oestradiol!levels!are!maintained!in!the!mid0follicular!physiological!range!
(600150pg/mL).!!As!a!consequence!oestrogen!deficiency!and!vasomotor!symptoms!that!
complication!GnRH!agonist!use!are!less!of!a!problem!with!ulipristal!acetate.(124)!
The!inhibition!of!ovulation!and!stable!oestrogen!levels!tends!to!promote!amenorrhoea!
but!ulipristal!acetate!also!has!a!direct!action!on!the!endometrial!progesterone!receptors!
that!may!influence!this.(190)!
!
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4.3! CLINICAL.RESEARCH.STUDIES.INVOLVING.ULIPRISTAL.ACETATE.
Four! randomised,! double0blind,! multinational,! Phase! 3! clinical! trials! have! been!
conducted! to! explore! the! therapeutic! efficacy! and! tolerability! profile.! ! They! are!
collectively!known!as! the!PEARL! (PGL4001! (Ulipristal!Acetate)!Efficacy!Assessment! in!
Reduction! of! Symptoms! Due! to! Uterine! Leiomyomata)! studies.! ! The! first! two! trials!
provided!the!evidence!to!secure!the!initial!pre0operative!licence!and!then!the!data!from!
the!second!two!allowed!the!licence!extension!to!include!intermittent!treatment:!
1)! PEARL. I! (Ulipristal! Acetate! versus! Placebo! for! Fibroid! Treatment! before!
Surgery),!compared!oral!UPA!(5!or!10mg/day)!with!placebo;(197)!
2)! PEARL. II! (Ulipristal! Acetate! versus! Leuprolide! Acetate! for! Uterine! Fibroids),!
compared!UPA!with!a!GnRH!analogue,!Leuprolide!acetate!(LA)!(3.75mg!once!
per!month);(198)!
3)! PEARL. III! (Long0term! treatment! of! uterine! fibroids! with! ulipristal! acetate),!
involved!four!separate!30month!courses!of!UPA!(open!label),!each!followed!by!
randomised!double!–blind!norethisterone!acetate!(NETA)!or!placebo;(199)!
4)! PEARL. IV! (Efficacy!and!safety!of! repeated!use!of!ulipristal!acetate! in!uterine!
fibroid),! evaluated! the! administration! of! two! 30month! courses! of!UPA! (5! or!
10mg!daily).(200)!
4.3.1! PEARL(I(
Symptomatic!women!with!heavy!menstrual!bleeding!(pictorial!blood0loss!assessment!
chart!(PBAC)!score!>100)!and!anaemia!(haemoglobin!level!of!≤10.2!g/L)!were!randomly!
assigned!to!13!weeks!of!oral!treatment:!96!women!received!5mg!ulipristal!acetate!daily,!
98!women!received!10mg!ulipristal!acetate!daily,!and!48!women!received!placebo.!!The!
primary! end! points! were! control! of! bleeding! (PBAC! <75)! and! a! reduction! of! fibroid!
volume!as!assessed!on!MRI.(197)!
The!trial!demonstrated!effective!control!of!menorrhagia!with!ulipristal!acetate.!!At!13!
weeks! bleeding! control! was! achieved! in! 91%! (P<0.001)! and! 92%! (P<0.001)! of! the!
5mg/daily!and!10mg/daily!groups,!respectively;!and!was!achieved!within!10!days!in!73%!
and! 82%,! respectively.! ! This! compares! to! only! 19%! in! the! placebo! group! achieving!
bleeding!control,!and!only!6%!achieving!this!at!8!days.(197)!!!
!
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A! clinically! significant! reduction! in! fibroid! size! was! achieved! with! ulipristal! acetate!
compared!to!placebo.!!The!median!change!in!total!fibroid!volume!was!021%!(p=0.002,!
for! comparison! of! 5mg! ulipristal! acetate! with! placebo)! and! 012%! (p=0.006,! for!
comparison!of!10mg!ulipristal!acetate!with!placebo),!whereas!the!total!fibroid!volume!
increased!by!3%!in!the!placebo!group.(197)!!
4.3.2! PEARL(II (
This!was! a! double0blind! noninferiority! trial! in!which! 307! symptomatic! patients!were!
randomly!assigned!to!either!5mg!or!10mg!of!oral!ulipristal!acetate!daily! (97!and!103!
patients,! respectively)! or! a! monthly! intra0muscular! injection! of! 3.75mg! leuprolide!
acetate! (101! patients)! for! a! period! of! 3! months.! ! The! primary! outcome! was! the!
proportion!of!patients!with!controlled!bleeding!at!13!weeks.(198)!
The!results!showed!that!heavy!menstrual!bleeding!was!controlled!in!90%,!98%,!and!89%!
of!the!women!receiving!5mg!UPA,!10mg!UPA!and!leuprolide!acetate!(LA),!respectively.!
All! treatments!reduced!the!fibroid!volume!with!5mg!ulipristal!acetate!causing!a!36%!
reduction,! 10mg!ulipristal! acetate! causing! 42%! reduction! and! LA! the!most! effective,!
causing! a! 53%! reduction.! ! However,! the! ulipristal! acetate! was! quicker! to! achieve!
bleeding! control!with! the!median! time! to! amenorrhoea! of! 7! days! (5mg!UPA! group)!
compared!to!the!21!days!taken!with!leuprolide!acetate.(198)!
The! study! also! highlighted! two! distinct! benefits! over! GnRHa! therapy! 0! the! effect! of!
ulipristal!acetate!is!sustained!for!six!months!after!completing!the!course!of!treatment!
and!patients!on!ulipristal!acetate!experience!fewer!hot!flushes!(11%!in!the!5mg!group,!
10%! in! the! 10! mg! group! and! 40%! in! the! LA! group),! due! to! higher! oestradiol!
concentrations,!when!compared!to!leuprolide!acetate!(p<0.001).(198)!
4.3.3! PEARL(III (
To!explore!the!possibility!of!long0term!treatment!of!symptomatic!fibroids!with!ulipristal!
acetate,!209!women!with!symptomatic!fibroids!were!recruited.!!Each!patient!received!
three!months!of!open!label!ulipristal!acetate!at!10mg!daily!followed!by!100day!double0
blind!treatment!with!10mg!NETA!(norethisterone!acetate)!daily!or!placebo.! !After!13!
weeks,!each!patient!was!given!the!option!of!enrolling!in!the!PEARL!III!extension!study!to!
have!a!further!three!courses!of!treatment,!which!was!taken!up!by!132!patients!with!107!
receiving!4!courses.!!!
!
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The!first!course!of!treatment!induced!amenorrhoea!in!79%,!with!a!median!onset!of!4!
days,!and!caused!a!median!fibroid!volume!change!of!045%.!!The!control!of!bleeding!with!
multiple!courses!was!greater!and!faster!than!the!initial!reduction;!with!amenorrhoea!
rates!of!89%,!88%,!and!90%!and!median!times!to!amenorrhoea!of!2,!3!and!3!days!for!
courses!2,!3!and!4,!respectively.! !Multiple!courses!also!had!a!beneficial!effect!on!the!
reduction!of!myoma!volume!with!the!median!change!from!baseline!of!063%,!067%,!and!
072%!after!treatment!courses!2,!3,!and!4,!respectively,!resulting!in!82%!of!those!taking!
4!courses!having!a!>25%!reduction!in!fibroid!volume.!
4.3.4! PEARL(IV(
This! randomised,! double0blind,! parallel! group,! long0term! study! was! undertaken! to!
investigate!the!efficacy!and!safety!of!5mg!and!10mg!doses!of!ulipristal!acetate.!!A!total!
of!451!patients!across!46!sites!were!recruited!and!62%!in!the!5mg!treatment!group!and!
73%! in! the! 10mg! treatment! group,! achieved! amenorrhoea! during! both! treatment!
courses.! !Menstruation!after!treatment!was! reduced! in!both!groups!and!the!median!
reduction!in!fibroid!volume!was!54%!and!58%!for!the!5mg!and!10mg!group,!respectively.!!
4.3.5! Summary(of(PEARL(studies(
Overall!the!PEARL!I!and!PEARL!II!studies!demonstrated!an!improvement!in!quality!of!life!
for!symptomatic!women!treated!with!ulipristal!acetate.!!The!increased!dose!of!10mg!did!
not!confer!any!significant!benefits!and!as!such!5mg!daily!was!defined!as!the!minimum!
effective!dose.(190,194)!!The!PEARL!III!and!PEARL!IV!studies!have!helped!to!demonstrate!
that!multiple!courses!are!effective!and!their!impact!is!cumulative!in!terms!of!bleeding!
control!and!fibroid!shrinkage!with!no!concerns!about!safety!(see!section!4.4.3).!
!
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4.4! PHARMACOLOGICAL.PROPERTIES.
4.4.1! Pharmacodynamics((
Ulipristal! acetate! ((11β)0110[40(Dimethylamino)phenyl]03,200dioxo0190norpregna04,90
dien0170yl! acetate)! is! a! 19! norprogesterone! derivative! and! belongs! to! the!
pharmacotherapeutic! group:! Sex! hormones! and! modulators! of! the! genital! system,!
progesterone!receptor!modulators!(ATC!code:!G03XB02).(189,201)!!
It!has!two!therapeutic!indications:!
!! pre0operative!treatment!of!moderate!to!severe!symptoms!of!uterine!fibroids!in!
adult!women!of!reproductive!age!
!! intermittent!treatment!of!moderate!to!severe!symptoms!of!uterine!fibroids!in!
adult!women!of!reproductive!age;!
and!treatment!consists!of!one!tablet!of!5!mg!to!be!taken!orally!once!daily!for!up!to!3!
months!each.!Ovulation! is! inhibited! such! that!progesterone! levels!are!maintained!at!
0.3ng/ml,!and!FSH!production!by!the!pituitary!is!partially!suppressed!to!maintain!serum!
oestradiol!levels!in!the!mid0follicular!range,!as!previously!discussed.(189)!!!
Ulipristal!acetate!exerts!a!direct!effect!on!the!endometrium!and!should!be!initiated!after!
menstruation! has! occurred.! ! In! most! subjects! (80%),! further! menstruation! will! be!
prevented! until! after! treatment! cessation! but! once! the! treatment! is! stopped! or!
completed,! menstruation! usually! resumes!within! 4! weeks.! ! The! drug! action! on! the!
endometrium!leads!to!endometrial! thickening!(>16mm)! in!10015%!of!users!and!PRM!
associated! endometrial! changes! (PAEC)! in! 60%! after! 3! months.! ! These! changes! are!
reversible!and!are!discussed!in!detail!in!section!4.5.!
4.4.2! (Pharmacokinetics(
Absorption*
Ulipristal!acetate!(5mg!or!10mg)!is!absorbed!rapidly,!with!a!Cmax!of!23.5!±!14.2!ng/ml!
and!50.0!±!34.4!ng/ml!occurring!approximately!1!h!after!ingestion,!and!with!an!AUC00∞!
of!61.3!±!31.7!ng.h/ml!and!134.0!±!83.8!ng.h/ml,!respectively.!!It!is!converted!quickly!to!
an!active!mono0N0demethylated!metabolite,!with!a!Cmax!of!9.0!±!4.4!ng/ml!and!20.6!±!
10.9!ng/ml!also!occurring!approximately!1!h!after!ingestion,!and!with!an!AUC00∞!of!26.0!
±!12.0!ng.h/ml!and!63.6!±!30.1!ng.h/ml!respectively.(189)!
!
!
CHUTE!Thesis!(1.4)! 0!95!0!
CHANGES(IN(HISTOLOGY(FOLLOWING(ULIPRISTAL(THERAPY(IN(ENDOMETRIOSIS(
(CHUTE)(
Distribution*&*Elimination*
Ulipristal!acetate!is!highly!(>98%)!bound!to!plasma!proteins!such!as!albumin.!!It!is!readily!
converted! to! a! mono0N0demethylated! metabolite! and! then! its! di0N0demethylated!
metabolites!by!the!cytochrome!P450!3A4!isoform.!!These!metabolites!are!excreted!in!
the!faeces!and!urine!(10%).!!The!terminal!half0life!of!the!5mg!dose!is!estimated!at!38!
hours.(189)!!!
4.4.3! Safety(data(
PreCclinical*
The!non0clinical!data!collected!on!ulipristal!acetate!has!not!highlighted!any!concerns!for!
use! in! humans! with! regards! to! safety! pharmacology,! repeated! dose! toxicity! and!
genotoxicity.!!There!are!no!specific!safety!concerns!with!respect!to!bone!health,!hepato0
renal!function!or!lipid!metabolism,!however!caution!should!be!exercised!in!users!with!
hepatic!dysfunction!as!this!may!cause!a!reduction!in!drug!elimination.(189)!!!
Ulipristal!acetate!has!been!shown!to!be!embryo!lethal!in!rats,!rabbits,!guinea!pigs!and!
monkeys!but!the!safety!for!the!human!embryo!is!unknown.!!At!doses,!low!enough!to!
allow!a!gestation!to!continue,!no!teratogenic!potential!has!been!observed.!!In!addition,!
no!impaired!fertility!has!been!seen!in!rats!or!their!offspring!following!treatment!with!
ulipristal! acetate.! ! There! is! also! no! evidence! of! carcinogenic! potential!with! ulipristal!
acetate!exposure.(189)!
Adverse*events*
The!most!common!side!effect!of!amenorrhoea!is!a!desirable!outcome!for!most!patients!
taking! ulipristal! acetate! (79.2%).! ! The!most! frequent! adverse! event! after! this! is! hot!
flushes! (8.1%)! with! varied! rates! across! the! PEARL! studies! (1024%).! ! Headache! was!
reported!by!5.8%!of!patients!and!ovarian!cyst!formation!seen!in!about!1%!of!users.!!The!
other!common!(≥1/100!to!<1/10)!adverse!reactions!noted!were!vertigo,!abdominal!pain,!
nausea,!acne,!musculoskeletal!pain,!pelvic!pain,!breast!tenderness,!fatigue,!and!weight!
gain.!!The!reported!adverse!events!were!mild!to!moderate!in!the!main!(95%),!did!not!
require!cessation!of!medicinal!product!(98%)!and!resolved!spontaneously.(189)!!!!!!!
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4.5! HISTOLOGICAL.IMPACT.
Ulipristal! acetate! (UPA)! treatment,! results! in! novel! endometrial! changes,! which! are!
unique!to!this!group!of!drugs.!The!histological!features!are!collectively!known!as!PRM!
(Progesterone! Receptor! Modulator)0Associated! Endometrial! Changes! (PAEC)! and!
‘include!endometrial! thickening!and!cystic! features!resembling!cystic!hyperplasia,!yet!
without! the! glandular! proliferation! characteristic! of! endometrial! hyperplasia’.(202)!
Initially!these!changes!were!thought!to!be!simple!hyperplasia,!raising!concerns!about!
the!safety!of!ulipristal!acetate,!particularly!with!prolonged!use,!but!they!have!now!been!
recognised!a!unique!histological!response!specific!to!SPRMs.(203)!!
The!PAEC!changes!seen!in!response!to!SPRMs!were!reviewed!at!a!US!National!Institute!
for! Health! (NIH)! workshop! on! ‘Progesterone! Receptor! Modulators! and! the!
Endometrium’!in!April!2006!(Bethesda,!Maryland!(USA)).!The!aim!of!the!meeting!was!to!
discuss!the!clinical!applications!of!PRMs,!the!pharmacokinetics!and!endocrine!effects!of!
PRMs!but!also! to! formulate!a! consensus!opinion!about! the!histological! changes! that!
were!becoming!evident.(154,164)!
Eighty0Four!H&E!(Haematoxylin!and!Eosin)!slides!of!endometrial!biopsies!from!women!
taking! an! SPRM! were! supplied! by! pharmaceutical! companies.! ! The! agents! under!
investigation! were! mifepristone,! ulipristal! acetate! (CDB02914),! JNJ017072341! and!
Asoprisnil.!At!the!meeting,!a!panel!of!seven!gynaecological!pathologists!reviewed!the!
slides! having! been! blinded! to! the! agent,! dose! and! exposure! interval.! ! Following! a!
microscopic!review!of!the!slides,!an!interactive!examination!and!discussion!of!the!results!
was! completed! to! establish! a! consensus! summary.! ! It! is! that! consensus,!which! now!
defines!the!features!of!PAEC.(154)!!!!!
Since!then!the!PEARL!studies!have!significantly!increased!the!scientific!understanding!of!
this!histological!entity!such!that! it!can!confidently!be!concluded!that!PAEC! is!distinct!
from! the! proliferative! response! seen! secondary! to! unopposed! estrogen! exposure! or!
endometrial! hyperplasia,! the! observed! changes! are! reversible! once! treatment! is!
stopped! (by! 6! months),! and! the! changes! do! not! carry! any! known! clinical!
significance.(203)!
!
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4.5.1! PRMW(Associated(Endometrial(Changes((PAEC)(
The!commonest!finding!seen!following!exposure!to!ulipristal!acetate!for!three!months!
is!that!of!cystically!dilated!endometrial!glands;!with!moderately!dilated!glands!scattered!
amongst!normal!appearing!glands.! !This! finding! is!comparable!to!what! is!seen! in!the!
disordered!proliferative!pattern!(DPP)!that!occurs!with!anovulation.!!However,!rather!
than!proliferative!epithelial! cells! as! you!might!expect! the! lining!of! the!glands! is!only!
weakly!mitotic!with!evidence!of!secretory!changes.!!As!such!it!can!be!classified!as!neither!
proliferative!or!secretory!and!is!defined!as!a!new!histopathological!entity0!PAEC.!(154)!
It!is!defined!as!a!‘benign,!inactive!and!weakly!proliferating!epithelium!associated!with!
asymmetry! of! stromal! and! epithelial! growth! resulting! in! prominent! cystically! dilated!
glands!with!admixed!oestrogen!(mitotic)!and!progestin!(secretory)!epithelial!cells!in!the!
endometrium.’!
4.5.2! PAEC(observed(in(ulipristal(acetate(phase(III(clinical(program(
The!occurrence!of!PAEC!in!the!PEARL!studies!of!the!phase!III!clinical!program!have!been!
monitored!closely.!!The!reported!figures!for!non0physiological!changes!consistent!with!
PAEC!seen!in!those!studies!are!summarised!in!Table!4.1.!!
In!the!PEARL!I!&!II!studies!endometrial!biopsies!were!taken!at!screening,!after!3!months!
of!ulipristal!acetate!treatment!(13!weeks)!and!6!months!after!treatment!had!finished!
(38!weeks).! ! The! detailed! histological! data!was! reported! by!Williams! et' al.! in! 2012!
highlighting!that!50060%!of!patients!exposed!to!ulipristal!acetate!had!features!of!PAEC!
at! the! end! of! treatment.! These! changes! had! resolved! by! 6! months! such! that! the!
incidence!of!non0physiological!changes!in!the!endometrium!at!38!weeks!was!similar!(60
7%)!across!both!treatment!groups!and!the!comparator!group!for!each!study.!In!PEARL!
III,!biopsies!were!taken!6!weeks!after!treatment!course!1!and!treatment!course!4.!!The!
occurrence!of!PAEC!was!similar!at!25026%!at!both!time!points! indicating!PAEC! is!not!
cumulative.!!In!PEARL!IV,!biopsies!were!taken!6!weeks!after!the!2nd!course!had!been!
completed!and!15020%!had!PAEC!features.!(190,203)!!!
As! typical! changes! related! to!unopposed!oestrogen!effect!are!not! seen,!endometrial!
hyperplasia!is!not!seen!and!the!PAEC!appears!to!resolve!the!risk!of!malignancy!and!pre0
malignant!change!appears!to!be!low.!!!!!
!
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Study. 5mg.UPA.daily.(%). 10mg.UPA.daily.(%). Comparator.(%).
PEARL.I. 62! 57! 6!
PEARL.II. 58! 59! 12!
PEARL.III. 0! 26!(single!course)! 11!
. 0! 25!(four!courses)! 11!
PEARL.IV. 16! 19! 8!
Table'4.1' NonHphysiological'changes'consistent'with'PAEC'seen'in'PEARL'studies.'''
Biopsies'were' taken'whilst' taking'UPA' in'PEARL' I'&' II'and'6'weeks'after' completing'
treatment' in'PEARL' III'&' IV'(UPA='Ulipristal'acetate;'Comparator='Placebo'(PEARL' I),'
Leuprolide'acetate'(PEARL'II),'Screening'(PEARL'III)'&'Screening'(PEARL'IV)).(197–200)!!
The!pathophysiology!underlying!PAEC!is!unknown.!!Ulipristal!acetate!is!a!predominant!
antagonist!at!the!progesterone!receptor!but!with!some!agonist!action.!!This!mixture!of!
agonist/antagonist!action!explains!the!poorly!developed!secretory!differentiation!in!the!
endometrial! glands0! tortuous! mid0secretory! phase! type! glands! with! only! focal!
cytoplasmic!vacuolisation.!!Also,!the!antagonist!action!explains!the!lack!of!pre0decidual!
change! in! the! stroma.! ! However,! the! cystic! dilatation! and! the! rapid! induction! of!
amenorrhoea!are!less!easily!explained.!
The!antagonistic!action!of!SPRMs!led!to!speculation!that!these!drugs!would!cause!the!
same!histological!changes!seen!with!unopposed!oestrogen;!but!with!ulipristal!acetate,!
mifepristone!and!asoprisnil! this!has!not!been!the!case.(203)! !However,! the!epithelial!
cells! appear! inactive! rather! than! proliferative! as! a! result! of! selective! inhibition! of!
oestrogen!dependent!endometrial!proliferation.(153)!!!!
4.5.3! Morphological(appearance(of(PAEC(
In!order!to!facilitate!appropriate!histopathological!endometrial!assessment!in!patients!
exposed!to!ulipristal!acetate,!a!pathologist’s!guide!has!been!developed!and!the!details!
of!this!guide!have!been!modified!and!described!below!with!permission!from!Gedeon!
Richter.(202)!
Architectural*irregularity*and*cystic*dilatation*
The!most!common!feature!of!PAEC!is!cystic!dilatation!of!the!endometrial!glands.!!This!
can! be! either! focal! dilatation! associated!with! simple! tubular! glands! or! quite! diffuse!
!
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dilatation! within! a! sample.! ! Those! glands! which! are! dilated! tend! to! be! lined! by! a!
secretory! or! ciliated! metaplastic! epithelium! (as! described! below).! ! In! areas!
demonstrating! this! unusual! architectural! pattern! there! tends! to! be! crowding! of! the!
glands!resulting!in!quite!compact!stromal!cells!(Figure!4.1).(202)!!
!
Figure'4.1. Architectural.features.of.PAEC....
Cystic'dilatation'is'shown'in'image'A>C,'with'areas'of'gland'crowding'demonstrated'in'
images' A&B' (white' arrow).' ' Image' D' contains' a' dilated' gland' lined' by' secretory'
epithelium' with' a' compact' layer' of' stromal' cells' surrounding' it' (reproduced' with'
permission).(202)!
Inactive*glandular*endometrium*
The!glandular!epithelium!usually!shows!an!inactive!appearance!with!each!gland!lined!by!
a!single!layer!of!cells!with!no!nuclear!stratification!and!infrequent!mitoses.!!The!cells!
lining! the! dilated! glands! have! a! cuboidal! or! flattened! columnar! shape! with! ciliated!
metaplasia!often!seen.(202)!!This!ciliated!metaplasia!is!usually!an!oestrogen!associated!
change!seen!a!proliferative!endometrium!but!in!PAEC!the!epithelium!is!either!inactive!
or!demonstrates!some!secretory!features!(Figure!4.2).(154)!!
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!
Figure'4.2. Inactive.or.weakly.secretory.epithelium.seen.in.PAEC....
Low'columnar'epithelial'cells'with'inactive'to'weakly'secretory'epithelium.''Image'E&F'
show' surface' apocrine' changes' (black' arrow)' but' with' no' sub>nuclear' vacuolation.'
Image'G'shows'flattened'columnar'cells'and'cuboidal'cells'with'small'ovoid'nuclei,' in'
keeping'with'PAEC'(reproduced'with'permission).(202)!
Stromal*vascular*changes*
The!endometrial!stroma!tends!to!be!compact!without!evidence!of!pre0decidual!change.!
Prominent! networks! of! anastomosing! capillaries! in! a! ‘chicken! wire’! pattern! are!
sometimes!seen.(154)!!However,!aggregates!of!arterioles!with!thickened!walls!are!more!
commonly! seen! within! the! stroma! much! like! vasculature! seen! in! polyps.! ! In! other!
samples,!occasional!ectatic!thin0walled!vessels!are!seen!but!not!with!fibrin!thrombi,!as!
are!seen!in!unopposed!oestrogen!states!(Figure!4.3).(202)!!
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'
Figure'4.3. Stromal.vascular.changes.seen.in.PAEC....
Branching' clusters' of' capillaries' (H'&' K)' and' small' arterioles' (J)' are' often' seen'with'
occasional'larger'thick'walled'small'arterioles'(I)'(reproduced'with'permission).(202)!
NonCphysiological*secretory*appearance*
A!mismatch!between!architecture!and!glandular!epithelial!cells!is!a!prominent!feature!
of!PAEC.!!The!glands!can!be!coiled!or!tortuous!in!nature!as!would!be!expected!in!the!
secretory!phase!but!with!a!poorly0developed!secretory!changes.! !Mitotic!activity!and!
apoptosis! are! seen! together;! cytoplasmic! vacuolation! and! surface! apocrine0type!
changes! are! seen! in! some! areas! but! most! glands! have! a! non0vacuolated!
appearance.(154)! !Overall! this!is!considered!non0physiological!as!the!features!do!not!
match!any!specific!phase!of!the!menstrual!cycle!(Figure!4.4).(202)!
!
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Figure'4.4. Weakly.proliferative.and.unusual.secretory.features.typical.of.PAEC....
Inactive' to'weakly' secretory' epithelium' (few'mitoses' and' apoptosis,' L)' with' ciliated'
metaplasia'(N,'black'arrow)'and'unusual'secretory'changes'(M).'Stellate'glands'are'seen'
(O).'Stromal'pillars'lined'on'both'sides'by'epithelium'are'indicative'of'large'cystic'glands'
(P)'(reproduced'with'permission).(202)!
4.5.4! Comparison(of(PAEC(with(unopposed(oestrogen(effect(and(hyperplasia(
As! discussed! above! the!most! striking! feature! of! PAEC! is! the! cystic! dilatation! of! the!
glands.! ! It! is! this! dilatation! that! results! in! the! endometrial! thickening! reported! after!
exposure!to!ulipristal!acetate.!!The!dilated!glands!of!PAEC!can!easily!be!confused!with!a!
disordered!proliferative!pattern!(DPP),!seen!with!unopposed!oestrogen,!except!for!the!
following!features:!
1)! low!mitotic!activity!in!both!the!glands!and!stroma,!
2)! abortive!sub0nuclear!vacuoles,!
3)! apoptosis,!
4)! occasional!stroma!pseudodecidual!change,!
5)! absent!fibrin!thrombi,!
6)! absent!stromal!breakdown!with!glandular!crowding.(154)!!
!
!
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Figure'4.5. Comparison.of.PAEC.with.unopposed.oestrogen.effect.and.hyperplasia....
An' example' of' PAEC' (Q)' with' scattered' cystic' glands' and' inactive' epithelium.' By'
comparison' complex' hyperplasia' (R,' S)' has' very' crowded' glands' with' an' active'
proliferative'epithelium.''Whereas,'disordered'proliferative'pattern'(DPP)'(T,'U)'shows'
less' crowding' with' dilated' venules' and' proliferative' epithelium' (reproduced' with'
permission).'(202)!
4.6! ENDOMETRIAL.IMPACT.&.USE.IN.ENDOMETRIOSIS..
Consideration! of! progesterone! receptor!modulators! for! other! clinical! indications! has!
been!discussed!in!chapter!3,!including!the!possibility!of!using!ulipristal!acetate.!!In!the!
majority! of! reviews! into! the! possible! clinical! uses! for! SPRMs! endometriosis! is! often!
highlighted!as!a!possible!target.(113,125,204)!!Given!the!encouraging!tolerability!and!
safety!profile!for!ulipristal!acetate!it!must!be!considered!a!good!candidate!for!further!
study.!!!
!
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4.6.1! Progesterone(receptor(modulation(&(endometriosis(
The!rationale!for!using!SPRMs!in!the!treatment!of!endometriosis!has!been!discussed!in!
detail!in!Chapter!3!and!was!clearly!set!out!in!a!review!by!Chwalisz!et'al.!in!2002.(205)!
They!highlighted!five!key!pharmacodynamic!properties!that!justify!SPRM!use:!
1)! reversible!suppression!of!menstruation!via!a!direct!effect!on!endometrial!blood!
vessels;!
2)! selective!inhibition!of!endometrial!proliferation!without!the!systemic!effects!of!
estrogen!deprivation;!
3)! inhibition!of!uterine!prostaglandins!and!potential!for!pain!relief;!
4)! inhibition! of! ovarian! progesterone! secretion! in! the! absence! of! estrogen!
deprivation;!
5)! no!stimulatory!effects!on!the!mammary!gland.!
Given! this! combination! of! endometrial! suppression! without! adversely! effecting!
oestrogen!levels,!an!SPRM!should!make!an!ideal!treatment!for!endometriosis.!!We!know!
many!endometriosis!patients!get! some!symptom!relief! from!GnRH!agonists,!but! the!
hypo0oestrogenic!side!effects!limit!its!tolerability!and!safety.!!As!such!SPRMs!may!offer!
the!key!to!counteracting!this!problem.!!However,!to!date!there!is!no!SPRM!licensed!for!
use!in!endometriosis.!!!
Ulipristal!acetate!has!a!current!licence!for!use!in!humans,!has!a!good!safety!record!and!
is!well!tolerated.!!As!each!of!the!SPRMs!have!slightly!different!actions!to!each!other!in!
human!tissues!a!trial!of!use!in!humans!is!needed!to!explore!their!potential.!!Although!
Asoprisnil!has!been!studied!in!the!context!of!endometriosis,!safety!concerns!specific!to!
that! compound! have! limited! any! further! investigation.! ! As! such,! ulipristal! acetate!
appears!to!be!the!most!appropriate!candidate!for!use!in!endometriosis.!!
4.6.2! Response(to(ulipristal(acetate(seen(in(a(rat(model(of(endometriosis(
Although!much!of!the!work!looking!at!SPRMs!and!ulipristal!acetate!is!theoretical!some!
work! animal! work! has! been! done! suggesting! it! may! be! effective! in! treating!
endometriosis.! ! Huniadi!et' al.! have! shown! that! ulipristal! acetate! contributed! to! the!
regression!and!atrophy!of!endometriotic!lesions!in!rats.(206)!!
Endometriosis!was!surgically!induced!in!40!female!Wistar!albino!rats!and!after!a!40week!
induction!period!randomised!into!two!groups.!!The!first!group!were!exposed!to!ulipristal!
!
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(UPA+)!for!8!weeks!and!the!second!group!exposed!to!vehicle!only!(UPA0)!for!8!weeks.!!
The! size! of! the! endometriotic! lesions,! histological! features! and! immunostaining! for!
Bax/Bcl02,!cytochrome!C,!Ki067!and!cyclooxygenase02!(COX02),!were!assessed.!
Treatment!with!ulipristal!acetate!caused!regression!and!atrophy!of!the!endometriotic!
lesions.! ! Although! encouraging! it! should! be! noted! that! the! method! for! inducing!
endometriosis! involves!a!direct!transplant!of!tissue,! including! its!extracellular!matrix,!
from! the! eutopic! location! to! an! ectopic! location.! ! This! is! not! representative! of! our!
understanding!of!how!ectopic!endometrium!is!established!in!endometriosis!and!so!the!
action!of!any!treatment!must!be!viewed!with!caution.!
However,! the! immunohistochemical! expression! findings! within! the! endometrial!
implants!following!ulipristal!acetate!treatment!were!also!encouraging.!!They!suggest!a!
pro0apoptotic! and! anti0proliferative! action! within! endometrial! tissue,! as! is! seen! in!
leiomyoma!tissue.!!Bax!and!cytochrome!C!expression!is!increased,!and!Bcl02!expression!
is!decreased!demonstrating!a!pro0apoptotic!action.!!A!reduction!in!cellular!proliferation!
was! reflected! by! a! reduction! in! Ki067! expression! and! an! anti0inflammatory! action!
indicated!by!a!reduction!of!COX02!expression.!!This!is!an!exciting!prospect!as!it!opens!
the!possibility!of!SPRMs!becoming!an!effective!long0term!treatment!for!endometriosis.!
4.6.3! Case(report(on(inadvertent(use(in(endometriosis(
In!January!2017,!Bateman!et'al.!reported!a!case!of!PAEC!changes!seen!in!a!patient!with!
concurrent! leiomyoma!and!endometriosis.! !The!patient!took!three!900day!courses!of!
ulipristal! acetate! to! control!her!heavy!menstrual!bleeding!prior! to!definitive! surgical!
management!for!uterine!fibroids.! !At!her!total!abdominal!hysterectomy!and!bilateral!
salpingo0oophorectomy! a! focus! of! endometriosis! was! noted.! ! On! histological!
examination! cystically! dilated! glands! lined! by! secretory! type! epithelial! cells! and!
occasional!apoptotic!bodies!were!noted.!!In!addition,!closely!packed!stromal!cells!with!
thick! walled! blood! vessels! were! observed! near! the! dilated! glands.! ! This! is! the! first!
reported!case!of!PAEC!features!in!ectopic!endometrium!in!humans.(207)!
4.6.4! (Return(of(endometrial(function(allowing(pregnancy(
Several! case! reports! have! been! published! relating! to! pregnancy! after! treatment! for!
fibroids!with!ulipristal!acetate.!!In!2013,!Wdowiak!reported!the!use!of!ulipristal!acetate!
for!30months!prior!to!a!successful!ICSI!(intracytoplasmic!sperm!injection)!procedure!in!a!
!
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350year0old! patient! with! two! intramural! fibroids! (2.26! cm! by! 2.53cm! fibroid! in! the!
anterior!wall!and!1.2cm!diameter!fibroid!in!the!posterior!wall).!!The!pregnancy!outcome!
come!was!good.(208)!
In!2014,!Monleon!et'al.!reported!the!use!of!ulipristal!acetate!in!a!370year!old!patient!
who!remained!symptomatic!eight!months!after!myomectomy.!!She!had!a!good!response!
to! ulipristal! acetate! and! three! months! after! completing! treatment! she! conceived!
naturally!and!had!an!uneventful!pregnancy!until!preterm!delivery!at!34!weeks!gestation!
by!caesarean!section!due!to!regular!uterine!contractions.(209)!
Murad!et'al.!recently!described!the!use!of!ulipristal!acetate!in!a!patient!with!a!single!
submucosal!fibroid!of!102.4cm2,!which!reduced!by!30%!to!72.1cm3!after!a!three0month!
course.! Two! months! after! completing! treatment! she! conceived,! had! an! uneventful!
pregnancy! and! delivered! vaginally! following! an! induction! of! labour! at! 38! weeks!
gestation.(210)!
In!2014,!Luyckx!et'al.!reported!the!first!series!of!pregnancies!achieved!after!ulipristal!
treatment!for! fibroids.! !At!one!of!the! institution!recruiting!to!the!PEARL!studies!they!
looked! at! a! series! of! patients!who!wished! to! conceive! after! completion! of! the! trial.!!
Twenty0one!patients!wanted!to!get!pregnant!and!underwent!myomectomy!as!planned!
with!two!no0longer!requiring!surgery!due!to!the!action!of!the!ulipristal!acetate.!!Fifteen!
patients! (71%)! conceived,! resulting! in! 18! pregnancies,! 13! live! births! and! 6! (33%)!
miscarriages.! ! This!miscarriage! rate!may! be! explained! by! the! underlying! leiomyoma!
diagnosis,! subfertility! need! for! IVF! (3! of! these! 6! cases!were! IVF! pregnancies)! or! the!
median!maternal!age!(38!years).! !The!outcome!for!the!remaining!12!pregnancies!was!
good!with!no!maternal!complications!secondary!to!the!fibroids!or!fibroid!re0growth.!!The!
majority!(11/12)!were!delivered!by!Caesarean!section!due!to!their!previous!surgery!or!
other!obstetric!indications.!!A!single!congenital!anomaly!was!identified!but!concluded!
to!be!unrelated!to!the!ulipristal!acetate.(211)!!
These! data! indicate! that! the! endometrial! changes! caused! by! ulipristal! acetate! are!
reversible! and! that! its! use! does! not! adversely! impact! on! the! functionality! of! the!
endometrium!with!relation!to!implantation,!in!the!long!term.!!They!also!highlight!the!
possible! use! of! ulipristal! acetate! to! shrink! fibroids! prior! to! attempting! spontaneous!
!
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pregnancy!or!assisted!reproductive!techniques,!particularly!in!those!with!submucosal!or!
intramural!fibroids.!
4.6.5! CHUTE(study(
The!expectation!of!an!anti0proliferative!effect!in!response!to!ulipristal!and!the!work!by!
Huniadi! et' al.! prompted! us! to! consider! a! study! to! explore! ulipristal! acetate! in!
endometriosis.! ! The! key! question! was! that! of! safety! and! what! impact! a! course! of!
ulipristal!would!have!on!ectopic!endometrium.!!We!know!the!ectopic!endometrium!is!
not! shed! in! the! same!way! the!eutopic!endometrium!so!would!any!PAEC!changes!be!
persistent!or!cumulative?!!The!case!report!from!Bateman!et'al.!indicates!that!PAEC!type!
changes! can! occur! in! ectopic! endometrium! but! there! is! no! indication! on! the! time!
between!treatment!cessation!and!surgery,!or!if! indeed!surgery!was!completed!whilst!
taking!ulipristal.!
As! such! the! histological! examination! of! ectopic! endometrium! following! treatment!
formed!the!basis!of!the!CHUTE!study!and!our!research!question.!!Ulipristal!acetate!was!
used!as!the!investigational!medicinal!product!(IMP)!in!the!form!described!in!the!SmPC,!
as!outlined!in!the!study!protocol!(Appendix!28)!and!discussed!in!detail!in!Chapter!6.!!
!
!!!
!
!
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Chapter.5:!AIMS,. OBJECTIVES,. ETHICAL. CONSIDERATION.
&.RISK.ASSESSMENT.
5.1! RESEARCH.QUESTION.
What! impact! do! selective! progesterone! receptor! modulators! have! on! ectopic!
endometrial! deposits! and! can! they! be! used! as! a! treatment! option! for! patients!with!
endometriosis?!
5.2! RESEARCH.AIM.
When!investigating!a!new!treatment!for!endometriosis!the!first!consideration!should!be!
whether!the!treatment!is!safe!to!use!for!the!new!indication.!!This!safety!question!had!
been!answered!in!part!by!the!PEARL!studies,!which!demonstrated!the!safety!of!ulipristal!
acetate!in!the!management!of!uterine!fibroids.!!The!current!licensed!indication!for!pre0
operative! and! long0term!medical! management! of! leiomyomata! means! we! could! be!
relatively!certain!about!the!risks!associated!with!the!drug.!
However,!the!PAEC!(progesterone!receptor!modulator!associated!endometrial!changes)!
changes!seen!within!the!endometrium!of!patients!exposed!to!ulipristal!acetate,!raises!
concern!about!whether:!
a)! PAEC!changes!occur!in!ectopic!endometrial!deposits!(endometriosis);!
b)! PAEC! changes! promote! a! proliferative! action! on! ectopic! endometrium!
(endometriosis);!!
c)! and,! if!PAEC!changes!do!occur,!do!they!persist!after!menstruation!as!typical!
menstrual!shedding!does!not!occur!at!ectopic!sites.!
As! such! our! study! aim!was! to! explore! the! histological! action! of! ulipristal! acetate! on!
ectopic! endometrium! as! well! as! determining! the! clinical! impact! on! endometriosis!
symptoms.!
!
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5.3! RESEARCH.OBJECTIVES.
5.3.1! Primary(objectives(
!! To!describe!the!post0treatment!histological!appearance!in!ectopic!endometrial!
deposits!found!in!patients!with!pelvic!endometriosis!after!a!course!of!ulipristal!
acetate.!
5.3.2! Secondary(objectives(
!! To! study! the! change! in! disease! severity! (symptomatic! and! laparoscopic!
appearance)!following!treatment!with!ulipristal!acetate.!
!! To!correlate!any!symptom!changes!with!the!post!treatment!histological!changes!
in!the!ectopic!endometrium.!
!! To! assess! the! histological! changes! in! the! eutopic! endometrium! following!
treatment!with!ulipristal!acetate.!
5.4! ETHICAL.CONSIDERATIONS..
5.4.1! Diagnosis(
All!patients!considered!for!this!study!had!a!known!diagnosis!of!endometriosis.!!This!was!
either! a! recently! made! diagnosis,! from! a! recent! diagnostic! laparoscopy,! or! a! long0
standing!diagnosis.!!The!nature!of!the!disease!and!the!implications!of!the!diagnosis!had!
been!made!clear!to!each!patient!as!part!of!their!previous!care.!!!
5.4.2! Treatment(
In!the!recruitment!phase,! it!was!ensured!that!all!patients!had! information!about!the!
standard!approaches!to!endometriosis!care,!as!outlined!in!Chapter!1.!!It!was!explained!
that! a! conservative! approach! using! analgesia! &! lifestyle! modification,! hormonal!
suppression! with! progesterone! or! GnRHa,! or! surgical! excision! could! be! considered.!!
However,!it!was!highlighted!to!the!study!subjects!that!definitive!surgical!management!
was!considered!to!be!the!most!appropriate!step!in!their!disease!management.!!!It!was!
also!made!clear! to!each! potential! recruit!how! the! study,!with!pre0operative!medical!
treatment! and! then! surgical! excision,! compared! to! standard! management.! ! This!
discussion! was! supplemented! with! information! provided! in! the! Patient! Information!
Sheet!(PIS).!
!
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The!potential! side!effects!of!each!approach! to!management!were!also!discussed,!as!
would!normally!occur!during!a!tailored!review!of!the!treatment!of!endometriosis!for!a!
particular!patient.!!Progestogenic!side!effects!such!as!mood!disturbance,!skin!changes,!
bloating,!fluid!retention,!breast!tenderness!and!headache!were!highlighted.!!If!GnRHa!
therapy! was! considered! an! appropriate! option! for! the! patient! then! the! potential!
menopausal!side!effects!of!this!treatment!were!explained!as!well!as!the!need!to!consider!
add0back! HRT,! usually! in! the! form! of! Tibolone.! ! This! was! an! important! step! in! the!
recruitment! phase! to! ensure! subjects! were! fully! informed! about! their! treatment!
options,!knew!how!the!CHUTE!study!compared!to!standard!care!and!what!the!risks!were!
in!relation!to!both!standard!management!and!the!study!medication.!
5.4.3! Fertility(plans(
As!part!of!the!pre0screening!discussion!the!subject’s!fertility!wishes!were!discussed.!!This!
is!important!in!any!endometriosis!consultation!as!the!medical!treatment!options!are!not!
compatible!with! plans! for! pregnancy! and! surgical! treatment!would! be! postponed! if!
conception!occurred!before!the!surgical!date.!!Those!wishing!to!get!pregnant!in!the!near!
future!were!excluded!from!the!study!and!the!implications!of!their!chosen!management!
on!their!fertility!wishes!were!highlighted.!
5.4.4! Study(design(
The!key!ethical!consideration!in!this!study!was!the!fact!that!the!impact!the!study!drug!
has!on!ectopic!endometrial!deposits!and!the!consequent!change! in!macroscopic!and!
histological!appearance!was!unknown.!!The!expectation!was!that!the!study!drug!would!
suppress! the! ectopic! endometrium! and! symptoms! would! improve! but! this! was! not!
proven.!!It!was!also!important!to!consider!the!potential!for!adverse!events!related!to!
the!study!drug.!!The!drug!being!used!had!been!thoroughly!tested!and!currently!has!a!
marketing!authorisation!for!use!in!another!gynaecological!condition!0!heavy!menstrual!
bleeding!related!to!fibroids.!!As!such!it!had!a!known!safety!and!side!effect!profile.!!This!
was!fully!explained!in!the!Patient!Information!Sheet!(PIS)!and!the!participants!had!the!
opportunity!to!discuss!this!with!the!study!team!prior!to!signing!the!consent!form.!!The!
enrolled!patients!were!monitored!closely!and!were!provided!with!telephone!contact!
information! for!both! routine!office!hours!and! out!of!hours! for!advice!and!additional!
information.!
!
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Progesterone*receptor*modulator*associate*endometrial*changes*(PAEC)*
Previous!studies!into!this!study!drug!have!shown!some!abnormalities!within!the!eutopic!
endometrial! tissue! after! treatment.! ! The! changes! (progesterone! receptor!modulator!
associated! endometrial! changes! or! PAEC)! are! a! novel! histological! variant! that! are!
specific!to!this!group!of!drugs.!!These!changes!are!completely!reversible!after!a!short!(3!
month)!course!and!further!work!is!awaited!on!longer!term!therapy.!!The!significance!of!
these!changes!is!not!known!but!they!are!not!thought!to!be!pre0cancerous.!
Additional*visits*and*procedures*
The!study!required!patients!to!undergo!examinations!and!procedures!that!would!not!
normally!be!part!of!their!routine!care.!!This!included!two!additional!pelvic!examinations,!
a!breast!examination,!two!endometrial!biopsies!and!a!serum!assessment!of!renal!and!
liver! function! (blood! test).! ! Some! of! these! procedures! can! be! invasive! and!
uncomfortable.! ! This!was! documented! in! the! Participant! Information! Sheet! and! the!
reasons!for!the!extra!procedures!were!explained!to!the!participant.!!The!discomfort!was!
minimised! by! keeping! the! patient! fully! informed! and! reassured! at! all! times.! ! Each!
procedure!was!performed!by!an!experienced!member!of!medical!staff!to!minimise!any!
discomfort!or!complications.!
Participants!were! required! to!attend! the!hospital! for! two!additional! clinic! visits! that!
would!not!have!been!part!of!their!routine!care.!!The!expectations!of!the!study!protocol!
and!level!of!time!commitment!were!described!in!the!Participant!Information!Sheet!and!
patients!were! compensated! for! any! additional! travel! expenses! they! incurred.! ! If! the!
number!of!visits!or!any!other!aspect!of!the!study!became!too!onerous!the!patient!was!
free!to!withdraw!at!any!time.!
Surgical*delay*
There!were! no! other! deviations! from! the! usual! care! pathway! a! patient!with! newly!
diagnosed!endometriosis!would!follow.!!The!study!required!a!delay!between!diagnosis!
and!definitive!surgical!treatment!for!three!months!whilst!completing!the!course!of!study!
medication.!!This!was!comparable!to!the!delay!between!a!diagnostic!laparoscopy!and!
definitive!surgical!treatment!during!standard!care!at!the!time!the!study!was!undertaken.!!
This!delay!was!not!considered!clinically!significant!as!clinical!progression!would!not!be!
expected! over! that! time! scale.! ! During! the! treatment! period! the! patient! was! fully!
supported!and!provided!with!adequate!analgesia!as!and!when!they!needed!it.!
!
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Questionnaires*
In!addition!to!the!extra!hospital!visits,!the!participants!were!also!asked!to!complete!a!
number!of!questionnaires!about! their! symptoms!during! screening,! the!pre0operative!
visit!and!at!the!post0operative!follow!up!visit.!!These!questionnaires!were!all!validated!
for!this!purpose!and!quick!to!complete.!!The!patients!were!able!to!complete!them!as!
part! of! the! study! visits! allowing! the! study! team! to! offer! explanation! or! clarify! the!
requirements!with!the!participant.!!
Confidentiality*
Confidentiality!was!maintained!at!all!times!with!only!authorised!personnel!having!access!
to!study!and!patient!data.!!This!data!was!maintained!in!the!patient’s!case!file,!a!study!
file!in!a!locked!office!or!on!the!local,!password!protected,!computer!network.!!!
5.5! RISK.ASSESSMENT.
5.5.1! Potential(risks(and(burdens(for(research(participants(
The! side! effects! of! the! ulipristal! acetate! (UA)! are! (as! listed! in! the! BNF):! nausea,!
abdominal! pain,! oedema,! hot! flushes,! headache,! dizziness,! malaise,! menstrual!
disturbances,!uterine!haemorrhage,!endometrial!thickening,!ovarian!cysts,!breast!pain,!
pelvic!pain,!myalgia,!acne,!hyperhidrosis,!dyspepsia,!dry!mouth,!flatulence,!constipation,!
epistaxis,!anxiety,!urinary!incontinence.!!These!were!clearly!documented!in!the!Patient!
Information!Sheet!(PIS)!and!discussed!with!each!participant!prior!to!commencing!the!
study!drug.!!At!the!time!of!the!first!dose!the!common!side!effects!were!re0iterated!and!
the!points!of!contact!for!medical!advice!confirmed!with!the!participant.!
There!was!a!risk!that!the!participants!may!experience!increased!pain!symptoms!for!the!
duration!of!the!study!as!a!result!of!coming!off!any!hormonal!contraception!or!medical!
treatment!they!had!been!taking!prior!to!recruitment.!This!risk!and!the! length!of!the!
study!protocol!was!highlighted!to!all!participants!prior!to!enrollment.!We!minimised!the!
impact!of! symptom! flares!by!offering! close!medical! supervision!and!giving!advice!on!
analgesic!strategies!throughout!the!study!period.!
We!asked!the!patients!to!utilise!a!non0hormonal!method!of!contraception!during!the!
study.! This!was!made! clear! at! the! start! of! the! study! and! re0iterated! throughout! the!
study.!!It!was!made!clear!that!the!impact!of!ulipristal!acetate!on!an!early!developing!
embryo! was! unknown! and! contraception! was! paramount! to! ensure! no! exposure!
!
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occurred!in!early!pregnancy.!We!offered!advice!and!support!for!this!change!over!as!part!
of! the! study! protocol! and! again! after! the! study! was! complete! to! ensure! her!
contraceptive! needs! were! met! to! her! satisfaction! and! to! minimise! the! risk! of!
contraceptive!failures.!
5.5.2! Surgical(risks(
The!risks!related!to!surgical!management,!either!as!part!of!standard!care!or!following!a!
course!of!ulipristal!acetate!as!part!of!the!CHUTE!study!were!highlighted!to!all!potential!
patients.!!These!included;!frequent!risks!like!bruising,!post0op!pain,!wound!dehiscence,!
wound!infection;!as!well!as!more!serious!but!less!frequent!risks!of!injury!to!abdominal!
viscera! (2! in! 1000),! delayed! recognition! of! bowel! injury! (15%! of! cases),! failure! to!
complete!surgery,!hernia!and!death!(308!per!100!000).!
In!addition!to!or!as!part!of!the!planned!surgical!management,!three!peritoneal!biopsies!
were!taken.!They!were!taken!by!a!skilled!gynaecological!surgeon0!either!directly!by!or!
supervised!by!a!Consultant!Gynaecologist!with!specialist!skills!in!laparoscopic!surgery!
for! endometriosis.! Taking! the! biopsies! carried! a! risk! of! bleeding! and! damage! to!
underlying! structures.! ! However,! these! risks! exist! as! part! of! the! standard! surgical!
management!for!endometriosis!and!all!steps!were!taken!to!minimise!the!risk.!The!size!
and!site!of!the!biopsy!was!carefully!planned!to!minimise!risk!and!maximise!the!chance!
of!obtaining!an!appropriate!histological!sample.!!'
5.5.3! Potential(for(benefit(to(research(participants(
Our!understanding!of!the!way!the!Selective!Progesterone!Receptor!Modulators!(SPRMs)!
work!prior!to!the!study! led!us!to!the!conclusion!that!ulipristal!acetate!would!have!a!
positive! effect! on! the! patients’! endometriosis! symptoms.! However,! there! was! no!
guarantee!of!this!and!patients!were!made!aware!of!this!prior!to!consent.!
Taking!part!in!the!study!had!no!other!direct!benefits!to!the!patient!over!the!standard!
treatment!offered!to!patients!with!endometriosis.!However,!being!involved!in!research!
is!often!a!positive!experience!and!provides!more!contact!time!with!specialists!who!are!
knowledgeable!about!endometriosis.!As!such!the!patients!involved!in!the!CHUTE!study!
may!have!develop!a!better!understanding!of!their!condition!as!a!result!of!being!involved!
in!the!study.!
! !
!
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Chapter.6:!STUDY.DESIGN.&.METHODS.
6.1! STUDY.OVERVIEW.
Study*design:!An!interventional!descriptive!cohort!study.!
Study*setting:*Single!center!pilot!study!at!the!Norfolk!and!Norwich!University!Hospital.!
Study*subjects:!Women!with!pelvic!endometriosis!confirmed!by!diagnostic!laparoscopy,!
on!no!medical!treatment!for!endometriosis!and!not!planning!for!a!pregnancy!in!the!12!
months!following!recruitment.!!
Sample*size*and*study*duration:!A!sample!of!20!subjects!was!studied!over!a!period!of!12!
months.!!
Study*layout:!All!women!who!had!undergone!diagnostic!laparoscopy!and!were!found!to!
have!pelvic!endometriosis!were! staged!according! to! the! revised!American! society!of!
Reproductive! Medicine! classification! of! endometriosis! (ASRM! 1997).(44)! ! Those!
requiring!surgical!treatment!such!as!adhesiolysis!or!laparoscopic!excision/diathermy!of!
lesions!were!recruited!to!the!study!and!were!treated!with!5mg!of!ulipristal!acetate!daily!
for!three!months!prior!to!elective!surgery.!At!the!time!of!that!surgical!management,!
their!disease!was!staged!according!to!ASRM!1997!and!specimens!were!obtained!from!
the!ectopic!endometrium!for!histological!evaluation.!!There!was!no!other!pre0operative!
modification!to!the!clinical!management!of!the!study!subjects.!!
An!endometrial!biopsy!was!performed!with!a!Pipelle®!aspirator!in!all!subjects!following!
treatment!as!a!safety!measure.!Subjects!were!advised!to!use!a!non0hormonal!method!
of!contraception!during!the!study!period.!!
Data* analysis:! The! histological! appearance! of! the! ectopic! endometrium! has! been!
described!for!each!of!the!subjects!and!any!features!consistent!with!PAEC!highlighted.!
Changes! in!the!disease!stage!(from!the! laparoscopic!appearance)!and!the!associated!
symptoms! (from! disease! specific! questionnaires)! following! treatment! with! ulipristal!
acetate! have! been! collected! and! attempts!made! to! correlate! these!with! changes! in!
histology.!
The!histological! analysis!was!performed! following! standard! tissue! fixation,!mounting!
and! staining! with! Haematoxylin! &! Eosin.! ! Immunohistochemical! staining! was! also!
!
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undertaken!to!explore!the!expression!of!key!nuclear!receptors!(ER,!PR,!AR),!proliferation!
markers!(Ki67!and!VEGF)!and!PTEN!(tumour!suppressor).!
!
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6.1.1! Study(plan(
!
Figure'6.1! Graphic!representation!of!CHUTE!study!timeline.!!!
(UPA%5mg%OD=%Ulipristal%acetate%(5mg%once%per%day)%taken%for%a%duration%of%12%weeks,%EoT%=%end%of%treatment,%EoS=%end%of%study,%Integers=%whole%
weeks,%Q=%Questionnaires,%BSGEIQu=%British%Society%of%Gynaecological%Endoscopy%Pelvic%Pain%Questionnaire,%EHPI30=%Endometriosis%Health%Profile%
Questionnaire,%CPSSS=%Composite%Pelvic%Signs%&%Symptoms%Score,%PGIC=%Patients’%Global%Impression%of%Change%Score)%
!
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Graphic(representation(of(CHUTE(study(timeline((Figure(6.1)0!continued!
The$ study$was$ conducted$over$ 30$weeks$with$ 5$phases:$ screening,$ on:treatment$ (12$
weeks),$off$treatment$(6$+/:$2$weeks),$surgery,$and$post:operative$recovery$(12$weeks).$$
Questionnaire$ data$was$ obtained$ from$each$ subject$ at$ four$ different$ time$ points:$ at$
screening,$during$week$11$of$treatment,$one$week$prior$to$surgery$and$at$the$end$of$the$
study.$ $ The$ BSGE:Qu$ pain$ scores$ at$ EoS$were$ compared$ to$ baseline$ to$ evaluate$ the$
impact$of$the$entire$intervention$(ulipristal$acetate$treatment$and$surgical$excision)$on$
pain$symptoms.$$The$EHP:30$and$CPSSS$scores$during$treatment$and$following$treatment$
were$compared$with$baseline$and$linked$to$the$PGIC$scores$reported$by$each$subject.$
!
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6.2! STUDY(DESIGN(&(JUSTIFICATION(
6.2.1! Hypotheses(
Null$hypothesis:$$
Administration! of! the! selective! progesterone! receptor! modulator,! ulipristal! acetate!
(Esmya),!would!have!no!effect!in!patients!with!endometriosis!with!no!improvement!in!
symptoms!and!no!histological!changes!within!ectopic!endometrial!deposits.!
Alternate$hypothesis:$$
Administration! of! the! selective! progesterone! receptor! modulator,! ulipristal! acetate!
(Esmya),!would!suppress!endometriosis!leading!to!improved!symptoms!and!histological!
changes!within!ectopic!endometrial!deposits.!
6.2.2! Outcome(measures(
The!primary!outcome!measures!were!the!changes!in!histological!appearance!in!ectopic!
endometrial! deposits! after! a! course! of! ulipristal! acetate.! ! These! changes! have! been!
described! in! terms! of! the! architecture! and! cellular! features! of! both! the! glands! and!
stroma.!!This!approach!allowed!the!direct!comparison!of!our!histological!findings!with!
the!PAEC!findings!published!following!the!PEARL!studies.(203)!!!
In!addition,!the!expression!of!nuclear!receptors!and!other!cellular!markers!were!also!
explored!using!immunohistochemistry!and!have!been!described!semi!quantitatively.!!
Secondary! outcome! measures! were! changes! in! disease! severity! (symptomatic! and!
laparoscopic!appearance),!histological!changes!in!eutopic!endometrium,!and!correlation!
between!symptom!change!and!histological!change,!following!treatment!with!ulipristal!
acetate.!!
6.2.3! Study(population(
A!population!size!of!twenty!patients!was!chosen!to!maximise!the!chance!of!identifying!
changes!within! the! ectopic! endometrium!whilst!minimising! patient! exposure! to! the!
study!drug;!as!is!common!practice!with!pilot!studies!exploring!the!action!and!impact!of!
a!new!treatment.!
6.2.4! Descriptive(cohort(design(
At!the!time!of!designing!the!study!there!were!no!published!data!on!the!use!of!ulipristal!
acetate! in! endometriosis.! ! Although! multiple! data! existed! about! PAEC! and! the!
!
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histological!response!of!the!eutopic!endometrium!to!ulipristal!acetate!there!were!no!
data!on!histological!changes!within!ectopic!endometrium.!!!!
An! interventional! descriptive! cohort! study! design! was! decided! upon! as! the! most!
appropriate!way!to!investigate!the!potential!benefit!of!ulipristal!acetate.!!The!CHUTE!
study! was! designed! as! a! pilot! to! explore! the! possible! use! of! ulipristal! acetate! in!
endometriosis! and! to! identify! any! significant! histological! changes!within! the! ectopic!
endometrium!that!might!cause!safety!concerns.!!The!use!of!SPRMs!in!endometriosis!has!
been! suggested! in! the! literature! for! the! last!10015!years! but! their!use!has!not!been!
thoroughly! investigated.! ! Our! hope! was! that! the! CHUTE! study! would! provide!
reassurance!about! the! safety!of! ulipristal! acetate,! identify!the!potential!mechanisms!
behind!how!selective!progesterone!receptor!modulators!may!exert!a!positive!effect!and!
facilitate!the!commissioning!of!a!larger!study!to!clarify!the!role!SPRMs!may!have!in!the!
management!of!endometriosis.!
A!decision!was!taken!to!expose!all!participants!in!our!cohort!to!the!study!drug!and!not!
to!have!a!placebo!group!as!a!comparator.!!This!decision!was!taken!for!three!reasons:!
firstly,!our!primary!objective!was!to!identify!histological!changes!rather!than!compare!
ulipristal!acetate!to!placebo!or!existing!treatment;!secondly,!it!would!be!unusual!to!see!
significant!clinical!change!of!endometriosis!over!a!period!of!three!months!in!a!placebo!
group;! and! lastly,! some! data! about! the! expected! histological! appearance! of! ectopic!
endometrium!is!known!and!can!act!as!a!comparator.!
6.2.5! Treatment(duration(and(timing(of(surgery(
The!treatment!period!of!12!weeks!was!chosen!to!maximise!the!effect!of!the!IMP!on!the!
ectopic!endometrial!histology!and!clinical!symptoms.!!This!treatment!duration!is!also!in!
keeping!with!the!current!marketing!authorisation!for!the!IMP.!
We!considered!two!possible!time!points!for!surgery:!
!! At!the!end!of!the!120week!treatment!period!with!contingency!for!an!additional!
two!weeks!of!study!drug!to!ensure!the!patient!was!taking! IMP!at!the!time!of!
surgery!
!
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!
!! After!a!120week!course!of!IMP!and!menstruation!to!allow!assessment!of!residual!
PAEC!changes!after!endometrial!shedding!of!the!eutopic!endometrium.!!
The! initial!design!would!have!possibly! led! to!a!variable!duration!of!ulipristal! acetate!
treatment! across! the! study! population.! ! It! was! decided! that! a! definite! duration! of!
treatment!was!important!but!waiting!lists!and!fixed!operating!lists!within!the!NHS!meant!
that!we!could!not!guarantee!to!perform!surgery!immediately!after!the!treatment!course!
had!been!completed.!!!
Also,!the!objective!of!the!study!was!to!explore!safety!and!the!presence!of!PAEC!within!
the! eutopic! and! ectopic! endometrium.! ! The! presence! of! PAEC! in! the! eutopic!
endometrium!is!as!high!as!60%!after!a!single!12!week!course!of!ulipristal!acetate!but!
this! decreases! to! 16%,! 6!weeks! after! the! end! of! treatment! as! a! result! of!menstrual!
shedding.(198,200)! What! was! unknown! was! whether! the! same! would! be! true! for!
ectopic!endometrium!that!does!not!appear!to!shed!as!eutopic!endometrium!does,!or!
whether!the!ectopic!location!of!the!endometrium!would!make!the!PAEC!more!or!less!
likely.!
As!such,!the!design!was!changed!to!surgery!6!weeks!after!the!course!of!ulipristal!acetate!
had!been!completed.!!This!important!change!allowed!us!to!explore!PAEC!with!a!point!of!
comparison!from!previous!studies!and!to!obtain!questionnaire!data!from!the!subjects!
whilst! taking! ulipristal! acetate! and! once! they! had! stopped! pre0operatively.! ! The!
disadvantages!being!that!we!were!not!able!to!obtain!our!histological!samples!whilst!the!
patients!were!still!taking!ulipristal!acetate!so!subtle!signs!of!PAEC!may!have!been!missed!
and!any!changes!in!cellular!expression!caused!by!ulipristal!acetate!may!have!reverted!
by!the!time!of!surgery.!!
6.2.6! Histological(assessment(
In! addition! to! descriptive! data! relating! to! changes! seen!with! standard!H&E! staining,!
expression!of! the!oestrogen! receptor,!progesterone! receptor!and!androgen! receptor!
were!explored,!as!these!are!all!key!receptors!in!normal!endometrial!functioning!and!any!
changes!may!have!impacted!on!clinical!symptoms.!!
!
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As!active!endometriosis!is!a!proliferative!disease!and!PAEC!is!a!proliferative!response!to!
ulipristal!acetate,!Ki67!(a!proliferation!marker)!was!also!used!to!assess!whether!ulipristal!
acetate!had!an!influence!on!cellular!proliferation.!!The!original!method!included!these!
four!immunohistochemical!stains!with!plans!to!add!other!markers,!such!as!CD10,!PTEN!
and!VEGF!dependent!on!the!results!that!were!obtained.!!!
The!use!of!CD10!was!excluded!as!it!was!not!considered!to!be!of!value.!!The!condition!of!
the!ectopic!tissues!was!of!sufficient!quality!for!us!to!be!confident!in!the!diagnosis!and!
to! allow!us! to! distinguish! between! the! epithelium!and! stroma! of! the! endometriotic!
deposits.!!!
A! decision! was! taken! to! explore! VEGF! expression! as! it! is! key! mediator! of!
neovascularisation! in! the! stratum$ functionalis! of! eutopic! endometrium.! ! In!
endometriosis,!the!ectopic!foci!of!disease!promote!local!vascular!changes!and!in!PAEC!
one! of! the! key! features! described! are! the! vascular! changes.! ! Given! these! facts! we!
wanted!to!see!if!ulipristal!acetate!was!having!any!influence!on!the!vasculature!and!VEGF!
expression!was!chosen!as!a!marker!of!this.!!!
The!expression!of!the!tumour!suppressor!gene!(PTEN)!was!assessed!to!see!if!there!was!
any!suggestion!of!decreased!expression!in!response!to!ulipristal!acetate.!!As!progressive!
loss!of!expression!is!seen!in!un0opposed!oestrogen!use,!is!part!of!the!tumourigenesis!of!
endometrioid!adenocarcinoma!and!may!play!a!role!in!the!promotion!of!endometriosis,!
a!PTEN!antibody!was!used.(82,84)!!Although,!data!existed!on!expression!in!endometrial!
cells! in! culture!and! in!eutopic!endometrium,! there!were!no!published!data!on!PTEN!
immunohistochemistry!in!ectopic!foci!of!endometrium!in!human!studies!at!the!time!the!
study!was!designed.(109,110)!!
6.3! ETHICAL(APPROVAL(
The! study! design,! protocol,! patient! information! sheets! and! study! documents! were!
approved!by!the!Office!for!Research!Ethics!Committees!Northern!Ireland!(ORECNI)!on!
11th!August!2014.!!The!substantial!amendments!to!the!research!protocol! (Substantial!
amendment!2!&!Substantial!amendment!3)!were!approved!on!30th!October!2014!and!
11th!February!2015,!respectively.!!The!details!of!the!protocol!amendments!can!be!found!
in!Section!6.13.!
!
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6.4! TRIAL(SETUP(&(REGISTRATION(
6.4.1! Clinical(Trials(of(Investigational(Medicinal(Products((CTIMPs)(
The!CHUTE!study!required!the!administration!of!ulipristal!acetate!to!the!study!patients!
and!so!fell!under!the!EU!Clinical!Trials!Directive.!!Using!the!MHRA’s!on0line!algorithm,!it!
was!clear!that!clinic!trial!authorisation!(CTA)!was!needed!and!that!as!a!CTIMP!it!would!
also!require!additional!regulatory!requirements.(212,213)!!The!CHUTE!study!team!and!
local!R&D!department!had!limited!experience!of!such!a!study!setup!and!consequently!
this!phase!of!the!study!setup!required!additional!learning!and!time!to!ensure!all!aspects!
had!been!appropriately!considered!prior!to!start!of!the!study.!!
To!setup!and!appropriately!register!the!study!we!made!use!of!the!NIHR!Clinical!Trials!
Toolkit,! associated! Routemap! document! and! the! joint! guidance! from! the! Medical!
Research! Council/Department! of! Health/MHRA! on! Risk0adapted! Approaches! to! the!
Management! of! Clinical! Trial! of! Investigational!Medicinal! Products.(214–216)! ! These!
documents!highlighted!the!need!for!the!following:!
!! A!Protocol!
!! Peer!review!
!! Ethical!approval!
!! Clinical!Trials!Authorisation!from!the!MHRA!
!! Pharmacy!review!for!supply!and!control!of!the!IMP!!
!! The! Investigators!Brochure!(IB)!or!Summary!of!Product!Characteristics! (SmPC)!
for!the!IMP!
!! Sponsorship!and!liability!cover!
!! Human!Tissue!Act!consideration!
!! Contracts!
!! Safety!reporting!and!monitoring!
In!October!2013,!the!research!idea!had!been!formulated!and!an!agreement!in!principal!
existed!for!funding!from!Gedeon!Richter!Plc.!!The!first!step!in!the!process!was!to!involve!
our! local!R&D!department,!who!registered!the!CHUTE!trial! locally!with!a!protocol! ID!
2013O&G04L.!!The!application!process!was!initiated!through!the!Integrated!Research!
Application!System!(IRAS)!with!the!project!ID!number!137405.!
!
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To! determine! the! protocol! design! requirements,! patient! document! content,!
sponsorship! arrangements! and! advice! on! running! the! study;! we! used! the! European!
Medicine!Agency!International!Council!on!Harmonisation!of!Technical!Requirements!for!
Registration!of!Pharmaceuticals!for!Human!Use!(ICH)!Guideline!on!Good!Clinical!Practice!
E6!(R1)!to!guide!us.(217)!
6.4.2! CTN(
The!CHUTE!protocol!was!registered!with!the!European!Union!Clinical!Trials!Register!with!
the!study!start!date!of!16th!October!2014.!!The!EudraCT!Number!is!20130005494053.!
6.4.3! Sponsorship(
Although,!funding!from!Gedeon!Richter!Plc.!had!been!confirmed!under!an!Investigator!
Initiated!Trial!(IIT)!agreement!with!the!company,!the!trial!needed!a!sponsor!to!ensure!
appropriate! liability! cover.! ! The! Norfolk! and! Norwich! University! Hospitals! NHS!
Foundation!Trust!had!not!previously!acted!as!a!sponsor!for!a!CTIMP!and!so!agreement!
was! sought! from! the! Director! of! the! Research! and! Development! department! for!
approval.! !The!costing,!invoice!schedule!and!funding!contract!were!arranged!through!
the!R&D!department!and!all!agreements!signed!by!the!Trust!legal!representative!prior!
to!study!commencement.!!!
The! R&D! Director! (Professor! Flather),! Research! Services! Manager! (Lisa! Chalkley),!
Commercial! Research! Coordinator! (Julie! Dawson)! and! Research! Accountant! (Julie!
Mercer)!were!all!instrumental!in!achieving!local!support!and!approval!for!the!study.!!The!
designated!sponsors!representative!was!Lisa!Chalkley,!the!Research!Services!Manager.!!
6.4.4! MHRA(
An! application! for! approval! was! made! to! the! Medicines! and! Healthcare! Products!
Regulatory!Agency!on!the!19th!August!2014.!!Following!some!minor!amendments!to!the!
exclusion!criteria!and!wording!of! the! study!documents,! to! reflect! the!content!of! the!
SmPC,!authorisation!was!granted!on!the!16th!October!2014.!!!
In!line!with!the!MHRA!requirements!two!annual!Development!Safety!Update!Reports!
(DSUR)!have!been!compiled!and!submitted!to!the!MHRA;!DSUR!(CHUTE!Oct!2014!–!Oct!
2015)!v1.1!and!DSUR!9CHUTE!Oct!2015!–!Oct!2016)!v1.1.!!These!were!submitted!on!21st!
December!2015!and!20th!December!2016,!respectively.!
!
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6.4.5! Peer(review(
The!application!for!funding!from!Gedeon!Richter!through!an!Investigator!Initiated!Trial!
agreement!(IIT)!required!high!quality!peer!review.! !The! initial!step!was!review!by!an!
internal!company!committee!of!the!Chief!Medical!Officer,!Chief!Development!Officer,!
Chief! Commercial! Officer,! Head! of! Scientific! Affairs! and! the! Scientific! Manager.!!
Subsequently,!the!study!proposal!was!reviewed!by!Dr!I.!Osterloh!BSc!MSc!MBBS!MRCP!
before!approval!was!granted.!!!
6.4.6! NIHR(adoption(
Adoption!onto!the!NIHR!(National!Institute!for!Health!Research)!CRN!(Clinical!Research!
Network)!Portfolio!was!requested!to!ensure!access!to!funding!and!a!research!nurse!to!
assist!with!the!delivery!of!the!CHUTE!study.!!An!application!was!submitted!on!02nd!July!
2014.! !To!process!the!application,!the!details!of! the!funding!source!and!peer!review!
process!within! Gedeon! Richter!were! requested! by! the! portfolio! team.! ! These!were!
provided!on!19th!September!2014!and!progress!through!the!NIHR!Coordinated!System!
for!Gaining!NHS!Permission!(CSP)!was!confirmed!on!22nd!September!2014.!!!
The!CHUTE!study!was!uploaded!to!the!portfolio!on!07th!October!2014!with!a!UKCRN!ID!
17552.!Our!recruitment!data!was!uploaded!to!the!UKCRN!Portfolio!Database!monthly,!
as!per!the!requirements!of!adoption.!!!!
6.5! TRIAL(MONITORING(
Monitoring!of!the!study!was!undertaken!by!the!Clinical!Research!&!Trials!Monitor!of!the!
Research!&!Development!Department!of!the!Norfolk!and!Norwich!University!Hospitals!
NHS!Foundation!Trust.!!The!monitoring!plan!was!developed!in!line!with!the!EMA!ICH!
Guideline!on!Good!Clinical!Practice!E6!(R1).(217)!!The!following!monitoring!visits!were!
completed!and!monitoring!reports!were!produced:!
1)! Site!Initiation!Visit!(SIV)!&!initial!monitoring!visit0!13th!November!2014!
2)! Routine!Monitoring!Visit!(10!days!after!date!of!First!Patient!First!Visit)0!23rd!April!
2015!
3)! Routine!Monitoring!Visit!(5010!days!after!date!of!First!Patient!Pre0op!Visit)0!25th!
August!2015!
4)! Routine!Monitoring!Visit!(5010!days!after!date!of!First!Patient!Surgical!Visit!or!
as!appropriate)0!16th!September!2015!
!
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5)! Routine!Monitoring!Visit0!4th!February!2016!
6)! Routine!Monitoring!Visit0!11th!August!2016!
7)! Data!Verification!Visit0!18th!May!2017!
8)! Close!Down!Monitoring!Visit!(End!of!Trial!as!defined!by!Protocol)0!18th!July!2017!
No!major!concerns!were!raised!by!the!monitor.! !A!number!of!minor!corrections!and!
updates!to!the!study!files!were!required!at!various!time!points!but!overall!the!monitor!
recognised! ‘the!high!quality!of! the! study! records,!oversight!and!management!of! the!
trial’.!
6.6! INVESTIGATIONAL(MEDICINAL(PRODUCT((IMP)(
6.6.1! Study(drug(
Ulipristal!acetate!(Esmya)!5mg!tablets!were!manufactured!by!Gedeon!Richter!Plc!as!per!
the! details! of! the! SmPC! and! in! line! with! the! marketing! authorisation! (Marketing!
Authorisation!Number!EU/1/12/750/001).(218)!!The!white!to!off0white,!round!biconvex!
tablets!of!7mm!engraved!with!“ES5”!on!one!face!were!packaged!into!Alu0PVC/PE/PVDC!
blister!packs!of!28,!as!per!usual!manufacturing.!!!
These!were!then!stored!at!room!temperature!in!their!original!outer!carton!to!protect!
them!from!light,!giving!them!a!shelf!life!of!three!years.!!The!original!labelling!was!not!
changed!as!this!was!an!open!label!study!but!additional!study!specific!labelling!(Appendix!
2)! took! place! on0site! in! accordance! with! Annex! 13! of! the! EU! Guideline! on! Good!
Manufacturing!Practice!(GMP).!(219)!!
6.6.2! Dosing(regimen(&(prescription( (
Participants! were! required! to! complete! all! the! screening! investigations! and! for! the!
results!to!be!checked!prior!to!commencing!the!study!drug.!!At!the!Treatment!visit!the!
prescription!(Appendix!3)!was!completed!and!three,!280tablet!packs!were!dispensed.!
Participants!took!their!1st!dose!between!day!1!and!day!5!of!the!cycle,!to!minimise!the!
risk!of! irregular!vaginal!bleeding.! !The!timing!of! the!Treatment!visit!was!arranged!to!
allow!the!participant!to!start!the!drug!on!the!day!of!the!visit.!!Once!start!each!participant!
took!1!tablet!of!ulipristal!acetate!(UPA)!once!a!day!for!12!weeks.!They!were!instructed!
that!the!tablets!may!be!taken!with!or!without!food.!
!
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6.6.3! Dose(changes( (
No!dose!changes!were!necessary!as!part!of! the! protocol.! ! If! a!dose!was!missed,!the!
participant!was!instructed!to!take!the!ulipristal!acetate!as!soon!as!possible,!as!long!as!
this!was!not!more!than!12!hours!late.!!If!the!dose!was!missed!by!more!than!12!hours,!
the!participant!was!asked!not! to! take! the!missed!dose!and! simply! resume! the!usual!
dosing!schedule.!!They!were!asked!to!contact!the!study!team!if!that!occurred!so!that!
missed!doses!could!be!recorded.!
6.6.4! Participant(compliance( (
Study! drug! compliance! was! monitored! during! the! study! by! documentation! of! self0
reported! usage! at! the! End! of! Treatment! (EoT)! visit.! !Missed! doses,! total! number! of!
tablets!taken!and!any!returned!tablets!within!the!blister!packs!were!documented!on!a!
participant’s!CRF.!!Although!all!participants!were!asked!to!return!the!blister!packs!and!
cardboard! packaging,! some! forgot! to! do! this.! ! As! such! the! package! returns! to! the!
pharmacy!department!were!not!complete.!!
6.7! RECRUITMENT(
Patients!were!recruited!from!the!tertiary!referral!gynecology!clinic!at!the!Norfolk!and!
Norwich!University!Hospital.!!Those!patients!with!a!laparoscopically!confirmed!diagnosis!
of! endometriosis,! requiring! surgical! management! were! considered.! ! Many! of! the!
participants! had! undergone! a! diagnostic! laparoscopy! at! the! Norfolk! and! Norwich!
University!Hospital!but!patients!referred!from!other!centres!were!also!considered.!
Once! a! potential! participant! was! identified! by! the! clinical! team,! the! management!
options!were! discussed,! and! the! outline! details! of! the! CHUTE! study! explained.! ! The!
patient! information! sheet!was!provided,!and!any!questions!answered.! !Consent!was!
obtained!at!that!first!contact!for!future!contact!by!a!member!of!the!research!team.!!!
Those!enrolled!in!the!study!were!managed!by!the!study!team!and!the!participants!GP!
was! informed!about!the!details!of! the!CHUTE!study,!the!outcome!at!surgery!and!the!
future!endometriosis!management!that!was!agreed!at!the!End!of!Study!visit.!!Those!who!
chose!not!to!participate!or!were!excluded!were!offered!standard!care.!!!
!
!
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The! details! of! potential! participants! and! of! enrolled! subjects!was! stored! in! a! secure!
database0!an!Excel!spreadsheet!stored!on!the!hospital!network.!The!password!access!to!
this!database!was!restricted!to!the!study!team!only.!
6.8! SELECTION(OF(PATIENTS(
6.8.1! Eligibility(
All! women! with! pelvic! endometriosis! confirmed! by! diagnostic! laparoscopy,! on! no!
medical!treatment!for!endometriosis!and!not!planning!for!a!pregnancy!in!the!12!months!
following!recruitment!were!considered.! !No! limits!were!placed!on!the!time!between!
diagnostic!laparoscopy!and!inclusion!in!the!study!but!a!surgical!diagnosis!(inspection!+/0!
biopsy)!was!required.!!
6.8.2! Inclusion(criteria(
To! be! eligible! for! the! study,! patients!were! required! to!meet! the! following! inclusion!
criteria:!
1)! Provision!of!written!informed!consent!prior!to!any!study!related!procedures!
2)! Pre0menopausal!women!between!18!and!50!years!inclusive!!
3)! Subject!with!a!Body!Mass!Index!≥18!and!≤40!
4)! Regular!menstrual!pattern!with!cycle!length!22035!days!
5)! Surgically! (laparoscopic)! diagnosed! endometriosis! requiring! further! surgical!
treatment!
6)! If! sexually! active,! agrees! to! use! of! adequate! non0hormonal! contraceptive!
method(s)!to!prevent!pregnancy!for!the!duration!of!study!and!12!weeks!after!
the!last!dose:!
a)! subject!has!undergone!surgical!sterilisation!
b)! subjects! partner! has! undergone! surgical! sterilisation! (>12! weeks!
before!consent!signed)!
c)! condoms!
d)! non0hormonal!intra0uterine!device!
e)! abstinence!
7)! Normal!screening!breast!examination!
!
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8)! Subject!is!willing!to!take!part!in!study!and!understands!definitive!surgery!will!
be!delayed!until!course!of!ulipristal!acetate!is!completed!and!menstruation!has!
returned!
6.8.3! Exclusion(criteria(
The!following!criteria!prompted!exclusion!of!the!patient!from!the!study:!
1)! Genital! bleeding! of! unknown! aetiology! or! for! reasons! other! than! uterine!
fibroids!
2)! History!of!or!current!uterus,!cervix,!ovarian!or!breast!cancer!
3)! Significant!and!persisting!finding!on!cervical!screening!(liquid!based!cytology)!
within!the!past!12!months!
4)! History! of! endometrial! hyperplasia! or! abnormalities! detected! on! first!
endometrial!biopsy!
5)! History!of!medical!treatment!for!leiomyoma,!including!with!a!SPRM!
6)! Taking!prohibited!medication:!
a)! Treatments! with! progestins! (systemic! or! progestin! releasing! intra0
uterine!system)!or!an!oral!contraceptive:!within!the!month!before!the!
screening!visit!
b)! Acetylsalicylic!acid,!mefenamic!acid,!anticoagulants!such!as!cumarins!
and/or!antifibrinolytic!drugs!such!as!tranexamic!acid!within!one!week!
before!the!screening!visit!
c)! Systemic! glucocorticoid! treatments! and/or! systemic! depot!
glucocorticoid!treatments!within!one!week!or!two!months!before!the!
screening!visit,!respectively!
d)! GnRH!agonist!and!antagonist:!
i)! Immediate!or!monthly!sustained!release!depot!preparation!or!
immediate!release!form!within!6!months!of!screening!visit!
ii)! 3!or! 6!months! sustained! release! depot! preparation!within! 12!
months!before!the!screening!visit!
7)! Treatment! or! likely! treatment! during! the! study! with! drugs! that! are! not!
permitted!by! the! study!protocol:!progestins! (systemic!or!progestin! releasing!
intra0uterine!system),!hormonal!contraceptives,!systemic!glucocorticoids!(oral!
and!injectable),!GnRH!agonist!and!GnRH!antagonists!
!
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8)! Treatment!with!a!medication!which!includes!potent!inhibitors!of!CYP3A4!(such!
as!ketoconazole)!
9)! Treatment!with!a!medication!which!includes!potent!inducers!of!CYP3A4!(such!
as!rifampicin)!
10)!Abnormal! hepatic! function! at! study! entry! (defined! as! alanine! transaminase!
[ALT],!hepatic!alkaline!phosphatase,!or!total!bilirubin!above!twice!the!upper!
limit!of!normal)!
11)!Positive!pregnancy!test!at!baseline,!is!nursing!or!planning!a!pregnancy!during!
the!course!of!the!study!
12)!Current!(within!last!12!months)!problem!with!alcohol!or!drug!abuse!
13)!A!mental!condition!rendering!her!unable!to!understand!the!nature,!scope!and!
possible! consequences! of! the! study,! and/or! evidence! of! an! uncooperative!
attitude!
14)!Abnormal! baseline! findings,! any! other! medical! condition(s)! or! laboratory!
findings!that,!in!the!opinion!of!the!investigator,!might!jeopardise!the!subject’s!
safety!or!interfere!with!study!evaluations!
15)!An!allergy!to!SPRMs!or!progestins!or!any!of!the!ingredients!of!the!study!drug!
tablet! (Microcrystalline! cellulose,! Mannitol,! Croscarmellose! sodium,! Talc,!
Magnesium!Stearate!(vegetable!origin))!
16)!Current!enrollment!in!an!investigational!drug!or!device!study!or!participation!
in!such!a!study!within!the!previous!30!days!and!is!still!in!the!exclusion!period!
These!criteria!were!chosen!to!exclude!patients!with!known!or!suspected!conditions!that!
would! impact!on!the!safety!of!taking!the!study!drug!for!a!period!of!three!months!or!
would!adversely!affect!interpretation!of!the!research!outcomes.!
6.8.4! Information(provided(to(the(patients(on(selection(
All!patients!considering!the!CHUTE!trial!or!enrolled!on!the!CHUTE!trial!were!given!a!copy!
of!the!up!to!date!Patient!Information!Sheet!(PIS).!!Any!changes!to!the!PIS!resulting!from!
protocol!amendments!were!highlighted!and!an!updated!version!provided.!A!copy!of!the!
last!iteration!of!the!PIS!is!shown!in!Appendix!4.!
6.8.5! Withdrawal(
Participants! would! have! been! withdrawn! from! the! study! if! they! had! requested!
withdrawal.!!No!pressure!to!provide!a!reason!would!have!been!made!and!it!would!have!
!
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been!made!clear!that!any!decision!to!cease!involvement!in!the!study!would!have!had!no!
impact! on! the! care! provided.! ! No! patients! enrolled! in! the! CHUTE! study! requested!
withdrawal.!
A! plan!was! also!made! for! withdrawal! of! a! participant! if! the! investigation! team! felt!
continuing!would!be!harmful!for!the!patient,!the!patient!became!pregnant!or!there!was!
significant!progression!of!symptoms!requiring!a!change!to!the!management!plan!prior!
to!completion!of!the!study.! !Two!withdrawals! from!the!study!occurred!on!this!basis0!
CHUTE!17!due!to!pregnancy!and!CHUTE!20!due!to!a!change!in!management!plan.!
6.9! SCHEDULE(OF(VISITS(
There!was!a!total!of!five!study!visits!after!the!consent!was!signed.!!Two!of!these!were!
additional! visits! when! compared! to! standard! care! for! a! patient! having! surgical!
management!of!endometriosis.!!Compensation!to!cover!time!and!travel!as!well!as!re0
imbursement!of!parking!costs!was!offered!to!each!participant.!
A!flow!chart!of!the!study!visits!is!shown!in!Section!6.9.2!(Figure!6.2).!
6.9.1! Recruitment(
Pre3screening$
It!was!important!to!ensure!potential!participants!were!clear!about!their!diagnosis,!the!
nature!of!the!disease,!their!management!options,!the!implications!for!their!future!health!
and!where!the!CHUTE!study!fitted!into!the!standard!pattern!of!care.!!This!was!achieved!
through! a! verbal! discussion! with! a! member! of! the! study! team! as! well! as! written!
communication! in! the! form! of! the! patient! information! sheet.! ! Subjects! were! given!
sufficient! time! (>2! weeks)! to! consider! this! information! and! ask! questions! before!
scheduling!a!consent!visit.!A!total!of!66!participants!were!approached!with!25!being!
recruited!to!the!study!
Pre0screening! involved! taking! a! focused! gynaecological! history! concentrating! on!
endometriosis!symptoms!and!previous!endometriosis!management.!!The!benefits,!risks!
implications!of!conservative,!medical!and!surgical!management!were!all!explained!to!
any!potential!participants.!!They!were!then!asked!to!decide!if!surgical!management!was!
something!they!wished!to!consider!and!if!so!a!full!explanation!of!the!CHUTE!study!was!
offered.!!!
!
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There!were!four!key!areas!that!were!discussed:!the!unknown!impact!of!ulipristal!acetate!
on!endometriosis,!the!need!for!adequate!contraception,!the!extra!hospital!visits!&!study!
procedures,!and!the!delay!in!surgical!management!whilst!completing!the!course!of!study!
drug.! ! Our! expectation! that! ulipristal! acetate! would! improve! the! symptoms! of!
endometriosis!was!explained!but!it!was!made!clear!that!this!was!not!known!or!proven.!!
The! impact! of! the! study! on! any! plans! for! pregnancy,! the! need! for! adequate!
contraception! and! the! potential! risks! of! conceiving! whilst! taking! an! SPRM!were! all!
explained! to! highlight! the! importance! of! this! aspect! of! the! study! protocol.! ! Other!
negative!aspects,!such!as!additional!intimate!examinations,!endometrial!biopsies!and!
delays!to!surgical!management!were!all!made!clear.!!!!!!
In!addition,!the!inclusion!and!exclusion!criteria!were!discussed!and!checked!to!ensure!
the!patient!was!eligible!for!the!study.!!An!opportunity!for!asking!any!questions!was!made!
and!further!outpatient!appointments!offered!if!needed.!!
Informed$Consent$
Those!patients!willing! to!proceed!with! the! study!were!asked! to! sign!a! consent! form!
(Participant!Consent!Form!(CHUTE)0!Appendix!5).!!Entry!into!washout!or!screening!did!
not!occur!until!this!consent!form!was!completed.!!!
Washout$
Patients!taking!oral!contraceptives!(i.e.!the!combined!oral!contraceptive!pill!(COCP)!or!
the!progesterone!only!pill!(POP))!were!instructed!to!stop!these.!!Those!patients!using!
other! prohibited! hormonal!medication! such! as! the! Levonorgestrel! IUS! (Mirena®)! or!
monthly! GnRHa! were! advised! about! stopping! these.! ! The! washout! period! varied!
between! 4026! dependent! on! the! agent.! ! The! resumption! of! a! normal! regular!
menstruation!pattern!was!required!prior!to!entering!screening.!
!
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6.9.2! Study(flow(chart(
!
Figure'6.2' Study'Flow'Chart'showing'schedule'&'requirements'of'visits.'''
(BSGE&Qu=* British* Society* of* Gynaecological* Endoscopy* Pelvic* Pain* Questionnaire,* EHP&30=* Endometriosis* Health* Profile* Questionnaire,* CPSSS=*
Composite*Pelvic*Signs*&*Symptoms*Score,*PGIC=*Patients’*Global*Impression*of*Change*Score,*IHC=*immunohistochemistry)!
!
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6.9.3! Screening(
Screening!was!arranged!for!day!7012!of!the!participants!menstrual!cycle!to!ensure!she!
was! in! the!mid! proliferative! phase.! ! Consent!was! confirmed,! the! inclusion/exclusion!
criteria!were!checked,!and!any!adverse!events!recorded.!A!full!medical!history!was!taken!
to!cover!the!following!areas:!
!! demographic!data0!year!of!birth,!age,!ethnicity!and!occupation!
!! endometriosis! history0! current! symptoms! (dysmenorrhoea,! non0menstrual!
pelvic! pain,! dyspareunia,! bladder! symptoms,! dyschezia),! age! of! onset,! family!
history!
!! reproductive! and! menstrual! history0! menarche,! current! cycle! pattern,!
pregnancies!&!outcomes,!subfertility,!inter0menstrual!or!post0coital!bleeding!
!! past!medical!history0!previous!diagnoses!or!on0going!conditions,!and!a!full!list!of!
previous!surgery,!including!endometriosis!surgery!and!ASRM!classification!
!! drug!history0!including!all!current!medicines!being!used!and!documentation!of!
any!drug!allergies!or!intolerances!
!! smoking! habits,! documented! as! daily! usage! and! alcohol! consumption,!
documented!as!weekly!usage!
Each!participant!was!also!asked!to!complete!the!three!baseline!questionnaires!about!
their!symptoms:!the!BSGE!Pelvic!Pain!Questionnaire,!the!Endometriosis!Health!Profile!
Questionnaire!(EHP030)!and!the!Composite!Pelvic!Signs!and!Symptoms!Score!(CPSSS)!
(see!Section!6.12.1!for!details).!
A!full!physical!examination!was!performed,!based!on!the!clinical!history,!to!include!body!
weight,!height,!breast!examination!and!pelvic!examination.! !The!results!of!the!pelvic!
examination! were! recorded! and! the! CPSSS! questionnaire! completed.! ! A! urinary!
pregnancy! test! was! taken,! and! an! endometrial! biopsy! obtained! using! a! Pipelle®!
endometrial! sampler.! ! A! single! sample! of! blood!was! taken! and! sent! for! biochemical!
analysis0! ! creatinine,! potassium,! sodium,! urea,! total! protein,! albumin,! alanine!
aminotransferase! (ALT),! alkaline! phosphatase! and! total! bilirubin! were! all! measured!
using!standard!analysis!methodology!using!the!standard!operating!procedure!(SOP)!at!
the!Norfolk!and!Norwich!University!Hospital.!!The!results!of!the!blood!biochemistry!and!
endometrial! biopsy! were! reviewed! within! 205! working! days! to! ensure! no! exclusion!
criteria!had!been!met.!!!!
!
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6.9.4! Treatment(
The! treatment!visit!was!arranged! for!day!105! of! the! participant’s!menstrual! cycle! to!
ensure!she!could!commence!study!drug!on!the!day!of!the!visit.!!Consent!was!confirmed,!
the!inclusion/exclusion!criteria!were!re0checked,!any!adverse!events!were!noted,!and!
the!screening!results!were!recorded!in!the!CRF.!!
Ulipristal!acetate!was!dispensed!in!standard!packaging!(as!described!above)!and!advice!
given!on!when!to!start,!what!to!do!in!case!of!missed!pills,!possible!side!effects!and!when!
to!seek!medical!advice.!!Each!participant!was!asked!to!keep!the!empty!packaging!(foil!&!
cardboard)!and!return!it!at!the!End0of0treatment!visit.!
The!study!questionnaires!were!provided0!EHP030,!CPSSS!(symptom!domains!only)!and!
Patients’! Global! Impression! of! Change! (PGIC)! scale.! ! Instructions! were! given! about!
completing! the! questionnaires! in! the! final! week! of! taking! the! study! drug! and! a!
convenient!data!agreed!and!documented!on!each!questionnaire.!!
6.9.5! EndGofGtreatment(
Surgery!was!planned!for!6!weeks!(+/0!2!weeks)!after!the!cessation!of!IMP!to!allow!the!
resumption!of!the!ovarian!cycle!and!the!occurrence!of!at!least!one!menstrual!period.!!As!
such! the! End0of0treatment! visit! occurred! at! the! time! of! the! standard! pre0operation!
assessment!appointment,!usually!the!week!before!surgery.!
Patients!were!seen!by!the!pre0operative!team0!pre0op!doctor,!pre0op!nurse!and!pre0op!
anaesthetist! as! required.! ! Pre0operative! clerking! was! completed! as! per! usual!
departmental! protocols! and! consent! obtained! for! surgery! explaining! the! risks! and!
benefits! of! the! surgical! intervention.! ! Clear! discussion! and! documentation! of! the!
following!risks!took!place:!
Serious(Risks:(
!! risk!of!serious!complications!(e.g.!injury!to!bowel,!bladder,!uterus!or!major!blood!
vessels0!uncommon!(2!in!1000)!
!! 15%!of!bowel!injuries!might!not!be!immediately!recognised!
!! failure!to!gain!entry!into!the!abdomen!and!complete!the!intended!procedure!
!! risk!of!death0!very!rare!(308!in!100,000)!
!! hernia!formation!at!the!port!sites!
!
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Frequent(Risks:(
!! bruising!
!! shoulder!tip!pain!
!! wound!dehiscence!
!! wound!infection!
Additional(procedures:(
!! blood!transfusion!
!! laparotomy,!repair!of!damage!to!bowel,!bladder,!uterus!or!blood!vessel!!
Study!consent!was!also!confirmed,!the!inclusion/exclusion!criteria!were!re0checked,!and!
any! adverse! events! recorded.! The! participants! were! asked! to! complete! the! study!
questionnaires!0!!EHP030,!CPSSS!and!PGIC,!and!a!pelvic!examination!was!completed.!!
6.9.6! Surgical(management(
On! admission! for! surgery! the! study! and! surgical! consent! were! confirmed,! the!
inclusion/exclusion! criteria! were! re0checked,! and! any! adverse! events! recorded.! ! In!
theatre,!a!pelvic!examination!(under!anaesthetic)!was!performed!and!a!repeat!Pipelle®!
endometrial! biopsy! obtained.! ! The! surgical! management! was! individualised! and!
determined! by! the! operating! team!during! the! operative! laparoscopy.! ! The! sites! and!
severity!of!disease!were!recorded!as!per!the!revised!ASRM!classification!and!the!details!
of!the!surgery!was!recorded!as!per!usual!departmental!practice!with!the!use!of!printed!
surgical!notes,!photographs!and!video!as!appropriate.! !At! least!three!sites!of!ectopic!
endometrial! tissue!were!biopsied!as!part!of!the!excisional!surgery.! !All!samples!were!
placed!in!Formalin,!labelled!and!sent!for!histological!assessment.!
All! post0operative! care!was! routine,! and! the! participants! discharge! from! hospital! as!
clinically!indicated.!!Prior!to!discharge!a!study!follow!up!date!was!arranged.!
6.9.7! EndGof(study(visit(
Three!months!after!surgery!the!patient!was!seen!again!for!post0op!follow0up.!!At!the!
visit,! any! adverse! events!were! recorded,! a!menstrual! history!was! taken! to! ensure! a!
return! to! normal! menses! and! endometriosis! symptoms! determined.! ! The! clinical!
response!to!the!surgical!management!was!used!to!guide!further!treatment!or!discharge.!
!
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6.10! SAFETY!
6.10.1! Definition(of(adverse(events((AEs)(
An!adverse!event!(AE)!was!defined,!as!per!the!EMA!guidelines!on!Good!Clinical!Practice,!
as!any!untoward!medical!occurrence!in!a!subject!administered!the!study!drug!and!which!
does!not!necessarily!have!a!causal!relationship!with!the!treatment.(217)!As!such!any!
unfavourable!and!unintended!sign!(including!an!abnormal!laboratory!finding),!symptom,!
or!disease!temporally!associated!with!the!use!of!a!study!drug,!whether!or!not!related!to!
the!study!drug!or!associated!with!the!participation!in!this!clinical!study!was!considered!
from!the!moment!of!signing!to!study!consent!form!until!the!end!of!treatment!(EoT).!!!
Any!abnormality!identified!during!a!medical!test!(e.g.,!laboratory!parameter,!vital!sign,!
physical! examination)!was! only! defined! as! an!AE! if! the! abnormality!met! one! of! the!
following!criteria:!
!! Induced!clinical!signs!or!symptoms!
!! Required!active!intervention,!
!! Required!interruption!or!discontinuation!of!study!medication!
!! The!abnormality!or!investigational!value!was!clinically!significant.!
6.10.2! Definition(of(serious(adverse(events((SAEs)(
An!AE!was!considered!serious!in!any!of!the!following!circumstances:!
!! caused!death!
!! placed!the!subject!at!immediate!risk!of!death!
!! resulted!in!persistent!or!significant!disability/incapacity!or!substantial!disruption!
of!the!ability!of!the!individual!to!conduct!normal!life!functions!
!! resulted!in!congenital!anomaly,!or!birth!defect!
!! required!inpatient!hospitalisation!or!led!to!prolongation!of!hospitalisation!!
!! pregnancy!during!the!study!
All!SAEs!that!became!apparent!after!the!EoT!up!to!42!days!after!the!last!intake!of!the!
study!drug!were!reported.!!However,!hospitalisation!for!surgery,!planned!prior!to!the!
subject!signing!the!study!consent!did!not!need!to!be!reported!as!an!SAE.!
!
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6.10.3! Criteria(for(causal(relationship(to(the(study(drug(
The!criteria!used!to!define!a!causal!relationship!were:!
!! Not! Related! 0! A! clinical! event,! including! laboratory! test! abnormality,! with! a!
temporal!relationship!to!drug!administration!which!made!a!causal!relationship!
improbable,! and/or! in! which! other! drugs,! chemicals! or! underlying! disease!
provided!a!plausible!alternative!explanation.!
!! Possible! 0! A! clinical! event,! including! laboratory! test! abnormality,! with! a!
reasonable!time!sequence!to!administration!of!the!drug,!but!which!could!also!
have!been!explained!by!concurrent!disease!or!other!drugs!or!chemicals.!!
!! Probable! 0! A! clinical! event,! including! laboratory! test! abnormality,! with! a!
reasonable!time!sequence!to!administration!of!the!drug,!unlikely!to!be!attributed!
to!concurrent!disease!or!other!drugs!or!chemicals,!and!which!followed!a!clinically!
reasonable! response! on! re0! administration! (rechallenge)! or! withdrawal!
(dechallenge).!
6.10.4! Criteria(for(defining(the(severity(of(an(adverse(event(
The!criteria!used!to!define!the!severity!of!any!adverse!event!were:!!
!! Mild!0!No!disruption!of!normal!daily!activities.!
!! Moderate!0!Affect!normal!daily!activities.!
!! Severe!0!Inability!to!perform!daily!activities.!
6.10.5! Reporting(of(serious(adverse(events(
All!SAEs!were!reported!to!the!sponsor!(Norfolk!and!Norwich!University!Hospitals!NHS!
Foundation!Trust)!within!24!hours!of!the!event.!!This!was!followed!by!a!written!report!
to!the!sponsor.!!The!sponsor!provided!an!assessment!of!the!SAE!and!agreed!the!action!
plan!instigated!by!the!research!team.!
6.10.6! FollowGup(to(adverse(events(
All!adverse!events!occurring!during!the!study!were!followed!up!until!resolved!or!judged!
to!be!no!longer!clinically!significant.!!Otherwise!follow0up!of!ongoing!adverse!events!was!
recorded! up! to! End! of! Trial! visit! or! until! completion! of! the! last! follow0up! visit(s),!
whichever!is!last.!!!The!follow!up!of!SAEs!was!dependent!on!the!nature!of!the!event!and!
was!agreed!with!the!sponsor!on!an!individualised!basis.!
!
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6.11! INVESTIGATIONS/STUDY!TOOLS!
6.11.1! Questionnaires(
Four!different!questionnaires! (Appendix!7010)!were!used!to!collect! information! from!
patients!about!signs!&!symptoms,!pain!management,!quality!of!life!features!and!change!
in!disease!severity!following!treatment!with!ulipristal!acetate.!!These!were!chosen!as!
they! are! either! disease! specific! or! are! commonly! used! in! studies! evaluating! the!
management!of!endometriosis.!
BSGE((British(Society(of(Gynaecological(Endoscopy)(Pelvic(Pain(Questionnaire(
This!questionnaire!was!developed!by!the!BSGE!to!facilitate!data!collection!as!part!of!the!
Endometriosis!Centre!project.!!The!Endometriosis!Centre!Database!was!developed!to!
standardise! data! collection! and! investigate! the! morbidity! and! efficacy! of! surgical!
management! for! rectovaginal!endometriosis.! !As!an!Endometriosis!Centre,! the!study!
team!were!collecting!this!data!routinely!and!included!this!in!the!data!set!for!each!study!
patient.!
The!questionnaire!consists!of!seven!different!questions!about!pain,!symptoms,!previous!
treatment!and!general!health.!!The!areas!we!were!interested!in!for!the!CHUTE!study!
were!pain!(question!1),!which!has!nine!parts,!and!the!general!health!score!in!question!
5.!
Endometriosis(Health(Profile(Questionnaire((EHPD30)(
The! Endometriosis! Health! Profile! Questionnaire! (EHP030)! is! a! 300question! patient!
reported!tool,!which!was!developed!to!provide!psychometrically!based!measures!of!the!
Health!Related!Quality!of!Life!(HRQoL)!of!women!with!endometriosis.!It!was!developed!
from!interviews!with!women!with!the!condition!and!has!been!validated!to!ensure!it!is!
responsive!to!changes!in!disease!status.(220)!!!
The!published!evidence!concludes!that!the!EHP! is!a!reliable!and!valid! instrument!for!
assessing!areas!of! concern! to!women!with!endometriosis! that!are! not!addressed!by!
other!condition0specific!and!generic!questionnaires.!!The!impact!of!pain!symptoms!and!
interplay!of!psycho0social!wellbeing!contribute!to!the!reduced!QoL!(Quality!of!Life)!in!
patients! with! endometriosis! has! been! recognised! and! EHP030! was! developed! to!
measure! this.! ! It! is! particularly! appropriate! for! use! in! clinical! trials! to! assess! the!
!
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effectiveness! of! medical! or! surgical! therapies! for! endometriosis! on! the! HRQoL! of!
affected!women.(45,221)!
The!EHP030!consists!of!a!core!questionnaire!and!a!modular!questionnaire.!!Only!the!core!
questionnaire!was!used!as!the!modular!questionnaire!contained!domains!that!may!not!
have!been!relevant!to!the!study!patients!or!open!to!bias!because!of!the!study!itself!0!e.g.!
subfertility!or!interaction!with!the!medical!profession.!!The!core!questionnaire!covered!
five!areas:!
!! Pain!! ! ! ! ! (Question!1011)!
!! Control!&!powerlessness! ! (Question!12017)!
!! Emotional!well0being! ! ! (Question!18023)!
!! Social!support!! ! ! (Question!24027)!
!! Self0image! ! ! ! (Question!28030)!
Each! question! required! an! answer! of! never! (score! =0),! rarely! (score! =1),! sometimes!
(score!=2),!often!(score!=3)!or!always!(score!=4).!!These!raw!scores!were!then!used!to!
calculate! a! score! for! each! domain! and! a! total! for! the! core! questionnaire! using! the!
formula:!
Computed!score!=!! ! Sum!of!the!scores!for!each!item!in!the!dimension!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
4!(maximum!score!per!item)!x!nos.!of!items!in!the!dimension!
Composite(Pelvic(Signs(&(Symptoms(Score((CPSSS)(or(Biberoglu(and(Behrman((B&B)(
The!Composite!Pelvic!Signs!&!Symptoms!Score!(CPSSS)!or!Biberoglu!and!Behrman!(B&B)!
Scale! is! a! commonly! used! standard! for!assessing!endometriosis! symptoms! in!both!a!
clinical! and! research! setting.(45,47)! ! This! tool! was! chosen! to! provide! some!
standardisation!to!the!assessment!of!disease!severity!and!examination!findings!made!
by!the!study!team.!!However,!it!is!limited!by!both!patient!recall!bias!and!inter0!and!intra0!
rater!variability.(222)!
The!questionnaire!consists!of!two!sections0!the!first!is!a!patient!assessment!of!symptoms!
and!the!second!a!blinded!investigator!assessment!of!clinical!signs!determined!by!a!pelvic!
examination.! ! The! patient!was! asked! to! score! (absent! =0,!mild=! 1,!moderate! =2! or!
severe=! 3)! their! symptoms!of! dysmenorrhea,! dyspareunia! and! non0menstrual! pelvic!
pain!over!the!proceeding!28!days.! !A!pelvic!examination!was!then!performed!before!
!
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reviewing! the! symptom!scores!allowing!both!pelvic! tenderness!and! induration! to! be!
assessed!using!the!same!003!scoring!system.!
Patients’(Global(Impression(of(Change((PGIC)(scale.(
The!PGIC! is!a!commonly!used!assessment!tool! that!provides!a!standard!definition!of!
clinically! important! improvement! in! clinical! trials! investigating! chronic! pain.(45,223)!!
This!tool!was!included!to!assess!&!quantify!any!change!in!disease!severity!experienced!
by!the!study!patients.!
The!scale!consists!of!two!sections.!Section!1!asks!the!patient!to!describe!any!change!in!
activity,! limitations,! symptoms,! emotions! and! overall! quality! of! life,! related! to! their!
endometriosis.!!The!options!range!from!‘no!change’!(score!1)!to!‘a!great!deal!better,!and!
a!considerable!improvement!that!has!made!all!the!difference’!(score!7).!!Section!II!asks!
them!to! indicate! the!degree! of! change! since! the!beginning!of! treatment!on!a!visual!
analogue!scale.!!!
6.11.2! Surgery(
The!surgery!was!undertaken!at!the!Norfolk!and!Norwich!University!Hospital.!!All!surgery!
was! planned! and! completed! laparoscopically! using! high! definition! laparoscopic!
equipment! provided! by! Storz! &! Olympus.! ! The! optical! trocars! and! disposable!
instruments! were! provided! by! Covidien.! Surgery! was! completed! using! monopolar!
diathermy,!bipolar!diathermy!and! the!harmonic! devices! such!as! the!Lotus!ultrasonic!
scalpel!(SRA!Developments)!and!the!Thunderbeat!device!(Olympus).!!!
6.11.3! Histological(specimens(
The! eutopic! endometrial! samples! obtained! at! screening! and! surgery! as! well! as! the!
ectopic!endometrial!samples!obtained!by!excising!the!disease!were!processed!by!the!
histopathology! department! of! the! Norfolk! &! Norwich! University! Hospital! using! the!
pathology! departments! standard! operating! procedures! (Appendix! 11017)! and! the!
CHUTE!Histopathology!Plan!(Appendix!18).!!At!the!time!the!sample!was!obtained!it!was!
placed!into!a!fixative!solution!(10%!formalin).!
To!allow!the!microscopic!analysis!of!the!tissues,!very!thin!slices!of!tissue!were!mounted!
on!glass!slides!to!allow!sufficient! light!through!the!specimen!for!the!structures!to!be!
identified.!!To!achieve!this!fixation!occurred!to!prevent!tissue!degradation;!the!tissue!
was!then!dehydrated!and!infiltrated!with!paraffin!wax.!!Once!infiltrated!with!wax!it!was!
!
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embedded!in!a!wax!block!to!provide!support!to!the!sample!as!slices!of!the!tissue!were!
obtained!for!mounting,!staining!&!immunohistochemistry.!!
Fixation(
The!fixation!process!began!once!the!sample!was!placed! in!the!fixative!solution!(10%!
formalin)!in!clinic!or!theatre.!!The!samples!remained!in!fixative!until!processing!occurred!
and!the!length!of!time!varied!from!approximately!18072!hours!dependent!on!when!the!
sample!was!obtained.!Prior! to!processing!all! samples!were! transferred! to!processing!
cassettes.!
Processing(
Processing! occurred! using! a! five0hour! (xylene! free)! programme! on! a! Peloris! (fluid0
transfer)!processor!(Leica!Biosystems)!(Appendix!11).! !As!paraffin!wax!is!hydrophobic!
the!first!step! in!processing!was!dehydration!to!replace!the!water! in!the!sample!with!
industrial!denatured!alcohol!(IDA).!!This!was!achieved!using!a!series!of!IDA!solutions!to!
prevent!tissue!distortion.!!The!IDA!was!then!replaced!with!the!solvent!Isopropyl!alcohol!
before!finally!being!infiltrated!with!histology!grade!paraffin!wax.!!
Embedding(
Once!processed!the!sample!was!embedded!in!histology!grade!paraffin!at!63°C!before!
being!allowed!to!cool!to!create!a!paraffin!block!(Appendix!12).!
Sectioning(
The! paraffin! blocks! were! sectioned! at! 4! µm! using! a! microtome! (Thermo! Shandon!
Finesse)!and!floated!out!on!a!45°C!water!bath!to!flatten!the!slice!before!being!placed!
onto!a!standard!microscope!slide.!!The!slides!were!then!baked!on!a!hotplate!for!10030!
minutes! dependent! on! whether! they! were! for! staining! or! immunohistochemistry!
(Appendix!13!&!14).!!!
6.11.4! Haematoxylin(&(eosin(staining(
A!technique!of! regressive!staining!was!used0!the!haematoxylin!was!over!stained,!the!
excess! stain!was! removed!by! acid! alcohol! and! then! eosin! staining! of! the! acidophilic!
elements!of!the!tissue!followed.! !This!was!done!as!an!automated!process!on!a!Leica!
Biosystems! Autostainer! using! Protocol! 1! of! the! SOP! HIS.SL.P.! 3! (Appendix! 15).! ! The!
reagents!used!were!per!the!protocol!and!utilised!Harris!haematoxylin!and!1%!aqueous!
eosin.!!!
!
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6.11.5! Immunohistochemistry((IHC)(
All! immunohistochemistry! staining! was! performed! on! a! Leica! BOND!! (Leica!
Biosystems)! using! commercially! available! antibodies! and! a! proprietary! polymer!
detection!system!with!3,3’0Diaminobenzidine!(DAB)!as!the!chromagen.!!The!Compact!
Polymer!! system! (Bond! Polymer! Refine)! from! Leica! Biosystems! was! used! as! it! is!
extremely!sensitive,!highly!specific!and!can!be!optimised!for!automated!IHC!systems!like!
Leica!Bond!!(See!Figure!6.3).!!This!is!an!indirect!method!where!the!primary!antibody!
binds!to!the!target!epitope!and!then!a!secondary!antibody!binds!to!the!first!antibody.!!
The!second!antibody!is!bound!to!an!enzyme,!peroxidase!in!this!case,!which!catalyses!the!
conversion!of!DAB!to!a!brown!precipitate!that!is!insoluble!in!alcohol!and!xylene!and!so!
indicates!the!presence!of!the!epitope!of!interest!under!light!microscopy.!!This!method!
is!more!sensitive!because!of!signal!amplification!due!to!the!binding!of!several!secondary!
antibodies!to!each!primary!antibody.!
Protocol(
The!first!step!in!the!process!is!epitope!recovery!in!which!the!paraffin!from!the!sections!
of! tissue!must! be! completely! removed! and!methylene! bridges! crosslinking! proteins,!
caused!by!formaldehyde!fixation,!broken!down.!!This!is!usually!achieved!with!an!organic!
solvent!and!heat!(heat!induced!epitope!retrieval!or!HIER).!!Three!different!pre0treatment!
protocols!were!used!dependent!on!the!epitope!of!interest.!!Each!uses!a!specific!epitope!
retrieval!(ER)!solution!and!length!of!heat!treatment0!see!Table!6.1,!Table!6.2!&!appendix!
19021!for!details.!!!
The!next!step!is!to!block!the!action!of!any!endogenous!peroxidase!within!the!tissues!as!
this! would! cause! non0specific! reduction! of! the! DAB! substrate! and! so! non0specific!
staining! of! the! tissues.! ! After! that! step,! the! tissue! is! exposed! to! the! primary! and!
secondary!antibodies!diluted!in!a!stabilising!buffer!before!the!chromagen!substrate!is!
added.! ! The! dilution,! rinsing! steps! and! exposure! times! are! all! optimised! for! each!
antibody!used.!!The!two!protocols!used!are!shown!in!Appendix!22!&!23.!!!!!!!!
Initial(antibodies(
Initially! immunohistochemistry! was! performed! to! identify! the! following! epitopes:!
Oestrogen!Receptor!(ER),!Progesterone!Receptor!(PR),!Androgen!receptor!(AR)!and!the!
Ki67! proliferation! marker.! ! The! details! of! the! antibodies,! associated! dilutions,! pre0
treatment!and!protocols!are!shown!in!Table!6.1.!
!
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Figure'6.3' Bond'Compact'Polymer'system'used'for'immunohistochemistry.'''
(Primary(antibody=(green(‘Y’(shaped(structure,(Secondary(antibody=(yellow(‘Y’(shaped(
structure,( Peroxidase=( red( spheres,( DAB=( 3,3’0Diaminobenzidine! (reproduced! from!
promotional!material!provided!by!Leica!Biosystems))(!
Additional(antibodies(
Following!interim!assessment!of!the!initial!immunohistochemistry!a!decision!was!taken!
to! complete! further! immunohistochemistry! to! identify! the! following! epitopes:! VEGF!
(vascular! endothelial! growth! factor)! and! PTEN! (phosphatase! and! tensin! homolog!
deleted!on!chromosome!ten).!!The!details!of!the!antibodies,!associated!dilutions,!pre0
treatment!and!protocols!are!shown!in!Table!6.2.!
(
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MARKER& CLONE& MANUFACTURER& PRODUCT&CODE& DILUTION& PRE1TREATMENT& PROTOCOL&
ER& EP1! Dako!(Agilent)! M3643! 1:120! H1(30)! R;LP;E!
PR& 16! Leica!Biosystems! NCL;L;PGR;312! 1:200! H1(20)! R;LP;E!
AR& EP120! Epitomics! AC;0071! 1:50! H2(20)! R;LP;E!
Ki167& EP5! Epitomics! AC;0009! 1:100! H2(20)! Rout!
Table&6.1& Initial&antibodies,&dilutions&and&protocols&as&per&SOP&HIS.IM.P.10.&&&
(H1(30)'='Heat'Induced'Epitope'Retrieval'30'minutes'with'Epitope'Retrieval'solution'1,'H1(20)'='Heat'Induced'Epitope'Retrieval'20'minutes'with'Epitope'
Retrieval'solution'1,'H2(20)'='Heat'Induced'Epitope'Retrieval'20'minutes'with'Epitope'Retrieval'solution'2,'R?LP?E='Routine'long'protocol,'Rout='Routine'
protocol)''
MARKER& CLONE& MANUFACTURER& PRODUCT&CODE& DILUTION& PRE1TREATMENT& PROTOCOL&
PTEN& SP218! Spring!Bioscience! M5180! 1:200! H2(20)! Rout!
VEGF& EP1176Y! Menarini!Diagnostics! MP;356;CMK01! ;! ;! ;!
Table&6.2& Additional&antibodies,&dilutions&and&protocols&as&per&SOP&HIS.IM.P.10.&&&
(H2(20)'='Heat'Induced'Epitope'Retrieval'20'minutes'with'Epitope'Retrieval'solution'2,'Rout='Routine'protocol)!
!
!
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6.12! %ANALYTICAL%METHODS%
6.12.1! Data(recording(
Following!enrolment!into!the!study,!each!patient!was!assigned!a!study!number!(CHUTE!
01!–!CHUTE!25).!!The!name!and!hospital!number!of!the!participants!were!recorded!in!
the!Patient!ID!Log,!which!was!kept!in!the!site!file!at!the!Norfolk!and!Norwich!University!
Hospital.!!This!data,!along!with!a!contact!phone!number,!e0mail!address!and!log!of!visit!
dates!was!also!recorded!in!an!excel!spreadsheet!on!the!hospital!network.!!All!study!data!
relating! to! the! participants! was! recorded! under! their! study! number! to! maintain!
confidentiality.!
Once! the! consent! form! was! signed,! all! subsequent! study! related! patient! data! was!
recorded!in!both!the!medical!records!and!the!Case!Report!Form!(CRF)!(Case!Report!Form!
(CRF)!(CHUTE)!v3.0!(Appendix!6)).!Data!from!the!CRF!was!transcribed!from!the!paper!
CRF!to!an!electronic!database!‘CRF!&!Questionnaire!data’!(in!Microsoft!Excel!for!Mac!
2011),!which!was!password!protected.!
Clinical'data'
This!was!recorded!in!the!medical!records!as!for!any!clinical!interaction!with!a!patient.!!
This!data!was!then!transferred!to!the!CRF!at!the!time!of!the!appointment!or!immediately!
afterwards!to!ensure!data!was!correctly!recorded.!
Patient'questionnaire'data'
Each!questionnaire!was!completed! in!paper! format!and!secured!with!the!paper!CRF.!!
The!responses!to!the!questions!were!then!transcribed!to!the!‘CRF!&!Questionnaire!data’!
password!protected!database.!
Surgical'data'
Findings!from!the!primary!laparoscopy!were!obtained!from!the!operation!notes!in!the!
medical!record.!!The!surgical!stage!of!the!disease!was!classified!per!the!revised!American!
Society!for!Reproductive!Medicine!(ASRM)!classification!of!endometriosis,!based!on!the!
information!available0!either!written!description!or!photographic!records.!!!
At! the! post! treatment! surgery,! the! distribution! of! disease!was! again! described! and!
classified!per!the!revised!American!Society!for!Reproductive!Medicine!classification.!!The!
extent!of!the!disease,!location!of!the!disease,!sites!of!the!ectopic!endometrial!biopsies!
!
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and!surgical!steps!were!all!recorded!as!written!notes!in!the!medical!record.!!This!was!
supplemented!by!intra0operative!photographs!&!video!as!appropriate!and!in0line!with!
usual!departmental!practice.!!!!Anonymised!copies!of!the!written!notes!and!photos!were!
added! to! the! paper! CRF! and! an! electronic! version! stored! on! the! hospital! network!
(‘Operation!Images’!folder).!!!
Histological'data'
The!H&E!slides!for!the!eutopic!and!ectopic!endometrial!biopsies!were!reported!by!an!
experienced! gynaecological! histopathologist! in! accordance! with! local! protocol.! ! A!
written! report!was! produced! and! communicated! to! the! study! team!as! per! standard!
practice.!!An!anonymised!copy!of!this!report!was!filed!in!the!study!file.!
The!H&E!and!IHC!slides!were!then!reviewed!by!the!study!team!on!a!batch!basis.!The!
features! and! immunohistochemical! staining! were! described! as! outlined! in! the!
Histopathology! Plan! (Appendix! 24),! with! the! findings! being! recorded! on! the!
Histopathology!Report!Proforma!(Appendix!25).!!Any!features!consistent!with!PAEC!in!
the!eutopic!endometrium!were!described!with!reference!to:!
1)! Gland!architecture:!
a)! Cystic!dilatation!(present/absent,!focal/widespread)!
b)! Disordered!architecture!(absent/focal/diffuse)!
c)! Complex!architecture!(absent/focal/diffuse)!
d)! Budding!into!stroma!(present/absent)!
e)! Papillation!into!lumen!(present/absent)!
f)! Gland!crowding!(present/absent)!
g)! Gland0stroma!ratio!(decreased/unchanged/increased)!
2)! Glandular!epithelium:!
a)! Cell!type!(flat!cuboidal/tall!columnar)!
b)! Stratification!of!nuclei!(present/absent)!
c)! Mitoses!(infrequent/frequent)!
d)! Cytoplasmic!vacuolation!(common/uncommon)!
e)! Secretion!in!lumen!(present/absent)!
f)! Nuclear!size!(small/medium/large)!
g)! Nuclear!shape!(ovoid/rounded)!
h)! Nucleoli!(present/absent)!
!
!
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i)! Nuclear!atypia!(present/absent)!
j)! Squamous!metaplasia!(absent/occasional/frequent)!
3)! Stroma:!
a)! Stromal!density!(moderately!cellular/densely!cellular)!
b)! Foam!cells!(absent/infrequent/present)!
c)! Stromal!breakdown!(present/absent)!!
d)! Intravascular!fibrin!thrombi!(present/absent)!
These!features!were!chosen!as!they!were!used!by!the!PEARL!study!histopathologists!to!
distinguishing! between! PAEC,! unopposed! oestrogen! effect! and! endometrial!
hyperplasia.(203)!
The!immunohistochemistry!slides!for!detection!of!ER,!PR!&!AR!were!assessed!using!the!
Quick!(Allred)!score!as!outlined!in!Table!6.3.!The!proportion!score!and!intensity!score!
are!added!together!to!give!a!maximum!score!of!eight.!!The!Ki67!immunohistochemistry!
was!recorded!as!an!estimated!percentage!of!nuclear!staining.!
Score% PROPORTION% INTENSITY%
0% no!staining! no!staining!
1% <!1%!nuclei!staining! weak!staining!
2% 1–10%!nuclei!staining! moderate!staining!
3% 11–33%!nuclei!staining! strong!staining!
4% 34–66%!nuclei!staining! !
5% 67–100%!nuclei!staining! !
Table!6.3! Quick!(Allred)!score!for!immunohistochemistry!scoring.!!!
(Reproduced*from*Immunohistochemical*detection*of*steroid*receptors*in*breast*cancer:*
a*working*protocol,*as*per*the*local*departmental*policy*for*IHC*reporting.(224))*
The!same!reporting!structure!was!used!for!the!ectopic!endometrial!samples!except!only!
cystic!dilatation!could!be!assessed!in!the!gland!architecture!due!to!the!ectopic!location!
of!the!sample.!!!
The!H&E!and!initial!IHC!slides!were!also!assessed!by!a!second!histopathologist,!familiar!
with!PAEC!and!familiar!with!the!primary!studies!investigating!the!IMP0!Professor!Alistair!
R.W.! Williams.! ! This! was! required! for! the! purposes! of! external! review! and! quality!
!
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control.!!It!necessitated!the!temporary!transfer!of!the!histology!slides!to!the!Department!
of!Pathology!at!the!University!of!Edinburgh!in!keeping!with!the!terms!of!the!material!
transfer!agreement!(Appendix!26).!
The!data!for!each!study!patient!contained!in!both!copies!of!the!Histopathology!Report!
Proforma!was!then!transcribed!to!the!‘CRF!&!Questionnaire!data’!password!protected!
database.!!!
Histopathology'images'
All!slides!were!viewed!using!an!Olympus!BX51!Microscope!and!images!captured!using!
Olympus!cellSens!Entry!1.14!software.!!All!the!representative!slide!images!and!an!image!
log!for!each!participant!were!stored!on!the!hospital!network!(‘Histopathology!Images’!
folder).!
Results'summaries'
The! surgical! notes! and! histological! image! data! for! each! study! participant! was!
summarised!into!a!single!document!to!facilitate!data!analysis!(Appendix!27).!
6.12.2! Data(analysis(
Primary'Outcome'Measures'
As!an!interventional!descriptive!cohort!study!the!primary!outcome!data!was!qualitative!
and!descriptive.!!The!histological!data!for!the!ectopic!endometrium!has!been!described!
as!detailed!above!but!the!most!important!determinants!of!PAEC!were!assessed!to!be!
cystic!dilatation,!the!epithelial!features!of!cell!type,!nuclear!stratification,!mitoses!and!
cytoplasmic!vacuolation,!and!the!stromal!density.!These!features!have!been!focused!on!
primarily!during!the!analysis!of!the!H&E!slides.!
Secondary'Outcome'Measures'
Changes!in!disease!severity!were!assessed!by!comparing!the!laparoscopic!appearance!
of! endometriotic! lesions! between! the! diagnostic! surgery! and! the! second! definitive!
surgery!and!the!ASRM!scoring.!!These!changes!were!correlated!with!the!quantitative!
changes!identified!in!the!patient!reported!outcome!questionnaires!as!detailed!in!Table!
6.4.
!
!
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Questionnaire% Screening% vs.%
EoS%
Screening% vs.%
Treatment%
Screening% vs.%
EoT%
Treatment% vs.%
EoT%
BSGEIQu% Pain! Score! &!
Health!Score!
! ! !
EHPI30% ! Mean! Pain! &!
Total!Score!
Mean! Pain! &!
Total!Score!
Mean! Pain! &!
Total!Score!
CPSSS% ! Symptom!
Score!
Total!Score! !
PGIC% ! Total!Score! Total!Score! !
Table!6.4! Questionnaire!score!comparisons!!!
(The* details* of* the* sections* of* each* questionnaire* used* for* the* comparison* are* also*
highlighted.)!
These!comparisons!were!chosen!as!the!best!representation!of!clinical!improvement!over!
the!course!of!the!study,!improvement!in!QoL!in!response!to!ulipristal!acetate!use!and!
the!tolerability!of!the!treatment.!
Statistical'analysis'
The!nature!of!the!study!meant!there!was!limited!statistical!analysis!of!the!data.!!The!
differences! between! questionnaire! scores! has! been! analysed! 0! the! details! of! the!
methods!used!are!discussed!in!the!results!chapter.!!The!analysis!was!performed!using!
Microsoft!Excel!for!Mac!2016!&!IBM!SPSS!Statistics!22.!
6.12.3! Data(handling(
Source'data'
All!source!data!was!stored!in!either!the!medical!record!or!a!paper!study!file,!which!was!
kept!in!a!locked!office!or!as!an!electronic!record!stored!in!a!secure!folder!on!the!hospital!
network.!!!
Data'protection'
Data!collected!during!the!research!trial!was!kept!strictly!confidential!and!accessed!only!
by!members!of!the!trial!team.!The!participant’s!details!were!stored!on!a!secure!database!
!
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under!the!guidelines!of!the!1988!Data!Protection!Act!and!regular!checks!and!monitoring!
were!undertaken!to!ensure!compliance.!The!senior!IT!manager!(in!collaboration!with!
the!Chief!Investigator)!managed!access!rights!to!the!data!set.!
The! study!data!will!be!archived! to!a! secure!data! storage! facility!and!not!be!kept! for!
longer!than!is!required!as!per!the!local!R&D!department!SOP.!
6.13! CHANGES%TO%STUDY%DESIGN%
6.13.1! Substantial(amendments(
The! study! went! through! two! substantial! amendments,! which! each! requiring! a! new!
version!of!the!protocol0!first!to!version!2.0!and!then!to!version!3.0.!!The!first!amendment!
occurred!because!of!the!MHRA!review!of!the!protocol!and!the!second!occurred!after!
the!study!had!opened!to!recruitment!necessitating!notification!and!re0consenting!of!our!
first!recruited!patient0!CHUTE!01.!
Research'Protocol'(CHUTE)'v2.0'
The! addition! of! exclusion! criteria! 10! ‘the! subject! has! genital! bleeding! of! unknown!
aetiology!or!for!reasons!other!than!uterine!fibroids’,!was!requested!by!the!MHRA!and!
so! the! protocol! and! associated! study! documents! were! updated.! ! In! addition,! the!
eligibility!criteria!were!clarified,!and!the!risks!of!surgery!added!to!the!study!documents.!
The!plan!to!transfer!the!histology!slides!to!Professor!A.R.W.!Williams!at!the!University!
of! Edinburgh! had! been! formulated! and! the! protocol,! PIS! and! consent! form! were!
adjusted!to!reflect!this.!!The!formulation!and!signing!of!the!material!transfer!agreement!
was!also!arranged!at!this!time.!
Research'Protocol'(CHUTE)'v3.0'
The!decision!to!complete!the!surgical!intervention!6!weeks!after!stopping!the!study!drug!
rather!than!whilst!still!taking!it!required!a!substantial!amendment!to!the!protocol.!!The!
details!of!the!changes!have!already!been!discussed!and!the!final!protocol!represented!
in!Figure!6.1.!!This!major!change!in!the!design!was!accompanied!by!further!clarification!
of!the!eligibility!criteria,!inclusion!and!exclusion!criteria!to!ensure!maximal!recruitment!
to!the!study.!!!
!
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6.13.2! Minor(amendments(
The! timing! for! starting! study! drug! needed! clarification! to! ensure! that! if! a! patient!
attended!the!treatment!visit!between!day!105!of!her!cycle!they!were!permitted!to!start!
the!study!drug!immediately!rather!than!wait!another!month!off!treatment.!!The!patient!
information!sheet!indicated!that!this!was!acceptable,!but!the!wording!of!the!protocol!
needed!adjusting!for!clarity!taking!the!protocol!to!version!3.1.!
A!finalised!version!of!the!study!protocol!can!be!found!in!Appendix!280!Research!Protocol!
(CHUTE)!v3.1.!
6.14! CANDIDATE%CONTRIBUTION%TO%STUDY%
6.14.1! Study(design(
An!outline!proposal!and!funding!agreement!to!evaluate!Ulipristal!acetate!in!20!patients!
existed!when! I! began!work! on! the! study! but! the! original! study! design! and! iterative!
changes! to! achieve! the! final! study! protocol! were! completed! by! the! candidate!with!
support!from!Mr!E.!Morris!and!other!experts!in!the!field.!
6.14.2! Study( setNup,( registration,( regulatory( approval( and( NIHR( Portfolio(
adoption(
The! candidate!was! responsible! for! close! liaison!with! the! local! R&D!department! and!
negotiation!of!which!clinical!biochemistry!and!histopathology!tests!were!possible!within!
the!agreed!budget.! !The!completion!of!the! IRAS!application,!CTA!registration,!ethical!
approval! and! MHRA! approval,! including! the! appropriate! amendments! were! all!
undertaken!by!the!candidate.!
In!addition,!the!candidate!presented!the!proposed!study!to!the!local!R&D!director!and!
the! scientific! advisory! board! of! the! funding! body! to! ensure! adoption! onto! the!NIHR!
Portfolio,!local!research!nurse!support!and!continued!funding.!
6.14.3! Principal(Investigator((PI)(&(study(coordinator(role(
The! candidate! undertook! the! PI! and! study! co0ordinator! role! to! ensure! the! smooth!
running!of! the! study!and! to! complete! their!educational!objectives!within!a!UEA!PPD!
plan.!!This!included!independent!involvement!in!all!monitoring!visits!and!responsibility!
for!resolving!all!associated!queries.!
!
!
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6.14.4! Recruitment,(study(visits(and(patient(management(
The!recruitment,!selection!and!enrolment!of!study!patients!was!all!undertaken!by!the!
candidate!with!advice!and!support!from!Mr!E.!Morris.!!Following!inclusion!in!the!study;!
all! study! visits,! associated! procedures,! questionnaire! administration,! adverse! event!
recording!and!SAE!management!was!undertaken!by!the!candidate!under!the! indirect!
supervision!of!Mr!E.!Morris.!!!
The!candidate!was!involved!in!the!surgical!management!of!each!patient,!including!the!
assessment!of!the!patient!intra0operatively!and!the!surgical!excision!of!disease.!!In!the!
early!stages!of!the!study!this!was!as!an!assistant,!but!the!candidate!took!on!the!role!of!
the!primary!surgeon!in!the!final!few!cases,!as!their!surgical!skills!developed.!
6.14.5! Histopathology(and(immunohistochemistry(
Although! the!candidate!undertook!visits! to! the! histopathology! laboratory! to!gain!an!
understanding!of!the!steps!involved!the!processing!of!the!specimens!was!undertaken!by!
the!laboratory!technicians.!!As!a!working!NHS!laboratory!there!was!no!facility!to!allow!
the!candidate!to!be!more!closely!involved.!
The!evaluation!of!the!histopathology!slides!and!IHC!slides!was!undertaken!jointly!with!
Dr!R.!Lonsdale!to!ensure!correct!interpretation.!!The!use!of!the!camera!microscope!and!
selection! of! representative! images!was! undertaken! by! the! candidate! following! each!
reporting!episode,!under!the!indirect!supervision!of!Dr!Lonsdale.!
6.14.6! Data(recording,(analysis(and(thesis(presentation((
These!aspects!of!the!study!were!undertaken!by!the!candidate!with!advice!and!support!
from!those!outlined!in!the!Contributions!section.!
!
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Chapter%7:!RESULTS%
7.1! COHORT%DATA%
7.1.1! Recruitment(
Recruitment!started!on!the!14th!November!2014,!following!the!completion!of!the!Site!
Initiation!Visit!(SIV)!on!13th!November!2014.!!The!first!patient!was!recruited!and!signed!
their!consent!form!on!12th!December!2014,!ensuring!we!met!our!first!patient0first!visit!
(FFV)!target.!!Recruitment!continued!over!a!period!of!18!months!and!the!last!patient0
first!visit!was!conducted!on!5th!May!2016.!
During! recruitment,!a! total!of!66!patients!were!pre0screened! to! recruit!a! total!of!25!
patients!to!the!study!(CHUTE!01!0!CHUTE!25),!who!signed!the!consent!form!and!formally!
entered!screening.!!The!final!number!of!patients!completing!the!CHUTE!study!was!18,!
due!to!either!screen!fails!or!premature!discontinuation!because!of!meeting!exclusion!
criteria,!as!outline!in!Figure!7.1.!
7.1.2! Screen(fails(
There!was!a!total!of!five!screen!fails!during!washout!from!previous!medical!treatments!
for!endometriosis.!!CHUTE!03!was!using!GnRHa!and!Tibolone!at!the!time!of!recruitment!
and!went!into!washout!as!per!protocol.!!During!the!six!months!in!washout!her!periods!
did!not!return,!she!developed!vasomotor!symptoms!and!her!endometriosis!improved!
significantly.!!Having!reached!the!menopause,!she!decided!surgical!management!was!no!
longer!suitable!for!her!and!so!was!excluded.!
CHUTE!07!had!her!LNG0IUS!(Mirena!)!removed!to!enter!washout!and!felt!her!symptoms!
subsequently!improved!and!so!decided!to!post0pone!a!decision!on!surgical!management!
of! her! disease.! ! CHUTE! 16!moved! to! a! new! area! and!was! unable! to! keep! her! study!
appointments!at!the!study!site.!!She!requested!a!transfer!of!her!care!to!another!hospital!
and!this!was!facilitated.!!CHUTE!18!did!not!establish!a!regular!menstrual!pattern!after!
stopping!the!progesterone!only!pill!and!so!was!excluded.!
CHUTE!22!went!into!washout!following!stopping!the!progesterone!only!pill.!!She!did!not!
attend!several!study!appointments!and!was!difficult!to!reach!by!telephone!or!e0mail.!!It!
was! considered! inappropriate! for! her! to! continue! in! the! study,! in! view! of! these!
!
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communication!difficulties,!and!so!she!was!excluded.!!This!was!discussed!with!her!and!
she!went!on!to!have!standard!surgical!management!of!her!disease!to!good!effect.!
7.1.3! Premature(discontinuation(
CHUTE'17'
This! patient! was! recruited! on! 02nd! October! 2015! and! went! into! washout! from! the!
progesterone!only!pill!she!was!taking.! !Screening!was!undertaken!on!12th!November!
2015,!study!drug!was!commenced!on!7th!December!2016!and!surgery!was!planned!for!
18! April! 2016.! ! However,! a! urinary! pregnancy! test! followed! by! an! ultrasound! scan!
confirmed!a!pregnancy!of!seven!weeks’!gestation!(see!Section!7.1.5!for!further!details).!!
This!resulted!in!her!premature!discontinuation!from!the!study!as!surgery!was!no!longer!
clinically!appropriate.!
CHUTE'20'
Recruitment!and!signing!of!consent!took!place!for!this!patient!on!10th!December!2015,!
based!on!a!previous!diagnostic!laparoscopy!and!a!worsening!of!pelvic!symptoms.!!Study!
drug!was!then!taken!from!the!16th!February!2016!to!the!9th!May!2016,!and!surgery!was!
performed! on! 21st! June! 2016.! ! At! her! operative! laparoscopy,! no! significant!
endometriosis!was!seen,!which!was!later!confirmed!by!the!histological!evaluation!of!the!
biopsies! obtained.! ! However,! significantly! dilated! pelvic! veins! were! noted! and! a!
diagnosis! of! pelvic! congestion! was! made,! and! an! appropriate! management! plan!
instigated.!!Since!endometriosis!was!not!confirmed,!by!biopsy,!at!the!original!diagnostic!
procedure! it! cast!doubt!on! the!appropriateness!of!her! initial! inclusion!and! so! it!was!
considered!inappropriate!to!keep!her!in!the!study.!
7.1.4! Adherence(
All!study!patients!attended!all!the!study!visits!set!out!in!the!study!protocol.!!The!timing!
of!each!visit!was!in!accordance!with!the!protocol,!with!one!exception!(detailed!below).!!
No!visits!were!missed,!and!all!the!data!required!for!each!visit!was!recorded!in!the!CRF,!
patient!study!folder!and!hospital!notes,!as!appropriate.!
A!protocol!deviation!occurred!for!CHUTE!14!as!her!surgery!was!performed!27!days!later!
than!planned.!!Her!operation!had!to!be!postponed!on!the!day!of!surgery!(29th!January!
2016)!due!to!a!theatre!overrun!because!of!a!complex!case.!!The!earliest!availability!of!
both!surgeons!meant!her!surgery!did!not!occur!until!23rd!Feb!2016.
!
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Figure!7.1! Enrollment!&!outcomes!
A*total*of*25*subjects*were*consented*and*enrolled*in*the*study,*of*whom*5*were*excluded*
during*screening.**Treatment*was*completed*by*20*subjects*but*CHUTE*17*was*excluded*
due*to*pregnancy*and*CHUTE*20*was*excluded*as*there*was*no*evidence*of*endometriosis*
at*the*time*of*her*surgical*management.*This*left*18*subjects*for*the*final*analysis.*
 
Excluded (n= 41) 
• Not meeting inclusion criteria (n= 17) 
• Declined to participate (n= 23) 
• Other reasons (n= 1) 
Analysed (n= 18) 
• Excluded from analysis (give reasons) (n= 2) 
- CHUTE 17: Pregnancy 
- CHUTE 20: Endometriosis not present 
at surgical management 
Lost to follow-up (n= 0) 
Discontinued intervention (n= 0) 
Allocated to drug treatment (n= 20) 
• Received allocated intervention (n= 20) 
• Did not receive allocated intervention (n= 0) 
Allocation 
Analysis 
Follow-Up 
Enrolled (n= 25) 
Enrollment 
Excluded (n= 5) 
• Not meeting inclusion criteria (n= 2) 
• Declined to participate (n= 2) 
• Other reasons (n= 1) 
Assessed for eligibility (n= 66) 
!
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7.1.5! Serious(adverse(events((SAEs)(
CHUTE'17'
This! study! subject! completed! study! drug! on! 28th! Feb! 2016! and! her! elective! planned!
surgery!was!scheduled!for!18th!April!2016.!!On!15th!April!2016!at!06.17!she!notified!us!of!
two!positive!urinary!pregnancy!tests!via!e0mail.!!She!had!undertaken!these!tests!due!to!
the!lightness!of!her!period!and!two!weeks!of!“morning!sickness”!symptoms.!
An!urgent!appointment!was!arranged!for!09.00!the!same!day!to!assess!the!situation.!!A!
urinary! pregnancy! test! was! found! to! be! positive! and! a! plasma!"hCG! (130292! IU/L)!
confirmed!the!result.!!An!ultrasound!scan!demonstrated!an!intra0uterine!pregnancy!(CRL!
(Crown!Rump!Length)!9.8mm,!7w1d!gestation)!with!a!fetal!heartbeat!detected.! !Two!
follow!up!scans!were!arranged!in!the!early!pregnancy!assessment!unit!(EPAU)!–!on!the!
29th!April!2016!the!CRL!measured!20.0mm!(8!weeks,!4!days!gestation)!with!a!detectable!
fetal!heartbeat,!and!on!13th!May!2016!the!CRL!50.2mm,!11w5d!with!a!fetal!heartbeat!
detected.! She! was! then! discharged! from! EPAU! to! routine! antenatal! care! and! an!
antenatal!appointment!was!scheduled!for!21st!June!2016.!
Her!antenatal!care!included!progesterone!supplementation!in!the!first!trimester!and!a!
plan!for!additional!growth!scans!in!the!second!trimester.!!This!was!arranged!because!of!
uncertainty! about! the! action! of! ulipristal! acetate! on! the! endometrium! prior! to!
implantation!and!whether!poor!implantation!might!contribute!to!an!increased!risk!of!
miscarriage!or!growth!restriction.!
A! fetal! anomaly! scan! was! performed! on! 13th! August! 2016,! which! revealed! normal!
anatomy,! a! posterior! placenta! clear! of! the! internal! os! and! a! normal! amniotic! fluid!
volume.!!In!the!third!trimester,!she!was!admitted!on!two!separate!occasions!with!nausea!
and!vomiting!of!pregnancy,!but!this!settled!quickly!with!anti0emetics!and!intravenous!
fluid.!!There!were!no!concerns!relating!to!fetal!growth!during!the!antenatal!period.!
Following!an!episode!of!reduced!fetal!movements!on!21st!November!2016!at!39+2!weeks!
gestation!she!was!admitted!for!an!induction!of!labour!on!25th!November!2016.!!This!was!
achieved!using!10mg!dinoprostone,! followed!by! artificial! rupture! of!membranes!and!
oxytocin!augmentation!of!labour;!resulting!in!a!normal!vaginal!delivery!of!a!baby!boy!at!
10.19!on!27th!November!2016.!!He!weighed!3575!grams!and!there!were!no!concerns!
raised!at!his!new!born!assessment!by!the!paediatric!team.!!!
!
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CHUTE'23'
This! study! subject! was! enrolled! on! 16th! February! 2016! but! was! admitted! on! 29th!
February!with!abdominal!and!pelvic!pain,!prior!to!her!screening!appointment.!The!pain!
she!was!experiencing!was!in!keeping!with!her!typical!endometriosis!symptoms!but!was!
not!responding!to!analgesia.!!Her!period!was!due!6!days!later!so!the!clinical!impression!
was!one!of!a!typical!pre0menstrual!flare!of!pain.!
An! ultrasound! scan! of! the! pelvis!was! arranged! during! her! inpatient! stay,!which!was!
reported!as!normal!with!no!evidence!of!ovarian!pathology.!!Her!pain!resolved!by!18.00!
on!2nd!March!2016!and!she!was!discharged.!!This!event!was!recorded!as!an!SAE!in!view!
of! the!admission! to!hospital!but!was! considered! to!be!unrelated! to! the! study!as!no!
changes!to!her!management!had!occurred!at!that!time.!
7.1.6! Adverse(events((AEs)(
A!total!of!63!adverse!events!were!recorded!during!the!study.!!Many!of!these!were!not!
considered! to! be! related! to! the! study.! ! Those! that! were! either! possibly* related! or!
definitely* related! to! the! study,! and! the! frequency! with! which! they! occurred! are!
described!in!Table!7.1.!!A!total!of!41!events!were!recorded0!23!as!study!related!adverse!
events!and!18!as!perceived!side!effects!recorded!by!the!study!subjects.!
The!most!commonly!noted!symptom!was!headache,!in!line!with!the!known!safety!data!
related!to!ulipristal!acetate.!!The!other!commonly!mentioned!symptoms!of!constipation,!
mood!disturbance,!skin!changes!and!vaginal!discharge!are!typical!progesterone!related!
effects.!
7.1.7! Demographics(&(characteristics(
The!mean!age!of!the!study!subjects!was!35!(range!22049)!and!the!mean!average!BMI!
was!25!(range!20039);!with!20%!being!current!smokers!(4/18).!!All!the!subjects!(18/18,!
100%)! described! themselves! as! white! British.! ! Most! were! in! full! time! employment!
(15/18)!but!one!was!unemployed,!one!was!a!student!and!one!subject!described!herself!
as!a!housewife.!
The!mean!self0reported!age!at!onset!of!endometriosis!was!23!(range!11046),!giving!a!
mean!disease!duration!of!12!years!(range!1026).!!As!all!the!subjects!had!a!diagnosis!of!
endometriosis! they! consequently! had! a! surgical! history! that! included! a! diagnostic!
laparoscopy.!!In!addition,!eight!had!also!had!previous!laparoscopic!treatment!of!their!!
!
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Adverse%Events%or%Side%Effects% Frequency%
Headache! 6!
Constipation! 4!
Mood!disturbance! 4!
Skin!changes/spots! 3!
Vaginal!discharge! 3!
Abdominal/pelvic!pain! 2!
Alopecia! 2!
Hot!flushes! 2!
Joint!ache! 2!
Urinary!incontinence! 2!
Weight!gain! 2!
Back!pain! 1!
Dark!stool! 1!
Lymphadenopathy! 1!
Migraine! 1!
Neuropathic!leg!pain! 1!
Post0op!nausea! 1!
Uterine!cramps! 1!
Vaginal!dryness! 1!
Vertigo! 1!
Table!7.1! Adverse!Events!(AEs)!or!study!related!side!effects!!!!
The*adverse*events*recorded*during*the*study*that*were*considered*by*the*investigators*
to* be* either* possibly* related* or* definitely* related* to* the* study,* and* the* side* effects*
recorded*by*the*study*subjects*are*shown.*
!
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endometriosis,!one!had!a!history!of!a!laparoscopic!cholecystectomy!and!one!had!been!
sterilised!laparoscopically.!!Five!of!the!subjects!had!also!previously!had!a!laparotomy!0!
each!for!a!lower!segment!Caesarean!section.!
Three!subjects!had!been!treated!for!sexually!transmitted!infections!in!the!past,!but!none!
had!a!history!of!pelvic!inflammatory!disease.!!The!median!parity!of!the!cohort!was!one!
with!two!subjects!having!had!fertility!treatment.!
The!demographics!and!baseline!patient!characteristics!are!described!in!Table!7.2.!!
!
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Characteristic% Study%Cohort%(n%=18)%
Age%(yr)*% 35.0!+/0!8.2!
BMI%(kg/m2)*% 24.8!+/0!4.9!
Parity§% 1.0!(0,!2.0)!
Age%at%onset%(yr)*% 22.7!+/0!10.8!
Disease%duration%(yr)*% 11.6!+/0!7.7!
BSGE%Pelvic%Pain%Questionnaire%scores§:% !
"! PreImenstrual%pain% 8.0!(6.3,!9.0)!
"! Menstrual%pain% 8.0!(7.0,!9.0)!
"! NonIcyclical%pelvic%pain% 6.5!(4.5,!7.0)!
"! Pain%during%sexual%intercourse% 6.5!(3.0,!9.0)!
"! Pain%opening%bowels%during%period% 7.0!(1.5,!9.0)!
"! Pain%opening%bowels%at%other%times% 3.0!(0,!6.0)!
"! Lower%back%pain% 7.0!(4.5,!8.0)!
"! Bladder%Pain% 2.0!(0,!5.8)!
American%Society%for%Reproductive%Medicine%(ASRM)%staging:% !
"! Score*% 20.4!+/0!19.1!
"! Stage§% 2.0!(2.0,!3.0)!
Endometriosis%Health%Profile%Questionnaire%(EHPI30)%scores*:% !
"! Pain% 50.9!+/0!16.8!
"! Control%&%powerlessness% 63.2!+/0!25.8!
"! Emotional%wellIbeing% 43.1!+/0!22.6!
"! Social%support% 49.3!+/0!25.0!
"! SelfIimage% 51.4!+/0!30.6!
"! Total%EHPI30%score% 257.8!+/0!101.7!
Table!7.2! Demographics!and!baseline!characteristics!of!CHUTE!cohort!!!
The*demographics*and*baseline*characteristics*of*the*eighteen*CHUTE*study*subjects*is*
shown,*with*the*onset*age*being*the*age*the*patient*was*first*aware*of*symptoms*rather*
than*the*age*at*which*the*diagnosis*was*made*(*Mean*+/R*SD,*§Median*(IQR),*yr=*years).
!
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7.2! CLINICAL%DATA%
The!clinical! response! to! ulipristal! acetate!was! considered!based! on!patient! reported!
symptoms!and!the!results!of!the!EHP030!and!PGIC!questionnaires.!!The!results!of!these!
two!questionnaires!allowed!the!cohort!to!be!divided!into!responders!(10/18,!56%)!and!
non0responders!(8/18,!44%);!and!are!discussed!in!detail!in!Section!7.5.!!This!distinction!
between!responders!and!non0responders!has!been!used!throughout!the!analysis!of!the!
results!to!aid!in!the!recognition!of!patterns!that!might!indicate!the!mechanism!behind!
the!clinical!impact!seen.!
For!details!of!questionnaires!at!each!visit!and!time!points!for!comparisons,!please!see!
Figure!6.1.!!
7.2.1! Disease(status(
All!the!subjects!within!the!cohort!had!a!diagnosis!of!endometriosis!and!the!symptoms!
related! to! the! disease! were! evaluated! at! screening,! during! treatment! and! prior! to!
surgery.!!The!BSGE!Pelvic!Pain!Questionnaire!(BSGE0!Qu)!allowed!quantification!of!these!
symptoms!at!each!visit!and!the!Composite!Pelvic!Signs!and!Symptoms!Score! (CPSSS)!
provided!a!framework!for!describing!clinical!signs!associated!with!the!disease.!
Symptoms'
At! screening! the! five! classic! endometriosis! symptoms! were! enquired! about:!!
dysmenorrhoea! (14/18),! non0menstrual! pelvic! pain! (14/18),! dyspareunia! (14/18),!
bladder!symptoms!(6/18)!and!dyschezia!during!menstruation!(14/18)!were!reported!by!
the!18!subjects.!!The!severity!of!each!symptom!was!quantified!in!the!BSGE0Qu!using!a!
0010!scale,!with!10!being!the!maximum.!!The!median!scores!for!dysmenorrhoea!(8.0),!
non0menstrual!pelvic!pain!(6.5),!dyspareunia!(6.5)!and!dyschezia!during!menstruation!
(7.0)!indicated!severe!symptoms!but!the!median!score!for!bladder!symptoms!was!only!
2.0,!suggesting!this!was!a!much!less!bothersome!symptom!(See!Table!7.2).!
Signs'
The!clinical!signs!of!endometriosis!were!evaluated!at!screening!to!aid!clinical!assessment!
and!planning!of!pre0operative! investigations.! !Both!pelvic! tenderness!and! induration!
were!rated!as!moderate!with!both!having!median!scores!of!2!(interquartile!range!102).!
!
!
CHUTE!Thesis!(1.4)! 0!162!0!
CHANGES(IN(HISTOLOGY(FOLLOWING(ULIPRISTAL(THERAPY(IN(ENDOMETRIOSIS(
(CHUTE)(
7.2.2! Clinical(response(
Ulipristal'acetate'
All! the! study! subjects! completed! the! three0month! course! of! ulipristal! acetate,! with!
fourteen!taking!all!84!doses!as!instructed!and!four!subjects!missing!some!doses.!!The!
total!doses!missed!was!8!(range!105)!giving!a!mean!average!of!0.44!missed!doses!per!
patient.!
At!the!end!of!treatment!(EoT)!the!patient!reported!symptoms!of!the!cohort!were!as!
follows:!dysmenorrhoea!(2/18),!non0menstrual!pelvic!pain!(9/18),!dyspareunia!(8/18),!
bladder!symptoms!(3/18)!and!dyschezia!during!menstruation!(5/18).!!There!was!marked!
improvement! with! regards! to! prevalence! across! all! five! of! these! symptoms! when!
compared!to!screening.!!This!was!reflected!by!the!reduction!in!analgesia!usage!reported!
by!the!subjects;!10!subjects!reported!a!decrease,!8!reported!no!change!and!no!subjects!
reported!an!increase.!
Amenorrhoea!was!reported!in!15/18!(83%)!of!the!study!subjects.!!A!lack!of!menstrual!
bleeding!did!not!always!equate!to!improvement!of!endometriosis!symptoms0!seven!of!
the! eight! subjects! who!were! considered! to! be! non0responders!were! amenorrhoeic.!!
However,! those! subjects! who! continued! to! menstruate! whilst! taking! the! drug! still!
reported! a! good! clinical! response,! with! two! responders! having! a! regular! cycle!
throughout.!
Ulipristal'acetate'and'surgical'management'
The!results!obtained!at!the!end!of!study!(EoS)!visit!represent!the!combination!of!the!
pre0operative!drug!treatment!and!the!surgical!excision!of!disease.!!The!patient!reported!
symptoms! of! the! cohort! were:! dysmenorrhoea! (13/18),! non0menstrual! pelvic! pain!
(11/18),! dyspareunia! (4/18),! bladder! symptoms! (0/18)! and! dyschezia! during!
menstruation!(3/18).!!The!prevalence!of!all!the!main!five!symptoms!had!reduced!by!the!
end!of!the!study!but!dysmenorrhoea!remained!a!common!problem!within!the!cohort!
even! following! surgical! management.! ! However,! analgesia! usage! at! the! EoS! visit!
compared!to!the!screening!visit!was!reduced!in!8!of!the!18!subjects!(44%).!
The! patient! reported! severity! data! from! the! BSGE0Qu! is! shown! in! Table! 7.3.! ! It!
demonstrates!that!a!statistically!significant!reduction!in!median!symptom!severity!was!
achieved! between! screening! and! the! end! of! the! study! for! pre0menstrual! pain! (03.0,!
!
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p=0.0004),!menstrual!pain!(02.0,!p=0.006),!non0cyclical!pelvic!pain!(02.5,!p=0.0034),!pain!
during!sexual!intercourse!(04.0,!p=0.002)!and!lower!back!pain!(02.0,!p=0.0068).!!
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!!
BSGE%Pain%Questions% Subjects% End%of%Study%(EoS)% EoS%–%Screening%Difference%
(n=…)! Median! IQ!Range! Median! IQ!Range! P!Value§!
Pre<menstrual%pain% 17! 4.0! (3,6)! =3.0! (=5,=1)! 0.0004*!
Menstrual%pain% 17! 6.0! (3,8)! =2.0! (=4,0)! 0.0060*!
Non<cyclical%pelvic%pain% 18! 4.0! (0,6)! =2.5! (=4,0)! 0.0034*!
Pain%during%sexual%intercourse% 12! 1.5! (0,4.5)! =4.0! (=5.5,=2)! 0.0020*!
Pain%opening%bowels%during%period% 16! 2.5! (0,6)! =1.5! (=5.5,0)! 0.0518!
Pain%opening%bowels%at%other%times% 18! 0.0! (0,5)! 0.0! (=4,1)! 0.2319!
Lower%back%pain% 18! 3.5! (0,5)! =2.0! (=6,0)! 0.0068*!
Table&7.3& BSGE.Qu&end&of&study&data&&&&
The$median$average$and$interquartile$range$(IQ$Range)$are$shown$for$each$domain$of$the$pain$section$of$the$BSGE@Qu$questionnaire$completed$by$
study$subjects$at$the$EoS$visit.$$The$symptom$of$‘Bladder$Pain’$was$excluded$from$this$analysis$as$the$median$score$at$baseline$was$low,$indicating$that$
this$was$not$a$clinically$significant$symptom$for$this$cohort.$$The$median$average$and$IQ$Range$for$the$difference$between$screening$and$EoS$is$also$
shown$allowing$a$Wilcoxon$signed$rank$test$(§)$to$be$performed.$(*p<0.05)$
!
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7.2.3! Surgical(data(
The!descriptive!data!for!each!study!subject! including!the!operation!notes,!annotated!
surgical! photographs,! annotated! histology! (H&E)! photographs! and! annotated! IHC!
photographs!are! shown! in!appendix!27.! ! Figure! 7.2!gives!an!example!of! the! surgical!
management! undertaken! for! the! CHUTE! study! subjects! and! the! descriptive! data!
contained!within!appendix!27!for!each!subject.!
CHUTE&02&
This!subject!was!30!years!of!age!and!struggling!with!her!endometriosis!symptoms.!!She!
was! experiencing! debilitating! pelvic! pain! but! her!most! bothersome! symptoms!were!
dyspareunia!and!dyschezia!during!her!periods.! !On!pelvic!examination!nodules!were!
palpable!within!the!posterior!fornix!and!over!the!left!utero0sacral!ligament.!
At! laparoscopy,!a!dense!and!active! lesion!of!deeply! invasive!endometriosis!was!seen!
overlying!the!left!uterosacral!ligament!(Figure!7.2a!&!7.2c).!!In!addition,!there!was!rectal!
tethering!in!the!midline!(Figure!7.2b),!which!was!considered!to!be!the!likely!cause!for!
her! symptoms.! ! Stripping! of! the! peritoneum! and! partial! transection! of! the! left!
uterosacral!ligament!was!required!to!excise!the!first!nodule.!!Following!that!the!para0
rectal!space!was!opened!bilaterally!to!allow!excision!of!the!vaginal!nodule.!
She!had!an!uneventful!post0operative! course!and!was! reviewed!again! three!months!
after!surgery.!!At!that!review,!she!reported!complete!resolution!of!the!majority!of!her!
symptoms!although!her!dysmenorrhoea!persisted.!!!!
!
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Left!uterosacral!ligament!(a)!
!
Left!uterosacral!disease!clear!of!ureter!on!left!
Dense! and! active! disease! seen! overlying!
extensive!portion!of!left!uterosacral!ligament.!
Pouch!of!Douglas!(b)!
!
Rectal!tethering!in!midline!at!site!of!nodule.!
Left!uterosacral!ligament!with!rectovaginal!nodule!(c)!
!
Midline!nodule!palpable!laparoscopically.!
Para!rectal!dissection!revealing!nodule!(d)!
!
Peritoneum! opened! and! stripped! from!
uterosacral! ligament! on! left! in! two! separate!
portions! with! a! partial! transection! of! left!
uterosacral!ligament.!
Peritoneal! stripping! continued!over!midline! to!
excise! peritoneum! from! right! uterosacral!
ligament.!
Para0rectal! space! opened! bilaterally! and!
rectovaginal!disease!separated!from!rectum!to!
allow!excision!of!vaginal!nodule!in!mid!line.!
Figure'7.2' CHUTE'02'surgical'images'''
Annotated(photographs(demonstrating(the(surgical(excision(undertaken(for(CHUTE(02(
(Extract(from(the(surgical(data(record>(shown(in(appendix(27).
!
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7.2.4! ASRM(classification(
The!revised!American!Society!for!Reproductive!Medicine!classification!of!endometriosis!
was! used! to! quantify! the! disease! seen! at! both! the! diagnostic! laparoscopy! and! the!
subsequent!surgical!management!of!each!subject.!!These!data!are!shown!in!Table!7.4.!
At!the!diagnostic!procedure!(baseline)!the!mean!score!was!20!and!median!stage!was!2!
(range!104).!!Whereas!at!the!surgical!procedure!for!the!treatment!of!endometriosis!the!
mean!score!had!increased!to!29!and!the!median!stage!had!increased!to!3!(range!204),!
over!a!median!interval!of!12!months!(range!7062).!!!
There!were!three!cases!where!the!ASRM!score!was! lower!at!the!time!of!the!surgical!
management! with! an! interval! between! surgical! procedures! of! 20! to! 60! months.!!
However,!despite!this!reduced!score!they!each!required!surgical!management!for!their!
mild!(score!7),!moderate!(score!28)!and!severe!(score!56)!disease.!!Eight!subjects!had!
only!a!minimal!increase!in!ASRM!score!(score!range!7048,!score!difference!009,!interval!
7033!month)!and!five!had!a!more!moderate!increase!(score!range!16038,!score!difference!
12026,!interval!7058!months)!with!only!a!single!subject!having!a!severe!increase!in!ASRM!
from!34!to!129!(score!difference!=!95)!over!7!months.
!
!
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! Diagnostic!
Laparoscopy!
Surgical!
Management!
Score!
Difference!
Interval!
(Months)!
Score! Stage! Score! Stage!
CHUTE!01! 6! 2! 11! 2! +5! 15!
CHUTE!02! 6! 2! 7! 2! +1! 12!
CHUTE!04! 10! 2! 7! 2! 03! 53!
CHUTE!05! 46! 4! 48! 4! +2! 7!
CHUTE!06! 22! 3! 24! 3! +2! 10!
CHUTE!08! 76! 4! 56! 4! 020! 60!
CHUTE!09! 26! 3! 38! 3! +12! 7!
CHUTE!10! 6! 2! 32! 3! +26! 12!
CHUTE!11! 38! 3! 28! 3! 010! 20!
CHUTE!12! 17! 3! 34! 3! +17! 11!
CHUTE!13! UK! 2! 16! 3! 0! 44!
CHUTE!14! 10! 2! 10! 2! 0! 8!
CHUTE!15! 34! 3! 129! 4! +95! 7!
CHUTE!19! 20! 3! 36! 3! +16! 58!
CHUTE!21! 4! 1! 16! 3! +12! 62!
CHUTE!23! 6! 2! 9! 2! +3! 33!
CHUTE!24! 10! 2! 19! 3! +9! 8!
CHUTE!25! 10! 2! 10! 2! 0! 7!
Mean! 20! 0! 29! 0! +10! 24!
Median! 0! 2! 0! 3! 0! 12!
Range! 0! 104! 0! 204! ! 7062!
Table'7.4' ASRM'staging'data'''
The( ASRM( scores( and( staging( at( both( the( diagnostic( procedure( and( the( subsequent(
surgical( management.( ( The( Score( difference( is( the( calculated( difference( in( scores(
between( the( two( surgical( procedures.( ( The( interval,( in( months,( between( the( two(
surgeries(is(shown(in(the(final(column.((UK(=(unknown,(>(=(data(not(applicable)(
!
!
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7.2.5! Biopsy(data(
A!total!of!111!different!surgical!specimens!were!obtained!from!the!abdomen!and!pelvis!
as! part! of! excisional! surgery! for! the! study! cohort.! ! The! anatomical! locations! these!
specimens!were!obtained!from!are!shown!in!Table!7.5.!!The!disease!was!not!confined!to!
any! particular! anatomical! compartment! and! even! disease! in! more! complex! sites!
(rectal/pararectal)!was!excised!to!achieve!maximum!symptom!relief!for!the!patient.!!!
Anatomical!Site! Frequency!(n=111)!
Rectal/pararectal!disease! 22!
Left!ovary!disease/adhesions! 12!
Left!uterosacral! 11!
Left!pelvic!sidewall!peritoneum! 10!
Uterovesical!fold! 10!
Right!uterosacral! 10!
Right!pelvic!sidewall!peritoneum! 8!
Right!ovary!disease/adhesions! 7!
Left!tubal!disease/adhesions! 6!
Other!(POD,!uterus,!adhesions)! 13!
Table'7.5' Anatomical'location'of'disease'''
The(anatomical(site(of(each(deposit(of(endometriosis(excised(from(the(CHUTE(cohort.((
The(frequency(with(which(an(excisional(biopsy(was(obtained(at(each(location(is(shown.(
A(total(of(111(excisional(biopsies(were(obtained,(all(of(which(underwent(H&E(staining(
prior(to(review.(
Although,!all!due!care!was!taken!to!minimise!tissue!damage!during!the!excision!of!the!
specimens,!patient!safety!and!the!needs!of!surgery!were!the!first!priority.!!As!such!some!
specimens!were!distorted!by!the!surgical!process.!!However,!the!majority!of!specimen!
distortion!was! the! result! of! the! disease! process.! ! In! view!of! this! all! specimens!were!
viewed!following!H&E!staining!to!determine!the!most!appropriate!sample!to!perform!
the!immunohistochemistry!staining!on.!!This!created!a!subset!of!18!‘biopsies’,!one!for!
each!study!subject,!which!were!used!for!the!IHC!analysis.! !The!anatomical!location!of!
each!of!those!representative!biopsies!is!shown!in!Figure!7.3!and!Table!7.6.!!!!!!
!
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Figure'7.3' Anatomical'location'of'biopsies'''
Graphic(representation(of(the(anatomical(site(of(each(biopsy(used(for(IHC(analysis(within(
the(CHUTE(cohort((Red(star(=(biopsy(site,(associated(number(=(frequency,(n(=(18).(
!
!
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Subject! Anatomical!Site!
CHUTE!01! Peritoneum!overlying!left!pelvic!sidewall!
CHUTE!02! Upper!left!uterosacral!ligament,!medial!to!left!ureter!
CHUTE!04! Peritoneum!overlying!right!uterovesical!fold!
CHUTE!05! Peritoneum!overlying!bladder0!right!
CHUTE!06! Posterior!uterine!surface!biopsy!
CHUTE!08! Left!fallopian!tube!and!ovary!
CHUTE!09! Uterovesical!peritoneum!
CHUTE!10! Left!pelvic!side!wall!
CHUTE!11! Left!ovary!
CHUTE!12! Right!uterosacral!endometriotic!cyst!
CHUTE!13! Left!uterovesical!fold!peritoneum!
CHUTE!14! Peritoneum!from!right!side!of!uterovesical!fold!
CHUTE!15! Right!ovarian!tissue!
CHUTE!19! Left!pelvic!side!wall!peritoneum!and!left!uterosacral!ligament!
CHUTE!21! Left!uterosacral!ligament!peritoneum!
CHUTE!23! Pouch!of!Douglas!peritoneum!
CHUTE!24! Right!para0rectal!peritoneum!
CHUTE!25! Left!pelvic!side!wall!&!Pouch!of!Douglas!peritoneum!
Table'7.6' Anatomical'location'of'biopsies'''
The( anatomical( site(of( each(biopsy( used( for( IHC( analysis(within( the( CHUTE( cohort( is(
shown.
!
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7.2.6! Surgical(observations(
Widespread& &active&endometriosis&
An!active!and!“angry”!appearance!of!the!peritoneal!endometriosis!was!noted! in! four!
subjects.! ! The! appearance! was! thought! to! be! suggestive! of! recently! developed!
endometriosis!and!so,!given!the!recent!course!of!ulipristal!acetate,!was!photographed!
prior!to!excision.!!CHUTE!05!had!a!stable!ASRM!score!varying!by!2!points!(46!to!48)!over!
the! 7!months! between!operations.! ! At! surgery!multiple,! red! and! black! lesions!were!
noted!over!the!peritoneum!of!the!right!pelvic!side!wall!and!ovarian!fossa!(Figure!7.4!
images!a!&!b).!!Some!of!these!lesions!had!a!‘stuck!on’!appearance!suggesting!they!had!
recently!developed.!
A!similar!but!more!florid!appearance!was!seen!over!the!surface!of!the!uterus!and!in!the!
Pouch!of!Douglas!for!CHUTE!06!(Figure!7.4!image!c)!and!CHUTE!11!(Figure!7.4!image!d).!!
There!were!multiple!clear!and!red!deposits!forming!a!confluent!band!of!endometriosis!
extending!down!from!the!posterior!surface!of!the!uterus!to!the!uterosacral!complex.!!
Both!of!these!subjects!had!a!similar!ASRM!score0!24!and!28!respectively;!with!a!two0
point!increase!in!score!(22!to!24)!over!an!interval!of!10!months!for!CHUTE!06!and!a!100
point!decrease!in!score!(38!to!28)!over!an!interval!of!20!months!for!CHUTE!11.!
The!final!patient!showing!these!features!was!CHUTE!25!with!an!ASRM!score!of!10!that!
remained!unchanged!over!the!7!months!between!procedures.! !This!subject’s!disease!
appeared!to!be!a!combination!of!active!red!deposits!overlying!a!background!of!deeper!
more!well! established! endometriotic! deposits! (Figure! 7.4! images! e!&! f).! ! There!was!
associated! white! scar! tissue! overlying! both! uterosacral! ligaments! and! peritoneal!
pocketing!within!the!Pouch!of!Douglas.!
!!!
!
!
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a.! CHUTE! 05! right! pelvic! sidewall! and!
ovarian!fossa!
!
b.!CHUTE!05!Pouch!of!Douglas!
!
c.!CHUTE!06!Pouch!of!Douglas!
!
d.!CHUTE!11!Pouch!of!Douglas!
!
e.! CHUTE! 25! left! pelvic! sidewall! and!
uterosacral!ligament!
!
f.!CHUTE!25!Pouch!of!Douglas!
Figure'7.4' Active'endometriosis'following'ulipristal'acetate'treatment'''
Surgical( photographs( for( CHUTE( 05,( 06,( 11( &( 25( demonstrating( the( highly( active(
appearance(of(the(peritoneal(endometriosis(seen(in(these(four(study(subjects.((The(exact(
anatomical(location(is(described(with(each(image.(!
!
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Endometriomas&
Three! subjects!had!endometriomas,!which!were!managed!by! total!or!partial!ovarian!
cystectomy,!dependent!on!the!condition!of!the!tissues,!disease!related!adhesions,!and!
patient!wishes.!!Subjects!CHUTE!09!and!CHUTE!19!had!quite!similar!disease!with!6cm!&!
3cm!left!ovarian!endometriomas!respectively!(Figure!7.5!images!a!&!f).!!For!CHUTE!09!a!
partial! ovarian! cystectomy! was! performed! (Figure! 7.5! image! b)! and! the! remaining!
portion!of!the!pseudo!capsule!was!heat!treated!with!monopolar!diathermy.!!In!addition,!
uterovesical!deposits!and!a!rectovaginal!nodule!were!excised.!!Similarly,!for!CHUTE!19!
an! ovarian! cystectomy!was! performed! as!well! as! excision! of! a! dense! endometriotic!
nodule!within!the!left!pelvic!sidewall!and!uterovesical!disease.!!Each!of!these!subjects!
had!moderate!to!severe!endometriosis!with!a!ASRM!score!of!38!(score!difference!12)!
for!CHUTE!9!and!36!(score!difference!16)!for!CHUTE!19;!although!the!time!interval!was!
much!greater!for!CHUTE!19!(58!months)!compared!to!CHUTE!09!(7!months).!!!!
However,!CHUTE!15!had!a!much!greater!change!in!the!ASRM!score!over!only!7!months.!!
The!score!difference!was!95!(34!to!129)!resulting!in!bilateral!kissing!ovaries!obliterating!
the!Pouch!of!Douglas!(Figure!7.5!image!c!&!Figure!7.6!image!c).! !The!right!ovary!was!
enlarged! to! 8cm! with! two! endometrioma! containing! chocolate! material! (Figure! 7.5!
image! d).! There!were!multiple! peritoneal! pockets! around! the! right! ovary! containing!
clear! and! endometriotic! fluid! with! filmy! adhesions! forming! pockets! over! posterior!
surface! of! uterus! containing! altered! blood! or! peritoneal! fluid.! ! This! appearance!was!
similar!to!the!active!endometriosis!seen!in!other!CHUTE!subjects!and!described!above.!!
A!smaller!(3cm)!endometrioma!was!also!seen!within!the!left!ovary!and!this!was!adherent!
to!the!left!pelvic!sidewall!(Figure!7.5!image!e).!!
Surgical!management!included!extensive!adhesiolysis!to!normalise!anatomy!as!much!as!
possible.! !Bilateral!ovarian!cystectomies!were!performed,!and! the!widespread!active!
endometriosis!excised!where!possible!and! treated!with!monopolar!diathermy!where!
excision!was!not!feasible.
!
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a.!CHUTE!09!endometrioma!(6cm)!within!
left!ovary!and!adherent!to!pelvic!side!wall!
!
b.! CHUTE! 09! partial! ovarian! cystectomy!
with!monopolar!diathermy!to!ovary!
!
c.! CHUTE! 15! bilateral! kissing! ovaries!
obliterating!Pouch!of!Douglas!
!
d.! CHUTE! 15! two! endometrioma!within!
right!ovary!enlarged!to!8cm!diameter!
!
e.!CHUTE!15!endometrioma!(3cm)!within!
left!ovary!and!adherent!to!pelvic!side!wall!
!
f.! CHUTE! 19! endometrioma! (203cm)!
within! left!ovary!and!adherent! to!pelvic!
side!wall!
Figure'7.5' Endometriomas'''
Surgical(photographs( for(CHUTE(09,(15(&(19(demonstrating( the(endometriomas( that(
were( managed( surgically( with( total( or( partial( ovarian( cystectomy( and( monopolar(
diathermy.
!
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Dense&adhesions& &frozen&pelvis&
Two! subjects,! CHUTE! 08! and! CHUTE! 15,! had! severe! disease! causing! significant!
anatomical!distortion!and!a! frozen!pelvis! (Figure!7.6).! !Although! the!ASRM!score! for!
CHUTE!08!was!lower!(56!points)!than!the!score!for!CHUTE!15!the!excision!of!disease!was!
equally!challenging!for!each!subject.!!
!
a.!CHUTE! 08! left! ovary!and! tube! buried!
within! dense! adhesions! with! proximal!
sigmoid! colon! adherent! to! ovary! &! the!
posterior!surface!of!the!uterus,!and!the!
distal!sigmoid!colon!partially!adherent!to!
the!pelvic!sidewall!
!
b.!CHUTE!08!post!excision!
!
c.! CHUTE! 15! extensive! filmy! and! dense!
inflammatory! adhesions! secondary! to!
endometriosis! with! bilateral!
endometriomas!obliterating!the!Pouch!of!
Douglas!
!
d.!CHUTE!15!post!excision!
Figure'7.6' Severe'disease'with'‘Frozen'Pelvis’'''
Surgical(photographs(for(CHUTE(08(&(15(demonstrating(the(more(severe(spectrum(of(
disease(managed(within(the(CHUTE(cohort.!
!
!
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7.3! HISTOLOGY!DATA!
7.3.1! Histopathology(reporting(
All! 18! subjects! had! an! endometrial! biopsy! obtained,! processed! and! reported! at!
screening.! ! These! biopsies! were! obtained! between! day! 7012! and! revealed! healthy!
endometrium!with!mid!to!late!proliferative!features!in!keeping!with!the!menstrual!cycle!
day.!
At!surgery,!a!single!eutopic!sample!and!multiple!ectopic!samples!were!obtained!for!each!
subject.! ! These!were! processed! and! reported! as! previously! described,! using! the! 21!
domains!to!describe!the!architecture!and!features!of!the!epithelial!and!stromal!cells.!!
Through!the!process!of!reviewing!the!histopathology!slides!and!evaluating!the!presence!
of!any!PAEC!type!changes!it!became!clear!that!six!features!were!key!to!that!assessment:!
cystic! dilatation! of! glands,! cuboidal! epithelial! cells,! ciliated! metaplasia,! infrequent!
epithelial! mitoses! and! cytoplasmic! vacuolation! of! epithelial! cells! as! well! as! stromal!
vascular!changes.!The!data!described!below!focus!on!these!important!features!in!both!
the!eutopic!and!ectopic!samples.!
It! should! be! noted! that! all! the! ectopic! samples! were! viewed! and! considered! when!
producing! the! official! histopathology! report! and! any! conclusions! for! an! individual!
subject.!!However,!for!the!purposes!of!CHUTE!reporting!with!respect!to!the!21!domains!
described!in!the!Histopathology!Plan!(Appendix!24)!and!the!immunohistochemistry!the!
single!highest!quality!sample!was!selected!for!each!subject.!
7.3.2! PAEC(
The!features!of!PAEC!were!assessed!in!both!the!eutopic!and!ectopic!samples!to!establish!
whether! similar! patterns! were! seen! in! both! tissue! types.! ! The! conclusion! by! both!
histopathologists!was!that!no!subject!in!the!study!exhibited!enough!PAEC!features!in!
the!eutopic!endometrium!to!confirm!the!diagnosis.!!!
The! data! presented! in! Table! 7.7! show! the! features! reported! by! each! of! the!
histopathologists!and!the!similar!data!from!the!PEARL!I!and!II!as!a!comparison.!!Cystic!
dilatation!was!identified!in!6022%!of!the!samples!with!minimal!ciliated!metaplasia!(6%)!
and!infrequent!(11%)!stromal!vascular!changes.!!The!CHUTE!subjects!appeared!to!have!
quite! inactive! endometrium! with! infrequent! mitoses! being! identified! in! a! high!
proportion!(61078%).!
!
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When!using!the!PEARL!I!&!II!data!as!a!comparison!it!should!be!noted!that!the!eutopic!
samples! in! these! studies! were! obtained! whilst! the! subjects! were! taking! ulipristal!
acetate,!whereas!the!samples!obtained!in!this!study!were!six!weeks!after!subjects!had!
stopped!taking!ulipristal!acetate.!!Hence!the!reduced!frequency!of!PAEC!features!may!
be!the!result!of!a!different!response!in!the!CHUTE!subjects!or!a!consequence!of!features!
resolving!and!endometrium!normalising.!!
Features! PAEC! Eutopic!Endometrium! PEARL!Data!(Week!13)!
RL!(n=18)! AW!(n=18)! I!(n=282)! II!(n=288)!
Cystic!Dilatation! Present! 4!(22%)! 1!(6%)! 105!(45%)! 96!(38%)!
Cell!type! Cuboidal! 0!(0%)! 6!(33%)! 0! 0!
Ciliated!metaplasia! Present! 1!(6%)! 1!(6%)! 0! 0!
Infrequent!Mitoses! Present! 14!(78%)! 11!(61%)! 80!(34%)! 74!(29%)!
Cytoplasmic!
vacuolation!
Common! 4!(22%)! 4!(22%)! 162!(70%)! 161!(63%)!
Stromal! vascular!
changes!
Present! 2!(11%)! 0!(0%)! 107!(46%)! 87!(34%)!
Table'7.7' PAEC'features'within'eutopic'endometrium'''
The(histological(features(and(the(expected(findings(203)(seen(in(PAEC(are(shown(in(the(
first( two(columns.(The( frequency(and(percentage(as(determined(by( two( independent(
histopathologists(is(shown(and(the(PAEC(data(from(the(PEARL(I(and(PEARL(II(studies(are(
shown(for(comparison.(197,198)((RL=(Dr(Ray(Lonsdale,(AW=(Professor(Alistair(Williams)(
!
However,!despite!this!delay!of!six!weeks!there!were!still!quite!significant!histological!
changes! seen! in! the!ectopic! samples.! ! The!comparison!between!eutopic!and!ectopic!
samples!is!shown!in!Table!7.8,!highlighting!high!levels!of!cystic!dilatation!within!ectopic!
endometrial! glands! 0! 83089%,!with! ciliated!metaplasia! seen! in! 56%!of! samples.! ! The!
ectopic!glands!within!the!endometriosis!were!inactive!with!cuboidal!epithelial!cells!(330
89%)!and! infrequent!mitoses!(89094%).! ! There!were!no!examples!of!stromal!vascular!
changes!identified!but!the!volume!of!stromal!tissue!with!each!sample!of!endometriosis!
was!small!making!assessment!of!vascular!patterns!difficult.
! CHANGES(IN(HISTOLOGY(FOLLOWING(ULIPRISTAL(THERAPY(IN(ENDOMETRIOSIS(
(CHUTE)(
Features( PAEC( Eutopic(Endometrium( Ectopic(Endometrium(
RL((n=18)( AW((n=18)( Kappa( Overall(
agreement(
RL((n=18)( AW((n=18)( Kappa( Overall(
agreement(
Cystic(Dilatation( Present! 4!(22%)! 1!(6%)! 0.34! 0.83**! 15!(83%)! 16!(89%)! 0.17! 0.44!
Cell(type( Cuboidal! 0!(0%)! 6!(33%)! 0! 0.67! 6!(33%)! 16!(89%)! 0.12! 0.44!
Ciliated(metaplasia( Present! 1!(6%)! 1!(6%)! 1! 1**! 10!(56%)! @! @! @!
Infrequent(Mitoses( Present! 14!(78%)! 11!(61%)! 0.53! 0.78*! 17!(94%)! 16!(89%)! 0.34! 0.83**!
Cytoplasmic(vacuolation( Common! 4!(22%)! 4!(22%)! 0.49! 0.78*! 0!(0%)! 1!(0%)! @0.03! 0.89**!
Stromal(vascular(changes( Present! 2!(11%)! 0!(0%)! 0! 0.89**! 0!(0%)! 0!(0%)! 1! 1**!
Table&7.8& PAEC&features&comparing&eutopic&and&ectopic&endometrium&&
The$histological$features$and$the$expected$findings(203)$seen$in$PAEC$are$shown$in$the$first$two$columns.$The$frequency$and$percentage$as$determined$
by$two$independent$histopathologists$are$shown$for$both$the$eutopic$and$ectopic$endometrial$samples$from$the$CHUTE$cohort.$An$assessment$of$the$
inter@observer$agreement$for$each$histological$feature$is$shown$as$both$a$Kappa$coefficient$and$the$overall$level$of$agreement.$$The$Kappa$statistic$is$
not$reliable$for$this$data,$a$problem$called$‘High$Agreement$But$Low$Kappa’$and$so$the$more$simple$level$of$agreement$is$also$shown.(225–227)$$$(RL=$
Dr$Ray$Lonsdale,$AW=$Professor$Alistair$Williams,$**=$strong$agreement,$*=$moderate$agreement))$
$
!
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7.3.3! Eutopic(endometrial(features(
Cystic'dilatation'
Although!cystic!dilatation!was!not! seen!commonly!within! the!eutopic! samples! there!
were! some! examples.! ! Dr! R.! Lonsdale! considered! CHUTE! 08,! 12,! 13! &! 14! to! have!
evidence!of!glandular!dilatation!but!Professor!A.!Williams!felt!that!CHUTE!08!was!the!
only! clear!example.! ! The!changes!noted!by!Dr!R.! Lonsdale! for! subjects!12!&13!were!
considered!to!be!subtle!and!possibly!in!keeping!with!natural!variation.!!The!focal!cystic!
dilatation!and!associated!ciliated!cell!metaplasia!of!CHUTE!08!is!shown!in!Figure!7.7.a.!!
In!addition,!muscularised!arterioles!and!ectatic!vessels!were!also!noted!(Figure!7.7.b),!
which!together!were!considered!to!be!consistent!with!PAEC!but!not!diagnostic.!
Metaplastic'changes'
Subject!CHUTE!14!had!unusual!focal!changes!within!the!eutopic!endometrium,!which!
were!noted!by!both!pathologists!(Figure!7.8.a).!!This!subject!had!Grade!II!endometriosis!
with! an! ASRM! score! of! 10.! ! Her! disease! was! mostly! concentrated! over! the! right!
uterosacral! ligament! with! a! small! nodule! of! disease! over! the! right! side! of! the!
uterovesical! fold.! ! She! had! only! a! poor! response! to! the! study! drug! and! her! eutopic!
endometrium!showed!mildly!dilated!glands!lined!by!cuboidal!epithelium!and!a!hobnail!
pattern!protruding!into!the!lumen.!!In!parts!the!epithelial!cells!showed!micropapillation!
but! there! was! no! evidence! of! cellular! atypia! and! this! was! not! considered! to! be! a!
neoplastic!process.!
Vascular'changes'
In! addition! to! the! focal!metaplastic! changes! for! CHUTE! 14! there!were! also! stromal!
vascular! changes!with! some!ectatic! stromal! vessels! seen! (Figure!7.8.b).! ! These!were!
different!to!the!perivascular!eosinophilia!and!increased!muscularisation!seen!round!the!
vessels!for!CHUTE!21!(Figure!7.8.d).! !This!was!on!a!background!of!normal!mid0to0late!
secretory!phase!endometrium!(Figure!7.8.c).!
It! should! be! noted! that! neither! the! metaplastic! changes! or! the! vascular! changes!
described!for!these!eutopic!samples!of!these!subjects!were!mirrored!within!the!ectopic!
samples.!!Conversely,!cystic!dilatation!is!seen!within!the!ectopic!samples!but!at!much!
higher! frequency!suggesting!that!the!eutopic!and!ectopic!endometrium!are!behaving!
differently.!These!are!discussed!in!more!detail!below.
!
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a.! CHUTE! 08:! ‘There! are! focal! areas! of!
cystic!dilatation!and!within!those!dilated!
glands!there!is!ciliated!cell!metaplasia!and!
pseudo0stratification!of!the!nuclei’!
!
b.!CHUTE!08:!‘Muscularised!arterioles!and!
ectatic! vessels! within! the! stroma!
(consistent!with!PAEC!but!not!diagnostic)‘!
!
!
c.!CHUTE!08:!ectatic!vessels!(!)!!
!
d.!CHUTE!08:!muscularised!arterioles!(")!
Figure'7.7' PAEC'like'features'within'eutopic'endometrium'''
Histological* features* consistent* with* PAEC* that* were* noted* in* eutopic* endometrial*
specimens* for*CHUTE*08,*as*described.* (H&E*x* 100*magnificationD*a*&*b;*H&E*x*200*
magnificationD*c*&*d))*
!!
!!
"!
!
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a.! CHUTE! 14:! ‘Some! glands! are! dilated!
and! others! are! lined! by! cuboidal!
epithelium! with! a! hobnail! pattern!
protruding!into!the!lumen’!
!
b.!CHUTE!14:!hobnail!pattern!protruding!
into! the! lumen! of! gland! with! surface!
micropapillation!(!)!
!
c.!CHUTE!14:!Ectatic!stromal!vessels!(")!
!
d.!CHUTE!21:!‘Mid0to0late!secretory!phase!
endometrium!with!some!stromal!oedema!
consistent!with!phase’!
!
e.! CHUTE! 21:! ‘Vascular! changes…!
consistent!with!PAEC’!
!
f.!CHUTE!21:!Perivascular!eosinophilia!&!
increased!muscularisation!of!the!vessels!!
Figure'7.8' Metaplastic'and'vascular'changes'within'eutopic'endometrium'''
Histological* features,*consistent*with*PAEC,*which*were*noted* in*eutopic*endometrial*
specimens*for*CHUTE*14*&*21.*(H&E*Magnification*x*200*magnification*for*a,*c*&*f;*x400*
for*b;*x100*for*d*&*e))
!!
"!
!
!
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7.3.4! Ectopic(endometrial(features(
The! three! different! surgical! appearances! of! endometriosis! have! been! described! in!
Section! 7.2.6.! ! The! following! examples! demonstrate! the! corresponding! histological!
findings!in!those!subjects.!!!
Active'endometriosis'
CHUTE!06!had!a!florid!and!active!appearance!(Figure!7.4.c)!at!surgery!raising!concern!as!
to! whether! the! study! drug! had! adversely! influenced! clinical! progress.! ! The! eutopic!
endometrium!for!this!subject!was!unremarkable!(Figure!7.9.a)!and!the!ectopic!sample!
from!the!posterior!surface!of!the!uterus!showed!no!atypical!or!PAEC!features!but!was!
noted! to! demonstrate! very! well! formed! endometrial! structures! (Figure! 7.9.b).!!
Histologically!the!glandular!structure!of!the!endometriosis!was!much!more!similar!to!
eutopic!endometrium!than!would!be!expected.! !There!was!cystic!glandular!dilatation!
seen! within! the! specimen,! but! the! epithelial! cells! were! columnar! with! no! ciliated!
metaplasia.!!There!were!no!stromal!vascular!changes.!
!
a.! CHUTE! 06! (eutopic):! ‘Late! secretory!
phase!endometrium!(Day!27)’!
!
b.!CHUTE!06!(ectopic):!‘Very!well!formed!
endometrial! structures! with! no! atypical!
features!‘!
!
Figure'7.9' Comparison'of'eutopic'and'ectopic'endometrium'for'CHUTE'06'''
Histological*examples*for*CHUTE*06*with*ectopic*sample*from*florid*and*active*looking*
disease*from*the*Pouch*of*Douglas.*(H&E*x*100*magnification)*
A!similarly!active!appearance!to!the!disease!was!seen!for!CHUTE!25,!albeit!with!more!
associated!scarring!(Figure!7.4.e!&!f).!!The!eutopic!and!ectopic!samples!were!obtained!
on!day!4!of!the!cycle!and!show!changes!consistent!with!menstruation.!!There!was!no!
!
!
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cystic!dilatation!or!atypical!changes!noted!for!the!eutopic!sample!(Figure!7.10.a)!but!
cystic!dilation!was!seen!widely!in!the!ectopic!sample!(Figure!7.10.b).!!It!is!of!note!that!
the!ectopic!sample!showed!evidence!of!menstrual!breakdown!histologically.!
!
a.! CHUTE! 25! (eutopic):! ‘epithelial! cells!
have!supranuclear!vacuoles!that!have!not!
released!their!secretion,!which!is!more!in!
keeping! with! mid! secretory! phase,! but!
they! have! begun! to! breakdown! and!
appear!menstrual!(Day!4)’!
!
b.!CHUTE!25!(ectopic):!‘stromal!balling!&!
breakdown! (suggestive! of! menstrual!
breakdown)0! in! phase! with! eutopic!
sample!‘!
!
Figure'7.10' Comparison'of'eutopic'and'ectopic'endometrium'for'CHUTE'25''
Histological*examples*for*CHUTE*25*with*ectopic*sample*from*florid*and*active*looking*
disease*over*the*left*pelvic*sidewall*and*uterosacral*ligament.*(H&E*x*200*magnificationD*
a;*x100*magnificationD*b)*
Endometriomas'&'frozen'pelvis'
The!subjects!with!more!advanced!disease!with!large!endometriomas!(CHUTE!15,!Figure!
7.11.a)!and!associated!scarring!(CHUTE!08,!Figure!7.11.b)!appear!to!have!quite!similar!
appearances!histologically.!!There!is!widespread!cystic!dilation!with!evidence!of!ciliated!
metaplasia! and! an! inactive! epithelium.! ! Although! there! appears! to! be! a! clinical!
difference!at!surgery!across!the!CHUTE!subjects!and!different!clinical!response!to!study!
drug!there!does!not!appear!to!be!large!differences!histologically.!!
!
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!
a.!CHUTE!15! (ectopic):! ‘endometriosis! is!
confirmed!with!no!atypical!features’!
!
b.!CHUTE!15!(ectopic):!endometrial!gland!
(!)! and! surrounding! stroma! (")!
embedded! within! dense! fibrous! tissue!
(light!pink)!
!
c.! CHUTE! 08! (ectopic):! ‘ciliated! cell!
metaplasia!within!a!dilated!gland!(#)‘!
!
d.! CHUTE! 08! (ectopic):! ciliated! cell!
metaplasia!on!cuboidal!epithelial!cells!($)!
Figure'7.11' Ectopic'endometrium'in'advanced'disease'
Histological*examples* for*CHUTE*15*&*CHUTE*08*with*ectopic*sample*from*florid*and*
active*looking*disease.*(H&E*x*100*magnificationD*a*&*c;*H&E*x200*magnificationD*b*&*d)*
!
7.3.5! Cystic(dilatation(
Cystic!dilatation!within!ectopic!endometrium!has!been!assessed!as!part!of!investigating!
PAEC,!as!discussed!above.!!Whether!dilatation!within!the!ectopic!glands!is!a!feature!of!
endometriosis!or!the!result!of!exposure!to!study!drug! is!unclear!but! it!does!seem!to!
correlate!with! clinical! response.! ! The! data! shown! in! Table! 7.9! gives! the! number! of!
biopsies! obtained! for! each! subject,! how! many! biopsies! confirmed! endometriosis!
histologically!and!how!many!of!those!demonstrated!cystic!dilatation!with!or!without!an!
inactive!epithelium.!
!! "
#!
$!
!
!
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There!appears!to!be!a!correlation!between!the!proportion!of!endometriosis!samples!
showing! cystic! dilatation! and! the! clinical! response! observed.! ! There! is! no! significant!
difference!in!the!cystic!dilatation!frequency!for!responders!(N=10,!mean=!0.66,!SD=0.22)!
and!non0responders! (N=8,!mean=!0.44,!SD=!0.33);! t(16)=!1.74,!p=!0.10! (Independent!
Samples!T0Test).!!However,!there!is!a!trend!towards!significance,!which!may!be!clinically!
relevant.!
7.3.6! (Histological(features(and(ulipristal(acetate(
Although!there!are!histological!features!consistent!with!PAEC!no!sample!of!eutopic!or!
ectopic!endometrium!exhibited!enough!features!to!be!consistent!with!that!diagnosis.!!
However,!within!the!ectopic!samples!cystic!dilatation!and!ciliated!metaplasia!was!more!
consistently! demonstrated.! ! Despite! this,! there! does! not! appear! to! be! a! correlation!
between!these!features!and!the!severity!or!surgical!appearance!of!the!disease.!!!!There!
may! be! a!weak! correlation! between! the! presence! of! cystic! dilatation! in! the! ectopic!
endometrium!and!clinical!response!to!ulipristal!acetate;!this!may!be!a!tissue!response!
to!the!drug!or!natural!variation!within!the!histology!of!endometriosis!that!makes!the!
disease!more!susceptible!to!progesterone!receptor!modulation.
!
!
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! Clinical!
Response!
Number! of!
biopsies!
Endometriosis!
Confirmed!
Cystic!
dilatation!
+/9! inactive!
epithelium!
Proportion!
CHUTE!01! Good! 3! 3! 3! 1.00!
CHUTE!02! Good! 5! 4! 4! 1.00!
CHUTE!04! Poor! 3! 3! 2! 0.67!
CHUTE!05! Good! 6! 6! 4! 0.67!
CHUTE!06! Good! 5! 4! 2! 0.50!
CHUTE!08! Poor! 3! 2! 1! 0.50!
CHUTE!09! Poor! 4! 4! 1! 0.25!
CHUTE!10! Poor! 6! 6! 4! 0.67!
CHUTE!11! Poor! 4! 2! 0! 0.00!
CHUTE!12! Poor! 6! 6! 1! 0.17!
CHUTE!13! Good! 6! 6! 3! 0.50!
CHUTE!14! Poor! 4! 4! 1! 0.25!
CHUTE!15! Good! 6! 5! 2! 0.40!
CHUTE!19! Good! 4! 4! 3! 0.75!
CHUTE!21! Good! 4! 3! 2! 0.67!
CHUTE!23! Good! 5! 4! 3! 0.75!
CHUTE!24! Good! 5! 5! 2! 0.40!
CHUTE!25! Poor! 5! 4! 4! 1.00!
Table'7.9' Cystic'dilatation'in'ectopic'endometrium''
The*frequency*of*histologically*confirmed*endometriosis*within*the*biopsies*obtained*at*
surgery* with* the* frequency* of* cystic* dilatation* and* the* proportion* of* endometriosis*
samples*showing*cystic*dilatation.**These*data*are*also*correlated*to*whether*the*subject*
had*a*good*or*poor*clinical*response*to*the*study*drug.
!
!
CHUTE!Thesis!(1.4)! 0!188!0!
CHANGES(IN(HISTOLOGY(FOLLOWING(ULIPRISTAL(THERAPY(IN(ENDOMETRIOSIS(
(CHUTE)(
7.4! IMMUNOHISTOCHEMISTRY!DATA!
The!immunohistochemistry!(IHC)!staining!was!performed!on!a!batch!basis!throughout!
the!study!with!the!eutopic!biopsy!and!a!single!ectopic!sample!for!each!subject!being!
processed.!!After!initial!reporting!of!the!H&E!slides,!Dr!Lonsdale!made!an!assessment!of!
the!highest!quality!ectopic!sample!for!each!CHUTE!subject!before!the!lab!technicians!
ran!the!IHC!staining,!as!per!local!protocol.!
For!each!CHUTE!subject!the!slide!for!each!receptor!or!marker!was!assessed!to!produce!
an!Allred!score!and!describe!any!notable!features.!!A!representative!portion!of!each!slide!
was! also! photographed! to! facilitate! comparison! across! the! different! tissues! and! IHC!
antibodies.!No!pattern!of!expression!was!observed!based!on!clinical!response!to!study!
drug,!so!the!data!are!displayed!and!described!according!to!the!menstrual!cycle!day!on!
which!the!specimen!was!obtained.!The!initial!data!set!for!CHUTE!25!is!shown!in!Figure!
7.12!as!an!example.!!!
7.4.1! Oestrogen(and(progesterone(receptor(
The!oestrogen!receptor!(ER)!and!progesterone!receptor!(PR)!results!for!the!epithelial!
cells! and! the! stromal! cells! are! shown! according! to! menstrual! cycle! day! to! aid!
interpretation!(see!Figure!7.13!and!Figure!7.14,!respectively).!!However,!the!ER!and!PR!
staining!was!strong!and!largely!uniform!throughout!the!cohort,!irrespective!of!cycle!day.!!
Interestingly,! the! ER! and! PR! epithelial! expression! and! ER! stromal! expression! in! the!
eutopic!endometrium!was!slightly!reduced!for!those!samples!obtained!within!the!first!
three!days!of!the!cycle;!and!there!may!be!slightly!reduced!PR!expression!in!the!ectopic!
stromal!cells,!but!overall!no!clear!pattern!of!expression!was!observed.!
7.4.2! Androgen(receptor(
The! androgen! receptor! (AR)! does! appear! to! show! a! pattern! of! expression! in! the!
epithelial! cells! of! the! eutopic! endometrium!dependent! on! the! cycle! day! (see! Figure!
7.15).!!The!Allred!scores!appear!to!be!lower!in!these!cells!during!the!secretory!phase!of!
the!cycle!as!compared!to!the!proliferative!phase.!!This!pattern!does!not!seem!to!exist!
for!the!ectopic!endometrium,! in!which!expression! is!more!heterogeneous!across!the!
cohort.!
!!
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! ! ! !
a.!ER(Eu):!epithelium=!8,!stroma=!8! b.!PR(Eu):!epithelium=!8,!stroma=!8! c.!AR(Eu):!epithelium=!7,!stroma=!7! d.!Ki67(Eu):!epi.!<1%,!stroma!<1%!
! ! ! !
e.!ER(Ec):!epithelium=!7,!stroma=!7! f.!PR(Ec):!epithelium=!8,!stroma=!8! g.!AR(Ec):!epithelium=!6,!stroma=!7! h.!Ki67(Ec):!epi.!=50%,!stroma!<1%!
Figure'7.12' Immunohistochemistry'results:'CHUTE'25'(Day'4)'
Results' for'eutopic' (a0d)'and'ectopic' (e0h)'samples'with'Allred'scores' for'epithelial'cells' (epi.)'and'stromal'cells' (strom.)'are'shown.'The'oestrogen'
receptor'(ER)'(a'&'e),'the'progesterone'receptor'(PR)'(b'&'f),'the'androgen'receptor'(AR)'(c'&'g),'and'Ki67'marker'(d&'h)'panels'are'a'x'400'magnification.'
!
!
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!
a.!Oestrogen!&!progesterone!receptor!Allred!scores!for!eutopic!epithelial!cells!
!
b.!Oestrogen!&!progesterone!receptor!Allred!scores!for!ectopic!epithelial!cells!
Figure'7.13' Oestrogen' and' progesterone' receptor' immunohistochemistry'
(epithelial'cells)'
Immunohistochemistry.scores.for.the.CHUTE.subjects.are.shown.according.to.cycle.day...
Epithelial. cells. for. eutopic. (a). and. ectopic. (b). endometrial. samples. are. shown. for.
comparison.(ER=.oestrogen.receptor,.PR=.progesterone.receptor).
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!
a.!Oestrogen!&!progesterone!receptor!Allred!scores!for!eutopic!stromal!cells!
!
b.!Oestrogen!&!progesterone!receptor!Allred!scores!for!ectopic!stromal!cells!
Figure'7.14' Oestrogen'and'progesterone'receptor'immunohistochemistry'(stromal'
cells)'
Immunohistochemistry.scores.for.the.CHUTE.subjects.are.shown.according.to.cycle.day...
Stromal. cells. for. eutopic. (a). and. ectopic. (b). endometrial. samples. are. shown. for.
comparison.(ER=.oestrogen.receptor,.PR=.progesterone.receptor).
0
1
2
3
4
5
6
7
8
9
2 3 4 5 6 6 7 8 11 11 12 18 19 19 21 26 26 27
Al
lre
d!
Sc
or
e
Cycle!Day
IHC!Eutopic!Stromal!Cells
ER!Stroma PR!Stroma
0
1
2
3
4
5
6
7
8
9
2 3 4 5 6 6 7 8 11 11 12 18 19 19 21 26 26 27
Al
lre
d!
Sc
or
e
Cycle!Day
IHC!Ectopic!Stromal!Cells
ER!Stroma PR!Stroma
!
!
CHUTE!Thesis!(1.4)! 0!192!0!
CHANGES(IN(HISTOLOGY(FOLLOWING(ULIPRISTAL(THERAPY(IN(ENDOMETRIOSIS(
(CHUTE)(
!
a.!Androgen!receptor!Allred!scores!for!eutopic!epithelial!cells!
!
b.!Androgen!receptor!Allred!scores!for!ectopic!epithelial!cells!
Figure'7.15' Androgen'receptor'immunohistochemistry'(epithelial'cells)'
Immunohistochemistry.scores.for.the.CHUTE.subjects.are.shown.according.to.cycle.day...
Epithelial. cells. for. eutopic. (a). and. ectopic. (b). endometrial. samples. are. shown. for.
comparison.(AR=.androgen.receptor).
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!
a.!Androgen!receptor!Allred!scores!for!eutopic!stromal!cells!
!
b.!Androgen!receptor!Allred!scores!for!ectopic!stromal!cells!
Figure'7.16' Androgen'receptor'immunohistochemistry'(stromal'cells)'
Immunohistochemistry.scores.for.the.CHUTE.subjects.are.shown.according.to.cycle.day...
Epithelial. cells. for. eutopic. (a). and. ectopic. (b). endometrial. samples. are. shown. for.
comparison.(AR=.androgen.receptor).
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Similarly,!the!expression!of!AR!in!both!the!eutopic!and!ectopic!stromal!cells!does!not!
appear!to!be!cycle!dependent.!!The!results!for!the!stromal!cells!are!shown!in!Figure!7.16!
and!indicate!uniform!expression!throughout!the!cycle!in!both!tissue!types.!!!
7.4.3! Ki=67(proliferation(marker(
The! proliferation! marker! Ki067! demonstrates! a! cyclical! pattern! within! the! eutopic!
endometrium!for!both!epithelial!and!stromal!cells.!!For!the!stromal!cells,!there!appears!
to!be!a!peak!in!the!mid!proliferative!phase,!whereas!the!percentage!expression!for!the!
epithelial!cells!appears!to!continue!to!rise!until!the!mid0point!of!the!cycle.!!These!data!
are!shown!in!Figure!7.17a.!
The!ectopic!cells!show!much!less!cyclicity!(Figure!7.17b)!with!very!little!expression!of!Ki0
67!within! the! stromal! cells! and! variable! expression!within! the! epithelial! cells! of! the!
cohort.!!Overall,!there!appears!to!be!slightly!less!Ki067!expression!amongst!the!ectopic!
cells!as!compared!to!the!eutopic!cells.!
7.4.4! Proliferative(versus(secretory(phase(observations(
Proliferative+phase+
The!subjects!CHUTE!25!and!CHUTE!14!had!their!samples!obtained!in!the!proliferative!
phase!of!the!menstrual!cycle,!day!four!and!day!eight!respectively.!!Clinically!they!had!
similar!outcomes!with!a!poor!response!to!treatment.!A!comparison!of!their!AR!and!Ki0
67!IHC!is!shown!in!Figure!7.18.!!!!
In!the!eutopic!samples!AR!expression!in!the!stroma!is!consistent!but!expression!in!the!
epithelial!cells!is!reduced!in!the!later!sample!(CHUTE!14).!!Conversely,!the!expression!of!
epithelial!and!stromal!Ki067!is!greater!in!the!later!sample!(CHUTE!14).!!In!the!ectopic!
samples!stromal!expression!of!AR!and!Ki067!is!consistent,!whereas!in!the!epithelial!cells!
AR!and!Ki067!expression!is!greater!in!the!early!proliferative!sample!of!CHUTE!25.!!!!!
!
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!
a.!Ki67!percentage!staining!for!eutopic!epithelial!cells!
!
b.!Ki67!percentage!staining!for!ectopic!epithelial!cells!
Figure'7.17' Ki67'immunohistochemistry'(epithelial'&'stromal'cells)'
Immunohistochemistry.scores.for.the.CHUTE.subjects.using.the.Ki67.proliferation.marker.
are. shown.according. to. cycle.day.. . Epithelial.&. stromal. cells.are. shown. together. for.
comparison.with.eutopic.and.ectopic.endometrial.samples.shown.in.a.&.b,.respectively.
(ER=.oestrogen.receptor,.PR=.progesterone.receptor)..
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! ! ! !
a.!AR(Eu):!epithelium=7,!stroma=7! b.!Ki67(Eu):!epi.!1%,!stroma!1%! c.!AR(Eu):!epithelium=5,!stroma=7! d.!Ki67(Eu):!epi.!33%,!stroma!50%!
! ! ! !
e.!AR(Ec):!epithelium=!6,!stroma=!7! f.!Ki67(Ec):!epi.!50%,!stroma!1%! g.!AR(Ec):!epithelium=!8,!stroma=!7! h.!Ki67(Ec):!epi.!5%,!stroma!1%!
Figure'7.18' Immunohistochemistry'results:'CHUTE'25'(Day'4)'&'CHUTE'14'(Day'8)D'proliferative'phase'
The$androgen$receptor$(AR)$(a,$c,$e$&$g)$and$Ki67$marker$(b,$d,$f$&$h)$results$for$CHUTE$25$(a,$b,$e$&$f)$and$CHUTE$14$(c,$d,$g$&$h)$are$shown.$$Results$
for$eutopic$(aId)$and$ectopic$(eIh)$samples$with$Allred$scores$for$epithelial$cells$(epi.)$and$stromal$cells$(stroma)$are$shown$(x$400$magnification).
! CHANGES(IN(HISTOLOGY(FOLLOWING(ULIPRISTAL(THERAPY(IN(ENDOMETRIOSIS(
(CHUTE)(
! ! ! !
a.!AR(Eu):!epithelium=5,!stroma=7! b.!Ki67(Eu):!epi.!1%,!stroma!30%! c.!AR(Eu):!epithelium=5,!stroma=7! d.!Ki67(Eu):!epi.!1%,!stroma!10%!
! ! ! !
e.!AR(Ec):!epithelium=7,!stroma=7! f.!Ki67(Ec):!epi.!30%,!stroma!30%! g.!AR(Ec):!epithelium=3,!stroma=6! h.!Ki67(Ec):!epi.!1%,!stroma!5%!
Figure'7.19' Immunohistochemistry'results:'CHUTE'19'(Day'26)'&'CHUTE'21'(Day'26)D'secretory'phase'
The$androgen$receptor$(AR)$(a,$c,$e$&$g)$and$Ki67$marker$(b,$d,$f$&$h)$results$for$CHUTE$19$(a,$b,$e$&$f)$and$CHUTE$21$(c,$d,$g$&$h)$are$shown.$$Results$
for$eutopic$(aId)$and$ectopic$(eIh)$samples$with$Allred$scores$for$epithelial$cells$(epi.)$and$stromal$cells$(stroma)$are$shown$(x$400$magnification).$
!
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Secretory(phase(
As! a! comparison! CHUTE! 19! and!CHUTE! 21! had! their! samples! obtained! on! the! same!
menstrual!day!(day!26)!and!both!exhibited!a!good!response!to!treatment.!!A!comparison!
of!their!IHC!data!is!shown!in!Figure!7.19.!!For!CHUTE!19!expression!of!AR!and!Ki067!is!
higher!in!the!ectopic!epithelium!compared!to!the!eutopic!epithelium,!yet!the!stromal!
expression!is!identical!for!both!tissues.!!Conversely!for!CHUTE!21,!expression!of!AR!is!
lower!in!the!ectopic!epithelium,!but!Ki067!epithelium!expression!is!similar!in!both!tissue!
types.!!!
7.4.5! PTEN(
In!general,!the!stromal!cells!of!both!the!eutopic!and!ectopic!endometrium!stain!strong!
to!moderate!and!the!epithelial!cells!moderate!to!weak.!!Some!null!glands!were!noted!in!
the!epithelial!cells!of!the!eutopic!endometrium!for!CHUTE!09,!13,!15!and!23.!!The!most!
striking!example!of!this!is!for!CHUTE!09!and!is!shown!in!Figure!7.20.!!In!panel!a!there!are!
both!positive!(*)!and!negative!(§)!glands!with!uniform!stromal!staining.!!A!comparison!is!
shown!in!panel!b,!which!is!ectopic!tissue!is!which!uniform!positivity!is!seen.!!!
! !
a.!Eutopic!endometrium:!Heterogeneous!
pattern!of!epithelial!staining!with!clearly!
defined!positive! (*)!and!negative!glands!
(§).! Stromal! staining! is! more! uniformly!
positive.!!
b.! Ectopic! endometrium:! Uniform!
positive! staining! of! both! epithelial! and!
stromal!cells.!
Figure'7.20' Immunohistochemistry'results:'CHUTE'09'(Day'11)B'PTEN'
Immunohistochemistry. results. for. CHUTE. 09. using. PTEN. antibody.. . This. subject. had.
noticeably.reduced.epithelial.staining.within.the.epithelium.of.the.eutopic.endometrium.
with. a. number. of. null. glands. and. stretches. of. negative. surface. epithelium.
(MagnificationE.x.100)...
*"
§"
!
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7.4.6! VEGF(
A!uniform!pattern!of!epithelial!and!stromal!staining!was!seen!across!all!subjects!for!both!
tissue!types.!
7.4.7! Immunohistochemistry(and(ulipristal(acetate(
The! immunohistochemistry!data!obtained! for! the!CHUTE!subjects!are!not! consistent!
with!any!pattern!with!respect!to!response!to!ulipristal!acetate.!!The!aim!of!the!study!was!
to!establish! the!effect!of!ulipristal! acetate!on! the!histological! appearance!of!ectopic!
endometrium.! ! The! immunohistochemical! data! for! AR! and! Ki067! expression! in! the!
ectopic!endometrium!do!not!demonstrate!a!correlation!with!either!the!phase!of!the!
cycle!or!the!clinical!response!to!ulipristal!acetate.!!!!
!
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7.5! QUALITY"OF"LIFE"DATA"
7.5.1! The(EHPN30(questionnaire(
The!EHP030!questionnaire!was!completed!by!the!subjects!at!screening,!in!the!final!week!
of!taking!study!drug!and!six!weeks!after!the!study!drug!had!been!completed,!just!prior!
to!surgery.!!It!is!a!validated!questionnaire!containing!physical,!psychological!and!social!
domains,!in!which!the!higher!the!recorded!score!the!worse!the!disease!is!perceived!to!
be! by! the! subject.! ! As! such! it! has! provided! reliable! quality! of! life! data! relating! to!
endometriosis!throughout!the!study,!which!has!been!used!as!an!indicator!of!the!clinical!
impact!of!the!study!drug.!
EHP030(total(scores(
The!total!scores!and!score!differences!for!the!CHUTE!cohort!are!shown!in!Table!7.10.!!
The!scores!at!each!time!point!show!a!large!spread!of!values!as!indicated!by!high!standard!
deviation.!!Overall!the!pattern!of!change!across!the!cohort!is!for!a!reduction!in!the!mean!
total!score!between!screening!and!treatment,!indicating!the!perceived!clinical!impact!of!
ulipristal! acetate.! ! This! effect! then! appears! to! regress! once! the! drug! is! stopped.!!
However,! when! the! screening! and! end! of! treatment! mean! score! differences! are!
compared!there!still!appears!to!be!a!significant!reduction!of!the!EHP030!score!indicating!
there!remains!some!residual!effect.!
The!response!from!each!individual!subject!was!quite!variable.!!For!instance,!CHUTE!25!
scored! 125,! 38! &! 72,! in! keeping! with! the! mean! score! results! but! CHUTE! 02! had! a!
profound!and!maintained!reduction!(77,!0!&!2),!whereas!CHUTE!12!had!high!and!very!
uniform! scores! (316,! 333!&! 340)! throughout,! showing! a! deterioration! in! her! scores!
through!the!study!rather!than!an!improvement.!
The!mean!total!scores!and!standard!deviation!are!shown!in!Figure!7.21!together!with!
the!results!of!the!paired!T0tests!that!were!undertaken.!!A!paired!T0test!was!chosen!as!
the!variables!are!dependent.! !The!results!show!a!significant!score!decrease!between!
screening! and! treatment,! t(17)=! 04.47,! p<0.001;! and! a! significant! score! decrease!
between!screening!and!end!of!treatment,!t(17)=!03.30,!p=0.004;!but!a!non0significant!
score!increase!between!treatment!and!endo!of!treatment,!t(17)=!1.40,!p=0.180.!!This!
highlights!that!although!the!effect!appears!to!diminish!after!the!drug!is!stopped!the!rise!
!
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in!the!total!score!is!not!statistically!significant!over!this!six0week!timeframe!such!that!a!
significant!improvement!is!maintained!at!the!end!of!treatment.!
" Screening" Treatment" Screening" <"
treatment"
difference"
(%)"
EoT" Screening"–"
EoT"
difference"
(%)"
CHUTE"01" 199! 13! 0186!(093)! 170! 029!(015)!
CHUTE"02" 77! 0! 077!(0100)! 2! 075!(097)!
CHUTE"04" 390! 362! 028!(07)! 255! 0135!(035)!
CHUTE"05" 291! 126! 0165!(057)! 133! 0158!(054)!
CHUTE"06" 332! 227! 0105!(032)! 418! 86!(26)!
CHUTE"08" 268! 247! 021!(08)! 150! 0118!(044)!
CHUTE"09" 8! 21! 13!(163)! 21! 13!(163)!
CHUTE"10" 273! 256! 017!(06)! 79! 0194!(071)!
CHUTE"11" 298! 286! 012!(04)! 256! 042!(014)!
CHUTE"12" 316! 333! 17!(5)! 340! 24!(8)!
CHUTE"13" 265! 24! 0241!(091)! 271! 6!(2)!
CHUTE"14" 302! 321! 19!(6)! 302! 0!(0)!
CHUTE"15" 349! 197! 0152!(044)! 262! 087!(025)!
CHUTE"19" 240! 130! 0110!(046)! 236! 04!(02)!
CHUTE"21" 335! 123! 0212!(063)! 280! 055!(016)!
CHUTE"23" 364! 141! 0223!(061)! 290! 074!(020)!
CHUTE"24" 209! 141! 068!(033)! 116! 093!(044)!
CHUTE"25" 125! 38! 087!(070)! 72! 053!(042)!
Mean"score" 257.8! 165.8! 091.9! 202.9! 054.9!
Standard"
deviation"" 101.7! 118.5! 87.2! 115.1! 70.5!
Table'7.10' Endometriosis'Health'ProfileB30'(EHPB30)'(Total)'scores''
The.total.EHPE30.scores.for.each.CHUTE.subject.at.screening,.during.treatment.and.at.
the.end.of. treatment. (EoT).. . The. score. changes. between. screening.&. treatment.and.
screening.and.end.of.treatment.(EoT).are.also.shown...
!
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Figure'7.21' Mean'Endometriosis'Health'ProfileB30'(EHPB30)'(Total)'scores'
EHPE30. results. for. the. CHUTE. cohort. showing. the. mean. total. score. (blue. line). and.
standard.deviation.(vertical.bars).at.screening,.treatment.and.end.of.treatment.(EoT).
(Paired. TEtest:. **p<0.001. between. screening. and. treatment,. *p=0.004. between.
screening.and.EoT,.§p=0.180.between.treatment.and.EoT)..
.
Figure'7.22' Mean'Endometriosis'Health'ProfileB30'(EHPB30)'(Pain)'scores'
EHPE30. results. for. the. CHUTE. cohort. showing. the. mean. pain. score. (blue. line). and.
standard.deviation.(vertical.bars).at.screening,.treatment.and.end.of.treatment.(EoT).
(Paired. TEtest:. **p<0.001. between. screening. and. treatment,. *p=0.005. between.
screening.and.EoT,.§p=0.095.between.treatment.and.EoT)..
0
50
100
150
200
250
300
350
400
Screening Treatment EoT
Mean!CHUTE!EHP030!Total!Score
0
10
20
30
40
50
60
70
80
Screening Treatment EoT
Mean!CHUTE!EHP030!Pain!Score
**!
!
!
CHUTE!Thesis!(1.4)! 0!203!0!
CHANGES(IN(HISTOLOGY(FOLLOWING(ULIPRISTAL(THERAPY(IN(ENDOMETRIOSIS(
(CHUTE)(
EHP030(pain(scores(
The!mean!pain!scores!(51,!26!&!35)!are!illustrated!in!Table!7.11!and!show!a!very!similar!
pattern!to!the!mean!total!scores!but!the!initial!reduction!from!screening!to!treatment!is!
more!profound!reducing!the!mean!score!by!50%!between!screening!the!treatment.!!But,!
the! spread!of!data! remains! similarly!broad!with!the! standard!deviation!17,!22!&!23,!
respectively.!
The!mean!pain!scores!and!standard!deviation!are!shown!in!Figure!7.22!together!with!
the!results!of!the!paired!T0tests.!There!is!significant!score!decrease!between!screening!
and! treatment,! t(17)=! 04.75,! p<0.001;! and! a! significant! score! decrease! between!
screening!and!end!of!treatment,!t(17)=!03.27,!p=0.005;!but!again!a!non0significant!score!
increase!between!treatment!and!endo!of!treatment,!t(17)=!1.77,!p=0.095.!!
EHP030(domains(
The!data!shown!in!Table!7.12!indicate!how!each!of!the!five!EHP030!domains!contribute!
to!the!mean!difference!of!the!total!score.!!The!statistically!significant!reduction!(091.94,!
t(17)=! 04.47! ,p<0.001)! in! total! EHP030! score! between! screening! and! treatment! is!
contributed! to! by! a! statistically! significant! reduction! in! the! pain,! control! &!
powerlessness,!emotional!well0being!and!social!support!domains.!!Of!these,!the!pain!(0
25.17)!and!control!&!powerlessness!(028.56)!domains!make!the!greatest!contribution.!!
The!decrease!in!self0image!score!is!just!outside!statistical!significance!at!p=0.051.!
When! considering! the! non0significant! increase! in! total! EHP030! score! seen! between!
treatment!and!end!of! treatment! (mean!difference!37.06)!we! see! that! the!control!&!
powerlessness! domain! makes! the! biggest,! and! statistically! significant,! contribution!
(mean!difference!13.17,!p=!0.041)!to!that!change.!!All!the!other!domains!show!either!
increases!or!decreases!but!these!were!not!significant!when!tested.!
The!mean!difference!of!the!total!EHP030!score!between!screening!and!end!of!treatment!
remains!statistically!significant!(054.89,!t(17)=!03.30,!p=0.004).!!Again,!this!is!contributed!
to!by!significant!reductions!in!all!the!domains,!except!self0image;!with!pain!and!control!
&!powerlessness!making!the!biggest!difference.
!
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" Screening" Treatment" Screening" <"
treatment"
difference"
(%)"
EoT" Screening"–"
EoT"
difference"
(%)"
CHUTE"01" 41! 0! 041!(0100)! 36! 05!(012)!
CHUTE"02" 45! 0! 045!(0100)! 2! 043!(096)!
CHUTE"04" 59! 43! 016!(027)! 41! 018!(031)!
CHUTE"05" 45! 9! 036!(080)! 23! 022!(049)!
CHUTE"06" 55! 30! 025!(045)! 61! 6!(11)!
CHUTE"08" 66! 34! 032!(048)! 25! 041!(062)!
CHUTE"09" 0! 0! 0!(0)! 5! 5!(0)!
CHUTE"10" 50! 50! 0!(0)! 0! 050!(0100)!
CHUTE"11" 48! 55! 7!(15)! 48! 0!(0)!
CHUTE"12" 68! 73! 5!(7)! 77! 9!(13)!
CHUTE"13" 59! 9! 050!(085)! 50! 09!(015)!
CHUTE"14" 45! 52! 7!(15)! 50! 5!(11)!
CHUTE"15" 64! 34! 030!(047)! 41! 023!(034)!
CHUTE"19" 50! 32! 018!(036)! 57! 7!(14)!
CHUTE"21" 68! 2! 066!(097)! 34! 034!(050)!
CHUTE"23" 66! 14! 052!(078)! 59! 07!(011)!
CHUTE"24" 59! 16! 043!(072)! 11! 048!(081)!
CHUTE"25" 27! 9! 018!(067)! 14! 013!(048)!
Mean"score" 50.9! 25.2! 025.3! 35.2! 015.6!
Standard"
deviation" 16.8! 22.3! 22.4! 22.6! 20.2!
Table'7.11' Endometriosis'Health'ProfileB30'(EHPB30)'(Pain)'scores''
The.EHPE30.pain.scores.for.each.CHUTE.subject.at.screening,.during.treatment.and.at.
the.end.of. treatment. (EoT).. . The. score. changes. between. screening.&. treatment.and.
screening.and.end.of.treatment.(EoT).are.also.shown...The.mean.and.standard.deviation.
of.the.cohort.are.shown.and.represented.in.Figure.7.22.!
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EHP$30'Domains' Treatment$Screening'Difference! EOT'$Treatment'Difference! EOT'$'Screening'Difference!Mean' 95%'CI' P'value*' Mean' 95%'CI' P'value*' Mean' 95%'CI' P'value*'
Pain' "25.17! "36.34,!"13.99! <0.001§! 9.56! "1.85,!20.96! 0.095! "15.61! "25.69,!"5.53! 0.005§!
Control'&'powerlessness' "28.56! "40.60,!"16.52! <0.001§! 13.17! 0.57,!25.76! 0.041§! "15.39! "28.11,!"2.66! 0.021§!
Emotional'well$being' "15.06! "24.81,!"5.30! 0.005§! 6.89! "6.07,!19.85! 0.278! "8.17! "16.30,!"0.04! 0.049§!
Social'support' "10.83! "21.36,!"0.31! 0.044§! "2.72! "17.56,!12.11! 0.703! "13.56! "22.66,!"4.45! 0.006§!
Self$image' "12.44! "24.94,!0.05! 0.051! 10.06! "2.58,!22.69! 0.111! "2.39! "13.16,!8.38! 0.646!
EHP$30'(Total)' "91.94! "135.30,!"48.59! <0.001§! 37.06! "18.88,!92.99! 0.180! "54.89! "89.94,!"19.84! 0.004§!
Table&7.12& Endometriosis&Health&Profile830&(EHP830)&score&analysis&
The$mean$ difference$ between$ screening$ and$ treatment,$ treatment$ and$ end$ of$ treatment$ (EOT),$ and$ screening$ and$ EOT$ for$ the$ pain,$ control$ &$
powerlessness,$emotional$well;being,$social$support,$and$self;image$domains$are$shown$as$well$as$the$results$for$the$total$EHP;30$scores.$$A$paired$T;
test$was$performed$to$compare$the$means$at$each$time$point$to$explore$the$impact$of$ulipristal$acetate$treatment$on$the$EHP;30$scores$of$the$CHUTE$
cohort.$$The$mean,$95%$confidence$interval$(95%$CI)$and$P$value$is$shown$for$each$comparison$(n=$18,$*Paired$T;test,$§=$significant$result$(p<0.05)).
!
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7.5.2! Patients(global(impression(of(change((PGIC)(
The!PGIC!measured!the!cohort’s!views!on!the!clinical! impact!of!the!ulipristal!acetate!
treatment!directly!rather!than!through!QoL!indicators.!!It!also!provided!a!tool!to!define!
good! and! poor! clinical! response,!which! has! been! referred! to! throughout! the! results!
section.! !Section! I!asked!the!subjects!to!describe!their!change! in!activity,! limitations,!
symptoms,!emotions!and!overall!quality!of!life,!related!to!endometriosis!as!compared!
to!beginning!of!study!on!a!scale!of!1!to!7!(see!appendix!10).!!Those!giving!a!score!of!6!or!
7!were!considered!to!have!a!good!clinical!response.!!In!section!II!each!subject!rated!the!
degree!of!that!change,!with!a!score!of!2!or!less!being!taken!as!a!good!response.!!
The!results!for!section!I!and!section!II!are!shown!in!Figures!7.23!and!7.24,!respectively.!!
In! both! sections,! there! are! a! range! of! responses!with! CHUTE! 01,! 06,! 13! and! 21! all!
reporting!a!dramatic!change!as!a!result!of!the!treatment!and!then!others!such!as!CHUTE!
09!&!12!reporting!no!change!in!section!I!and!qualifying!that!in!section!II!as!a!worsening!
of! their! condition.! !Overall! the!median! (IQ)! score! for! section! I!was! 5.5! (3,! 7)! during!
treatment!and!this!increased!to!6.0!(5,!7)!at!the!end!of!treatment;!and!for!section!II!the!
median!score!was!2.5!(1.5,!3.5)!during!treatment!but!this!increased!to!3.0!(1,!3.5)!at!the!
end!of!treatment.!
The!dashed!lines!on!each!bar!chart!indicated!the!division!between!good!and!poor!clinical!
response.!!Using!this!division,!a!total!of!nine!subjects!(CHUTE!01,!02,!05,!06,!13,!15,!19,!
21,!23!&!24)!were!defined!as!good!responders!at!the!end!of!treatment.!!They!all!had!a!
section!I!score!greater!than!or!equal!to!6!and!all!but!CHUTE!23!had!a!section!II!score!less!
than!or!equal!to!2.!!Alternatively,!using!a!section!I!score!of!!!5!and!section!II!score!<5!
(no!change)!to!include!moderate!responders!in!the!group!adds!a!further!four!subjects!
(CHUTE!04,!08,!10,!11),!taking!the!clinical!response!to!14/18!(78%).!
PGIC%score%analysis%
A!Wilcoxon!Signed!Rank!test!was!performed,!the!results!of!which!are!shown!in!Table!
7.13.! ! The! PGIC! scores! for! both! sections! at! both! time! points! are! highly! statistically!
significant!with!p!values!"0.0026.
!
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! Treatment! End!of!Treatment!
Median! IQ! P!value*,±! Median! IQ! P!value*,±!
Section!1! 5.50! 3,7! <!0.0001§! 6.00! 5,7! <0.0001§!
Section!2! 2.50! 1.5,3.5! <0.0001§! 3.00! 1,3.5! 0.0026§!
Table&7.13& Patient&Global&Impression&of&Change&(PGIC)&score&analysis&&
The$ PGIC$median$ scores$ showing$ significant$ change$ during$ treatment$ and$ at$ end$ of$
treatment$ for$both$ sections$of$PGIC$questionnaire.$A$Wilcoxon$Signed$Rank$ test$was$
performed$ to$ explore$ the$ PGIC$ results$ reported$ by$ the$ CHUTE$ cohort.$ $ The$median,$
interquartile$range$(IQ)$and$P$value$is$shown$for$each$section$at$both$time$points$(*Sign$
Test$for$value=1$(No$Change)$for$Section$I,$±Sign$Test$for$value=5$(No$Change)$for$Section$
II),$§=$significant$result$(p<0.05)).
! CHANGES(IN(HISTOLOGY(FOLLOWING(ULIPRISTAL(THERAPY(IN(ENDOMETRIOSIS(
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!
!
a.!Change!in!activity,!limitations,!symptoms,!emotions!and!overall!quality!of!life,!related!to!endometriosis!as!compared!to!beginning!of!study.!!The!
blue!bars!represent!the!patient!views!during!treatment!and!the!grey!bars!represent!the!patient!views!after!treatment!had!discontinued.!!The!dashed!
line!is!the!cut!off!between!good!and!poor!clinical!response!(Scale!of!1?7!with!1=!no!change,!…!7=!a!great!deal!better,!and!a!considerable!improvement!
that!has!made!all!the!difference!(See!appendix!10)).!
Figure'7.23' Patient'Global'Impression'of'Change'(PGIC)'scores>'Section'I'
The$patients’$global$impression$of$change$(Section$I)$compared$to$the$beginning$of$the$study,$during$treatment$and$after$treatment$had$discontinued.$
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!
b.!Degree!of!change!since!beginning!the!treatment!as!part!of!the!study.!!The!blue!bars!represent!the!patient!views!during!treatment!and!the!orange!
bars!represent!the!patient!views!after!treatment!had!discontinued.!!The!dashed!line!is!the!cut!off!between!good!and!poor!clinical!response!(Scale!of!
0?10!with!0=!much!better,…5=!no!change,…10=!much!worse!(See!appendix!10)).!
Figure'7.24' Patient'Global'Impression'of'Change'(PGIC)'scores>'Section'II'
The$patients’$global$impression$of$change$(Section$II)$compared$to$the$beginning$of$the$study,$during$treatment$and$after$treatment$had$discontinued.$
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Chapter(8:!DISCUSSION(
8.1! STUDY(OBJECTIVES(AND(DESIGN(
The! pharmacological! treatment! of! endometriosis! is! becoming! the! mainstay! of!
management!as!specialists!are!realising!that!surgical!management!has! limitations,!as!
discussed!in!Chapter!1.!! ! !Although!conventional!medical!treatments!are!effective!for!
some! there! remains! a! significant! number! of! patients! in! whom! symptom! control! is!
inadequate.!!As!such!the!evaluation!of!new!treatments!that!may!offer!more!effective!
symptom! control! and! broaden! the! range! of! treatment! options! available! must! be! a!
priority!for!the!future!of!endometriosis!management.!
Selective!progesterone!receptor!modulators,!such!as!ulipristal!acetate,!may!be!effective!
in!the!treatment!of!endometriosis!but!the!primary!concern!for!any!evaluation!of!these!
drugs!must!be!patient!safety!and!the! long0term!implications!of!drug!treatment.! !The!
PEARL! studies! that! are! discussed! in! Chapter! 4! highlight! the! progesterone! receptor!
modulator0associate! endometrial! changes! (PAEC)! associated! with! ulipristal! acetate.!!
Whether! these! changes! occur! in! ectopic! endometrium,! whether! they! have! a!
proliferative!effect!at!that!ectopic!location!and!whether!any!PAEC!type!changes!persist!
after!menstrual!shedding!are!all! important!safety!questions!with!respect!to!ulipristal!
acetate!use!in!endometriosis.!
The!aim!of!this!pilot!study!was!to!explore!the!safety!question!whilst!also!considering!the!
clinical! utility! of! ulipristal! acetate! for! the! treatment! of! endometriosis.! ! The! primary!
outcome!measure!was!histological! changes!within! the!ectopic!endometrium!and! the!
decisions!taken!with!regard!to!study!design!have!been!described! in!Section!6.2.! !The!
most! difficult! of! these! was! the! decision! as! to! whether! to! undertake! surgical!
management!whilst!on!study!drug!or!after!the!first!menstrual!loss!following!stopping!
study!drug.!!!
The!initial!design!with!surgery!being!completed!whilst!on!study!drug!may!have!provided!
a! clearer! picture! as! to! the! histological! impact! of! ulipristal! acetate! but! would! have!
provided! no!useful! information!about! the! persistence!of!any!changes!after! stopping!
treatment.! !Whereas!the!six0week!delay! incorporated! in!the!final!design!allowed!the!
!
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assessment!of!both!the!eutopic!and!ectopic!endometrium!following!the!cessation!of!
treatment.!!As!the!expected!prevalence!of!PAEC!in!eutopic!endometrium!is!known!from!
the! PEARL! IV! study,! the! eutopic! changes! could! be! compared! and! then! any! ectopic!
endometrial!changes!evaluated!against!this!baseline.!!!!!!
This!decision!was!taken!following!a!full!and!open!discussion!between!the!study!team!
and!the!scientific!advisory!board!of!Gedeon!Richter,!including!Professor!Alistair!Williams!
(lead! histopathologist! on! the! PEARL! studies).! ! During! that! discussion,! it! was! also!
highlighted!that!a!six0week!delay!would!also!allow!an!evaluation!of!the!persistence!of!
any!clinical!improvement!seen!in!the!study!subjects!after!stopping!treatment.!!Although!
the! clinical! impact! of! ulipristal! acetate! on! endometriosis! symptoms! was! only! a!
secondary!outcome!measure!it!was!still!considered!a!very!important!aim!of!this!pilot!
study!and!so!the!final!study!design!was!agreed.!
The!disadvantage!of!this!decision!is!that!our!samples!of!ectopic!endometrium!were!not!
obtained!whilst!the!study!subjects!were!still!exposed!to!study!drug.!!This!has!made!the!
interpretation!of!the!patterns!of!histopathology!particularly!challenging!and!may!also!
have!rendered!the!immunohistochemical!results!unusable.!!!!!!!!
A!further!consideration!when!designing!the!study!was!the!level!of!secured!funding!and!
how!to!maximise!the!scientific!data!with!the!resources!available.!!The!decision!not!to!
include!a!control!group!in!the!study!was!largely!influenced!by!this!restriction.!!In!an!ideal!
study,!we!would!have!had!a!control!group!as!a!comparator.!!However,!this!would!have!
necessitated!further!recruitment!to!keep!the!treatment!group!at!20!subjects!and!the!
prospect!of!12!weeks!of!no!treatment!prior!to!surgical!management!in!patients!with!
severe!symptoms!may!have!negatively!impacted!on!recruitment.!!!
It!was! felt! that! each! subject! could! act! as! their! own! control!with! respect! to! eutopic!
endometrial!changes!and!that!we!should!maximise!the!number!of!subjects!exposed!to!
study!drug!to!explore!the!ectopic!changes.!!This!has!meant!we!have!had!to!rely!on!the!
known!histological!features!of!endometriosis!as!a!comparator,!which!has!offered!some!
challenges!to!interpretation!of!the!data.!!!!!
!
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8.2! PRINCIPAL(FINDINGS(
The!principle!findings!of!the!study!are!as!follows:!
1)! the!majority!of!subjects!showed!an!improvement!of!their!perceived!disease!as!
a!result!of!involvement!in!the!study!with!a!statistically!significant!reduction!in!
severity! of! pre0menstrual! pain,! menstrual! pain,! non0cyclical! pelvic! pain,!
dyspareunia!and!lower!back!pain!between!screening!and!the!end!of!the!study;!
2)! histological!assessment!of!ectopic!endometrium!was!possible!due!to!the!high!
quality! of! surgical! specimens,! which! were! obtained! without! significant!
mechanical! or! thermal! disturbance! to! the! tissues! resulting! in! minimal!
histological!artefact;!
3)! features!of!PAEC!were!seen!within!eutopic!endometrial!samples!but!no!single!
specimen!exhibited!enough!features!to!be!described!as!confirming!PAEC;!
4)! cystic!dilatation!with!ciliated!metaplasia!and! infrequent!mitoses!was!a!more!
common!finding!within!the!ectopic!endometrium;!
5)! no!clear!abnormalities!of!ectopic!receptor!expression!were!seen!six!weeks!after!
stopping!study!drug!and!the!eutopic!samples!exhibited!typical!cyclical!changes!
in!keeping!with!healthy!endometrium;!
6)! clinical!response!to!ulipristal!acetate!was!seen!in!the!cohort!as!evidenced!by!
statistically! significant! improvements! in! the! validated! EHP030! QoL!
questionnaire!results!through!the!drug!treatment!phase!of!the!study;!
7)! overall,!ulipristal!acetate!treatment!was!considered!acceptable!by!the!cohort!
with!the!median!change!at!the!end!of!treatment!being!assessed!as!‘Better,!and!
a!definite!improvement!that!has!made!a!real!and!worthwhile!difference’.!
These!findings!suggest!that!whilst!questions!remain!with!regards!to!safety!&!efficacy!
ulipristal! acetate! appears! to! be! worth! pursuing! as! a! medical! treatment! for!
endometriosis.!!
8.3! STUDY(COHORT(
Recruitment!of!the!cohort!took!six!months!longer!than!expected!due!to!a!lower!than!
expected!numbers!of! suitable! candidates! to!approach! for! the! study!and! higher! than!
expected!numbers!of!screen!fails.!!The!commonest!reason!for!failing!screening!was!that!
surgical!management!was!no!longer!indicated!or!desired!by!the!patient.!!Although!the!
!
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exclusion!criteria!were!quite!strict!their!impact!on!recruitment!was!minimal0!the!main!
barrier! to! inclusion! being! failure! to! establish! a! regular! menstrual! pattern! after!
discontinuing!hormonal!medication,!which!is!a!known!complication!of!such!medicines.!!!
The! planned! cohort! of! twenty! patients! was! reduced! to! eighteen! by! two! early!
discontinuations!that!were!described!in!Section!7.1.3.!!This!resultant!cohort!of!patients!
was!representative!of!the!endometriosis!population!in!Norfolk!and!tolerated!the!study!
well!with!excellent!adherence!to!the!study!protocol!and!study!procedures.! !The!only!
protocol!deviation!occurred!as!a!result!of!bed!pressures!within!the!Trust!at!the!time!of!
planned!surgery!for!CHUTE!14.!!This!could!not!have!been!predicted!or!avoided!and!is!a!
feature!of!healthcare!provision!within!the!NHS.!!!!
The!mean!age!of!the!study!subjects!was!35,!which!is!in!keeping!with!the!peak!incidence!
of!endometriosis!between!30!and!45!years!of!age.(5)!!The!average!BMI!was!just!within!
the!normal!range!and!the!median!parity!was!one.!!Twenty!percent!of!the!cohort!were!
smokers.!!This!smoking!frequency!is!in!keeping!with!published!data!for!this!age!group!at!
24%.(228)!!The!mean!duration!of!endometriosis!symptoms!was!12!years!suggesting!this!
population!had!either!early!diagnosis!or!earlier!than!average!onset!of!disease!at!23!years!
of!age.!!Unsurprisingly,!some!of!the!subjects!had!previously!undergone!surgery!for!the!
management!of!their!disease.!!!!
8.4! ADVERSE(EVENTS(
In!any!study,!adverse!events!are!to!be!expected!and!these!were!recorded!throughout!
the!study!as!per!good!clinical!practice!(GCP).!!The!most!notable!of!these!was!the!SAE!
(serious! adverse! event)! recorded! for! CHUTE! 17! as! a! result! of! conceiving! between!
stopping!the!study!drug!and!admission!for!surgical!management!of!her!disease.!!This!
occurred!due!to!inadequate!contraceptive!precautions!on!the!part!of!the!patient!despite!
the! need! for! reliable! contraception! being! discussed! in! detail! at! recruitment! and!
reiterated!at!each!study!visit.!
The!implications!of!conceiving!immediately!following!a!course!of!ulipristal!acetate!were!
discussed!once!the!pregnancy!was!confirmed.! !Unfortunately,! there!are! little!data!to!
guide!such!a!discussion,!but!the!information!contained!in!Section!4.6.4!was!explained!to!
the! patient! and! her! partner.! ! The! only! data! pertaining! to! conception! whilst! taking!
ulipristal! acetate! was! within! a! review! of! 18! pregnancies! in! one! of! the! recruitment!
!
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centres!for!PEARL!II!and!III.(211)!!A!single!birth!defect!(ectopic!kidney)!was!noted!in!the!
series,!which!was!explained!to!the!subject!and!termination!of!pregnancy!offered.!!This!
was!declined!and!a!decision!to!prescribe!progesterone!support!during!the!first!trimester!
was!taken!in!view!of!the!theoretical!increased!risk!of!miscarriage.!!!
As!surgical!management!was!no!longer!appropriate,!and!the!data!collected!with!respect!
to!quality!of!life!at!the!end!of!treatment!may!have!been!influenced!by!her!conception!a!
decision!was!taken!to!exclude!all!her!data!from!the!study.!!!
The!other!adverse!events!(AEs)!and!side!effects!recorded!are!described!in!section!7.1.6.!!
They!were!all!mild!to!moderate,!in!keeping!with!the!frequency!recorded!in!the!summary!
of! product! characteristics! (SmPC)! (95.0%).(189)! ! Headache! was! reported! most!
frequently! as! is! seen! with! patients! using! ulipristal! acetate! for! the! management! of!
fibroids!but!this!resolved!within!the!first!seven!days!for!all!the!subjects!in!the!study.!!In!
addition,!the!following!common!(<1/10)!adverse!reactions!recorded!in!the!SmPC,!such!
as!skin!changes,!abdominal!pain,!hot!flushes,!weight!gain!and!vertigo,!were!experienced!
by!the!cohort.!!And,!some!uncommon!(<1/100)!reactions!were!also!seen!–!constipation,!
mood! disturbance,! vaginal! discharge,! alopecia,! urinary! incontinence! and! dizziness.!!
None!of!the!recorded!AEs!were!considered!serious!or!raised!significant!safety!concerns.!
8.5! CLINICAL(
The!management!of!endometriosis!is!centred!round!symptom!control,!be!that!through!
simple!analgesia,!hormonal!suppression!or!surgical!excision!of!disease.!!We!know!that!
the!clinical!appearance!of!disease!does!not!always!correlate!with!the!pain!symptoms!
experienced!by!patients;!and!that!staging!and!classification!systems!such!as!ASRM!are!
imperfect! when! used! as! clinical! indicators.! ! However,! visual! inspection! of! disease!
remains!an!important!part!of!clinical!assessment!and!the!ASRM!classification!is!widely!
accepted!amongst!researchers.(45)!These!were!both!used!to!describe!and!evaluate!the!
CHUTE!cohort!and!ascertain!the!impact!of!ulipristal!acetate.!!
8.5.1! Symptom(control(
A! good! clinical! response! was! seen! in! 56%! of! the! cohort! following! treatment! with!
ulipristal!acetate;!with!ten!of!the!eighteen!giving!a!score!of!6!or!7!in!section!I!of!the!PGIC!
questionnaire.!!However,!the!symptom!control!seen!as!a!result!of!the!CHUTE!study!was!
!
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a!combination!of!the!drug!treatment!and!the!surgical!clearance!of!disease.!!The!results!
of!the!BSGE!Pelvic!Pain!Questionnaire!(BSGE0Qu)!were!used!to!demonstrate!this.!
The!five!classic!symptoms!of!endometriosis0!dysmenorrhoea,!non0menstrual!pelvic!pain,!
dyspareunia,!dysuria!and!dyschezia,!were!assessed!at!the!outset!and!all!but!dysuria!had!
high!median!scores!for!severity.!!When!these!symptoms!were!enquired!about!at!the!end!
of!treatment!they!had!become!less!frequent,!but!they!were!not!formally!assessed!with!
the!BSGE0Qu!until!the!post0operative!review,!3!months!after!surgery.!!This!showed!that!
although! the! frequency! of! dysmenorrhoea! and! non0menstrual! pelvic! pain! had! not!
altered!a!great!deal!the!frequency!of!the!other!symptoms!had!decreased!markedly,!with!
dyspareunia!reducing!from!14!to!6!subjects!within!the!cohort.!!This!was!not!a!surprise!
as!it!is!these!symptoms!that!often!respond!to!surgical!management.!!!
Interestingly,!whilst!dysmenorrhoea!and!non0menstrual!pelvic!pain!remained!common!
within! the! cohort! at! the! end! of! the! study! the! median! scores! for! severity! were!
significantly! improved.! ! Taken! together! these! data! suggest! that! the! combination! of!
ulipristal!acetate!treatment!and!surgery!had!a!positive!impact!on!symptom!control!but!
without!a!control!group!it!is!not!possible!to!assess!whether!such!improvement!would!be!
seen!with!surgery!alone.! ! The!observed! improvement! in! clinical! symptoms! is! further!
supported!by!the!fact!that!analgesia!use!decreased!by!44%!within!the!cohort.!
As!the!study!progressed!it!was!clear!that!there!were!some!subjects!in!whom!the!study!
drug!had!very!little!impact.!!The!PGIC!questionnaire!allowed!a!distinction!to!be!made!
between! good! responders! and! those!who!had! little! or! no! improvement.! !Using! this!
division,! it!was!possible!to!see!if! the! initiation!of!amenorrhoea!was!related!–! i.e.!are!
those! whom! are! not! amenorrhoeic! less! likely! to! show! improvement! of! symptoms.!!
Amenorrhoea! is! expected! in! 79%! of! users(189),! and! occurred! in! 83%! of! the! CHUTE!
subjects.! ! However,! three! subjects! continued! to! cycle! throughout! the! study,! two! of!
whom! showed! an! excellent! clinical! response! to! the! drug.! ! This! suggests! that!
amenorrhoea!cannot!be!relied!upon!as!a!marker!of!biological!action!in!endometriosis!
and!that!the!action!of!the!drug!is!doing!more!than!just!preventing!menstruation!and!so!
improving!dysmenorrhoea!by!default.!
!
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8.5.2! Disease(status(
The!ASRM! classification! of! disease!was! used! to! define! the! disease! at! the! diagnostic!
procedure!prior!to!recruitment!and!compare!this!to!the!disease!status!at!the!time!of!
surgical!excision.!!The!mean!score!of!20!(median!stage!II)!did!increase!by!nine!points!to!
a!mean!score!of!29!(median!stage!III)!suggesting!a!worsening!of!disease.!!However,!it!
should!be!noted!that!there!was!a!mean!time!interval!of!24!months!(range!7062!months)!
during!which!time!progress!of!disease!would!be!expected.!!As!such,!the!design!of!the!
CHUTE!study!does!not!allow!a!causative!assessment!of!this!progression!of!disease;! it!
may!have!been!secondary!to!drug!therapy,!indicating!a!proliferative!impact!of!ulipristal!
acetate!or!it!may!represent!the!known!deterioration!of!disease!over!time.!
Disease&type&
As! endometriosis! exists! in! three! clinically! distinct! forms:! peritoneal! disease,!
endometriomas! and! deeply! invasive! disease(4),! and! peritoneal! disease! can! have! a!
different!histological! appearance! to!more!deeply! invasive! tissue,! it!was! important! to!
ensure!a!broad! range!of! surgical! specimens!were!obtained!and!evaluated.! ! This!was!
achieved,!with!a!total!of!111!specimens!and!a!good!anatomical!spread!of!biopsy!sites.!!
In! addition,! the! frequency! of! occurrence! at! each! location!was! in! keeping!with! that!
expected!of!patients!with!severe!endometriosis,!giving!further!reassurance!about!how!
representative!the!cohort!was.!!!
The!subset!of!biopsies!used!for!the!immunohistochemistry!was!similarly!broad!with!no!
anatomical!location!overlooked!and!a!range!of!tissue!types!included.!!The!peritoneum!
over!the!uterovesical!fold!often!contains!more!superficial!disease,!which!was!utilised!for!
the!IHC!in!five!out!of!the!eighteen!cases!due!to!the!higher!quality!of!this!tissue.!!The!ease!
of!surgical!access!may!explain!this!but!it!may!have!resulted!in!the!data!being!skewed!
towards!a!more!superficial!type!of!peritoneal!disease.!!!!!
8.5.3! Surgical(findings(
The!three!different!types!of!disease!were!seen!represented!in!the!CHUTE!cohort!and!are!
described! in! section! 7.2.6.! ! The! most! interesting! finding! was! the! active,! “angry”!
appearance!of!the!peritoneal!disease!seen!in!four!of!the!cohort.!!It!was!most!notable!in!
CHUTE!06!where!it!appeared!to!be!stuck!to!the!posterior!surface!of!the!uterus.!!When!
examined! under! the! microscope! this! tissue! was! largely! indistinguishable! from! the!
eutopic!endometrium!with!similar!immunohistochemistry!for!both!tissue!types.!
!
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Concern!about!the!impact!of!SPRMs!on!ectopic!endometrium!and!the!possibility!of!a!
proliferative! effect,! particularly! in! the! Pouch! of! Douglas! have! been! raised! through!
various!personal!communications!with!the!author.!!Whether!the!changes!seen!in!these!
four!subjects!support!these!concerns!is!difficult!to!assess.!!Using!the!ASRM!classification!
there!appears!to!be!minimal!progression!in!score!over!a!time!period!of!7020!months!but!
the!disease!in!these!subjects!does!appear!to!be!more!active!and!erythematous.!!It!is!not!
possible!to!say!if!this!is!a!variant!of!endometriosis!or!as!a!result!of!drug!therapy,!but!it!
does!raise!the!suspicion!that!ulipristal!acetate!is!associated!with!proliferation!within!the!
ectopic! endometrium.! ! The! histological! and! histochemical! assessment! of! the! biopsy!
material!from!these!subjects!was!unremarkable!with!respect!to!the!rest!of!the!cohort!
and!so!offered!no!further!reassurance!or!cause!for!concern.!
Further!evidence!of!possible!proliferation!was!seen!in!CHUTE!15.!!Although!this!subject!
exhibited!less!of!the!angry!erythematous!peritoneal!disease,!she!still!showed!a!950point!
score!increase!over!the!course!of!seven!months.!!This!was!the!result!of!the!rapid!growth!
of!three!endometriomas!0!two!in!the!right!ovary!and!one!in!the!left!ovary!resulting!in!
obliteration!in!the!Pouch!of!Douglas.!!!!!!!!!
The!questions!this!raises!are:!
1)! Are!these!proliferative!changes!related!to!ulipristal!acetate?!
2)! If!they!are,!do!they!persist!after!stopping!ulipristal!acetate?!
3)! If!they!persist,!are!the!changes!cumulative?!!
4)! What! impact! do! these! changes! have! on! the! symptoms! experienced! by! the!
patient?!!!
However,!it!should!be!noted!that!in!the!two!most!notable!cases!described!above!a!good!
clinical! response! to! study! drug! was! noted! with! the! symptoms! of! endometriosis!
improving!through!treatment.!!If!the!underlying!disease!changed!as!a!result!of!30months!
of!ulipristal!acetate!this!did!not!translate!to!a!deterioration!of!endometriosis!symptoms!
or!a!failure!to!control!baseline!symptoms.!
!
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8.6! HISTOPATHOLOGY(
The!argument!to!support!the!use!of!SPRMs!in!endometriosis!has!been!set!out!in!section!
4.6.1.! In! summary,! these! drugs! have! the! potential! to! suppress! the! endometrium!&!
inhibit!ovarian!progesterone!production!without!leading!to!the!side!effects!of!oestrogen!
deprivation.! !Consequently,! they!may!offer!a!more!tolerable!management!option!for!
patients!with!endometriosis!as!compared!to!GnRH!analogues.!!However,!the!key!to!this!
potential!is!understanding!and!exploring!the!histological!impact!of!such!compounds!with!
respect!to!PRM0associated!endometrial!changes!(PAEC).!
Unfortunately,! there! is! no! classic! histopathological! appearance! of! endometriosis! so!
evaluating!the!histological!impact!of!a!treatment!such!as!ulipristal!acetate!is!difficult.!!
The!disease!is!defined!as!epithelial!and!stromal!endometrial!cells!in!an!ectopic!location!
with!inflammatory!infiltrates!and!associated!fibrosis.(2)!!!The!histological!features!are!
variable! between! patients,! can! be! variable! within! the! same! specimen! and! are!
sometimes!congruous!with! the!eutopic!endometrium,!but!not!always.! !Overall,! they!
tend!to!have!an!irregular!proliferative!rather!than!secretory!pattern!and!often!contain!
dilated!glands!with!inactive!epithelial!cells!demonstrating!ciliated!metaplasia.!
Given! this! heterogeneity! of! appearance! the! opinion! of! the! two! consultant!
histopathologists!involved!has!become!paramount.!!The!system!of!utilising!more!than!
one!histopathologist!and!obtaining!a! consensus! opinion!was!employed! in! the!PEARL!
studies.! ! Similar! to! those! studies! the! sample! processing! and! reporting! criteria! were!
defined! before! any! samples! were! viewed! (see! Histopathology! Report! Proforma!
(Appendix!25))!and!each!histopathologist!viewed!and!reported!the!slides!in!a!blinded!
and!independent!fashion.!!!!!!!
A!decision!about!whether!certain!observations!were!significant!or!not!and!whether!the!
ulipristal!acetate!had!affected!the!histology!of!the!endometrium!was!heavily!influenced!
by!their!expert!opinion.!!The!use!of!standardised!reporting!and!defined!features!of!PAEC!
helped!in!the!analysis!but!histopathology!is!often!about!pattern!recognition!based!on!
years!of!experience,!so!their!overall!impression!was!also!viewed!as!scientifically!valid.!
There! were! high! levels! of! agreement! between! Dr! Lonsdale! and! Professor! Williams!
throughout!the!histological!analysis.! !The!reporting!of!PAEC!features!for!eutopic!and!
ectopic! endometrium! are! shown! in! Table! 7.8,! with! Kappa! and! overall! agreement!
!
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statistics!to!illustrate!levels!of!agreement.!!The!Kappa!statistic!was!found!to!be!unreliable!
for!this!data!set!and!so!the!overall! level!of!agreement!across!the!whole!data!set!was!
used.!!It!demonstrated!strong!or!moderate!agreement!for!five!of!the!six!PAEC!domains!
for! eutopic! endometrium! reporting! and! three! out! of! five! PAEC! domains! for! ectopic!
endometrium! reporting.! ! This! level!of!agreement!between! two!experts!adds! further!
weight!to!the!conclusions!drawn!about!histopathological!changes.!
Some!subtle!differences!existed!between!their!reports,!but!their!overall!impression!was!
that!no!specimen!of!either!eutopic!or!ectopic!endometrium!exhibited!all!the!features!of!
PAEC;! or! showed! features! of! hyperplasia,! endometritis! or! neoplasia.! ! This! is! a! key!
conclusion!for!the!on0going!investigation!of!ulipristal!acetate!with!respect!to!safety.!
8.6.1! PAEC(type(changes(
The!PAEC!features!seen!in!the!eutopic!endometrium!were!compared!to!the!published!
data!from!PEARL!I!and!II!(197,198)!to!put!them!into!context.!!The!pattern!of!features!
seen! in! the! CHUTE! cohort! was! clearly! different! with! cystic! dilatation,! cytoplasmic!
vacuolation!and!stromal!vascular!changes!all!being!less!common!than!was!seen!in!PEARL!
I&II.! !However,! it!should!be!noted!that!the!PAEC!features!reported! in!the!PEARL! I&II!
studies!were!assessed!whilst!the!study!subjects!were!taking!ulipristal!acetate.!!Whereas!
the!CHUTE!samples!were!obtained!six!weeks!after!completion!of!study!drug.!!!
A!more!accurate!comparison!would!be!the!data!from!PEARL!III!&!PEARL!IV,!where!non0!
physiological! changes!were! seen! in!26%!&!16%!of! the! subjects!10018!days!after! first!
menstruation!following!treatment!cessation.(199,200)!Our!data!for!PAEC!type!changes!
are!much!more!in!keeping!with!this!frequency!and!suggest!that!any!changes!that!occur!
in! response! to! ulipristal! acetate! normalise! quickly! after! menstrual! shedding.! ! This!
recovery! of! functionality! would! be! supported! by! the! unremarkable! nature! of! the!
immunohistochemistry!data!in!the!cohort!and!the!successful!implantation!of!an!embryo!
for!CHUTE!17!within!10!days!of!completing!the!study!drug.!
Although!no!subject!had!all!the!histological!features!consistent!with!PAEC,!CHUTE!08!
showed! clear! cystic! dilatation! and! vascular! changes! that! were! consistent! with! it.!!
However,!the!most!unusual!changes!seen!were!the!metaplastic!changes!exhibited!by!
CHUTE!14.!!Whether!these!observations!are!secondary!to!drug!action!is!impossible!to!
know.! !The! subject! showed!vascular! changes,! typical!of!PAEC,! suggesting! some!drug!
!
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related!action!on!the!histology!but!attributing!the!unique!epithelial!changes!seen!in!this!
subject! to! ulipristal! acetate! may! not! be! appropriate,! as! it! is! a! single! observation.!!
Interestingly,! no! metaplastic! changes! were! seen! in! the! ectopic! samples! and! cystic!
dilatation!was!only!noted!in!one!of!the!four!specimens.!
When!the!PAEC!type!features!were!used!to!compare!the!eutopic!and!ectopic!samples!
there!was!a!marked!difference.!!Cystic!dilatation!with!ciliated!metaplasia!of!the!epithelial!
cells!is!much!more!prevalent!in!the!ectopic!samples.!!The!epithelial!cells!appear!inactive!
with!cuboidal!shaped!cells,! infrequent!mitoses!and!no!evidence!of!secretory!activity.!!
This! finding!may! just!represent!the!typical!appearance!of!endometriosis!or!may!be!a!
response!to!ulipristal!acetate.!!The!impression!from!both!histopathologist!was!that!the!
ectopic!samples!were!in!keeping!with!their!expectations!for!endometriosis!but!they!each!
noted!that!the!cystic!dilatation!was!a!more!prominent!feature!within!the!samples!than!
they!were! expecting.! ! It! is! difficult! to! assess! this! feature! in! isolation! as! samples! of!
endometriosis!in!normal!clinical!practice!tend!to!contain!more!surgery!artefact!and!are!
evaluated!in!a!less!detailed!manner,!making!the!known!‘control’!difficult!to!define!for!
this!tissue!type.!
Four!of!the!subjects!showed!florid!disease!at!surgical!inspection.!!The!active!appearance!
of! the! disease! raised! concern! about! whether! the! ulipristal! acetate! had! caused! a!
proliferative! type! change! in! the! ectopic! endometrium.! ! The! ectopic! samples! did!
demonstrate!cystic!dilatation!but!no!other!PAEC!type!features!and!they!did!not!differ!
significantly!from!other!samples!obtained!from!more!standard!looking!endometriosis.!
Some!of!the!subjects!exhibiting!these!florid!changes!reported!a!good!response!to!the!
study! drug! with! respect! to! symptoms! and! EHP030! scores,! and! others! did! not.!!
Interestingly,! the!Ki67! IHC! in! the!epithelial! cells! for! these! subjects!was!prominent! in!
some!cases!and!minimal!in!others.!!This!pattern!did!not!correlate!to!whether!the!subject!
showed!a!good!clinical!response.!!As!such!the!active!appearance!of!the!disease!does!not!
appear!to!be!associated!with!either!a!histological!or!clinical!worsening!of!disease,!over!
the!time!course!of!the!study.!
Of! note,! the! florid! peritoneal! disease! described! above! and! the! samples! from! those!
subjects!with!severe!invasive!disease!resulting!in!a!frozen!pelvis!did!not!appear!to!differ!
significantly.! ! Although!we! consider! peritoneal! disease,! ovarian! endometriomas! and!
deeply!invasive!disease!as!three!different!forms!of!the!disease!that!behave!differently!
!
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with! respect! to! our! conventional!management! options,! histologically! they! appeared!
quite! similar!within! this! cohort.! ! ! This!uniformity!may!be!helpful!when!assessing! the!
clinical!impact!and!safety!of!ulipristal!acetate!for!endometriosis!in!future!studies!as!the!
surgical!sub0types!may!not!need!to!be!considered!separately.!
8.6.2! Cystic(dilatation,(PAEC(and(safety(
Cystic!dilatation!is!an!easily!identifiable!histological!feature!but!as!it!is!a!feature!of!both!
PAEC! and! untreated! endometriosis,! using! it! to! evaluate! PAEC! within! ectopic!
endometrium!is!challenging.!!However,!the!prevalence!of!these!changes!was!noted!to!
be!higher!in!the!CHUTE!subjects!than!the!histopathologists!were!expecting!suggesting!
this!might!be!the!result!of!drug!action.!!This!raises!the!interesting!question!as!to!whether!
such! changes! relate! to! the! clinical! impact! of! the! drug! or! are! just! a! consequence! of!
ulipristal!acetate!exposure.!
The!proportion!of!ectopic!endometrium!samples!demonstrating! cystic!dilatation!was!
compared! between! the! responders! and! non0responders.! ! There! was! no! significant!
difference!between!the!groups!using!an!independent!T!test!(t(16)=!1.74,!p=!0.10)!but!
there!appears!to!be!a!trend!towards!significance.!!As!the!sample!size!is!only!small!this!
finding! may! suggest! an! association! between! cystic! dilatation! and! a! positive! clinical!
response!to!ulipristal!acetate!that!the!study!is!underpowered!to!demonstrate.!
If!we! assume! that! the! observation! of! the! histopathologists! is! accurate! and! ulipristal!
acetate!is!causing!a!degree!of!cystic!dilatation.!The!association!between!clinical!response!
and!that!dilatation!suggests!cystic!dilatation!of!the!glands!may!pay!a!part!in!the!drug!
action! in! endometriosis.! ! As! such! the! establishment! of! PAEC! within! the! ectopic!
endometrium!could!be!viewed!as!a!positive!rather!than!a!cause!for!concern.!!However,!
safety!must!be!a!priority!and!the!potential!for!such!PAEC!type!changes!to!evolve!into!
proliferative!or!suspicious!changes!within!endometriotic!deposits!needs!much!greater!
evaluation.!!!!!!!
The!key!consideration!for!safety!is!the!fact!that!menstrual!shedding!does!not!occur!in!
the!same!way!it!does!within!the!eutopic!endometrium.!!Some!menstrual!breakdown!of!
the!tissues!can!occur!within!ectopic!deposits,!but!those!tissues!are!not!completely!lost!
as!they!are!within!menstrual!flow.!!As!such,!any!changes!with!the!tissue!related!to!drug!
action!could!accumulate!during!drug!treatment!and!then!persist!after!drug!cessation.!!If!
!
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multiple!courses!of!ulipristal!acetate!are!taken!as!per!the!current!medial!licence!those!
PAEC! type!changes!may!become!cumulative!and! result! in!hyperplastic! type!changes.!!
However,!some!reassurance!can!be!taken!from!the!PEARL!III!data.!!During!that!study!
multiple!courses!of!ulipristal!acetate!were!given!and!no!cumulative!effect!in!the!eutopic!
endometrium! was! demonstrated.! ! In! fact! the! frequency! of! PAEC! decreased! slightly!
following!four!repeated!doses.(199)!
Although!confidence!is!building!that!PAEC!is!not!a!pre0cursor!to!endometrial!hyperplasia!
or!endometrial!cancer!in!eutopic!endometrium!it!is!difficult!to!be!as!reassured!about!the!
safety! in! ectopic! endometrium! without! further! evidence.! ! The! PAEC! type! changes!
observed!in!the!eutopic!endometrium!of!the!CHUTE!subjects!has!been!consistent!with!
the! expected! changes! from! previous! studies,! whereas! the! changes! seen! in! ectopic!
endometrium! have! shown! less! secretory! and! stromal! vascular! changes! but! a! much!
higher! frequency! of! cystic! dilatation! with! ciliated! metaplasia.! ! As! such! we! cannot!
conclude!that!the!eutopic!and!ectopic!endometrium!behave!in!the!same!manner!under!
the! influence! of! ulipristal! acetate.! ! Consequently,! there! is! insufficient! evidence! to!
support! the! use! of! eutopic! endometrial! sampling! as! a! safety! assessment! in! those!
subjects!with!endometriosis.!
It!must!be!noted!that!the!heterogeneity!of!the!histopathological!appearance!of!ectopic!
endometrium!together!with!the!design!of!the!study!have!hampered!interpretation.!!The!
histological!features!of!endometriosis!are!not!well!defined!and!there!is!huge!inter0!and!
intra0subject! variation,!preventing! the!establishment!of!a! normal!baseline! in!a! study!
such!as!CHUTE.! !When!combined!with!the!six0week! lag!between!drug!treatment!and!
obtaining!the!ectopic!endometrial!biopsies!there!are!too!many!variables!to!be!certain!
about!any!conclusions!with!respect!to!histopathological!changes!in!response!to!ulipristal!
acetate.!!This!confounder!must!be!addressed!in!any!future!studies.!!
8.7! IMMUNOHISTOCHEMISTRY(
Immunohistochemistry! is! not! extensively! utilised! during! routine! assessment! of!
endometriosis.!!The!diagnosis!tends!to!be!dependent!on!the!histological!features!rather!
than!expression!of!receptors,!but!when!doubt!exists!the!stromal!marker!CD10!is!used!to!
aid!the!diagnosis.!
!
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Normal!eutopic!endometrium!tends!to!show!minimal!ER!and!PR!expression!in!the!early!
proliferative!phase,!which!is!largely!oestrogen!dependent.!!Once!in!the!mid!proliferative!
phase!ER!and!PR!expression!increases!as!does!Ki067.(71)!The!expression!of!all!of!these!
then!decreases!in!the!secretory!phase.!However,!this!pattern!does!not!seem!to!be!true!
in! the! eutopic! endometrium! of! endometriosis! patients,! who! have! demonstrated!
significant!variation!in!PR!expression!with!no!cycle!dependent!pattern.(94)!!!
Endometriosis! and! endometrial! hyperplasia! are! both! oestrogen! dependent! &!
proliferative!conditions!that!can!be!treated!with!continuous!progesterone!therapy.!!This!
treatment!leads!to!a!reduction!in!PR!expression!and!promotes!an!increase!in!the!PR0
A:PR0B!ratio,!helping!to!counter!oestrogen!driven!proliferation!of!the!endometrium.!!As!
such!an!increase!in!PR!expression!within!tissues!would!raise!the!suspicion!of!proliferative!
changes!within!the!tissues!being!evaluated.(82)!!Whereas!a!decrease!in!PR!expression!
within!a!sample!may!be!indicative!of!endometrial!suppression.!
There!is!also!evidence!that!anti0progestins!such!as!ulipristal!acetate!may!exert!their!anti0
proliferative!effect!on! the!endometrium!by! influencing!AR!expression,!which! in! turn!
causes!a!reduction!in!PR!expression.!(92,97)!!As!such!a!reduction!in!PR!expression!&!Ki0
67,! together!with! an! increase! in! AR! expression!within! the! tissue! could! be! taken! as!
evidence! of! drug! action.! Whether! such! changes! would! also! occur! within! ectopic!
endometrium!was!uncertain!but!high!levels!of!variability!were!expected.!
8.7.1! Oestrogen(and(progesterone(receptors(
There!was!strong!positive!staining!across!both!cell!types,!in!both!tissue!types.!!There!was!
no! clear! cycle! dependent! expression! other! than! a! suggestion! of! slightly! reduced!
expression!of!ER!and!PR,!particularly!in!the!eutopic!tissue,!in!the!first!three!days!of!the!
cycle.! ! This! reduced! expression! in! the! early! proliferative! phase!was! in! keeping!with!
expectations!but!the!reduced!expression!that!would!also!be!expected!in!the!secretory!
phase!was!not!demonstrated.!!It!is!unclear!whether!this!is!an!upregulation!of!expression,!
resulting!from!drug!action,!or!the!result!of!strong!antibody!binding!that!prevented!subtle!
differences!in!expression!being!identified.!
8.7.2! Androgen(receptor(&(KiT67(proliferation(marker(
The!expression!of!the!AR!in!the!endometrium!is!known!to!be!reduced!when!compared!
to!ER!and!PR!and!tends!to!be!more!marked!in!stromal!cells.!!This!was!seen!in!the!CHUTE!
!
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subjects!where!both!eutopic!and!ectopic! stromal!expression!was! strong!and! did!not!
appear! to! be! influenced! by! the! phase! of! the! cycle.! ! A! clearer! cyclical! pattern! of!
expression!was!seen!in!the!eutopic!epithelial!cells;!with!increasing!AR!expression,!up!to!
the!mid0proliferative!phase!of!the!cycle!followed!by!decreasing!expression!through!to!
the!mid0secretory!phase.! !After!this!the!AR!expression!began!to! increase!again.! !The!
possible!link!to!ulipristal!acetate!and!the!clinical!significance!of!this!is!unknown.!!!!!!!
The!expression!of!Ki67!should!increase!through!the!proliferative!phase!in!response!to!
rising! oestrogen! levels! and! then! decrease! in! the! secretory! phase! when! mitosis! is!
less.(103)!!This!is!the!pattern!that!was!observed!within!the!eutopic!endometrium!with!
the!peak!of!expression!occurring!slightly!later!in!the!epithelial!cells!as!compared!to!the!
stromal!cells.!!A!similar!pattern!of!cyclical!expression!was!not!seen!in!the!ectopic!cells.!!
In! those,! there!appeared! to! be!more! uniform!expression!of!Ki067,!particularly! in! the!
epithelial!cells;!in!keeping!with!known!data!on!the!association!between!Ki067!expression!
and!stage!of!disease.!(100)!!
There!did!not!appear!to!be!a!correlation!between!AR!and!Ki067!expression,!and!clinical!
response!to!ulipristal!acetate.! !The!comparison!of!responders!and!non0responders!at!
different!points!in!the!menstrual!cycle!did!not!reveal!an!interpretable!pattern!that!could!
be!used!to!comment!on!study!drug!action.!!As!with!the!H&E!observations!the!six!weeks!
off!study!drug!before!obtaining!tissue!samples!has!hampered!interpretation.!!
8.7.3! PTEN(&(VEGF(
The! expression! of! PTEN! within! endometrial! cells! should! be! uniform.! ! Although! the!
occasional!null!gland!can!be!seen!any!significant! loss!of!PTEN!expression!would!be!a!
marker!of!early!hyperplastic!changes.!!Within!the!CHUTE!cohort!no!significant!pattern!
of!loss!of!PTEN!expression!was!seen.!!However,!a!heterogeneous!pattern!of!positive!and!
negative! glands!was! noted! in! the! eutopic! endometrium! of! CHUTE! 09.! ! This! did! not!
correlate!with!similar!changes!in!the!ectopic!endometrium!of!this!subject.!!The!ectopic!
sample!showed!uniform!staining!in!keeping!with!all!the!other!subjects.!!This!pattern!of!
expression!in!the!eutopic!endometrium!of!CHUTE!09!is!of!uncertain!significance.!
Similarly,!the!VEGF!immunohistochemistry!staining!was!unremarkable.!!The!eutopic!and!
ectopic!endometrial!tissues!showed!uniform!epithelial!and!stromal!staining!irrespective!
of!cycle!day.!!!
!
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Overall,! the! significant! reductions! in!PR!and!Ki067!expression!expected!as!a! result!of!
ulipristal!acetate!were!not!seen!but!evidence!of!significant!proliferation!was!also!not!
demonstrated.!!The!eutopic!tissues,!in!particular,!showed!typical!cyclical!changes!and!
there!was! little!to!suggest!any!residual!drug!effect.! !This!may!have!been!because!no!
changes!occurred!but!more!probably!is!a!consequence!of!the!six0week!delay!between!
completing!the!medication!and!the!samples!being!obtained,!allowing!the!normalisation!
of!any!drug!related!changes!in!receptor!expression.!!!
8.8! QUALITY(OF(LIFE(
One!of!the!secondary!objectives!of!the!study!was!to!assess!the!change!in!disease!severity!
as!a!result!of!treatment.!!The!EHP030!questionnaire!was!used!to!provide!an!assessment!
of!the!impact!of!the!disease!at!three!different!time!points,!thus!illustrating!changes!in!
quality!of!life!as!a!result!of!ulipristal!acetate!treatment.!
The!total!scores!given!by!the!subjects!suggested!the! impact!of!the!disease! improved!
significantly!(t(17)=!04.47,!p<0.001)!by!the!end!of!the!treatment!course.!!Following!the!
cessation!of! treatment! some!of! that! improvement!was! lost!but! the! increase! in! total!
score! was! not! statistically! significant! over! that! 60week! period.! ! As! such! the! score!
decrease! between! baseline! and! end! of! treatment,! just! prior! to! surgery,! was! still!
significant! (t(17)=! 03.30,! p=0.004).! ! Given! the! small! sample! size! these! data! are! very!
encouraging.!
The!breakdown!of!all!five!domains!of!the!EHP030!(shown!in!Table!7.13)!questionnaire!
shows!that!the!study!drug!is!having!a!positive!impact!across!a!range!of!domains.!!Pain!
and,!control!&!powerlessness!make!the!biggest!contribution!but!the!emotional!well0
being! and! social! support! domains! also! significant! contributions! to! the! final! result.!!
However,!an!assessment!of!effective!pain!control!when!evaluating!a!new!treatment!for!
endometriosis!is!paramount.!!Happily,!the!pain!domain!scores!reported!by!the!cohort!
were!very!much!in!line!with!the!total!scores;!demonstrating!a!significant!drop!in!the!pain!
domain!scores!between!screening!and!treatment,!which!was!then!maintained!after!the!
cessation!of!treatment.!
The!IMMPACT!recommendations!for!chronic!pain!clinical!trials!suggest!a!reduction!in!
pain!scores!of!30%!should!be!taken!as!significant.(229)!!The!data!from!the!pain!domain!
of!the!EHP030!questionnaire!shows!that!12!subjects!have!a!>30%!reduction!in!their!pain!
!
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score!whilst!on!the!study!drug!and!that!9!subjects!have!a!>30%!reduction!in!their!pain!
scores!in!the!six!weeks!following!drug!cessation.!
The!patient!global!impression!of!change!(PGIC)!median!scores!during!the!final!week!of!
treatment! and! 60weeks! after! treatment! suggested! a! significant! change! in! ‘activity,!
limitations,! symptoms,! emotions! and! overall! quality! of! life’! as! a! result! of! ulipristal!
acetate.!!The!degree!of!that!change!was!reported!to!be!an!improvement!for!all!but!2!
subjects.!!The!scores!in!both!sections!for!both!time!points!were!statistically!significant!
and!also!allowed!a!distinction!between!good!and!poor/no!clinical!response.!!Using!this!
division,!14!showed!some!response!to!treatment!and!a!total!of!10!were!classified!as!
showing!a!strong!response.!!Whereas!four!showed!little!or!no!response.!!For!those!who!
showed!little!clinical!response!there!did!not!appear!to!be!any!predictors!of!this;!be!it!
disease! location,! depth! of! disease,! histological! make! up! of! tissues! or! receptor!
expression.! ! For! those! who! experienced! improvement,! it! was! often! dramatic! with!
subjects!reporting!that!they!“have!their!life!back”!or!“feel!normal!again”.!!One!subject!
explained! that! ulipristal! acetate!was! the! first! treatment! she! had! tried! “that! actually!
worked”!and!was!desperate!to!continue!the!drug!even!after!the!study!was!complete.!
The! questionnaire! data! also! suggest! that! subjects! experienced! sustained! pain! relief,!
even!after!the!study!drug!was!discontinued.!!This!could!suggest!some!residual!endocrine!
suppression!or!altered!inflammatory!response!as!a!result!of!treatment!but!the!design!of!
the!study!does!not!allow!any!further!assessment!of!these!factors.!
8.9! LIMITATIONS(
As!a!small!pilot!study,!the!size!of!the!cohort!is!an!obvious!limitation.!!The!small!numbers!
make! spotting! patterns! of! histological! features! difficult! and! limit! the! validity! of! any!
statistical! test! performed! to! explore! questionnaire! date.! ! The! original! cohort! size! of!
twenty!subjects!was!chosen!to!be!in!line!with!other!pilot!studies!in!this!area;!and!was!
considered!appropriate!given!the!study!objectives.!
The!decision!to!proceed!without!a!placebo!group!was!well!considered!but!did!lead!to!
significant!difficulties!when!interpreting!the!data.!!The!primary!objective!was!histological!
assessment!of!endometriosis!in!response!to!ulipristal!acetate,!so!a!decision!was!taken!
to! maximise! numbers! exposed! to! study! drug! and! use! published! data! on! eutopic!
!
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response!to!ulipristal!acetate!as!a!comparator.!!The!assessment!of!endometrial!samples!
at!screening!also!allowed!each!subject!to!act!as!her!own!eutopic!endometrial!control.!
The!argument!for!ectopic!endometrial!controls,!either!as!pre0treatment!biopsies!or!a!
non0treatment!group!is!a!valid!one.!!However,!the!study!team!felt!it!was!unethical!to!
design!a!study!in!which!a!mandatory!diagnostic!laparoscopy!was!planned!to!confirm!the!
diagnosis!and!obtain!a!biopsy!as!part!of!screening.!!It!was!also!considered!unethical!to!
map!and!partially!excise!a!portion!of!disease!with!a!view!to!treating!it!medically!for!three!
months!before!returning!for!further!laparoscopic!excision.!
Unfortunately,!the!lack!of!existing!knowledge!on!the!histopathological!appearance!of!
endometriosis,! combined! with! a! decision! not! to! have! a! non0treatment! group! as! a!
comparator! and! the! six0week! lag! between! drug! therapy! and! surgery! made!
interpretation!of! the!histopathological! features! seen!very! challenging.! ! These! factors!
also!compromised!the!validity!of!the!immunohistochemistry!data!to!such!an!extent!that!
no!safe!conclusions!can!be!drawn!on!this!data.!
A!further!consequence!of!not!including!a!control!group!is!that!it!prevents!any!blinding!
to!treatment!on!behalf!of!the!subjects!or!investigators.!!This!combined!with!the!small!
numbers! and! semi0subjective! nature! of! the! histopathological! interpretation! has! the!
potential!to!introduce!significant!bias!to!the!study!interpretation.!!
The! distinction! between! patients! requiring!medical! treatment! of! endometriosis! and!
those!requiring!surgical!excision!has!been!described!in!chapter!1.!!The!subjects!included!
in!the!CHUTE!study!were!by!the!nature!of!the!inclusion!criteria,!patients!needing!surgery.!!
As!such!our!study!was!conducted!on!subjects!where!medical!treatment!may!have!been!
less!effective.!!This!has!the!potential!to!have!diminished!the!clinical!impact!observed!
and!should!be!taken!into!account!in!future!study!design.!!!!!
When!considering! the!observed! clinical! impact,! it!must!be!highlighted! that! the! time!
between! the!diagnostic!procedure!and! recruitment!was!not!defined! in! the! inclusion!
criteria.!!This!led!to!a!broad!range!of!intervals!resulting!in!reduced!accuracy!of!staging!
data!at!screening.!!This!may!have!influenced!the!apparent!increase!in!ASRM!score!and!
stage!seen!between!screening!and!excision.!!As!such!there!is!insufficient!evidence!to!
support! the! conclusion! that! clinical! progression! of! the! disease! is! seen! as! a! result! of!
ulipristal!acetate!treatment.!!
!
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The!relatively!short!duration!of!treatment,!the!fact!that!all!subjects!received!study!drug!
and!all!subjects!knew!surgical!management!of!disease!would!occur!at!the!end!of!the!
study!were!all! significant! confounding! factors.! ! The!Hawthorne!effect! (230)! resulting!
from!being!observed!may!well!have!influenced!the!scores!given!in!the!questionnaires.!!
This!bias!may!have!also!been!compounded!by!the!extra!clinical!visits,!access!to!medical!
expertise! and! research! nurse! support0! all! factors! that! can! contribute! to! patient!
perception!of!improvement!in!disease.!
This!placebo!effect!is!seen!in!blinded!endometriosis!trials.!!The!two!studies!using!GnRH!
analogues! evaluated! by! J! Brown,! et# al.,! in! a! recent! overview! of! treatments! for!
endometriosis!demonstrated!an!18%!and!16%!improvement!of!disease!in!the!placebo!
arms! of! the! studies.(231)! ! The! lack! of! placebo! or! blinding,! combined! with! the!
questionnaire!based!patient!evaluation!of!disease!has!the!potential!to!compromise!the!
quality!of!life!data!completely.!
!
!
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Chapter(9:!CONCLUSIONS(&(FUTURE(DIRECTION(
The! histopathology! of! the! ectopic! endometrium! is! very! variable,! and! this! makes!
interpreting!the!results!of!the!study!difficult.!!However,!despite!this!confounding!factor,!
possible!PAEC! type! changes!were! observed!within! the! ectopic! endometrium.! ! Cystic!
dilatation! with! ciliated! metaplasia! was! a! more! prominent! feature! than! expected!
suggesting! this!may! be! the! result! of! drug! action.! ! This! observation! also! appears! to!
correlate!with!the!clinical!response!of!subjects!to!the!drug,!although!the!study!was!not!
suitably!powered!to!demonstrate!a!statistically!significant!association.!!This!finding!is!
particularly! interesting! as! it!may! suggest! that! PAEC! type! changes!within! the! ectopic!
endometrium!and!possible!alterations!in!the!balance!of!PR0A!and!PR0B!expression!are!
key!to!the!clinical!impact!of!the!drug!on!endometriosis.!
Concern! exists! amongst! endometriosis! specialists! that! the! use! of! SPRMs! such! as!
ulipristal! acetate! may! have! a! proliferative! effect! on! ectopic! endometrium! and! that!
prolonged!use!may!cause!a!hyperplastic!type!effect!within!endometriotic!deposits.!!Such!
reservations!should!be!noted,!and!studies!conducted!to!help!answer!that!question.!!The!
florid!appearance!of!the!disease!in!some!CHUTE!subjects!does!highlight!concerns!about!
proliferation,! however! it! is! reassuring! that! the! histological! appearance! and!
immunohistochemical!staining!was!not!markedly!different!for!those!subjects!with!florid!
disease.!
The!most!encouraging!result!is!the!clinical!impact!of!ulipristal!acetate!over!the!three0
month!course0!a!number!of!the!subjects!describing!it!as!“the!best!treatment”!they!have!
ever!taken.! !Analgesia!use!decreased! in!44%!of! subjects!and!there!was!a!statistically!
significant!reduction!in!symptom!severity!for!pre0menstrual!pain,!menstrual!pain,!non0
cyclical!pelvic!pain!and!pain!during!sex.!!These!data!were!also!backed!up!with!statistically!
significant!improvements!in!quality!of!life!scores!and!global#impression#of#change!data!
showing!high!tolerability.!
Overall,! the! study!has!demonstrated! some!encouraging!evidence! for! those!clinicians!
already! using! ulipristal! acetate!off# licence! to! treat! endometriosis! but! concern! about!
long0term!safety!has!not!been!resolved!and!caution!should!still!be!exercised.!
!
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9.1! FUTURE(WORK(
The!priority! for!any!future!research!would!be!to!answer!two!broad!questions,!which!
remain! unanswered! by! the! CHUTE! study;! is! ulipristal! acetate! safe! to! use! in!
endometriosis! from! a! PAEC! point! of! view! &! what! efficacy! does! it! demonstrate! in!
controlling! symptoms.! ! Further! studies! are! required! to! answer! these! questions! and!
those!studies!should!involve!greater!numbers,!irrespective!of!design,!to!ensure!robust!
&!reliable!data!are!obtained.!
The!development!of!PAEC!is!key!to!the!safety!question!and!it!must!be!considered!for!
both!eutopic!endometrium!and!ectopic!endometrium.!!There!is!evidence!to!suggest!that!
the!eutopic!endometrium!in!endometriosis!patients!behaves!differently!to!the!eutopic!
endometrium!of!healthy!individuals.!!However,!the!key!area!of!interest!is!whether!PAEC!
occurs!in!ectopic!endometrium.!!A!clearer!answer!to!that!question!would!be!achieved!if!
endometrial!samples!were!obtained!whilst!the!study!subjects!were!still!taking!the!study!
drug.!
Amongst!researchers!familiar!with!ulipristal!acetate!there!remains!concern!that!it!may!
have! a! proliferative! effect! on! ectopic! endometrium.! ! This! needs! further! exploration!
through!surgical!inspection!&!histopathological!analysis.!!This!must!be!conducted!whilst!
the!subjects!are!taking!study!drug!in!a!future!study.!!The!histopathology!data!should!be!
assessed! by! three! independent! histopathologists! and! receptor! expression! assessed!
using!microbiology! techniques! such! as!Western! blotting! or!DNA!microarrays! to! give!
quantitative!results.!
The!majority!of!current!medical! therapy!for!endometriosis!is!used!for!a!period!of!six!
months!to!assess!its!effectiveness.!!Given!the!current!medical!licence!for!taking!multiple!
course!of!ulipristal!acetate,!consideration!should!be!given!to!the!length!of!treatment.!!A!
longer!course!would!allow!an!assessment!of!the!longevity!of!any!clinical!response!and!
would!help!minimise!some!of!the!Hawthorn!effect!seen!in!the!current!CHUTE!design.!
The!study!population! in!a! future!study!should!also!be!considered.! !The!design!of!the!
CHUTE!study! included! subjects! considered! suitable! for! surgical!management!of! their!
disease.!!As!such!their!disease!may!not!have!been!suitable!for!medical!treatment.!!Once!
the!safety!of!ulipristal!acetate!in!endometriosis!is!more!established!a!study!looking!at!
!
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medical!management!without!recourse!to!surgery!should!be!considered!either!with!a!
placebo!arm!or!with!an!existing!treatment!as!a!comparator.!
9.1.1! Study(features((
Placebo&arm&
Given!the!uncertainty!about!the!histopathological!features!of!ectopic!endometrium!and!
any! overlap!with! PAEC! a! future! study! should! contain! a! placebo! arm.! ! In! addition! to!
providing! a! comparator! for! histopathology! it! would! add! weight! to! any! clinical! or!
questionnaire0based!disease!assessment!following!drug!treatment.!
Blinding&
The!bias! introduced!by!not!blinding!the!subjects!or!the!study!team!to!the!treatment!
received!in!the!CHUTE!study!should!be!corrected.!!This!would!add!much!greater!weight!
to!any!conclusions!and!give!a!clear!picture!of!the!placebo!effect!generated!as!a!result!of!
a!subject!being!enrolled!in!a!study.!
Surgical&timing&
Surgical!specimens!and!visual!inspection!of!either!disease!suppression!or!staging!would!
need! to! be! made! whilst! subjects! were! still! taking! the! study! drug.! ! The! problems!
associated!with!a!treatment!gap!have!been!highlighted!in!the!CHUTE!study.!!This!would!
be! particularly! important! if! quantitative! receptor! expression! assessment!were! being!
undertaken.!
Head&to&head&
A! further! assessment! of! efficacy! of! ulipristal! acetate! in! endometriosis!management!
would! be! to! compare! it! head0to0head! with! an! existing! treatment! such! as! a! GnRH!
analogue.!!!!!!!!
9.1.2! CHUTE(2(
A!number!of!possible!study!designs!have!been!considered,!to!incorporate!as!many!of!
the!desired!features!as!possible.!!The!current!design!of!CHUTE!2!is!shown!in!Figure!9.1.!!
There!will!be!two!treatment!arms!as!shown!with!a!placebo!group! running!alongside.!!
The!study!will!be!double!blinded!with!dummy!injections!and!placebo!tablets.!!All!samples!
will!be!obtained!whilst!subjects!are!still!in!treatment!and!the!EHP030!questionnaire!and!
PGIC!will!be!used!at!all!time!points!for!consistency.!
!
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9.2! CONCLUDING(REMARKS(
The!results!of!the!CHUTE!study!support!the!largely!theoretical!conclusion!that!SPRMs!
can!successfully!treat!endometriosis.! !Ulipristal!acetate!potentially!offers!an!effective!
treatment!for!endometriosis!with!histological!changes!of!the!eutopic!endometrium!in!
keeping!with!the!known!experience!of!PAEC.!!The!safety!of!this!compound!remains!to!
be!elucidated!but!the!results!from!this!pilot!study!are!encouraging!and!should!prompt!
further!exploration.!
! CHANGES(IN(HISTOLOGY(FOLLOWING(ULIPRISTAL(THERAPY(IN(ENDOMETRIOSIS(
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Figure'9.1! Graphic!representation!of!CHUTE!2!study!timeline.!!!
(UPA%5mg%OD=%Ulipristal%acetate%(5mg%once%per%day)%taken%for%a%duration%of%12%weeks,%EoS=%end%of%study,%Integers=%whole%weeks,%Q=%Questionnaires)
!
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GLOSSARY*
AR!! Androgen!Receptor!
ASRM! American!Society!for!Reproductive!Medicine!
!hCG! Beta!Human!Chorionic!Gonadotrophin!!
B&B! Biberoglu!and!Behrman!
BSGE0!Qu! BSGE!pelvic!pain!Questionnaire!
COCP! Combined!Oral!Contraceptive!Pill!
COX02! Cyclooxygenase02!
CPSSS!! Composite!Pelvic!Signs!and!Symptoms!Score!
CRF! Case!Report!Form!
CRN! Clinical!Research!Network!
CRL! Crown!Rump!Length!
CTA! Clinical!Trials!Authorisation!
DIE! Deeply!Invasive!Endometriosis!
DBD! DNA0Binding!Domain!
DPP! Disordered!Proliferative!Pattern!
EPAU! Early!Pregnancy!Assessment!Unit!
EHP030! Endometriosis!Health!Profile!questionnaire!
ER!! Oestrogen!Receptor!!
ESHRE! European!Society!of!Human!Reproduction!and!Embryology!
FSH!! Follicle!Stimulating!Hormone!
GM0CSF! Granulocyte0Macrophage!Colony0Stimulating!Factor!
GnRHa! Gonadotrophin!Releasing!Hormone!agonist!
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H&E! Haematoxylin!and!Eosin!
HIER! Heat!Induced!Epitope!Retrieval! !
HPO! Hypothalamic0Pituitary0Ovarian!
HRE! Hormone!Response!Element!
HRT! Hormone!Replacement!Therapy!
17!0HSD02! 17!0Hydroxy0Steroid!Dehydrogenase!type!2!
ICAM! Inter0Cellular!Adhesion!Molecule!
IHC! Immunohistochemistry!
IMP! Investigational!Medicinal!Product!
IFN0"! Inter0Feron!Gamma!
IQ! Interquartile!range!
LBD! Ligand0Binding!Domain!
LNG0IUS! Levonorgestrel!Intra0Uterine!System!(Mirena®)!
LH!! Luteinising!Hormone!!
MAPK! Mitogen0Activated!Protein!Kinase!
MHRA! Medicine!and!Healthcare!products!Regulatory!Agency!
MMP! Matrix!Metallo0Proteinase!
MPA! Medroxy0Progesterone!Acetate!
MRI! Magnetic!Resonance!Imaging!
NCoR! Nuclear!Receptor!Corepressor!
NET! Norethisterone!
NIHR! National!Institute!for!Health!Research!
NSAID! Non0Steroidal!Anti0Inflammatory!Drug!
!
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PAEC! PRM!Associated!Endometrial!Changes!
PCOS! Polycystic!Ovarian!Syndrome! !
PGIC!! Patients’!Global!Impression!of!Change!
POD! Pouch!of!Douglas!
POP! Progesterone!Only!Pill!
PR!! Progesterone!Receptor!
PRM! Progesterone!Receptor!Modulator!
PTEN!! Phosphatase!and!tensin!homolog!deleted!on!chromosome!10!
QoL! Quality!of!Life!
RCT! Randomised!Controlled!Trial!
SMRT! Silencing!Mediator!of!Retinoic!acid!and!Thyroid!hormone!receptor!
SPRM! Selective!Progesterone!Receptor!Modulator!
SRC01! Steroid!Receptor!activator!!
TGF0!! Transforming!Growth!Factor0Beta!
TNF0#! Tumor!Necrosis!Factor0#!
TvUSS! Transvaginal!Ultra0Sound!Scan!
uPA! Urokinase!type!Plasminogen!Activator!
UPA! Ulipristal!Acetate!
VEGF! Vascular!Endothelial!Growth!Factor!
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